<?xml version="1.0" encoding="UTF-8"?>
<root>
    <row>
        <APP_ID>2002047</APP_ID>
        <Date_Announced>2021-03-16T00:00:00</Date_Announced>
        <CIA_Name>A/Pr Victoria Palmer</CIA_Name>
        <Grant_Type>Special Initiative</Grant_Type>
        <Sub_Type>Special Initiative in Mental Health</Sub_Type>
        <Grant_Title>ALIVE - A National Research Translation Centre to implement Mental Health Care at Scale</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$10,000,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Mental Health</Field_s__of_Research>
        <Res_KW1>mental health </Res_KW1>
        <Res_KW2>implementation </Res_KW2>
        <Res_KW3>translation </Res_KW3>
        <Res_KW4>aboriginal mental health </Res_KW4>
        <Res_KW5>intervention</Res_KW5>
        <Plain_Description>ALIVE is a national research translation Centre to implement mental health care at scale. Our vision is to reduce the individual, social and economic impacts of mental illness burden and health inequities by transforming the primary care and community settings to: 1) embed novel preventive life course models; 2) implement mental-physical health tailored models of care with priority populations; 3) be informed by lived-experience models and leadership.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007001</APP_ID>
        <Date_Announced>2021-03-26T00:00:00</Date_Announced>
        <CIA_Name>Prof Juha Toyras</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>NHMRC-EU Collaborative Research Grants</Sub_Type>
        <Grant_Title>Revolution of sleep diagnostics and personalized health care based on digital diagnostics and therapeutics with health data integration</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$499,999.75</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Respiratory Diseases</Field_s__of_Research>
        <Res_KW1>obstructive sleep apnoea </Res_KW1>
        <Res_KW2>apnoea </Res_KW2>
        <Res_KW3>biomedical engineering </Res_KW3>
        <Res_KW4>sleep </Res_KW4>
        <Res_KW5>somnolence</Res_KW5>
        <Plain_Description>Almost 1 billion people suffer from sleep apnoea. Unfortunately, the current diagnostic metric relates poorly to the symptoms and comorbidities of sleep apnoea merely measuring the frequency of breathing cessations. We aim to develop machine learning techniques to better estimate sleep apnoea severity. These techniques are implemented to high-end wearables developed in this project. Finally, we aim to design a digital diagnostic platform and create new standardised guidelines for sleep medicine.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007006</APP_ID>
        <Date_Announced>2021-03-26T00:00:00</Date_Announced>
        <CIA_Name>A/Pr George Moschonis</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>NHMRC-EU Collaborative Research Grants </Sub_Type>
        <Grant_Title>DigiCare4You - An intersectoral innovative solution involving DIGItal tools, empowering families and integrating community CARE services for the prevention and management of type 2 diabetes and hypertension</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$489,307.09</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Public Nutrition Intervention</Field_s__of_Research>
        <Res_KW1>community health care </Res_KW1>
        <Res_KW2>health promotion </Res_KW2>
        <Res_KW3>diabetes prevention </Res_KW3>
        <Res_KW4>behaviour change </Res_KW4>
        <Res_KW5>electronic health information</Res_KW5>
        <Plain_Description>The overall aim of the research is to design and implement an innovative intervention that will bring together the available community-care infrastructure, human resources and services, as well as technological advancements on digital health, for the early prevention and treatment of type 2 diabetes and hypertension. The active involvement of Australian researchers in this international collaboration ensures that this innovation and its benefits will be transferred to Australia in the future.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007014</APP_ID>
        <Date_Announced>2021-03-26T00:00:00</Date_Announced>
        <CIA_Name>Prof H. Peter Soyer</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>NHMRC-EU Collaborative Research Grants </Sub_Type>
        <Grant_Title>Intelligent total body scanner for early detection of melanoma</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$499,963.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Medical Biotechnology Diagnostics (incl. Biosensors)</Field_s__of_Research>
        <Res_KW1>melanoma </Res_KW1>
        <Res_KW2>artificial neural networks </Res_KW2>
        <Res_KW3>diagnostic imaging </Res_KW3>
        <Res_KW4>multiple risk factors </Res_KW4>
        <Res_KW5>risk assessment</Res_KW5>
        <Plain_Description>Melanoma is the 4th most common cancer in Australia; the main screening tool is a time-consuming total body examination with a hand-held dermoscope. This project aims to develop a total body scanner using fast-refocusing lenses to take total body dermoscopy images of all skin lesions in approximately 6 minutes, integrated with a computer aided diagnostic tool providing a risk score for each lesion incorporating medical history, genotypic and phenotypic risk markers.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007048</APP_ID>
        <Date_Announced>2021-03-26T00:00:00</Date_Announced>
        <CIA_Name>A/Pr Helga Zoega</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>NHMRC-EU Collaborative Research Grants </Sub_Type>
        <Grant_Title>ManagemenT of chronIc cardioMetabolic diseasE and treatment diScontinuity in adult ADHD PAtieNts (TIMESPAN)</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$499,612.50</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Mental Health</Field_s__of_Research>
        <Res_KW1>attention deficit hyperactivity disorder (adhd) </Res_KW1>
        <Res_KW2>cardiovascular disease </Res_KW2>
        <Res_KW3>type 2 diabetes mellitus (non-insulin dependent diabetes mellitus) </Res_KW3>
        <Res_KW4>pharmacoepidemiology </Res_KW4>
        <Res_KW5>data linkage</Res_KW5>
        <Plain_Description>The aim of TIMESPAN is to improve the management of patients with Attention Deficit Hyperactivity Disorders (ADHD) and co-occurring cardiometabolic disease (i.e. obesity, type-2 diabetes, and cardiovascular disease). Inadequate treatment of these common conditions can lead to premature death and substantial societal costs. We will use linked electronic health records and novel research methods to improve clinical outcomes and quality of life of adults with ADHD and cardiometabolic disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007059</APP_ID>
        <Date_Announced>2021-03-26T00:00:00</Date_Announced>
        <CIA_Name>Prof Sarah Bekessy</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>NHMRC-EU Collaborative Research Grants </Sub_Type>
        <Grant_Title>Re-imagining Environments for Connection and Engagement: Testing Actions for Social Prescribing in Natural Spaces</Grant_Title>
        <Admin_Institution>RMIT University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$499,749.50</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Mental Health</Field_s__of_Research>
        <Res_KW1>mental health </Res_KW1>
        <Res_KW2>social health issues </Res_KW2>
        <Res_KW3>psychosocial </Res_KW3>
        <Res_KW4>environmental influences </Res_KW4>
        <Res_KW5>environmental intervention</Res_KW5>
        <Plain_Description>This project will evaluate whether and how nature-based social prescribing (NBSP) can address mental well-being. We will experimentally test the effectiveness of NBSP in promoting connection among populations experiencing social isolation and loneliness with socially oriented opportunities in safe, inclusive and accessible, green and blue outdoor urban spaces. The project will build the evidence base for the value of NBSP investments in improving mental health.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2002381</APP_ID>
        <Date_Announced>2021-03-27T00:00:00</Date_Announced>
        <CIA_Name>Prof Kirsten McCaffery</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 1st call for 2020</Sub_Type>
        <Grant_Title>Parenting+ Improving health and service-use outcomes through health literacy training for new parents: an effectiveness-implementation hybrid trial</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$495,760.80</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Family Care</Field_s__of_Research>
        <Res_KW1>health literacy </Res_KW1>
        <Res_KW2>maternal and child health </Res_KW2>
        <Res_KW3>socioeconomic </Res_KW3>
        <Res_KW4>health education </Res_KW4>
        <Res_KW5>ethnic health</Res_KW5>
        <Plain_Description>The Parenting+ project will evaluate an educational program for socio-economically and culturally diverse new parents. The study will assess the impact of the program on parents' health literacy, parent and infant health and psychosocial outcomes and health service use over one year. It additionally will identify key characteristics and reproducible steps in the successful implementation of the program in order to support wider adoption by other health services.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2002625</APP_ID>
        <Date_Announced>2021-03-27T00:00:00</Date_Announced>
        <CIA_Name>Prof Martin Holt</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 1st call for 2020</Sub_Type>
        <Grant_Title>Enhancing behavioural surveillance to address gaps and disparities in Australia's HIV response in a changing HIV epidemic</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,268,159.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Health Information Systems (incl. Surveillance)</Field_s__of_Research>
        <Res_KW1>human immunodeficiency virus (hiv) </Res_KW1>
        <Res_KW2>sexual behaviour </Res_KW2>
        <Res_KW3>prevention </Res_KW3>
        <Res_KW4>social identity </Res_KW4>
        <Res_KW5>social and cultural issues</Res_KW5>
        <Plain_Description>This project will test and evaluate changes to Australia's HIV behavioural surveillance system, increasing recruitment and data collection from overseas-born, bisexual and heterosexual men who have sex with men (MSM). This is necessary because Australia's HIV epidemic is changing, with falling infections among Australian-born gay men, but rising infections in other groups, such as Asian-born MSM. The project will use technological advancements in recruitment, survey research and interviews.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2003399</APP_ID>
        <Date_Announced>2021-03-27T00:00:00</Date_Announced>
        <CIA_Name>Prof Marcus Chen</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 1st call for 2020</Sub_Type>
        <Grant_Title>Novel strategies for improving syphilis testing and control</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,256,040.80</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Venereology</Field_s__of_Research>
        <Res_KW1>syphilis </Res_KW1>
        <Res_KW2>sexually-transmitted infections (sti) </Res_KW2>
        <Res_KW3>public health </Res_KW3>
        <Res_KW4>screening </Res_KW4>
        <Res_KW5>surveillance</Res_KW5>
        <Plain_Description>Syphilis has been resurgent in many countries including Australia. Our research will evaluate novel strategies to improve syphilis testing, surveillance, and control and ensure these new strategies are effective at targeting affected groups attending health services. The research findings will help guide better syphilis testing and control by health care providers, pathology services and health policy makers.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2005191</APP_ID>
        <Date_Announced>2021-03-27T00:00:00</Date_Announced>
        <CIA_Name>Dr Nikki McCaffrey</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 1st call for 2020</Sub_Type>
        <Grant_Title>Defining and optimising the economic and social return on investment of telephone cancer information and support services for all Australians</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$936,786.70</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Health Economics</Field_s__of_Research>
        <Res_KW1>evidence-based health care </Res_KW1>
        <Res_KW2>cancer </Res_KW2>
        <Res_KW3>health care delivery </Res_KW3>
        <Res_KW4>health care evaluation </Res_KW4>
        <Res_KW5>economic analysis</Res_KW5>
        <Plain_Description>The economic and social value of telephone cancer information and support services (CISS) for Australia is undefined thus hindering decisions about the future direction of services and levels of funding. This research will identify and compare the broad monetised, social benefits of CISS with the costs of providing the service. We will identify different strategies to deliver, promote and target services to improve cancer outcomes for all Australians and maximise the return on investment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2005403</APP_ID>
        <Date_Announced>2021-03-27T00:00:00</Date_Announced>
        <CIA_Name>Prof Kate Curtis</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 1st call for 2020</Sub_Type>
        <Grant_Title>Improving the safety and quality of emergency nursing care</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,498,877.45</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Clinical Nursing: Secondary (Acute Care)</Field_s__of_Research>
        <Res_KW1>nursing practice </Res_KW1>
        <Res_KW2>emergency medicine </Res_KW2>
        <Res_KW3>deterioration </Res_KW3>
        <Res_KW4>adverse events </Res_KW4>
        <Res_KW5>patient safety</Res_KW5>
        <Plain_Description>Failure to assess, treat comprehensively and escalate emergency patient care can be catastrophic. However, there is no emergency nursing framework in use for the 29,000+ emergency nurses working in Australia. We aim to improve access, consistency, safety and quality of emergency care for the best possible patient outcomes through system wide implementation of HIRAID - the only validated framework designed to teach emergency nurses how to systematically assess and manage emergency patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2005589</APP_ID>
        <Date_Announced>2021-03-27T00:00:00</Date_Announced>
        <CIA_Name>Prof Andrea Driscoll</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 1st call for 2020</Sub_Type>
        <Grant_Title>I-HEART - Implementation of HEArt failure guidelines in Regional AusTralia</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,266,172.55</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Clinical Nursing: Secondary (Acute Care)</Field_s__of_Research>
        <Res_KW1>heart failure </Res_KW1>
        <Res_KW2>nursing </Res_KW2>
        <Res_KW3>translational research </Res_KW3>
        <Res_KW4>health services </Res_KW4>
        <Res_KW5>regional health</Res_KW5>
        <Plain_Description>Heart failure (HF) is a common disease of the heart with a high rehospitalisation and mortality rate. Regional HF patients rarely receive the full benefits of evidence-based care simply due to inaccessibility to a HF specialist team. This translational project will implement key recommendations from clinical guidelines in regional health services and improve access to specialist services. It has the potential to keep patients out of hospital and save lives.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2005759</APP_ID>
        <Date_Announced>2021-03-27T00:00:00</Date_Announced>
        <CIA_Name>A/Pr Bianca Brijnath</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 1st call for 2020</Sub_Type>
        <Grant_Title>Improving interpreting for dementia assessments: The MINDSET Study</Grant_Title>
        <Admin_Institution>National Ageing Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$271,586.20</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Aged Health Care</Field_s__of_Research>
        <Res_KW1>cognitive assessment </Res_KW1>
        <Res_KW2>cross-cultural </Res_KW2>
        <Res_KW3>communication skills </Res_KW3>
        <Res_KW4>translational research </Res_KW4>
        <Res_KW5>dementia</Res_KW5>
        <Plain_Description>The MINDSET Study aims to improve the quality of communication in an interpreter mediated cognitive assessment for dementia. Working with interpreters, clinicians, culturally and linguistically diverse people with dementia, and their carers we will co-design, trial, and implement national online training targeted at interpreters. This training will enable interpreters to be prepared and confident in performing their role impartially, effectively, and accurately.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2005779</APP_ID>
        <Date_Announced>2021-03-27T00:00:00</Date_Announced>
        <CIA_Name>Prof Robert Adams</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 1st call for 2020</Sub_Type>
        <Grant_Title>Improving the management of Obstructive Sleep Apnea and Insomnia in General Practice</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,439,099.70</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Primary Health Care</Field_s__of_Research>
        <Res_KW1>primary care </Res_KW1>
        <Res_KW2>obstructive sleep apnoea </Res_KW2>
        <Res_KW3>insomnia </Res_KW3>
        <Res_KW4>general practice </Res_KW4>
        <Res_KW5>health service management</Res_KW5>
        <Plain_Description>The two most common clinical sleep disorders, insomnia and obstructive sleep apnea (OSA), affect >4 million Australians, costing Australia over $66 billion annually. People with sleep disorders are receiving care that is far from best practice and is potentially dangerous. This novel partnership study represents a major step towards improving management of sleep disorders in primary care (PC) using new, evidence-based, models of care for insomnia and OSA, designed specifically for PC.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2005790</APP_ID>
        <Date_Announced>2021-03-27T00:00:00</Date_Announced>
        <CIA_Name>Prof Gemma Figtree</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 1st call for 2020</Sub_Type>
        <Grant_Title>Partnership for Precision Prevention in CAD (PPP-CAD)</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,413,165.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Cardiology (incl. Cardiovascular Diseases)</Field_s__of_Research>
        <Res_KW1>cardiovascular risk factors </Res_KW1>
        <Res_KW2>cohort study </Res_KW2>
        <Res_KW3>implementation </Res_KW3>
        <Res_KW4>health economics </Res_KW4>
        <Res_KW5>primary care</Res_KW5>
        <Plain_Description>There is an urgent need for new tools to improve risk prediction for coronary artery disease which accounts for one fifth of deaths in Australia. Polygenic risk scores that incorporate the information from millions of genetic variants have shown great promise, but need prospective evaluation. Our team of clinical, research, industry and government leaders will develop clinical pathways and implement polygenic risk scores in primary care to improve precision of preventative strategies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2005797</APP_ID>
        <Date_Announced>2021-03-27T00:00:00</Date_Announced>
        <CIA_Name>Prof John Beltrame</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 1st call for 2020</Sub_Type>
        <Grant_Title>The Personalising Acute Myocardial Infarction Care to improve Outcomes (PAMICO Project)</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,499,233.80</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Cardiology (incl. Cardiovascular Diseases)</Field_s__of_Research>
        <Res_KW1>acute myocardial infarction (ami) </Res_KW1>
        <Res_KW2>acute care </Res_KW2>
        <Res_KW3>evidence-based health care </Res_KW3>
        <Res_KW4>quality of care </Res_KW4>
        <Res_KW5>clinical practice</Res_KW5>
        <Plain_Description>The modern management of heart attacks has improved survival dramatically, however, not all patients receive the best care available, leading to variation in quality and health outcomes. The PAMICO Project (Personalising Acute Myocardial Infarction Care to improve Outcomes) aims to bridge this gap using sophisticated electronic data systems and integrated care teams to produce personalised clinical management pathways so that care is patient-centered and aligned with best practice.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006408</APP_ID>
        <Date_Announced>2021-05-11T00:00:00</Date_Announced>
        <CIA_Name>Prof Catherine Hill</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2019 NHMRC-NIHR Collaborative Research Grants Round 3</Sub_Type>
        <Grant_Title>Steroid-Reducing Options for ReLapsING PMR (STERLING-PMR): a pragmatic, randomised trial to compare the clinical and cost-effectiveness of adding immunosuppression to steroid-tapering treatment for patients with relapsing PMR, versus steroid-tapering</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$823,722.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Rheumatology and Arthritis</Field_s__of_Research>
        <Res_KW1>clinical trial </Res_KW1>
        <Res_KW2>methotrexate </Res_KW2>
        <Res_KW3>glucocorticoids </Res_KW3>
        <Res_KW4>rheumatic diseases </Res_KW4>
        <Res_KW5>musculoskeletal disorders</Res_KW5>
        <Plain_Description>Polymyalgia rheumatica (PMR) is a common inflammatory disease of older people, treated with prednisolone (steroid tablet). About 50% will relapse and often suffer from steroid side effects (eg diabetes, bone fracture). This study will determine whether an extra treatment can reduce prednisolone use in people with relapsing PMR; and improve quality of life. The study will include participants in UK and Australia and provide a unique opportunity for further research in this under-researched area.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007142</APP_ID>
        <Date_Announced>2021-05-11T00:00:00</Date_Announced>
        <CIA_Name>Prof Manuela Ferreira</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2019 NHMRC-NIHR Collaborative Research Grants Round 3</Sub_Type>
        <Grant_Title>The Meniscal Transplant surgery or Optimised Rehabilitation full randomised trial (MeTeOR2)</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,025,882.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Orthopaedics</Field_s__of_Research>
        <Res_KW1>knee cartilage </Res_KW1>
        <Res_KW2>orthopaedic surgery </Res_KW2>
        <Res_KW3>physiotherapy management </Res_KW3>
        <Res_KW4>clinical trial </Res_KW4>
        <Res_KW5>cost-effectiveness</Res_KW5>
        <Plain_Description>It can be hard to decide what treatment to use for people with pain and disability who have had the meniscus cartilage removed from the knee. Some surgeons try to improve pain and function by replacing the lost meniscus with a transplant from a donor who has died. The alternatives include exercises, physiotherapy, and bracing. This study will help us understand if the results for people who have the transplant are better or worse than for exercise and physiotherapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2005944</APP_ID>
        <Date_Announced>2021-05-11T00:00:00</Date_Announced>
        <CIA_Name>Prof Gail Garvey</CIA_Name>
        <Grant_Type>National Network for Aboriginal and Torres Strait Islander health researchers</Grant_Type>
        <Sub_Type>National Network for Aboriginal and Torres Strait Islander health researchers</Sub_Type>
        <Grant_Title>National First Nations Research Network</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$10,000,000.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Aboriginal and Torres Strait Islander Health</Field_s__of_Research>
        <Res_KW1>indigenous australians </Res_KW1>
        <Res_KW2>capacity building </Res_KW2>
        <Res_KW3>indigenous health </Res_KW3>
        <Res_KW4>social support networks </Res_KW4>
        <Res_KW5>education</Res_KW5>
        <Plain_Description>The National First Nations Research Network will mark a transformation in First Peoples livelihoods and Health Equity. Delivered and led by Indigenous Peoples for Indigenous Peoples, guided by self-determination, this Network will nurture culturally safe environments, connect expertise, catalyse research methods, training and development. The Network will create career pathways to achieve national capability and generational growth, for sustained health and wellbeing of our communities.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006719</APP_ID>
        <Date_Announced>2021-05-11T00:00:00</Date_Announced>
        <CIA_Name>Prof Malcolm Sim</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>NHMRC Co-funding of the MRFF - Emerging Priorities and Consumer Driven Research Initiative (EPCDRI) – 2020 Silicosis Research Grant</Sub_Type>
        <Grant_Title>Emerging techniques for earlier diagnosis and assessment of severity and progression of artificial stone silicosis</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$994,642.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Radiology and Organ Imaging</Field_s__of_Research>
        <Res_KW1>adult respiratory diseases </Res_KW1>
        <Res_KW2>medical imaging </Res_KW2>
        <Res_KW3>occupational health </Res_KW3>
        <Res_KW4>occupational rehabilitation </Res_KW4>
        <Res_KW5>screening</Res_KW5>
        <Plain_Description>Stonemasons who have worked with engineered stone have been shown to develop a rapidly progressive and potentially fatal form of silicosis. This research will use data from affected workers from Victoria, Western Australia and Queensland. The research will comprise a suite of projects to investigate many uncertainties related to radiological screening methods, as well as investigating new methods to assess disease severity and identify indicators of progression to inform future practice.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009196</APP_ID>
        <Date_Announced>2021-06-16T00:00:00</Date_Announced>
        <CIA_Name>Prof Andrew Vallely</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>GACD Cancer Prevention Call funding commencing 2021</Sub_Type>
        <Grant_Title>HPV-based testing and treatment for the elimination of cervical cancer in Papua New Guinea (HPVTATE)</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,590,166.78</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Public Health and Health Services not elsewhere classified</Field_s__of_Research>
        <Res_KW1>cervical screening </Res_KW1>
        <Res_KW2>cervical precancer </Res_KW2>
        <Res_KW3>cervical cancer </Res_KW3>
        <Res_KW4>health services research </Res_KW4>
        <Res_KW5>developing countries</Res_KW5>
        <Plain_Description>Building on the innovative cervical screening model that we successfully designed and delivered in partnership with provincial health authorities in urban primary care settings in PNG, the overarching aim of the proposed study is to determine the reach, effectiveness, cost-effectiveness, acceptability and scalability of HPV-based testing and treatment for the elimination of cervical cancer (HPVTATE) among women in rural and remote communities in Papua New Guinea.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009206</APP_ID>
        <Date_Announced>2021-06-16T00:00:00</Date_Announced>
        <CIA_Name>A/Pr Gillian Gould</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>GACD Cancer Prevention Call funding commencing 2021</Sub_Type>
        <Grant_Title>SISTAQUIT scale-up in Indigenous populations in Australia</Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,800,000.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Aboriginal and Torres Strait Islander Health</Field_s__of_Research>
        <Res_KW1>smoking cessation </Res_KW1>
        <Res_KW2>indigenous health </Res_KW2>
        <Res_KW3>pregnancy </Res_KW3>
        <Res_KW4>health professionals </Res_KW4>
        <Res_KW5>health advice</Res_KW5>
        <Plain_Description>SISTAQUIT®(Supporting Indigenous Smokers to Assist Quitting) is a research backed training program that provides free, online training in quit smoking methods to health providers. This study aims to expand the SISTAQUIT intervention to all Australian health services that cater to Indigenous women during pregnancy. This research will test numerous methods to implement SISTAQUIT to identify the most effective and economical strategy suitable for roll-out, and build Indigenous workforce capacity.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009317</APP_ID>
        <Date_Announced>2021-06-16T00:00:00</Date_Announced>
        <CIA_Name>A/Pr Julia Brotherton</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>GACD Cancer Prevention Call funding commencing 2021</Sub_Type>
        <Grant_Title>Developing a scalable, woman-centred model for cervical cancer screening in vulnerable women in India</Grant_Title>
        <Admin_Institution>VCS Foundation Limited</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,330,369.04</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Preventive Medicine</Field_s__of_Research>
        <Res_KW1>cervical screening </Res_KW1>
        <Res_KW2>cervical precancer </Res_KW2>
        <Res_KW3>cancer screening </Res_KW3>
        <Res_KW4>population screening </Res_KW4>
        <Res_KW5>health services research</Res_KW5>
        <Plain_Description>Cervical cancer is a devastating but preventable disease and 1 in 5 cases of cervical cancer in the world occur in India. We will work with women, communities, and health services in two States of India (Tamil Nadu and Mizoram) to design a woman friendly approach to prevent cervical cancer. This project brings together international and Indian experts to overcome current barriers to cervical screening by using a newer, more effective way of screening to reach underserved women and save lives.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010271</APP_ID>
        <Date_Announced>2021-06-16T00:00:00</Date_Announced>
        <CIA_Name>Prof Robert Sanson-Fisher</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>GACD Cancer Prevention Call funding commencing 2021</Sub_Type>
        <Grant_Title>Developing and testing a community-informed intervention to increase VIA cervical cancer screening in Eswatini</Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,206,527.95</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Public Health and Health Services not elsewhere classified</Field_s__of_Research>
        <Res_KW1>cervical screening </Res_KW1>
        <Res_KW2>cancer prevention </Res_KW2>
        <Res_KW3>implementation </Res_KW3>
        <Res_KW4>community health care </Res_KW4>
        <Res_KW5>nursing practice</Res_KW5>
        <Plain_Description>Eswatini has the highest rate of cervical cancer in the world. Cervical cancer screening is effective at reducing deaths from this disease. However, in Eswatini rates of cervical screening are very low, with one study estimating that only 5% of women had ever undergone screening. This project will explore barriers to cervical screening in Eswatini, and develop and test culturally appropriate strategies to improve participation in cervical screening.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2000344</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>A/Pr Simon Rice</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>Pragmatic trial of a targeted digital intervention for youth with suicidal thoughts and behaviours attending outpatient care</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,443,572.40</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Psychiatry (incl. Psychotherapy)</Field_s__of_Research>
        <Res_KW1>major depression </Res_KW1>
        <Res_KW2>youth </Res_KW2>
        <Res_KW3>mental health </Res_KW3>
        <Res_KW4>suicide prevention </Res_KW4>
        <Res_KW5>suicide risk</Res_KW5>
        <Plain_Description>Existing programs aiming to reduce suicide ideation in youth often fail to impart lasting benefits in helping young people stay well. Our team have developed an online social media-based intervention (called Affinity) that addresses limitations of past programs by allowing 24/7 access to digital therapy, alongside therapist and peer support. This trial will aim to uncover whether Affinity is effective in reducing suicide ideation in young people, relative to a control program.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2000375</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>A/Pr Rebecca McKetin</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>A Phase III randomised placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine ("Ice") dependence</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,923,009.33</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Mental Health</Field_s__of_Research>
        <Res_KW1>substance dependence </Res_KW1>
        <Res_KW2>pharmacotherapy </Res_KW2>
        <Res_KW3>clinical trial </Res_KW3>
        <Res_KW4>amphetamine </Res_KW4>
        <Res_KW5>medications</Res_KW5>
        <Plain_Description>Crystalline methamphetamine ('ice') is a growing concern in Australia. There are no approved medications that can be used to treat dependence on this drug. This clinical trial will examine whether mirtazapine, a newly identified treatment agent for methamphetamine use, can be used safely and effectively in routine clinical care to manage methamphetamine dependence in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2000376</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>Prof Richard Kanaan</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>Breathing Control as a treatment for Non-Epileptic Seizures</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,740,186.67</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Psychiatry (incl. Psychotherapy)</Field_s__of_Research>
        <Res_KW1>control of breathing </Res_KW1>
        <Res_KW2>seizures </Res_KW2>
        <Res_KW3>somatoform disorders </Res_KW3>
        <Res_KW4>clinical trial </Res_KW4>
        <Res_KW5>physiotherapy management</Res_KW5>
        <Plain_Description>Non-epileptic Seizures (NES) are fits that look like epilepsy but are not, and are instead thought to be a psychological response to problems. Treating them psychologically is difficult, however, and doesn't usually work. We have discovered that patients' fits involve hyperventilation, like a panic attack, and can be stopped by teaching them to control their breathing in a similar way. In this study we aim to prove this, by completing a trial of breath control training in NES.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2000404</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>Prof Shyamali Dharmage</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>Providing translatable evidence to advance prevention and management of COPD: a longitudinal study from the 1st to 7th decade of life</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,893,319.94</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Respiratory Diseases</Field_s__of_Research>
        <Res_KW1>disease prevention </Res_KW1>
        <Res_KW2>risk prediction </Res_KW2>
        <Res_KW3>chronic obstructive pulmonary disease (copd) </Res_KW3>
        <Res_KW4>asthma </Res_KW4>
        <Res_KW5>lung function</Res_KW5>
        <Plain_Description>Chronic obstructive pulmonary disease (COPD) makes breathing difficult and reduces wellbeing. People are more likely to get COPD from the age of 60 years, but we do not know why and who. Our study will develop tools to identify early who will develop COPD by 60 years. We will also develop a tool to identify 60-year-old individuals whose lung function is declining faster than normal. These findings will help us to better prevent and manage COPD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2000540</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>Prof Jonathan Shaw</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>PRogrEssion of DIabetic ComplicaTions - PREDICT</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$4,784,627.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Epidemiology</Field_s__of_Research>
        <Res_KW1>diabetes </Res_KW1>
        <Res_KW2>diabetic complications </Res_KW2>
        <Res_KW3>biomarkers </Res_KW3>
        <Res_KW4>cardiovascular complications </Res_KW4>
        <Res_KW5>kidney disease</Res_KW5>
        <Plain_Description>The PREDICT study will fill a very important gap in our understanding of diabetes. By studying what happens to over 3,000 people with type 2 diabetes over the next decade, it will identify improved ways of identifying which people with diabetes will develop its devastating complications. This will allow targeting of intensive treatment on those who need it the most, and will also provide an important means of identifying potential new ways of treating and supporting people with type 2 diabetes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2000711</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>Prof Trevor Leong</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>AGITG TOP GEAR: A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$621,644.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Radiation Therapy</Field_s__of_Research>
        <Res_KW1>clinical trial </Res_KW1>
        <Res_KW2>gastric cancer </Res_KW2>
        <Res_KW3>radiotherapy </Res_KW3>
        <Res_KW4>surgery </Res_KW4>
        <Res_KW5>chemotherapy</Res_KW5>
        <Plain_Description>While surgery to remove stomach cancer has been traditionally accepted as the only way to potentially cure the disease, there have been several recent advances using chemotherapy and/or radiotherapy both before and after surgery. Doctors' opinions remain divided regarding best treatments to give and in what order. This trial will address the important question of whether combined chemotherapy plus radiotherapy is more effective than chemotherapy alone in improving cure rates for stomach cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2000780</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>Dr Holger Unger</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>Intermittent preventive treatment in pregnancy with sulphadoxine-pyrimethamine plus dihydroartemisinin-piperaquine to reduce adverse pregnancy outcomes and prevent malaria in Papua New Guinea: a randomised controlled trial</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,938,452.97</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Medical Parasitology</Field_s__of_Research>
        <Res_KW1>clinical trial </Res_KW1>
        <Res_KW2>antimalarial </Res_KW2>
        <Res_KW3>malaria </Res_KW3>
        <Res_KW4>pregnancy </Res_KW4>
        <Res_KW5>low birth weight infant</Res_KW5>
        <Plain_Description>Millions of pregnancies are complicated by malaria worldwide. Monthly sulphadoxine-pyrimethamine (SP) treatments, the current treatment strategy, no longer protects from malaria but improves birth outcomes through non-malarial effects. Dihydroartemisinin-piperaquine clears malaria but babies are smaller compared to women who received SP. A clinical trial of their combination has potential to substantially improve health outcomes for women and babies in Papua New Guinea and beyond.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2000842</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>Prof Stephanie Brown</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>Uncovering the hidden impacts and costs of exposure to intimate partner violence in childhood: a 20-year cohort study</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,595,473.40</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Epidemiology</Field_s__of_Research>
        <Res_KW1>maternal and child health </Res_KW1>
        <Res_KW2>domestic violence </Res_KW2>
        <Res_KW3>adolescent health </Res_KW3>
        <Res_KW4>maternal mental health </Res_KW4>
        <Res_KW5>health economics</Res_KW5>
        <Plain_Description>Intimate partner violence (IPV) and adverse childhood experiences are common, and cluster within families. This longitudinal study will improve understanding of intergenerational impacts and costs of IPV and provide evidence regarding strategies that may reduce the risk of poor mental health in adult life for the more than 1 in 3 Australian children growing up in households where IPV is occurring.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2000989</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>Dr Christina Abdel Shaheed</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>IMPLORE - Implementing an opioid stewardship intervention to reduce opioid use</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,352,236.17</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Primary Health Care</Field_s__of_Research>
        <Res_KW1>clinical trial </Res_KW1>
        <Res_KW2>opioid analgesia </Res_KW2>
        <Res_KW3>patient education </Res_KW3>
        <Res_KW4>low back pain </Res_KW4>
        <Res_KW5>clinical decision making</Res_KW5>
        <Plain_Description>Back pain is the leading cause for opioid use globally. Guidelines actively discourage opioid use for this condition but unfortunately it commonly ends up managed with opioid medicines. Urgent efforts are needed to reduce the burden of harm associated with excessive prescribing of opioids for back pain. This trial will evaluate a clinical care model that is grounded in research, and designed to curb opioid analgesic use and achieve better health outcomes for people with back pain.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2001237</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>Prof Carol Hodgson</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>Low OxyGen Intervention for Cardiac Arrest injury Limitation trial (LOGICAL)</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,314,402.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Intensive Care</Field_s__of_Research>
        <Res_KW1>oxygen therapy </Res_KW1>
        <Res_KW2>mechanical ventilation </Res_KW2>
        <Res_KW3>randomised controlled trial (rct) </Res_KW3>
        <Res_KW4>intensive care </Res_KW4>
        <Res_KW5>clinical research</Res_KW5>
        <Plain_Description>Life support with mechanical ventilation (MV) is required for most patients after cardiac arrest. Delivery of liberal oxygen therapy to patients receiving MV is standard care and exposes them to a high oxygen dose and higher blood oxygen levels. A higher amount of oxygen might be harmful after cardiac arrest, but the optimal oxygen therapy in these patients is uncertain. This study tests standard care versus a protective conservative dose of oxygen on neurological recovery after cardiac arrest.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2001264</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>A/Pr Camille Raynes-Greenow</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>Reducing household air pollution exposure to improve early child health and development; extending the intervention and follow-up of "Poriborton: the CHANge trial".</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,916,420.55</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Epidemiology</Field_s__of_Research>
        <Res_KW1>clinical trial </Res_KW1>
        <Res_KW2>indoor air pollution </Res_KW2>
        <Res_KW3>child development </Res_KW3>
        <Res_KW4>respiratory diseases </Res_KW4>
        <Res_KW5>public health</Res_KW5>
        <Plain_Description>Around the world each year household air pollution causes 4.3 million deaths. Mothers, babies and children, who spend the most time at home are extremely vulnerable. We will study the health of infants who have had reduced exposure in their first critical years of life and compare them to infants whose exposure was not reduced. This will provide compelling evidence for governments around the world of the need to assist families in developing settings to adopt clean energy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2001375</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>A/Pr Kirsten Morley</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>A randomised controlled trial of N-acetylcysteine for the treatment of alcohol use disorder</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,294,923.44</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Psychiatry (incl. Psychotherapy)</Field_s__of_Research>
        <Res_KW1>alcohol use disorders </Res_KW1>
        <Res_KW2>alcohol dependence </Res_KW2>
        <Res_KW3>pharmacotherapy </Res_KW3>
        <Res_KW4>substance use </Res_KW4>
        <Res_KW5>alcoholic liver disease</Res_KW5>
        <Plain_Description>We urgently require new treatment strategies. Alcohol misuse is a leading cause of preventable death yet treatment options are limited. We will undertake the first human trial of N-acetylcysteine (NAC) for the management of alcohol use disorder (NAC-AUD). The NAC-AUD project will evaluate the efficacy and cost-efficacy of NAC to reduce alcohol consumption. The results will generate high level clinical evidence for a safe new treatment for a common life threatening disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2001391</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>Prof Jane Pillow</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>Cognitive Improvement through early Restoration of cirCADian rhythms in very preterm Infants via Environmental Modification: The CIRCA DIEM Study</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$3,077,039.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Foetal Development and Medicine</Field_s__of_Research>
        <Res_KW1>circadian rhythms </Res_KW1>
        <Res_KW2>neurodevelopment </Res_KW2>
        <Res_KW3>premature infant </Res_KW3>
        <Res_KW4>maternal mental health </Res_KW4>
        <Res_KW5>sleep</Res_KW5>
        <Plain_Description>When very premature infants are born, they no longer receive important signals from their mother about whether it is daytime or night-time, and are cared for in hospital environments that are noisy and brightly lit all day. The absence of the maternal signals and the constant light and noise may interfere with normal brain development. We will determine if wearing eye masks and ear muffs at night in hospital will improve brain development and general health in premature babies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2001517</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>A/Pr Victoria Mar</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>Reconceiving early detection of melanoma</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,217,920.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Dermatology</Field_s__of_Research>
        <Res_KW1>malignant melanoma </Res_KW1>
        <Res_KW2>skin cancer </Res_KW2>
        <Res_KW3>computer-assisted diagnosis </Res_KW3>
        <Res_KW4>risk prediction </Res_KW4>
        <Res_KW5>dermatology</Res_KW5>
        <Plain_Description>Treatment for skin cancer costs the Australian healthcare system >$1 billion annually. Early detection and accurate diagnosis of melanoma improves survival, however a standardised approach to diagnosis does not currently exist. This study will prospectively recruit 15,000 patients to develop and validate a risk stratified image-based approach to melanoma prevention, early detection and surveillance which will incorporate cutting edge technologies to standardise diagnosis and optimise care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2001568</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>Prof Ian Hickie</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>A large-scale clinical effectiveness (health services) trial to determine whether personalised health care packages, combined with digitally-supported measurement-based care, improve functional outcomes in young people with mood disorders</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,434,588.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Psychiatry (incl. Psychotherapy)</Field_s__of_Research>
        <Res_KW1>mood disorders </Res_KW1>
        <Res_KW2>depression </Res_KW2>
        <Res_KW3>youth </Res_KW3>
        <Res_KW4>intervention </Res_KW4>
        <Res_KW5>translational research</Res_KW5>
        <Plain_Description>One of our greatest current health challenges is to develop highly-personalised interventions for teenagers and young adults with emerging mood disorders. This research will combine our national expertise to develop and implement care packages utilising digital technologies, personalised assessment techniques, targeted treatment choices, and long-term outcome tracking. In a clinical trial we will assess the clinical effectiveness of these innovative healthcare packages.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2001578</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>Prof Y C Gary Lee</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>Australasian Malignant Pleural Effusion (AMPLE)-3 trial</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,105,748.65</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Respiratory Diseases</Field_s__of_Research>
        <Res_KW1>adult respiratory diseases </Res_KW1>
        <Res_KW2>cancer care </Res_KW2>
        <Res_KW3>palliative treatment </Res_KW3>
        <Res_KW4>malignant mesothelioma </Res_KW4>
        <Res_KW5>lung cancer</Res_KW5>
        <Plain_Description>Cancers can spread to the lung causing fluid build-up and requires drainages in hospital that are painful and costly. Surgery is previously seen as the definitive option to stop fluid forming, but is invasive with complications. Indwelling pleural catheter (IPC) is a novel implanted device inside the chest that allows patients to drain fluid at home. AMPLE Trial-3 is the first multicenter randomized clinical trial to compare surgery vs IPC to provide fluid control and improve quality of life.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2001751</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>Prof Peter Morris</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>'Azithromycin before Birth'- Single dose azithromycin shortly before birth to reduce infection in Aboriginal mothers and babies: a randomised controlled trial.</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$3,205,108.60</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Paediatrics</Field_s__of_Research>
        <Res_KW1>clinical trial </Res_KW1>
        <Res_KW2>aboriginal health </Res_KW2>
        <Res_KW3>pregnancy </Res_KW3>
        <Res_KW4>neonatal </Res_KW4>
        <Res_KW5>evidence-based clinical practice</Res_KW5>
        <Plain_Description>Aboriginal mothers and babies in the Northern Territory have high rates of infection. A single dose of azithromycin given during labour (or prior to caesarean section) may reduce the rates of subsequent bacterial infection. This pragmatic clinical trial ('Azithromycin before Birth') will assess a simple intervention that has the potential to substantially improve health outcomes for women and babies at risk of new bacterial infection after birth.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2001834</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>Dr Bei Bei</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>A Scalable Insomnia Program during the Pregnancy and Postpartum Periods: An Effectiveness-Implementation Hybrid Trial</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$877,335.40</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Health, Clinical and Counselling Psychology</Field_s__of_Research>
        <Res_KW1>insomnia </Res_KW1>
        <Res_KW2>pregnancy </Res_KW2>
        <Res_KW3>cognitive behaviour therapy </Res_KW3>
        <Res_KW4>sleep </Res_KW4>
        <Res_KW5>postnatal</Res_KW5>
        <Plain_Description>Persistent sleep problems are common during pregnancy/postpartum periods and have significant consequences. Cognitive behavioural interventions are efficacious for improving sleep but are not currently available in perinatal care. This study examines the effectiveness, cost- effectiveness, and implementation potential of an innovative nonpharmacological intervention for better maternal sleep and wellbeing, with high potential for sustainable integration with routine perinatal care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006101</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>Prof Susan Ramus</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>Prospective Ovarian Cancer Cohort to Authenticate Stratification of Prognosis in Ovarian Tumours (POCCA-SPOT)</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$993,580.25</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Pathology</Field_s__of_Research>
        <Res_KW1>cancer prognosis </Res_KW1>
        <Res_KW2>cancer follow-up </Res_KW2>
        <Res_KW3>ovarian cancer </Res_KW3>
        <Res_KW4>cancer treatment </Res_KW4>
        <Res_KW5>validation</Res_KW5>
        <Plain_Description>Ovarian cancer has poor survival, with less than 40% of women surviving 5 years. There is a wide range of survival, but very few characteristics that indicate which patients will do well or poorly. We have developed a tumour test at diagnosis, that can predict prognosis at 5 years. In newly diagnosed cases, we will test tumours to predict prognosis and then determine the accuracy and assess patient acceptability. This study will lead to clinical use of the test and improve treatment decisions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006403</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>Prof Andrew Wei</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>INTERCEPT (Investigating Novel Therapy to target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): a multi-arm, precision-based, recursive, platform trial</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$5,789,515.10</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Haematological Tumours</Field_s__of_Research>
        <Res_KW1>acute myeloid leukaemia (aml) </Res_KW1>
        <Res_KW2>targeted therapy </Res_KW2>
        <Res_KW3>myeloid leukaemia </Res_KW3>
        <Res_KW4>clinical trial </Res_KW4>
        <Res_KW5>drug resistance</Res_KW5>
        <Plain_Description>Acute myeloid leukemia is a rare and lethal blood cancer with limitless potential to evolve resistance. New technologies allow early detection of molecular 'fingerprints' of returning disease. We propose an international research team to conduct a multi-arm, precision-based platform trial aimed at increasing and extending the duration of patient response and survival using novel combination options. INTERCEPT will suppress and eradicate relapse before the patient becomes clinically unwell.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006415</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>Prof Georgina Long</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>Anti-PD 1 Brain Collaboration + Radiotherapy Extension: The ABC-X Study</Grant_Title>
        <Admin_Institution>Melanoma Institute Australia</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,010,141.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Cancer Therapy (excl. Chemotherapy and Radiation Therapy)</Field_s__of_Research>
        <Res_KW1>cancer immunotherapy </Res_KW1>
        <Res_KW2>melanoma </Res_KW2>
        <Res_KW3>brain lesion </Res_KW3>
        <Res_KW4>radiotherapy </Res_KW4>
        <Res_KW5>cohort study</Res_KW5>
        <Plain_Description>The purpose of this research study is to determine whether administering radiotherapy to melanoma brain tumours, in combination with 2 drugs called nivolumab and ipilimumab(also known as Immunotherapy), will be more effective than treating brain tumours with immunotherapy. Patients in this trial will be randomly assigned to 1 of 2 treatment groups. Group 1 will receive radiotherapy to their melanoma brain lesion(s), combined with immunotherapy. Group 2 will receive immunotherapy treatment alone.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006451</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>Prof Erica Wood</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>Preventing infections in patients with blood cancer through evidence-based use of immunoglobulin or alternatives: The RATIONALISE trial</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,490,421.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Haematology</Field_s__of_Research>
        <Res_KW1>blood transfusion </Res_KW1>
        <Res_KW2>infectious diseases </Res_KW2>
        <Res_KW3>haematological malignancy </Res_KW3>
        <Res_KW4>immunoglobulin (ig) </Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>Patients with blood cancers, with immune deficiency from low antibody levels and other disease or treatment factors, are at risk of life-threatening infection. Immunoglobulins (Ig) made from plasma can supplement antibody levels. Government criteria recommend stopping Ig therapy in stable patients, but with no evidence for when or how to do so. RATIONALISE will provide this evidence, to improve patient outcomes, reduce risks and costs, and make better use of blood products for the community.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006491</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>A/Pr Valerie Sung</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>Whole-of-population CRISPR point-of-care testing for congenital cytomegalovirus to prevent hearing and neurodevelopment disabilities through a public health approach</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,058,920.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Infectious Diseases</Field_s__of_Research>
        <Res_KW1>cytomegalovirus (cmv) infection </Res_KW1>
        <Res_KW2>congenital disease </Res_KW2>
        <Res_KW3>population screening </Res_KW3>
        <Res_KW4>public health costs </Res_KW4>
        <Res_KW5>treatment</Res_KW5>
        <Plain_Description>Congenital cytomegalovirus infection (cCMV) is the major infective cause of deafness and brain disability, both of which are potentially reversible with early treatment. Currently, there is no screening at birth, and cCMV is diagnosed too late for treatment. Our team will test and validate CRISPR, a new and cheap technology, on 110,000+ newborns to detect cCMV. This will revolutionise how cCMV is detected, make treatment more accessible and pave way to lower rates of deafness and cerebral palsy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006529</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>A/Pr Kenneth Pang</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>Trans20: A longitudinal cohort study to improve outcomes for transgender children and adolescents</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,566,662.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Gender Psychology</Field_s__of_Research>
        <Res_KW1>gender </Res_KW1>
        <Res_KW2>paediatric </Res_KW2>
        <Res_KW3>mental health </Res_KW3>
        <Res_KW4>psychological distress </Res_KW4>
        <Res_KW5>health services research</Res_KW5>
        <Plain_Description>1% of young people now identify as transgender or gender diverse (TGD), and increasing numbers are presenting for specialist gender-affirming clinical care. This study will prospectively evaluate the health outcomes and well being of a large cohort of TGD children and adolescents who received such care. By doing so, this research will address critical knowledge gaps in this important and emerging area of health care so as to maximise health outcomes and minimise harm for this vulnerable group.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006611</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>A/Pr Joanne Ryan</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>Clinical trial to determine the effects of statins on cognition: STAREE-Mind</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,795,199.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Preventive Medicine</Field_s__of_Research>
        <Res_KW1>cognition </Res_KW1>
        <Res_KW2>clinical trial </Res_KW2>
        <Res_KW3>statins </Res_KW3>
        <Res_KW4>primary prevention </Res_KW4>
        <Res_KW5>dementia</Res_KW5>
        <Plain_Description>Statins may improve brain health in older individuals but there is need for a large randomised trial to directly address this important question. This study of 10,000 community dwelling older individuals aged 70 years and over will provide crucial, high quality evidence on the effects of statins on cognitive function and dementia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006658</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>Dr Rachel Peters</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>Food allergy in the first 15 year of life: wave 5 of the HealthNuts longitudinal study</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,435,075.24</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Epidemiology</Field_s__of_Research>
        <Res_KW1>food allergy </Res_KW1>
        <Res_KW2>anaphylaxis </Res_KW2>
        <Res_KW3>asthma </Res_KW3>
        <Res_KW4>lung function assessment </Res_KW4>
        <Res_KW5>risk factors</Res_KW5>
        <Plain_Description>Understanding why some food allergy persists into adolescence is critical because adolescents are at highest risk of life-threatening allergic reactions. Food allergy also has lifelong impacts on children's health. HealthNuts is a longitudinal study of 5300 children that measured allergic diseases from infancy. At the age 15 follow-up, we will identify predictors of food allergy persistence and severity, and the consequences of infant food allergy on later respiratory health.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006773</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>Prof Rachel Neale</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>The effect of high SPF sunscreen application on vitamin D</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,175,123.60</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Preventive Medicine</Field_s__of_Research>
        <Res_KW1>sunscreens </Res_KW1>
        <Res_KW2>skin cancer </Res_KW2>
        <Res_KW3>vitamin d </Res_KW3>
        <Res_KW4>clinical trial </Res_KW4>
        <Res_KW5>cancer prevention</Res_KW5>
        <Plain_Description>Sunscreen prevents sunburn and skin cancer, and current guidelines are that it should be routinely used when the maximum UV index is forecast to reach at least 3. However, applying sunscreen in laboratory experiments reduces vitamin D production, and there is concern that regular application of high SPF sunscreens might increase the risk of vitamin D deficiency. We propose a randomised controlled trial to determine if adhering to the current guidelines decreases vitamin D.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006867</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>A/Pr Leanne Sakzewski</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>ACTIVE STRIDES-CP: Randomised trial of Intensive Rehabilitation (Combined Intensive Gait and Cycling Training) for children with moderate to severe bilateral cerebral palsy</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,401,294.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Physiotherapy</Field_s__of_Research>
        <Res_KW1>cerebral palsy treatments </Res_KW1>
        <Res_KW2>physiotherapy management </Res_KW2>
        <Res_KW3>mobility </Res_KW3>
        <Res_KW4>participation </Res_KW4>
        <Res_KW5>randomised controlled trial (rct)</Res_KW5>
        <Plain_Description>In Australia, 35,000 people have cerebral palsy, and 40% experience moderate to severe difficulties with movement and reduced participation in physical activity. There are currently no effective interventions for children with moderate to severe CP to improve their ability to move, perform daily life tasks and engage in physically active leisure. We have promising data about a new intervention, called Active Strides-CP, which we will test in 150 children with CP and compare to usual care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006883</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>Prof Alex Brown</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>Predicting Renal, Ophthalmic and Heart Events in the Aboriginal Community: The PROPHECY Diabetes Multi-Omics Cohort Study</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$3,955,505.38</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Aboriginal and Torres Strait Islander Health</Field_s__of_Research>
        <Res_KW1>type 2 diabetes mellitus (non-insulin dependent diabetes mellitus) </Res_KW1>
        <Res_KW2>aboriginal health </Res_KW2>
        <Res_KW3>diabetic complications </Res_KW3>
        <Res_KW4>genomics </Res_KW4>
        <Res_KW5>population health</Res_KW5>
        <Plain_Description>Diabetes is at epidemic levels in Indigenous Australians, impairing quality of life, and contributing to poor health. This is a result of rapid development of kidney, heart and eye complications. We have established a large long-term population study among Aboriginal communities within South Australia and will explore the burden, natural history and the social, psychological, environmental, clinical and genomic predictors of diabetes and its complications.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006893</APP_ID>
        <Date_Announced>2021-06-20T00:00:00</Date_Announced>
        <CIA_Name>Prof Bruce Neal</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>A randomised trial of the effects of SGLT2 inhibition versus metformin on decline in renal function when used as first line therapy in type 2 diabetes</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,815,692.70</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Cardiology (incl. Cardiovascular Diseases)</Field_s__of_Research>
        <Res_KW1>diabetes </Res_KW1>
        <Res_KW2>kidney disease </Res_KW2>
        <Res_KW3>clinical trial </Res_KW3>
        <Res_KW4>diabetic nephropathy </Res_KW4>
        <Res_KW5>blood pressure</Res_KW5>
        <Plain_Description>Type 2 diabetes affects 5 in 100 Australians with many going on to develop serious heart and kidney complications. Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new type of medicine that may provide benefit when used early in diabetes, but that are currently only used once complications have developed. This study will test the value of SGLT2 inhibitor treatment for kidney protection in Australians with newly diagnosed type 2 diabetes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006514</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Carol Hodgson</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Centre of Research Excellence - Clinical</Sub_Type>
        <Grant_Title>A Centre for Research Excellence to Transform Outcomes of Critically Ill Patients in ICU (CRE-ICU)</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Intensive Care</Field_s__of_Research>
        <Res_KW1>intensive care </Res_KW1>
        <Res_KW2>critical care </Res_KW2>
        <Res_KW3>critical illness </Res_KW3>
        <Res_KW4>adult </Res_KW4>
        <Res_KW5>intensive care medicine</Res_KW5>
        <Plain_Description>Patients who are admitted to intensive care (ICU) and require mechanical ventilation for life support account for 63,000 ICU admissions and 8,190 deaths each year in Australia, higher than the national road toll. CRE-ICU will transform outcomes for these patients by using data within registries and electronic medical records to perform high-impact, low cost clinical trials, generating new knowledge to inform national guidelines and policies and training the next generation of researchers.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006523</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Vicki Flenady</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Centre of Research Excellence - Clinical</Sub_Type>
        <Grant_Title>Centre of Research Excellence in Stillbirth</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Foetal Development and Medicine</Field_s__of_Research>
        <Res_KW1>stillbirth </Res_KW1>
        <Res_KW2>antenatal care </Res_KW2>
        <Res_KW3>bereavement </Res_KW3>
        <Res_KW4>implementation </Res_KW4>
        <Res_KW5>prediction</Res_KW5>
        <Plain_Description>In Australia, over 2000 families suffer the tragedy of stillbirth each year. By building on our achievements of the first Stillbirth CRE rapidly translating new research into maternity care, we will reduce stillbirth rates by 20%, and reduce inequities in stillbirth rates by Australia by 2025. We also anticipate a reduction in adverse neonatal outcomes. When stillbirth or neonatal death does occur, our research aims to ensure that all women and families receive optimal care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006545</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Kirsten McCaffery</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Centre of Research Excellence - Public Health</Sub_Type>
        <Grant_Title>Wiser healthcare: better value care for all Australians</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Public Health and Health Services not elsewhere classified</Field_s__of_Research>
        <Res_KW1>health policy </Res_KW1>
        <Res_KW2>early detection </Res_KW2>
        <Res_KW3>public health impact </Res_KW3>
        <Res_KW4>behavioural science </Res_KW4>
        <Res_KW5>evidence-based health care</Res_KW5>
        <Plain_Description>This CRE develops a new solutions-based approach to overuse of unnecessary, ineffective healthcare. Overuse causes harm and diverts resources from areas of need. We will produce new solutions to address four drivers of overuse. We will: build health literacy in patients, communities and health professionals; respond to changing screening and diagnostic technology; address financial drivers; and change clinical practices, to minimise harm and waste, achieving more sustainable healthcare for all.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006551</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Monika Janda</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Centre of Research Excellence - Clinical</Sub_Type>
        <Grant_Title>Skin Imaging and Precision Diagnosis</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Dermatology</Field_s__of_Research>
        <Res_KW1>melanoma </Res_KW1>
        <Res_KW2>non-melanoma skin cancer </Res_KW2>
        <Res_KW3>cancer prevention </Res_KW3>
        <Res_KW4>cancer screening </Res_KW4>
        <Res_KW5>early detection</Res_KW5>
        <Plain_Description>Skin cancers, including melanoma, present a significant health, social and economic burden in Australia. Despite the rising incidence of melanoma, the most deadly form of skin cancer, there is currently no national or population-based screening program available. The aim of this CRE is to identify how novel skin imaging technologies can be integrated into the pathway to improve early detection, and ultimately reduce the health and economic burden caused by melanoma skin cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006579</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Lyn March</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Centre of Research Excellence - Clinical</Sub_Type>
        <Grant_Title>CRE for Better Outcomes in Inflammatory Arthritis</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Rheumatology and Arthritis</Field_s__of_Research>
        <Res_KW1>data linkage </Res_KW1>
        <Res_KW2>targeted therapy </Res_KW2>
        <Res_KW3>outcomes research </Res_KW3>
        <Res_KW4>biomarkers </Res_KW4>
        <Res_KW5>health economics</Res_KW5>
        <Plain_Description>We aim to find the right treatment for children and adults with inflammatory arthritis to give the best path to symptom relief with least risk of side effects. We will build on our national data-base and biospecimens bank (A3BC-ARAD) to collect a broad range of patient-reported, biological, environmental and health information to unlock the answers using big-data analysis. We will build a resource and workforce to continue to look for cures to deliver the best outcomes for patients and society.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006595</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Raina MacIntyre</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Centre of Research Excellence - Health Services</Sub_Type>
        <Grant_Title>BREATHE - mitigating airborne threats to health</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Public Health and Health Services not elsewhere classified</Field_s__of_Research>
        <Res_KW1>respiratory </Res_KW1>
        <Res_KW2>coronavirus </Res_KW2>
        <Res_KW3>health services </Res_KW3>
        <Res_KW4>epidemiology </Res_KW4>
        <Res_KW5>prevention</Res_KW5>
        <Plain_Description>The COVID-19 pandemic has highlighted the risk of closed, indoor settings due to accumulation of aerosols generated from breathing, speaking, coughing or sneezing. Any airborne threat, whether an infectious virus or a chemical agent, will create a higher exposure in indoor settings. To mitigate this risk, using inter-disciplinary expertise, this research will improve preparedness, reduce health impacts of airborne threats, inform worker and occupant safety, building design and healthy futures.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006620</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Simone Pettigrew</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Centre of Research Excellence - Public Health</Sub_Type>
        <Grant_Title>Healthy Food, Healthy Planet, Healthy People</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Health Promotion</Field_s__of_Research>
        <Res_KW1>food </Res_KW1>
        <Res_KW2>nutrition </Res_KW2>
        <Res_KW3>environmental health </Res_KW3>
        <Res_KW4>prevention </Res_KW4>
        <Res_KW5>health policy</Res_KW5>
        <Plain_Description>Food is the biggest issue for health on the planet. High levels of obesity and related illnesses such as heart disease, diabetes, and cancer highlight the need for consumers to have better access to meaningful nutrition information across more food choice contexts. The substantial contribution of the food system to climate change means consumers, industry, and governments need information about which products are better or worse for the environment. This Centre will provide this information.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006765</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Perminder Sachdev</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Centre of Research Excellence - Dementia Research</Sub_Type>
        <Grant_Title>Vascular Contributions to Dementia (VCD-CRE) - a transformative approach to reducing the burden of cognitive disorders</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Central Nervous System</Field_s__of_Research>
        <Res_KW1>vascular dementia </Res_KW1>
        <Res_KW2>cerebrovascular disorders </Res_KW2>
        <Res_KW3>mild cognitive impairment </Res_KW3>
        <Res_KW4>prevention </Res_KW4>
        <Res_KW5>diagnosis</Res_KW5>
        <Plain_Description>The total contribution of vascular pathology to dementia is estimated to be as high as 50-70%. The Vascular Contributions to Dementia CRE brings together leading researchers in cerebrovascular disease and dementia to address the most important issues relating to the epidemiology of Vascular Dementia, its robust biomarkers and its treatment and prevention, so as to reduce its overall health burden, and meet the promise of vascular dementia as a truly 'preventable dementia''.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006797</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Pr Dina LoGiudice</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Centre of Research Excellence - Dementia Research</Sub_Type>
        <Grant_Title>On TRACK (Teaching, Research And Community Knowledges) : CRE promoting brain health with older Aboriginal and Torres Strait Islander peoples.</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Geriatrics and Gerontology</Field_s__of_Research>
        <Res_KW1>aboriginal health </Res_KW1>
        <Res_KW2>dementia </Res_KW2>
        <Res_KW3>ageing population </Res_KW3>
        <Res_KW4>risk factors </Res_KW4>
        <Res_KW5>community preferences</Res_KW5>
        <Plain_Description>Aboriginal and Torres Strait Islander peoples experience high rates of dementia at younger ages of onset, having far reaching consequences for the person, their family and their communities. The OnTRACK (Teaching, Research and Community Knowledges) Centre for Research Excellence will generate knowledge about culturally safe approaches to optimise the well being and quality of life of Aboriginal and Torres Strait Islander peoples at risk of or living with dementia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006841</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Ingrid Scheffer</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Centre of Research Excellence - Clinical</Sub_Type>
        <Grant_Title>Centre for Research Excellence in Developmental and Epileptic Encephalopathies</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Neurogenetics</Field_s__of_Research>
        <Res_KW1>epilepsy </Res_KW1>
        <Res_KW2>natural history </Res_KW2>
        <Res_KW3>genetics </Res_KW3>
        <Res_KW4>health outcomes </Res_KW4>
        <Res_KW5>paediatric</Res_KW5>
        <Plain_Description>We will study the clinical, genetic and psychological aspects of patients with the most severe group of epilepsies, the Developmental and Epileptic Encephalopathies (DEEs). We will define the clinical spectrum of each genetic DEE, improve health outcomes through understanding the natural history of these diseases, build an integrated model of care, produce family resources and assess health economic impacts. This program will ensure Australia is poised for emerging Precision Medicine trials.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006899</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof John Hopper</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Centre of Research Excellence - Public Health</Sub_Type>
        <Grant_Title>Centre of Research Excellence in Precision Public Health Approaches to Breast Cancer Screening, Early Detection and Mortality Reduction</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Public Health and Health Services not elsewhere classified</Field_s__of_Research>
        <Res_KW1>breast cancer </Res_KW1>
        <Res_KW2>mammogram screening </Res_KW2>
        <Res_KW3>breast cancer prevention </Res_KW3>
        <Res_KW4>radiological diagnostics </Res_KW4>
        <Res_KW5>general practice</Res_KW5>
        <Plain_Description>The ultimate aim of the CRE is to make it possible to further reduce mortality from breast cancer, and in a more effective way, by identifying women at vastly different levels of risk at younger ages, determining which screening modalities are likely to be more effective, and helping radiologists to better detect cancers. Given that digital mammography is the contemporary standard, and the incidence of breast cancer is increasing across the world, this CRE has global relevance.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006999</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Louise Baur</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Centre of Research Excellence - Public Health</Sub_Type>
        <Grant_Title>Centre of Research Excellence in the Early Prevention of Obesity in Childhood -Translate (EPOCH-Translate)</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Health Promotion</Field_s__of_Research>
        <Res_KW1>early childhood </Res_KW1>
        <Res_KW2>obesity </Res_KW2>
        <Res_KW3>implementation </Res_KW3>
        <Res_KW4>health economics </Res_KW4>
        <Res_KW5>behavioural intervention</Res_KW5>
        <Plain_Description>Overweight &amp; obesity affect 1:4 Australian children by the time they start school. The Centre of Research Excellence in the Early Prevention of Obesity in Childhood: Translate (EPOCH-translate) brings together researchers from across Australia and New Zealand to work out how best to prevent obesity in children aged 0-5 years. We will look at what works in the long-term, what is the best value for money, and what works for parents as well as health professionals.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007007</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Jason Roberts</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Centre of Research Excellence - Health Services</Sub_Type>
        <Grant_Title>Centre of Research Excellence - REduce the burden of antimicrobial reSistance through oPtimal, persONalised Dosing (RESPOND)</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Infectious Diseases</Field_s__of_Research>
        <Res_KW1>antibiotic resistance </Res_KW1>
        <Res_KW2>pharmacotherapy </Res_KW2>
        <Res_KW3>sepsis </Res_KW3>
        <Res_KW4>critical illness </Res_KW4>
        <Res_KW5>microbiology</Res_KW5>
        <Plain_Description>Each year more than 17 million people die from infectious diseases. Many of these deaths are due to the poor use of antimicrobial drugs and an increase in infections caused by antimicrobial-resistant 'superbugs'. CRE RESPOND will enable an optimal treatment of infection by empowering clinicians with an evidence-based, patient-centred approach to guide antimicrobial dosing. We will generate new knowledge, educate healthcare workers, and build research capacity through our network of collaborators</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007026</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Allison Tong</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Centre of Research Excellence - Clinical</Sub_Type>
        <Grant_Title>Centre of Research Excellence: Partnering with patients with chronic kidney disease to transform care and outcomes (CRE-PACT)</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Epidemiology</Field_s__of_Research>
        <Res_KW1>clinical epidemiology </Res_KW1>
        <Res_KW2>patient participation </Res_KW2>
        <Res_KW3>patient outcomes </Res_KW3>
        <Res_KW4>patient preference </Res_KW4>
        <Res_KW5>kidney failure</Res_KW5>
        <Plain_Description>CRE-PACT will partner with patients to generate and translate new high-priority evidence to improve outcomes that are important to people living with chronic kidney disease (CKD). We will address the topics and questions most important to patients. We will build the next generation of research leaders and a community of research-ready patient-partners. There will be an integrated pathway for evidence translation and implementation at a global scale to improve patient-centred outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007037</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Scott Ayton</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Centre of Research Excellence - Dementia Research</Sub_Type>
        <Grant_Title>Centre of Research Excellence in Enhanced Dementia Diagnosis (CREEDD)</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,000,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Neurology and Neuromuscular Diseases</Field_s__of_Research>
        <Res_KW1>dementia </Res_KW1>
        <Res_KW2>diagnosis </Res_KW2>
        <Res_KW3>magnetic resonance imaging (mri) </Res_KW3>
        <Res_KW4>biomarkers </Res_KW4>
        <Res_KW5>cognitive assessment</Res_KW5>
        <Plain_Description>The diagnosis of dementia is often difficult, especially in its early stages. The current delays and uncertainties in diagnosing dementia cause anxiety in patients and limit treatment options. A number of new technologies have demonstrated their value in clinical dementia research, but have not been adopted into clinical practice. The Centre of Research Excellence in Enhanced Dementia Diagnosis will provide a pathway to implement new technologies to transform dementia diagnosis in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007049</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Leanne Hides</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Centre of Research Excellence - Health Services</Sub_Type>
        <Grant_Title>Centre of Research Excellence in Alcohol and Other Drug sector capacity building for outcome focused, evidence based and cost effective care (CRE in AOD -CB)</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Mental Health</Field_s__of_Research>
        <Res_KW1>substance dependence </Res_KW1>
        <Res_KW2>addiction treatment </Res_KW2>
        <Res_KW3>health services research </Res_KW3>
        <Res_KW4>clinical outcome </Res_KW4>
        <Res_KW5>measurement</Res_KW5>
        <Plain_Description>AOD use is the number one risk factor for the most death and disability combined in all age groups in Australia. This CRE's mission is to reduce the burden and cost of primary and complex comorbid AOD problems in Australia, by using MBC to increase the capacity of the AOD sector to deliver evidence based, efficient and cost effective care to clients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007062</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Michele Sterling</CIA_Name>
        <Grant_Type>Centres of Research Excellence</Grant_Type>
        <Sub_Type>Centre of Research Excellence - Health Services</Sub_Type>
        <Grant_Title>Centre of Research Excellence - Better Health Outcomes for Compensable Injury</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Public Health and Health Services not elsewhere classified</Field_s__of_Research>
        <Res_KW1>motor vehicle accidents </Res_KW1>
        <Res_KW2>injury </Res_KW2>
        <Res_KW3>workers compensation </Res_KW3>
        <Res_KW4>pain </Res_KW4>
        <Res_KW5>legal issues</Res_KW5>
        <Plain_Description>Many people do not recover after a road traffic injury but develop chronic pain, disability and poor mental health. Health outcomes are worse for people who lodge a claim for injury compensation and/or engage a lawyer. The CRE will extend research and implementation beyond health services to the compensation and legal systems. Results will improve health outcomes advancing knowledge of system processes mediating recovery and implementing interventions that promote not hinder recovery.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008140</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Richard Page</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2020 NHMRC-NIHR Collaborative Research Grants Round 2   </Sub_Type>
        <Grant_Title>Reverse or Anatomical (replacement) for Painful Shoulder Osteoarthritis: Differences between Interventions -Aus</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,540,874.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Orthopaedics</Field_s__of_Research>
        <Res_KW1>orthopaedic </Res_KW1>
        <Res_KW2>arthritis </Res_KW2>
        <Res_KW3>joint replacement </Res_KW3>
        <Res_KW4>surgery </Res_KW4>
        <Res_KW5>randomised controlled trial (rct)</Res_KW5>
        <Plain_Description>Shoulder osteoarthritis is common in older adults, causing severe pain and making daily life difficult. Shoulder replacement is an effective treatment - it replaces the damaged joint with metal and plastic implants. Two types of shoulder replacement exist, but the best option is uncertain as they have not been compared in randomised trials. We will produce evidence about the benefits, harms and cost-effectiveness of each shoulder surgery to enable patients to receive the best type of surgery.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006089</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Sarah Larkins</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 2nd call for 2020</Sub_Type>
        <Grant_Title>Working it Out Together! Aboriginal and Torres Strait Islander led co-design for a strong and deadly health workforce</Grant_Title>
        <Admin_Institution>James Cook University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$904,772.20</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Aboriginal and Torres Strait Islander Health</Field_s__of_Research>
        <Res_KW1>primary care </Res_KW1>
        <Res_KW2>indigenous health </Res_KW2>
        <Res_KW3>rural and remote health services </Res_KW3>
        <Res_KW4>rural workforce </Res_KW4>
        <Res_KW5>community participation</Res_KW5>
        <Plain_Description>High primary health care (PHC) workforce turnover and few Aboriginal and Torres Strait Islander staff in rural/remote areas affects community trust and cultural safety. This impacts health care quality and costs. This Indigenous-led project sees local communities in four rural/remote areas driving new workforce plans with PHC services and partners. Implementation with continuous evaluation and adaption will increase workforce stability, trust, engagement and health improvements.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006138</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Alexandra McCarthy</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 2nd call for 2020</Sub_Type>
        <Grant_Title>BALANCE: Promoting wellBeing in AdoLescent and young Adult caNCEr survivors</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,250,178.35</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Health Promotion</Field_s__of_Research>
        <Res_KW1>adolescent health </Res_KW1>
        <Res_KW2>cancer therapy </Res_KW2>
        <Res_KW3>quality of life </Res_KW3>
        <Res_KW4>behavioural intervention </Res_KW4>
        <Res_KW5>wellbeing</Res_KW5>
        <Plain_Description>Almost 5000 adolescents and young adults (AYAs) in Australia were diagnosed with cancer in the last 5 years, and many will survive well into adulthood. Survival does not mean AYAs return to their former state of health. They need support to manage the detrimental effects of their cancer experience - support that is scarce in this country. This project tests a lifestyle program to address this issue. We aim to ensure young people who survive cancer have the same quality of life as their peers.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006240</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Julian Trollor</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 2nd call for 2020</Sub_Type>
        <Grant_Title>Developing a model of Preventative Healthcare for People with Intellectual Disability</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,244,755.50</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Primary Health Care</Field_s__of_Research>
        <Res_KW1>intellectual disability </Res_KW1>
        <Res_KW2>preventive health </Res_KW2>
        <Res_KW3>population health </Res_KW3>
        <Res_KW4>health promotion </Res_KW4>
        <Res_KW5>health policy</Res_KW5>
        <Plain_Description>People with intellectual disability face stark health inequalities, die prematurely from potentially avoidable causes and experience poor access to preventative health care. Access to preventative health care is one of the key pillars of Australia's long-term national health plan. This project will find out why there are gaps in preventative health care for people with intellectual disability, determine how these gaps affect people and develop a new model of health care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006282</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Jason Grebely</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 2nd call for 2020</Sub_Type>
        <Grant_Title>Enhancing hepatitis C testing and treatment among people who inject drugs in drug treatment settings: the ETHOS III Study</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,349,603.80</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Infectious Diseases</Field_s__of_Research>
        <Res_KW1>liver disease </Res_KW1>
        <Res_KW2>hepatitis c infection </Res_KW2>
        <Res_KW3>injecting drug use </Res_KW3>
        <Res_KW4>treatment strategies </Res_KW4>
        <Res_KW5>health policy</Res_KW5>
        <Plain_Description>Progress towards hepatitis C elimination has been slowed. Given that most people with hepatitis C have a history of injecting drug use, reducing hepatitis C burden requires scale-up of enhanced testing and treatment for people who inject drugs. This Partnership project will evaluate an intervention to enhance hepatitis C testing and treatment in drug treatment clinics and develop a translational framework to scale-up hepatitis C care in this setting nationally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006306</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Pr Julia Marley</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 2nd call for 2020</Sub_Type>
        <Grant_Title>Be Healthy: Implementing culturally secure programs for obesity and chronic disease prevention with remote Aboriginal communities and families</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,499,972.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Aboriginal and Torres Strait Islander Health</Field_s__of_Research>
        <Res_KW1>chronic illness prevention </Res_KW1>
        <Res_KW2>overweight/obesity </Res_KW2>
        <Res_KW3>aboriginal health </Res_KW3>
        <Res_KW4>community development </Res_KW4>
        <Res_KW5>program evaluation</Res_KW5>
        <Plain_Description>Environments cultivated in recent decades encouraging physical inactivity and poor diet have disproportionately affected Aboriginal people. Appropriate lifestyle modification programs substantially improves outcomes. We have co-designed, piloted and refined the 'Be Healthy' program with Derby Aboriginal people. This project aims to show how this program can be scaled up and transferred to other Aboriginal communities, leading to reduced rates of obesity, and improved health and quality of life.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006448</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Andrew Grulich</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 2nd call for 2020</Sub_Type>
        <Grant_Title>Implementation research to guide the elimination of HIV transmission in NSW</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,499,408.50</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Preventive Medicine</Field_s__of_Research>
        <Res_KW1>human immunodeficiency virus (hiv) </Res_KW1>
        <Res_KW2>prevention </Res_KW2>
        <Res_KW3>implementation </Res_KW3>
        <Res_KW4>prophylaxis </Res_KW4>
        <Res_KW5>sexually-transmitted infections (sti)</Res_KW5>
        <Plain_Description>The implementation of new biomedical forms of HIV prevention since 2015 has been accompanied by a 40% reduction in HIV diagnoses in gay and bisexual men in New South Wales (NSW). Reductions in HIV have been much smaller in the overseas-born, the young, and in those living outside of inner Sydney. We propose a 5-year program of implementation research, integrated with the NSW HIV Strategy 2021-25, which will see NSW become the first jurisdiction globally to virtually eliminate HIV.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006486</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Jane Hocking</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 2nd call for 2020</Sub_Type>
        <Grant_Title>A digital sexual health hub: Co-design, development and evaluation of an online sexual health clinic</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,424,364.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Primary Health Care</Field_s__of_Research>
        <Res_KW1>sexually-transmitted infections (sti) </Res_KW1>
        <Res_KW2>sexual health </Res_KW2>
        <Res_KW3>primary care </Res_KW3>
        <Res_KW4>health services research </Res_KW4>
        <Res_KW5>information systems/decision support systems</Res_KW5>
        <Plain_Description>Sexually transmitted infection rates have increased dramatically in recent years in Australia, with major health consequences - congenital syphilis is killing babies, chlamydia in females is causing pelvic inflammatory disease, increasing the risk of infertility, and drug-resistant gonorrhoea is an urgent global threat. Our specialist sexual health services are at capacity. We will develop an innovative online sexual health hub providing online testing and treatment for STIs and HIV.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006528</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Jeffrey Dunn</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 2nd call for 2020</Sub_Type>
        <Grant_Title>Prostate Cancer Survivorship Essentials for Men with Prostate Cancer on Androgen Deprivation Therapy: Transforming Care to Improve Outcomes</Grant_Title>
        <Admin_Institution>University of Southern Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,133,942.05</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Health Counselling</Field_s__of_Research>
        <Res_KW1>prostate cancer </Res_KW1>
        <Res_KW2>survivorship </Res_KW2>
        <Res_KW3>health psychology </Res_KW3>
        <Res_KW4>quality of life </Res_KW4>
        <Res_KW5>health care delivery</Res_KW5>
        <Plain_Description>Up to half of all men diagnosed with prostate cancer will undergo androgen deprivation therapy (ADT) as part of their treatment at some point. Although ADT is effective in treating prostate cancer, many men will experience considerable side effects that negatively impact their quality of life. This research study will identify if a nurse-led survivorship care intervention, delivered by phone or video-call, improves the quality of life for men with prostate cancer who are receiving ADT.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006628</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Kim Bennell</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 2nd call for 2020</Sub_Type>
        <Grant_Title>Improving outcomes for hip osteoarthritis: program evaluation of HipHealth, an evidence-based telehealth exercise and weight loss program</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,005,359.15</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Physiotherapy</Field_s__of_Research>
        <Res_KW1>osteoarthritis </Res_KW1>
        <Res_KW2>exercise </Res_KW2>
        <Res_KW3>rehabilitation </Res_KW3>
        <Res_KW4>allied health </Res_KW4>
        <Res_KW5>telemedicine</Res_KW5>
        <Plain_Description>Hip osteoarthritis is a common problem leading to chronic pain and disability and high rates of joint replacement surgery. This project aims to improve the health and well-being of Australians with hip osteoarthritis (OA) by implementing and evaluating an education, exercise and weight loss program (HipHealth) delivered remotely by physiotherapists and dietitians. The program will be tested in the private health insurance setting with view to future scale-up in this and other settings.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006751</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Mark Parsons</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 2nd call for 2020</Sub_Type>
        <Grant_Title>Talk stroke: Developing Australia's first National tele stroke framework and communications platform</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,164,847.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Cardiology (incl. Cardiovascular Diseases)</Field_s__of_Research>
        <Res_KW1>stroke </Res_KW1>
        <Res_KW2>brain imaging </Res_KW2>
        <Res_KW3>thrombolysis treatment </Res_KW3>
        <Res_KW4>regional health </Res_KW4>
        <Res_KW5>policy development</Res_KW5>
        <Plain_Description>Patients with a stroke in the regional areas are twice as likely to suffer significant disability compared to patients living in inner city regions. We propose to develop technology to close this gap, and guide its implementation with a national tele stroke policy framework. The technology we develop with our partner organisations will facilitate tele medicine to close the gaps in critical patient care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006755</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Andrew Georgiou</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 2nd call for 2020</Sub_Type>
        <Grant_Title>Establishing a digital health foundation for outcomes-based diagnostic excellence, safety and value</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,027,500.90</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Health Informatics</Field_s__of_Research>
        <Res_KW1>health informatics </Res_KW1>
        <Res_KW2>health services research </Res_KW2>
        <Res_KW3>quality of care </Res_KW3>
        <Res_KW4>information systems/decision support systems </Res_KW4>
        <Res_KW5>patient safety</Res_KW5>
        <Plain_Description>Our partnership proposal will lead to the development of a digital infrastructure (involving big data resources and sophisticated decision support systems) as a foundation for outcomes-based research, optimised clinical care processes and translation into policy and practice. The partnership will encompass key research areas involving the quality, safety and value of care in musculoskeletal care, infectious diseases, diabetes care and emergency/intensive care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006950</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Pr Carol Maher</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 2nd call for 2020</Sub_Type>
        <Grant_Title>Improving physical activity and screen time in Outside School Hours Care through evidence-based guidelines: an effectiveness-implementation hybrid trial</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,398,569.90</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Community Child Health</Field_s__of_Research>
        <Res_KW1>health services research </Res_KW1>
        <Res_KW2>community child health </Res_KW2>
        <Res_KW3>community intervention study </Res_KW3>
        <Res_KW4>child health </Res_KW4>
        <Res_KW5>school health services</Res_KW5>
        <Plain_Description>This study aims to lift the standards of physical activity and screen time offerings in Out of School Hours Care services throughout Australia, by implementing and evaluating newly developed Australian OSHC physical activity and screen time guidelines. The guidelines will be evaluated in a rigorous trial in OSHC services in SA, NSW and WA, prior to national release and evaluation Australia-wide.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006957</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Johanna Westbrook</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 2nd call for 2020</Sub_Type>
        <Grant_Title>A National Aged Care Medication Roundtable - Translating aged care data into action to improve quality of care through collaboration and co-design</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,444,499.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Residential Client Care</Field_s__of_Research>
        <Res_KW1>medications </Res_KW1>
        <Res_KW2>health informatics </Res_KW2>
        <Res_KW3>electronic health information </Res_KW3>
        <Res_KW4>patient safety </Res_KW4>
        <Res_KW5>aged care</Res_KW5>
        <Plain_Description>Older Australians with the most complex health needs live in residential care. Greater than 80% of residents are on five or more medications daily, and 40% are taking 10 or more. Poor medication management is the greatest source of complaint to the Aged Care Quality &amp; Safety Commission. This project will provide timely information to a group of providers and consumers about the medicines residents receive, identify problem areas and trial innovative interventions to address these issues.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006969</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Pr Susana Nery</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 2nd call for 2020</Sub_Type>
        <Grant_Title>Control of neglected tropical diseases in the Pacific: integration of programs to increase their impact</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,499,801.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Epidemiology</Field_s__of_Research>
        <Res_KW1>helminth infection </Res_KW1>
        <Res_KW2>scabies </Res_KW2>
        <Res_KW3>infectious diseases </Res_KW3>
        <Res_KW4>tropical disease </Res_KW4>
        <Res_KW5>population health</Res_KW5>
        <Plain_Description>Our goal is to improve programs to control neglected tropical diseases, diseases of poverty common in Australia's neighbours: Papua New Guinea, Solomon Islands and Vanuatu. Our partners are supporting the Ministries of Health in these countries to implement integrated programs to better control these diseases. Our multidisciplinary research will use improved diagnostics, spatial mapping, health systems, social science and health economics to evaluate this integrated approach to disease control.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006970</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Bronwyn Griffin</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 2nd call for 2020</Sub_Type>
        <Grant_Title>Implementation of Negative Pressure for Acute Paediatric Burns</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,410,475.76</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Clinical Sciences not elsewhere classified</Field_s__of_Research>
        <Res_KW1>burn injury </Res_KW1>
        <Res_KW2>implementation </Res_KW2>
        <Res_KW3>traumatic injury </Res_KW3>
        <Res_KW4>child </Res_KW4>
        <Res_KW5>multicentre</Res_KW5>
        <Plain_Description>Over 4000 children present to our burns services every year. Contemporary burn care aims to speed up a patients time to healing which directly avoids the child's risk of developing a scar. We know that applying negative pressure wound therapy (NPWT) to a child's burn within 72 hours post injury will improve a child's time to healing, decreasing the risk of scarring &amp; cost of care. Co-developing a NPWT Pathway and implementation strategies will improve outcomes for childhood burns nationally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006987</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof James Ward</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>Partnership Projects - 2nd call for 2020</Sub_Type>
        <Grant_Title>Integration and expansion of a sentinel surveillance system to improve infectious disease outcomes for Indigenous Australians; the ATLAS network</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,137,218.90</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Aboriginal and Torres Strait Islander Health</Field_s__of_Research>
        <Res_KW1>aboriginal health </Res_KW1>
        <Res_KW2>sexual health </Res_KW2>
        <Res_KW3>vaccine-preventable diseases </Res_KW3>
        <Res_KW4>blood-borne communicable diseases </Res_KW4>
        <Res_KW5>population health</Res_KW5>
        <Plain_Description>Infectious diseases remain a significant health issue for Indigenous Australians. Our proposal is to extend a sentinel surveillance network operating in 32 Aboriginal primary care services, with a focus on sexually transmissible infections and blood borne virsuses. By expanding, we will increase the number of sites, and add vaccine preventable diseases to the network. In doing this, we move from a surveillance system to a research network that can inform health service strategies and practice.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006061</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Pr Glenn Arendts</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>End of Life Care</Sub_Type>
        <Grant_Title>A randomised trial of a Carer End of Life Planning Intervention (CELPI) in people dying with dementia</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,486,231.50</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Geriatrics and Gerontology</Field_s__of_Research>
        <Res_KW1>dementia </Res_KW1>
        <Res_KW2>palliative care </Res_KW2>
        <Res_KW3>caregiver burden </Res_KW3>
        <Res_KW4>emergency medicine </Res_KW4>
        <Res_KW5>health economics</Res_KW5>
        <Plain_Description>Dementia is the second highest cause of death in Australia. Although palliative care helps individuals avoid suffering and futile interventions at the end of life, only 6% of people that die of dementia receive such care. Many older people with dementia attend an ED in their final year of life. In CELPI we will trial using that opportunity of an ED visit as the trigger to implement a triad of carer education, access to palliative care and a formal planning process for participants.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006121</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Wen Lim</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>End of Life Care</Sub_Type>
        <Grant_Title>IMPART - IMproving PAlliative care in Residential aged care using Telehealth</Grant_Title>
        <Admin_Institution>National Ageing Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,047,057.77</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Aged Health Care</Field_s__of_Research>
        <Res_KW1>randomised controlled trial (rct) </Res_KW1>
        <Res_KW2>intervention study </Res_KW2>
        <Res_KW3>nursing homes </Res_KW3>
        <Res_KW4>aged care </Res_KW4>
        <Res_KW5>palliative care</Res_KW5>
        <Plain_Description>Sixty-thousand Australians die every year in residential aged care facilities but the quality of their end-of-life care varies. The IMPART program aims to improve palliative care in residential aged care using telehealth. We provide training and palliative-geriatric support to aged care staff and general practitioners to enable timely end-of-life discussions, improve documentation of care preferences, reduce avoidable hospitalisation and improve residents' quality of care at the end of life.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006170</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Peter Hudson</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>End of Life Care</Sub_Type>
        <Grant_Title>Improving the wellbeing of people with advanced cancer and their family carers: An effectiveness-implementation trial of an Australian dyadic digital health intervention (FOCUSau)</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,095,278.03</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Solid Tumours</Field_s__of_Research>
        <Res_KW1>palliative care </Res_KW1>
        <Res_KW2>end-of-life decision making </Res_KW2>
        <Res_KW3>psycho-oncology </Res_KW3>
        <Res_KW4>family support </Res_KW4>
        <Res_KW5>patient education</Res_KW5>
        <Plain_Description>The end-of-life-wishes for many Australians are not upheld which has a negative impact on their quality of life as well as their family carers. However, patient and carer wellbeing is improved when they are supported together. Our research will adapt and then examine the clinical and health economic benefits of an internet-based strategy (developed in the USA) which aims to improve the quality of life of patients with advanced cancer and their family carers.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2006283</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Craig Sinclair</CIA_Name>
        <Grant_Type>Targeted Call for Research</Grant_Type>
        <Sub_Type>End of Life Care</Sub_Type>
        <Grant_Title>The Enhanced Advance care planning and life Review Longitudinal Intervention (EARLI) study: Increasing proactive care planning in Australian community aged care settings</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$955,827.82</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Aged Care Nursing</Field_s__of_Research>
        <Res_KW1>dementia care </Res_KW1>
        <Res_KW2>end-of-life decision making </Res_KW2>
        <Res_KW3>home care services </Res_KW3>
        <Res_KW4>palliative care </Res_KW4>
        <Res_KW5>decision support</Res_KW5>
        <Plain_Description>The Enhanced Advance care planning and life Review Longitudinal Intervention (EARLI) project will proactively screen older adults at high-risk of health decline and provide assistance to discuss and document preferences for future care. The intervention is implemented in the community aged care setting, through partnerships with home care providers. Expected benefits include increased rates of advance care planning, higher quality documents and improved wellbeing among older adults and carers.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007718</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Lena Oestreich</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Post-stroke depression: vulnerability, mechanisms and novel treatment targets</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Health, Clinical and Counselling Psychology</Field_s__of_Research>
        <Res_KW1>neuroimaging</Res_KW1>
        <Res_KW2>neuropsychological impairments</Res_KW2>
        <Res_KW3>magnetic resonance imaging (MRI)</Res_KW3>
        <Res_KW4>stroke outcome</Res_KW4>
        <Res_KW5>secondary prevention</Res_KW5>
        <Plain_Description>People with post-stroke depression have poor rehabilitation outcomes and reduced quality of life. Acute treatment has done very little to shift the burden of disability, which is largely due to the fact that brain-based mechanisms that lead to these problems are poorly understood. This project will combine neuroimaging and computational neuroscience approaches to identify vulnerability states, reveal underlying mechanisms, and propose promising new treatment targets for post-stroke depression. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007722</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Jessica Heerde</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Improving the health status and reducing the mortality gap for vulnerable young Australians</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Health Promotion</Field_s__of_Research>
        <Res_KW1>public health</Res_KW1>
        <Res_KW2>health inequalities</Res_KW2>
        <Res_KW3>health promotion</Res_KW3>
        <Res_KW4>young adults</Res_KW4>
        <Res_KW5>mortality</Res_KW5>
        <Plain_Description>Disadvantage and inequality in health status emerge during adolescence and young adulthood, with profound consequences for later life, including premature death. My program of research will for the first-time characterise mortality and access to health care among 700,000 young Australians who have sought homeless services in the past decade. This work will inform policy regarding vulnerable adolescents and young adults as well as guide a range of services including health care and housing.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007725</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Stephen Stick</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Priority driven childhood respiratory research</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,899,839.13</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Paediatrics and Reproductive Medicine not elsewhere classified</Field_s__of_Research>
        <Res_KW1>asthma</Res_KW1>
        <Res_KW2>cystic fibrosis</Res_KW2>
        <Res_KW3>airway epithelium</Res_KW3>
        <Res_KW4>SARS-CoV-2</Res_KW4>
        <Res_KW5>innate immunity</Res_KW5>
        <Plain_Description>My research program will focus on children’s lung health. I will measure how tissues in the nose fight viruses. These results will help develop new prevention methods and vaccines. Children with cystic fibrosis (CF), a genetic lung disease, often have difficult-to-treat lung infections. I will use friendly viruses to kill antibiotic-resistant bacteria causing these infections. We will investigate whether wearable devices can detect health changes so children with CF can receive treatment early.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007726</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Nicholas Buckley</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Applied research to tackle the Australian poisoning epidemic</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,500,000.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Toxicology (incl. Clinical Toxicology)</Field_s__of_Research>
        <Res_KW1>poisoning</Res_KW1>
        <Res_KW2>pharmacoepidemiology</Res_KW2>
        <Res_KW3>suicide prevention</Res_KW3>
        <Res_KW4>toxicology</Res_KW4>
        <Res_KW5>substance misuse</Res_KW5>
        <Plain_Description>Poisoning is a large and increasing cause of deaths and hospitalisation in Australia. The research will use poisons centre calls, medical and coronial records, and prescribing data to identify agents with higher toxicity. Restrictions or tighter regulation could reduce the risks from such poisoning. This research will also evaluate the effect of recent policies, clinical guidelines, and service enhancements that aim to reduce the harms from poisoning.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007731</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Michelle Torok</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Prevention is better than cure: Development and implementation of an effective multi-strategy approach for youth suicide prevention</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,570,120.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Preventive Medicine</Field_s__of_Research>
        <Res_KW1>suicide prevention</Res_KW1>
        <Res_KW2>mental health</Res_KW2>
        <Res_KW3>young adults</Res_KW3>
        <Res_KW4>child health</Res_KW4>
        <Res_KW5>implementation</Res_KW5>
        <Plain_Description>Suicide is a leading cause of death in young Australians, and young people are consistently identified as a group requiring specific attention in suicide prevention policy. By leading an innovative program of research which focuses on solving how to sustainably embed proven effective prevention practices into key settings of young people, at scale, this Fellowship will enable me to address grand challenges in youth suicide prevention both in Australia and internationally.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007732</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Raissa Fonseca</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Engineering T cells to promote peripheral immunity</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Immunology not elsewhere classified</Field_s__of_Research>
        <Res_KW1>immunology</Res_KW1>
        <Res_KW2>molecular immunology</Res_KW2>
        <Res_KW3>CD8 T cells</Res_KW3>
        <Res_KW4>immunologic memory</Res_KW4>
        <Res_KW5>T cell immunity</Res_KW5>
        <Plain_Description>Tissue-resident memory T cells (TRM) are key for immune protection against diseases. This has led to much interest in understanding how TRM develop, although elucidation of molecules that regulate TRM formation are still scarce. This project aims to identify genetic regulators of TRM in peripheral organs. Expected outcomes are to identify molecules shaping TRM development and modulate genetic regulators to enhance immune protection against infections and cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007734</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Linda Wakim</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Generating an effective T-cell based influenza vaccine</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,398,844.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Cellular Immunology</Field_s__of_Research>
        <Res_KW1>influenza virus</Res_KW1>
        <Res_KW2>vaccines</Res_KW2>
        <Res_KW3>staphylococcus</Res_KW3>
        <Res_KW4>CD8 T cells</Res_KW4>
        <Res_KW5>mucosal immunity</Res_KW5>
        <Plain_Description>Influenza is a highly contagious, rapidly spreading respiratory pathogen that causes profound morbidity and mortality. Current influenza vaccines are suboptimal, they need to be updated  and administered annually, and provide no protection in the event of a pandemic influenza outbreak. This research program will see the development of a novel universal 'one-shot’ influenza vaccine that provides long term protection against both seasonal and newly emerging pandemic influenza strains.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007739</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Sharad Kumar</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Control of cellular homeostasis in health and disease</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$2,927,015.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Cell Development, Proliferation and Death</Field_s__of_Research>
        <Res_KW1>caspases</Res_KW1>
        <Res_KW2>mouse models</Res_KW2>
        <Res_KW3>epithelial transport</Res_KW3>
        <Res_KW4>ubiquitination</Res_KW4>
        <Res_KW5>cell death</Res_KW5>
        <Plain_Description>This research program will explore the roles of an essential cellular process called ubiquitination in influencing human health and disease. Abnormal ubiquitination is associated with many human ailments including cancer, inflammatory diseases, cardiovascular diseases and chronic kidney disease. Our research will uncover new mechanisms involved in these common diseases, thus generating new knowledge to better understand, prevent and help develop new therapeutic tools for their treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007741</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Manuela Ferreira</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Less pain in the back: how new approaches can improve care for low back pain </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,548,555.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Rheumatology and Arthritis</Field_s__of_Research>
        <Res_KW1>back pain</Res_KW1>
        <Res_KW2>orthopaedic surgery</Res_KW2>
        <Res_KW3>clinical trial</Res_KW3>
        <Res_KW4>disability</Res_KW4>
        <Res_KW5>access to health care</Res_KW5>
        <Plain_Description>Low back pain causes more disability than any other health condition. Low back pain directly impacts a person’s ability to perform simple daily activities, such as lifting objects, bending and even working. Many treatments currently offered to patients with low back pain may be causing more harm than benefit. The project will improve access to high quality LBP care and will provide knowledge on the safety and efficacy of LBP treatments such as surgery.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007747</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Lisa Jamieson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Advancing Indigenous Australian oral health through clinical trials, cohort studies and surveillance</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$2,598,056.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Aboriginal and Torres Strait Islander Health</Field_s__of_Research>
        <Res_KW1>Aboriginal</Res_KW1>
        <Res_KW2>epidemiology</Res_KW2>
        <Res_KW3>access to dental care</Res_KW3>
        <Res_KW4>clinical trial</Res_KW4>
        <Res_KW5>translation</Res_KW5>
        <Plain_Description>There are gaps between what optimises Indigenous Australian oral health and what is experienced in everyday practice. In partnership with Indigenous stakeholders, this proposal will facilitate best practice oral care models for Indigenous Australians and result in: (1) improved Indigenous oral health outcomes; (2) raised standards of oral clinical care for Indigenous Australians through cultural competency workshops and; (3) capacity building of Indigenous oral health workforce.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007765</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Kate Churruca</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Building a culture of safety in Australian residential aged care facilities</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Aged Health Care</Field_s__of_Research>
        <Res_KW1>culture</Res_KW1>
        <Res_KW2>organisational processes</Res_KW2>
        <Res_KW3>aged care</Res_KW3>
        <Res_KW4>patient safety</Res_KW4>
        <Res_KW5>quality improvement</Res_KW5>
        <Plain_Description>In Australia, the aged care sector has been challenged by issues of quality and safety, including toxic cultures neglect and poor respect for residents. This research program will identify how the culture of residential aged care facilities affects the safety and quality of care provided to residents and put into action strategies to improve culture and thereby residents’ outcomes. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007769</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Gianina Ravenscroft</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>The missing genetics of rare diseases</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,284,836.30</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Neurogenetics</Field_s__of_Research>
        <Res_KW1>medical genetics</Res_KW1>
        <Res_KW2>neurogenetics</Res_KW2>
        <Res_KW3>neuromuscular diseases</Res_KW3>
        <Res_KW4>miscarriage</Res_KW4>
        <Res_KW5>genetics</Res_KW5>
        <Plain_Description>to find the genetic causes of rare, often severely debilitating, disease and recurrent miscarriage. These diseases result in a significant burden to the affected individuals and their families and also on Australia’s health care system. A genetic diagnosis provides families with answers, allows family planning, such that couples do not have another affected pregnancy or child, enables appropriate clinical management and gives researchers targets for development of new therapies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007778</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Lisanne Spenkelink</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Rapid evolution of a genome editing tool</Grant_Title>
        <Admin_Institution>University of Wollongong</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Enzymes</Field_s__of_Research>
        <Res_KW1>systematic evolution of ligands by exponential enrichment (SELEX)</Res_KW1>
        <Res_KW2>fluorescence spectroscopy</Res_KW2>
        <Res_KW3>phenotype-genotype correlation</Res_KW3>
        <Res_KW4>biotechnology</Res_KW4>
        <Res_KW5>molecular diagnostics</Res_KW5>
        <Plain_Description>CRISPR–Cas9 is a powerful DNA targeting tool for genome editing and gene therapy. While the tool already shows promising results, its accuracy is not good enough for use in treatment of patients. I aim to develop a novel, high-throughput directed-evolution tool to improve the accuracy and specificity of Cas9 enzymes. The Cas9 with improved specificity will allow the wider and more reliable use of CRISPR technology in medical applications. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007800</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Emily Shepherd</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Preterm birth and neurodevelopment: improving long-term outcomes</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Paediatrics and Reproductive Medicine not elsewhere classified</Field_s__of_Research>
        <Res_KW1>maternal and child health</Res_KW1>
        <Res_KW2>prematurity</Res_KW2>
        <Res_KW3>evidence-based clinical practice</Res_KW3>
        <Res_KW4>implementation</Res_KW4>
        <Res_KW5>neurodevelopment</Res_KW5>
        <Plain_Description>Globally, more than one in ten babies is born preterm (early). While most preterm babies survive, many face life-long health consequences, including impaired development. My program will focus on three important treatments (magnesium sulphate; omega-3 fatty acids; donor breast milk) for mothers and preterm babies. I will assess the effects of the treatments on preterm birth and long-term development of preterm babies, in order to improve and maximise their use and impact in Australia and beyond.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007812</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Joanna Groom</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Targeting T cell Interactions for Tailored Immunity</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,948,555.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Cellular Immunology</Field_s__of_Research>
        <Res_KW1>T cells</Res_KW1>
        <Res_KW2>cell migration</Res_KW2>
        <Res_KW3>cellular interactions</Res_KW3>
        <Res_KW4>humoral immunology</Res_KW4>
        <Res_KW5>infection</Res_KW5>
        <Plain_Description>Dynamic immune cell interactions determine the way our body responds to infection and cancer. My laboratory has developed imaging methods that allow us to observe and track immune cell interactions in real time. We will use this information to catalyse the development of precision immunotherapies that either eliminate chronic infection and cancer, or to prevent current and emerging infectious diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007839</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Georgina Long</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Towards Zero Deaths from Melanoma: Innovative Clinical Trials with Multi-omics Analyses</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,927,015.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research> Tumour Immunology</Field_s__of_Research>
        <Res_KW1>melanoma</Res_KW1>
        <Res_KW2>immunotherapy</Res_KW2>
        <Res_KW3>clinical trial</Res_KW3>
        <Res_KW4>drug resistance</Res_KW4>
        <Res_KW5>cancer therapy</Res_KW5>
        <Plain_Description>Australia has the highest incidence of melanoma in the world. Survival in advanced-stage disease has risen from &lt;10% to >50% at 5 yrs in a decade due to the unprecedented success of immunotherapy. But 30% of melanoma patients have had no change in survival due to drug resistance. This research proposal will rapidly develop novel drug therapies using innovative clinical trial designs, collecting unique high-value tumour, blood &amp; stool samples to understand the causes, and conquer drug resistance.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007884</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Lauren Howson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Discovery of novel inborn errors of immunity that underlie Common Variable Immunodeficiency</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Cellular Immunology</Field_s__of_Research>
        <Res_KW1>immunodeficiency</Res_KW1>
        <Res_KW2>adaptive immunity</Res_KW2>
        <Res_KW3>cellular immunology</Res_KW3>
        <Res_KW4>complex genetic disease</Res_KW4>
        <Res_KW5>immunogenetics</Res_KW5>
        <Plain_Description>My research will study the underlying causes of Common Variable Immunodeficiency (CVID), the most common type of inherited immunodeficiency. It is caused by mutations in genes that are important for normal immune function. However, diagnosis is complex as many different gene mutations cause CVID, and most are still unknown. This research will identify new gene mutations and determine how they cause disease. The findings will support future gene-based diagnoses and guide targeted therapies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007887</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Andreas Strasser</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Understanding the control of cell death and the functions of the tumour suppressor p53 to develop improved therapies for cancer</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$3,927,015.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Cell Development, Proliferation and Death</Field_s__of_Research>
        <Res_KW1>apoptosis</Res_KW1>
        <Res_KW2>p53</Res_KW2>
        <Res_KW3>cancer</Res_KW3>
        <Res_KW4>novel therapeutic agents</Res_KW4>
        <Res_KW5>translational research</Res_KW5>
        <Plain_Description>Cancer is a leading cause of morbidity and mortality in Australia and worldwide, imposing a substantial burden on affected families and the health care system. I will build on my previous success of delivering a highly successful new anti-cancer drug (venetoclax) to market by determining the mechanisms that control the killing of cancer cells and the suppression of tumour development. My aim is to kick-start translational programs to develop new anti-cancer drugs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007896</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Sally Dunwoodie</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Towards a Mechanistic Understanding of the Causes of Congenital Heart Disease and Associated Extra-Cardiac Anomalies</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,991,612.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Developmental Genetics (incl. Sex Determination)</Field_s__of_Research>
        <Res_KW1>embryogenesis</Res_KW1>
        <Res_KW2>developmental genetics</Res_KW2>
        <Res_KW3>heart development</Res_KW3>
        <Res_KW4>gene-environment interaction</Res_KW4>
        <Res_KW5>clinical genetics</Res_KW5>
        <Plain_Description>Birth defects are common, devastating and costly. Heart defects are the most common type affecting about 9 per 1,000 babies. In most cases the cause of the birth defect is not known. This research seeks to identify the gene mutations and other factors, that cause birth defects and uses experimental models to understand why babies do not develop normally. This research will help families understand why birth defects occur and will help to prevent some cases in the future.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007901</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Andrew Vallely</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Innovative technologies to improve sexual and reproductive health among women in high-burden, low-resource settings</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,011,259.92</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Public Health and Health Services not elsewhere classified</Field_s__of_Research>
        <Res_KW1>cervical screening</Res_KW1>
        <Res_KW2>cervical cancer</Res_KW2>
        <Res_KW3>cervical precancer</Res_KW3>
        <Res_KW4>maternal and child health</Res_KW4>
        <Res_KW5>maternal infection</Res_KW5>
        <Plain_Description>I will evaluate novel, newly-available point-of-care technologies to improve sexual and reproductive health outcomes among women living in high-burden, low-resource settings. My vision is to improve the health of women and infants by reducing adverse birth outcomes due to undiagnosed and untreated sexually transmitted infections in pregnancy; and to prevent premature deaths due to cervical cancer by establishing and scaling-up robust clinical screening algorithms. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007904</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Carly Johnco</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Using translational neuroscience to optimise treatment for older adults with anxiety disorders </Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Developmental Psychology and Ageing</Field_s__of_Research>
        <Res_KW1>anxiety disorders</Res_KW1>
        <Res_KW2>psychological treatment</Res_KW2>
        <Res_KW3>ageing</Res_KW3>
        <Res_KW4>clinical psychology</Res_KW4>
        <Res_KW5>neuropsychological impairments</Res_KW5>
        <Plain_Description>The best way to treat anxiety disorders in older adults remains a critical question. Despite significant advances in our understanding of how we can most effectively reduce fears in younger adults based on experimental neuroscience research, this has not been extended to older adults where age-related changes in cognition may alter the efficacy. This research program will bridge this gap to examine whether treatment for late-life anxiety can be improved by targeting the underlying mechanisms.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007908</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Timothy Hughes</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>A curative approach for chronic myeloid leukaemia</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$2,241,612.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Cancer Therapy (excl. Chemotherapy and Radiation Therapy)</Field_s__of_Research>
        <Res_KW1>chronic myeloid leukaemia (CML)</Res_KW1>
        <Res_KW2>kinase inhibitors</Res_KW2>
        <Res_KW3>genomics</Res_KW3>
        <Res_KW4>novel therapeutic agents</Res_KW4>
        <Res_KW5>molecular oncology</Res_KW5>
        <Plain_Description>Patients with chronic myeloid leukaemia (CML) still have adverse outcomes in 2021 with the majority requiring ongoing toxic therapy to control their disease. My program will focus on improving outcomes by determining the key genetic events driving drug resistance and disease progression, further developing the new, highly targeted drug asciminib which promises to revolutionise CML therapy, and remove the current barriers to treatment free remission, the ultimate goal of CML therapy today. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007912</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr YIJUN PAN</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Precise medication use in people with Alzheimer's disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Pharmaceutical Sciences</Field_s__of_Research>
        <Res_KW1>drug delivery</Res_KW1>
        <Res_KW2>dose optimisation</Res_KW2>
        <Res_KW3>pharmacokinetics</Res_KW3>
        <Res_KW4>Alzheimer disease</Res_KW4>
        <Res_KW5>aged health</Res_KW5>
        <Plain_Description>New evidence suggests that Alzheimer’s disease (AD) not only affects the brain, but also impacts on how our body handles medicines. That is to say, if one has AD, he/she will have a much higher chance to experience undesirable effects from medication(s). This project aims to develop a dose calculator specifically designed for people with AD, so that they can be given with the right dose of medication for better treatment outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007919</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Kirsty Short</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Pandemic-proofing our future</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,370,120.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Medical Virology</Field_s__of_Research>
        <Res_KW1>SARS-CoV-2</Res_KW1>
        <Res_KW2>COVID-19</Res_KW2>
        <Res_KW3>angiotensin-converting enzyme (ACE)</Res_KW3>
        <Res_KW4>influenza virus</Res_KW4>
        <Res_KW5>immunopathology</Res_KW5>
        <Plain_Description>We  urgently need to generate better diagnostics and treatments for the next viral pandemic. Here, I will develop novel diagnostics and therapies for both severe influenza virus and coronavirus infections – two viruses of significant pandemic potential. The aim is to bring these treatments and diagnostics to clinical development now, so that we will have a ready stockpile of validated therapeutics and diagnostics to treat infected individuals at the inevitable outset of the next viral pandemic.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007920</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Gregory Fox</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>New directions in global tuberculosis control</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,149,133.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Infectious Diseases</Field_s__of_Research>
        <Res_KW1>Mycobacterium tuberculosis</Res_KW1>
        <Res_KW2>tuberculosis</Res_KW2>
        <Res_KW3>clinical trial</Res_KW3>
        <Res_KW4>multidrug resistance</Res_KW4>
        <Res_KW5>screening</Res_KW5>
        <Plain_Description>Tuberculosis (TB) is the greatest infectious killer in history, and still affects 10 million people each year. One third of cases are never diagnosed, and few of the 2 billion people with dormant infection ever receive treatment. This research programme addresses the major gaps in prevention, detection and treatment of TB. A series of trials will help to reduce the spread of infection and improve treatment outcomes globally and in Australia. Findings will underpin new global TB control policies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007929</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Sophie Valkenburg</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Harnessing immunity for optimal SARS-CoV-2 and influenza vaccines</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,570,120.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Immunology not elsewhere classified</Field_s__of_Research>
        <Res_KW1>SARS-CoV-2</Res_KW1>
        <Res_KW2>influenza virus</Res_KW2>
        <Res_KW3>vaccine</Res_KW3>
        <Res_KW4>T cells</Res_KW4>
        <Res_KW5>antibody</Res_KW5>
        <Plain_Description>Vaccines are our most important public health measure to combat infection, however the optimal vaccine format and dosing, or duration of immunity towards influenza virus and SARS-CoV-2 is poorly understood. We need to pre-arm our immune system against antigenic drift and future outbreak strains. This proposal will determine the protective potential of broadly-reactive immune responses by current vaccines, recovered patients, and experimental vaccines for influenza viruses and SARS-CoV-2. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007944</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Carola Vinuesa</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Harnessing T follicular regulatory cell products and knowledge from monogenic models to improve treatment for autoimmune disorders</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$3,927,015.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Autoimmunity</Field_s__of_Research>
        <Res_KW1>autoimmunity</Res_KW1>
        <Res_KW2>T cells</Res_KW2>
        <Res_KW3>B cells</Res_KW3>
        <Res_KW4>regulatory T cells</Res_KW4>
        <Res_KW5>lupus</Res_KW5>
        <Plain_Description>B cells of our immune system that have the potential to destroy our own tissues are normally kept in check by quality controls. If these controls fail, rogue B cells produce harmful antibodies that cause autoimmune diseases like lupus and allergies. We have discovered that a protein previously only known to function in the brain called “neuritin” keeps B cells in check. Understanding how neuritin acts, may uncover a completely novel and non-toxic treatment for autoimmune diseases and allergies. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007946</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Julie Redfern</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Modernising cardiac rehabilitation and secondary prevention of heart disease</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,872,570.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Preventive Medicine</Field_s__of_Research>
        <Res_KW1>allied health</Res_KW1>
        <Res_KW2>cardiovascular disease prevention</Res_KW2>
        <Res_KW3>health services research</Res_KW3>
        <Res_KW4>prevention</Res_KW4>
        <Res_KW5>physiotherapy</Res_KW5>
        <Plain_Description>Heart disease causes nearly 20% of deaths around the world. Unfortunately, the ongoing care people receive after they leave hospital has not kept up with medical advances. To fix this, I will lead a team of researchers and clinicians who will unite and join with people with heart disease to change care so it becomes more effective and efficient. I will set up and test tracking and monitoring systems, develop new ways to reach and support more people and improve clinician and researcher training.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007957</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Sarah Price</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Improving maternal metabolic health prior to pregnancy to prevent metabolic disease in the offspring</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Endocrinology</Field_s__of_Research>
        <Res_KW1>obesity</Res_KW1>
        <Res_KW2>pregnancy</Res_KW2>
        <Res_KW3>pregnancy outcome</Res_KW3>
        <Res_KW4>fetal programming</Res_KW4>
        <Res_KW5>metabolic disease</Res_KW5>
        <Plain_Description>The incidence of obesity in Australia is increasing most rapidly in young women of reproductive age. Currently around 1 in 5 Australian women enter pregnancy with obesity. This places both mother and baby at serious risk of complications during the pregnancy. It leaves the baby prone to metabolic diseases, such as obesity, which may present even before school-age. My program of research aims to prevent metabolic disease in children by addressing the health of women before and during pregnancy.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007970</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Mitchell Sarkies</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Implementing and scaling an evidence-informed model for hip fracture management: harnessing implementation science for complex adaptive healthcare systems</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$617,582.88</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Health Care Administration</Field_s__of_Research>
        <Res_KW1>implementation</Res_KW1>
        <Res_KW2>translational research</Res_KW2>
        <Res_KW3>quality improvement</Res_KW3>
        <Res_KW4>evidence-based health care</Res_KW4>
        <Res_KW5>hip fracture</Res_KW5>
        <Plain_Description>This project aims to improve the care provided in Australian hospitals for people with hip fractures. Approximately 50,000 Australians are hospitalised with hip fractures every year. Supporting health professionals to deliver care according to recommended guidelines will assist in reducing wait times for surgery, ensure more Australians with hip fractures get back on their feet after surgery, and help alleviate pain and suffering.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007991</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Natasha Rogers</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Improving translational pathways in kidney injury: from discovery to clinical practice</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,156,096.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Nephrology and Urology</Field_s__of_Research>
        <Res_KW1>kidney</Res_KW1>
        <Res_KW2>ischaemia/reperfusion</Res_KW2>
        <Res_KW3>kidney transplantation</Res_KW3>
        <Res_KW4>cell therapy</Res_KW4>
        <Res_KW5>drug delivery</Res_KW5>
        <Plain_Description>Acute kidney injury is a common cause of death in hospitalized patients, with multiple negative long-term health implications in survivors. It greatly increases the cost of healthcare. No effective treatments exist. New targets for pharmaceutical intervention are desperately needed to improve the clinical outcomes of patients with this devastating disease. This proposal using cutting-edge technology, bioinformatics, drug repurposing and molecular biology to develop potential treatment options.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2007996</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Quentin Gouil</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Unifying epigenetics with long-read sequencing to reveal hidden mechanisms of health and disease</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Epigenetics (incl. Genome Methylation and Epigenomics)</Field_s__of_Research>
        <Res_KW1>epigenetics</Res_KW1>
        <Res_KW2>DNA methylation</Res_KW2>
        <Res_KW3>sequencing</Res_KW3>
        <Res_KW4>chromatin</Res_KW4>
        <Res_KW5>genomic imprinting</Res_KW5>
        <Plain_Description>Superimposed on the genetic sequence, the "epigenetic state" dictates how genes are expressed and silenced. Disrupted epigenetics are common to many diseases, but we lack a thorough understanding of epigenetics even in health. This project will develop a new and broadly applicable epigenetic toolkit to investigate epigenetic phenomena in patients and mouse models, including an incurable muscular dystrophy. The new insights into epigenetic mechanisms will drive the development of treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008000</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Azmeraw Amare</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Developing Genetic Testing Tools for Optimising Pharmacotherapy and Enabling a Precision Mental Health Care</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Medical Genetics (excl. Cancer Genetics)</Field_s__of_Research>
        <Res_KW1>bipolar disorder</Res_KW1>
        <Res_KW2>depression</Res_KW2>
        <Res_KW3>pharmacogenomics</Res_KW3>
        <Res_KW4>genetic epidemiology</Res_KW4>
        <Res_KW5>antidepressants</Res_KW5>
        <Plain_Description>On average, 30-60% of patients with mental illness receiving medication do not show adequate response to treatment. Novel tools are needed to augment the current ‘trial and error’ approach to treatment selection. Over the next five years, I will apply advanced data science techniques on internationally collected datasets to develop genetic testing tools for optimising the treatment of patients with mental illness. Better prediction of treatment outcomes will reduce the burden of mental illness.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008001</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Angela D'Rozario</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Investigating sleep biomarkers of cognitive impairment and improving cognitive outcomes through targeted sleep interventions in adults at risk for dementia</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,570,120.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Developmental Psychology and Ageing</Field_s__of_Research>
        <Res_KW1>mild cognitive impairment</Res_KW1>
        <Res_KW2>obstructive sleep apnoea</Res_KW2>
        <Res_KW3>electroencephalogram (EEG)</Res_KW3>
        <Res_KW4>memory</Res_KW4>
        <Res_KW5>sleep</Res_KW5>
        <Plain_Description>Sleep disturbance accelerates age-related memory decline and increases dementia risk. Monitoring the brain during sleep to understand how sleep disturbance underpins memory problems and contribute to dementia risk is of critical importance.  This work will use innovative technology to identify abnormal brain waves that predict memory deficits and evaluate novel treatments that could enhance sleep and improve memory.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008017</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof David Kaye</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Better care for HFpEF patients through integrated basic, clinical and translational research</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,741,612.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Cardiology (incl. Cardiovascular Diseases)</Field_s__of_Research>
        <Res_KW1>heart failure</Res_KW1>
        <Res_KW2>diastolic dysfunction</Res_KW2>
        <Res_KW3>pathophysiology</Res_KW3>
        <Res_KW4>cardiovascular physiology</Res_KW4>
        <Res_KW5>end-stage heart disease</Res_KW5>
        <Plain_Description>Heart failure (HF) is a very common, life-limiting cardiovascular condition in which patients have a poor quality of life and require frequent hospitalization. As the population ages, the burden of HF is increasing and the patterns of HF are changing; 'HFpEF', in particular, is now the commonest cause of HF and the are no effective treatments. My program of research will address this challenge by comprehensively studying the cause of HFpEF and developing effective treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008018</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Dietmar W. Hutmacher</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Transformation of the implant paradigm in breast rehabilitation</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Biomaterials</Field_s__of_Research>
        <Res_KW1>tissue engineering</Res_KW1>
        <Res_KW2>biomaterials</Res_KW2>
        <Res_KW3>biomedical engineering</Res_KW3>
        <Res_KW4>bacterial biofilm</Res_KW4>
        <Res_KW5>antibiotic therapy</Res_KW5>
        <Plain_Description>Breast reconstruction via silicone implants require in 10-25% of cancer patients 5-10years post-surgery implant removal and/or additional surgery. Scaffold guided breast tissue engineering rooted in convergence of 3D printing, reconstructive surgery,  drug delivery, &amp; liposuction processed adipose tissue grafts redefines rehabilitation for the breast cancer patient by providing a holistic therapy that addresses limitations realized with all other contemporary reconstructive surgery procedures.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008019</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Caroline Lodge</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Identifying and addressing preventable causes of asthma over the lifespan</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,570,120.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Respiratory Diseases</Field_s__of_Research>
        <Res_KW1>asthma</Res_KW1>
        <Res_KW2>aetiology</Res_KW2>
        <Res_KW3>prospective cohort study</Res_KW3>
        <Res_KW4>phenotype</Res_KW4>
        <Res_KW5>randomised controlled trial (RCT)</Res_KW5>
        <Plain_Description>Asthma is the most common chronic non-communicable disease in children affecting more than 300 million children and adults worldwide. Little is known about what causes asthma so there are few preventive measures and resources are aimed at treating established disease. I aim to discover potential causes of asthma by investigating specific types of asthma (phenotypes) and to translate findings clinical practice and public health guidelines.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008020</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Olivier Piguet</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Maximising quality of life in frontotemporal dementia</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,072,570.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Biological Psychology (Neuropsychology, Psychopharmacology, Physiological Psychology)</Field_s__of_Research>
        <Res_KW1>frontotemporal dementia</Res_KW1>
        <Res_KW2>early diagnosis</Res_KW2>
        <Res_KW3>early intervention</Res_KW3>
        <Res_KW4>social cognition</Res_KW4>
        <Res_KW5>brain imaging</Res_KW5>
        <Plain_Description>An early diagnosis is essential for the appropriate management of care of individuals with dementia. This is often missed in frontotemporal dementia, because of the variable symptoms and confusion with psychiatric disorders. Over the next 5 years, the objectives of this research program are to improve diagnosis and understanding of disease progression in frontotemporal dementia, and develop relevant therapeutic interventions that will maximise the quality of life of patients and their families.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008024</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Ameneh Khatami</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Phage Therapy - a novel solution for difficult-to-treat infections in children</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$570,592.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Respiratory Diseases</Field_s__of_Research>
        <Res_KW1>bacteriophage</Res_KW1>
        <Res_KW2>cystic fibrosis</Res_KW2>
        <Res_KW3>Pseudomonas aeruginosa</Res_KW3>
        <Res_KW4>Staphylococcus aureus</Res_KW4>
        <Res_KW5>mycobacterial infection</Res_KW5>
        <Plain_Description>Phages are viruses that kill bacteria and offer a novel solution to treat infections, including antibiotic-resistant ones. This research aims to develop phage therapy as a treatment option for difficult-to-treat infections in children. It will combine the latest advances in bacterial genomics, rapid phage-bacteria matching and clinical trial methods to assess the value of phage therapy to treat serious infections in children with cystic fibrosis and other chronic debilitating infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008064</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Sharon Naismith</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Improving dementia outcomes with new targets, trials and national standards </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,160,070.01</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Clinical Sciences not elsewhere classified</Field_s__of_Research>
        <Res_KW1>dementia</Res_KW1>
        <Res_KW2>dementia-related decline in memory</Res_KW2>
        <Res_KW3>sleep</Res_KW3>
        <Res_KW4>health care delivery</Res_KW4>
        <Res_KW5>mild cognitive impairment</Res_KW5>
        <Plain_Description>While there is no cure for dementia, we know that almost half the risk for dementia is due to factors that can be tackled from midlife.  My work aims to a) improve understanding of how new emerging risk factors, namely sleep disturbance contribute to dementia onset and progression b) generate robust evidence for new treatments targeting modifiable risks and c) change practices in our health services to develop national standards, timely diagnoses and provision of appropriate treatments and care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008066</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Jonathan Danon</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Molecular innovations for imaging microglial contributions to brain disorders</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Basic Pharmacology</Field_s__of_Research>
        <Res_KW1>medicinal chemistry</Res_KW1>
        <Res_KW2>drug discovery</Res_KW2>
        <Res_KW3>drug design</Res_KW3>
        <Res_KW4>drug development</Res_KW4>
        <Res_KW5>positron emission tomography (PET)</Res_KW5>
        <Plain_Description>Microglia are the main defender cells in our brains. When injury or disease strikes, they rush to the affected area and perform a host of critical jobs to repair the damage caused, although the fine details of how they do this are unknown. I plan to develop molecules that can 1) track microglia when carrying out specific jobs and 2) be detected using a PET scanner to unravel some of these mysteries. This research could lead to better diagnostics and effective treatments for Alzheimer’s disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008071</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Jason Trubiano</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Implementing point-of-care tools and precision medicine approaches for antibiotic allergy to improve prescribing and medication safety in health services</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,212,069.75</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Infectious Diseases</Field_s__of_Research>
        <Res_KW1>health services research</Res_KW1>
        <Res_KW2>allergy testing</Res_KW2>
        <Res_KW3>antimicrobial therapy</Res_KW3>
        <Res_KW4>antimicrobial resistance</Res_KW4>
        <Res_KW5>adverse drug reactions</Res_KW5>
        <Plain_Description>Antibiotic allergies impact 1 in 4 hospitalised patients and range from low-risk allergies which can be removed by a test dose (e.g., childhood penicillin allergy) to high-risk allergies associated with 25% mortality (e.g., Stevens-Johnson Syndrome). This program will translate piloted allergy tools into easy-to-use bedside tests, that are able to prevent, diagnose and remove antibiotic allergies to improve safe and appropriate antibiotic prescribing.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008073</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Rohan Borschmann</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Reducing self-harm, suicide and early mortality in marginalised young people. </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,420,120.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Mental Health</Field_s__of_Research>
        <Res_KW1>suicide prevention</Res_KW1>
        <Res_KW2>mental health</Res_KW2>
        <Res_KW3>adolescent health</Res_KW3>
        <Res_KW4>prison population</Res_KW4>
        <Res_KW5>epidemiology</Res_KW5>
        <Plain_Description>Rates of mental disorders, self-harm, and suicide are all increasing, yet not enough is currently known to develop effective prevention strategies. My research will generate evidence on which we can base decisions regarding the best treatment options and the young people who will most benefit from them, including vulnerable populations at increased risk – such as young people in contact with the criminal justice system and those presenting to emergency departments following self-harm. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008079</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Paul Myles</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Improving the Impact and Efficiency of Perioperative Clinical Trials</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,241,612.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Anaesthesiology</Field_s__of_Research>
        <Res_KW1>anaesthesia</Res_KW1>
        <Res_KW2>abdominal surgery</Res_KW2>
        <Res_KW3>cardiac surgery</Res_KW3>
        <Res_KW4>clinical outcome</Res_KW4>
        <Res_KW5>biostatistics</Res_KW5>
        <Plain_Description>More than 2 million Australians undergo surgery each year. A high proportion are elderly and many have chronic medical conditions that increase the risk of serious complications, ongoing disability, and death. My research aims to improve the design and usefulness of large clinical trials in perioperative medicine and surgery. Simpler designs that allow faster recruitment and completion at much lower cost, and better value because the trial outcomes are focussed on what matters to the patient.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008090</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Cyril Seillet</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Circadian control of innate immunity: strategies for treatment of chronic diseases</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,570,120.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Innate Immunity</Field_s__of_Research>
        <Res_KW1>innate immunity</Res_KW1>
        <Res_KW2>chronic inflammatory disease</Res_KW2>
        <Res_KW3>circadian rhythms</Res_KW3>
        <Res_KW4>chronic inflammation</Res_KW4>
        <Res_KW5>neuroimmunology</Res_KW5>
        <Plain_Description>Living organisms adapt to light–dark rhythms using internal clocks. This body clock not only regulates our sleep and feeding behaviour but also our immune system. Disruption of the body clock can increase the risk of developing cancer, diabetes and asthma. We will discover how our body clock regulates our immune cells to allow future development of therapeutic targets to control these diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008092</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Amy Chung</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Serological Correlates of Protection and Pathogenesis in Infectious and Autoimmune Disease</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,434,836.30</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Humoural Immunology and Immunochemistry</Field_s__of_Research>
        <Res_KW1>antibody</Res_KW1>
        <Res_KW2>Fc receptors</Res_KW2>
        <Res_KW3>serology</Res_KW3>
        <Res_KW4>virology</Res_KW4>
        <Res_KW5>autoantibodies</Res_KW5>
        <Plain_Description>Antibodies are a vital component of the immune response required for protection and control of infectious diseases. Conversely, in rare circumstances, the body can produce antibodies that mistakenly target a person’s own organs, damaging the body. Applying "Systems serology," a novel technology developed by Dr Chung, these studies will dissect how antibodies contribute to protection or pathogenesis of disease, in order to develop improved antibody-based vaccines, therapies and diagnostic tools.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008096</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Joshua Hardy</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Harnessing cryo-electron microscopy to study the engineering of microtubule networks in cancer and neurogenesis</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Structural Biology (incl. Macromolecular Modelling)</Field_s__of_Research>
        <Res_KW1>structural biology</Res_KW1>
        <Res_KW2>microtubules</Res_KW2>
        <Res_KW3>microtubule associated protein (MAP)</Res_KW3>
        <Res_KW4>electron microscopy</Res_KW4>
        <Res_KW5>protein kinases</Res_KW5>
        <Plain_Description>Just as our skeletons provide structure to our body and facilitate movement, our cells have internal structures which form a dynamic scaffold. This scaffold is composed of long filaments called microtubules. Microtubules are needed for healthy cell division and growth, but mutations can cause cells to divide too rapidly, resulting in cancer. This research program will focus on elucidating how the microtubule scaffold is constructed and maintained in healthy cells and how mutations cause disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008097</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Tamara Butler</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Improving cancer outcomes for Aboriginal and Torres Strait Islander women diagnosed with gynaecological cancers</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$621,995.38</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Aboriginal and Torres Strait Islander Health</Field_s__of_Research>
        <Res_KW1>qualitative research</Res_KW1>
        <Res_KW2>gynaecological cancers</Res_KW2>
        <Res_KW3>cancer care</Res_KW3>
        <Res_KW4>survivorship</Res_KW4>
        <Res_KW5>equity</Res_KW5>
        <Plain_Description>Aboriginal and Torres Strait Islander women carry a higher burden of gynaecological cancers relative to other Australian women. Reducing this disparity will require mixed-methods evidence-based action across the cancer care continuum. Guided by an Indigenist research approach, this research program will improve outcomes for Aboriginal and Torres Strait Islander women diagnosed with gynaecological cancers through cancer prevention and improved the quality of treatment and survivorship care. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008099</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Rebecca Guy</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Public health interventions to control sexually transmitted infections</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,297,570.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Preventive Medicine</Field_s__of_Research>
        <Res_KW1>sexually-transmitted infections (STI)</Res_KW1>
        <Res_KW2>human immunodeficiency virus (HIV)</Res_KW2>
        <Res_KW3>prevention</Res_KW3>
        <Res_KW4>diagnostic</Res_KW4>
        <Res_KW5>epidemiology</Res_KW5>
        <Plain_Description>Each year there are >600 million new cases of sexually transmissible infections (STIs) which can lead to infertility, neonatal death and cancers. My vision for the next 5 years is to develop and trial more effective interventions which will move Australia and the Asia-Pacific Region substantially closer to the goal of controlling STIs in high-risk populations.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008104</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Anna Nowak</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Leading the way in mesothelioma – a program of immunotherapy translational research nested within novel clinical trials</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Solid Tumours</Field_s__of_Research>
        <Res_KW1>cancer</Res_KW1>
        <Res_KW2>immunotherapy</Res_KW2>
        <Res_KW3>mesothelioma</Res_KW3>
        <Res_KW4>clinical trial</Res_KW4>
        <Res_KW5>translational research</Res_KW5>
        <Plain_Description>Mesothelioma is a devastating cancer which is almost always fatal. My research is focused on clinical trials in mesothelioma and on understanding, from patient tumour samples and blood samples, why some people respond to treatment and others do not. This research will use cutting edge laboratory techniques to study samples from people participating in a 480-patient clinical trial of chemo-immunotherapy in mesothelioma, in addition to working with animal models of mesothelioma and immunotherapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008119</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Ashley Hopkins</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Precision Medicine and Cancer Immunotherapy: A Multifactorial Paradigm</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Chemotherapy</Field_s__of_Research>
        <Res_KW1>cancer epidemiology</Res_KW1>
        <Res_KW2>cancer prognosis</Res_KW2>
        <Res_KW3>cancer immunotherapy</Res_KW3>
        <Res_KW4>cancer therapy</Res_KW4>
        <Res_KW5>cancer research</Res_KW5>
        <Plain_Description>Big data from clinical trials and routine care will be pooled with novel laboratory information generated in collaboration with industry partners to identify biomarkers defining who will and will not respond to immune checkpoint inhibitors in advanced lung cancer. State-of-the-art machine learning and systems biology methodologies will unlock translational world leading insights that enable better treatment decisions and patient outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008129</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Thomas Marwick</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Cardiovascular Disease Prevention in Cancer Survivors by Recognition and Treatment of Subclinical Disease</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,944,017.22</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Cardiology (incl. Cardiovascular Diseases)</Field_s__of_Research>
        <Res_KW1>heart failure</Res_KW1>
        <Res_KW2>atrial fibrillation</Res_KW2>
        <Res_KW3>coronary artery disease</Res_KW3>
        <Res_KW4>medical oncology</Res_KW4>
        <Res_KW5>survivorship</Res_KW5>
        <Plain_Description>This research program seeks to develop a cardiovascular diseases (CVD) screening program and subsequent risk-based CVD prevention program to reduce the development of CVD in cancer survivors. This is important because survivors are at risk of CVD, both because of their cancer therapy and because the risk factors for cancer are shared with CVD. Early detection of CVD by screening will enable targeted prevention efforts to reduce incident CVD in cancer survivors.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008157</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Peter Cistulli</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>A deadly duo: Defining the link between Obstructive Sleep Apnoea and  Cardiovascular Disease</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,427,015.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Respiratory Diseases</Field_s__of_Research>
        <Res_KW1>obstructive sleep apnoea</Res_KW1>
        <Res_KW2>cardiovascular risk factors</Res_KW2>
        <Res_KW3>cardiovascular complications</Res_KW3>
        <Res_KW4>cardiovascular health</Res_KW4>
        <Res_KW5>cardiovascular disease prevention</Res_KW5>
        <Plain_Description>Obstructive Sleep Apnoea (OSA) is a very common breathing disorder during sleep that causes low oxygen levels and disturbed sleep. This causes individuals to feel tired, increasing the risk of injury and reducing quality of life. OSA directly affects the heart and increases the risk of high blood pressure, heart attack, heart rhythm disorders, and stroke. This project aims to better understand this connection and to determine whether effective treatment of OSA improves heart health.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008166</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Elizabeth Palmer</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Gene2Care:  a comprehensive program of research to revolutionise care for children with rare genetic conditions</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$390,444.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Genomics</Field_s__of_Research>
        <Res_KW1>clinical genetics</Res_KW1>
        <Res_KW2>health education</Res_KW2>
        <Res_KW3>access to health care</Res_KW3>
        <Res_KW4>child health</Res_KW4>
        <Res_KW5>health inequalities</Res_KW5>
        <Plain_Description>There are at least 1.3 million Australians with a rare genetic disease. 1 in 2 patients with rare genetic diseases are children.  6 out of 10 deaths in childhood are attributed to rare disease.   Gene2Care will explore how to improve the patient journey for children with rare genetic diseases and their families. We will find out how to get genetic diagnoses for more children, more quickly. We will show how to move from a diagnosis to the best possible lifelong support and care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008170</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Zac Seidler</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Men in Mind: Training clinicians to engage men in mental health treatment</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$490,444.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Gender Psychology</Field_s__of_Research>
        <Res_KW1>health care worker education</Res_KW1>
        <Res_KW2>masculinity</Res_KW2>
        <Res_KW3>men's mental health</Res_KW3>
        <Res_KW4>depression</Res_KW4>
        <Res_KW5>psychotherapy</Res_KW5>
        <Plain_Description>While more men than ever are seeking help for their mental health, the male suicide rate is high and rising. The onus needs to move away from the male client adapting to treatment, and onto the systems and services designed to help them. This project focuses on training clinicians who work with men, to ensure they have evidence-based education to better understand and respond to their male clients' distress and suicidality.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008190</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Aaron Darling</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Advanced graph genome analytics for clinical and public health genomics</Grant_Title>
        <Admin_Institution>University of Technology Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,872,570.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Bioinformatics</Field_s__of_Research>
        <Res_KW1>comparative genomics</Res_KW1>
        <Res_KW2>evolution</Res_KW2>
        <Res_KW3>molecular epidemiology</Res_KW3>
        <Res_KW4>antimicrobial resistance</Res_KW4>
        <Res_KW5>genomics</Res_KW5>
        <Plain_Description>By analysing the DNA of infectious microbes, public health officials can determine whether patients are part of the same or different outbreaks, and even determine the source of the outbreak. This has become common practice for many diseases, but genome data is rich and could be used to do much more. The proposed work enhances public health by providing advanced data analytics that will increase the precision of existing analyses and extends them to outbreaks of antibiotic resistance genes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008193</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Shalini Arunogiri</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Transforming outcomes by investigating integrated treatments for methamphetamine use and trauma</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$450,370.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Mental Health</Field_s__of_Research>
        <Res_KW1>addiction treatment</Res_KW1>
        <Res_KW2>drug dependence</Res_KW2>
        <Res_KW3>substance use disorders</Res_KW3>
        <Res_KW4>comorbidity</Res_KW4>
        <Res_KW5>posttraumatic stress disorder (PTSD)</Res_KW5>
        <Plain_Description>Methamphetamine use disorder is associated with a $5 billion burden annually in Australia, in part due to untreated co-occurring mental health problems. This program of research will address a gap in the treatment of methamphetamine use, by firstly quantifying the prevalence and impact of trauma and post-traumatic stress disorder in people who use methamphetamine; and secondly, by testing two new targeted approaches for trauma and methamphetamine use. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008197</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Jacob Crouse</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Investigating body clock dysfunction in mood disorders using wearable sensors</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Psychiatry (incl. Psychotherapy)</Field_s__of_Research>
        <Res_KW1>circadian rhythms</Res_KW1>
        <Res_KW2>depression</Res_KW2>
        <Res_KW3>bipolar disorder</Res_KW3>
        <Res_KW4>mental health</Res_KW4>
        <Res_KW5>youth</Res_KW5>
        <Plain_Description>We don't yet understand what causes depression and bipolar disorder or why some people don't get better after treatment. This Investigator Fellowship will allow me to explore whether dysfunction of “biological clocks”—which control the timing of most of our behaviours and bodily functions—are responsible for a number of problems that young people with mood disorders face, including fatigue, depressed mood, sleep/wake cycle irregularities, and bodily symptoms like upset stomach and muscle pain.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008212</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof David Tingay</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Improving preterm respiratory outcomes from birth</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,649,133.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Respiratory Diseases</Field_s__of_Research>
        <Res_KW1>newborn infant</Res_KW1>
        <Res_KW2>lung mechanics</Res_KW2>
        <Res_KW3>mechanical ventilation</Res_KW3>
        <Res_KW4>lung injury</Res_KW4>
        <Res_KW5>lung function assessment</Res_KW5>
        <Plain_Description>Rates of preterm birth are increasing, and survivors are now entering adulthood with chronic respiratory problems. My program addresses the clear need to re-define how we manage the fragile lung of preterm infants from their very first breaths, before the injury events leading to life long problems occur. My program uses world-leading lung imaging and molecular tools and large trials to understand the preterm lung and then develop new therapies that meaningfully impact infants and families.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008255</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Yet Khor</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Interstitial lung disease: Improving patient outcomes through risk prediction and disease burden management</Grant_Title>
        <Admin_Institution>Institute for Breathing and Sleep</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Respiratory Diseases</Field_s__of_Research>
        <Res_KW1>pulmonary fibrosis</Res_KW1>
        <Res_KW2>symptom reduction</Res_KW2>
        <Res_KW3>risk prediction</Res_KW3>
        <Res_KW4>oxygen therapy</Res_KW4>
        <Res_KW5>health outcomes</Res_KW5>
        <Plain_Description>Interstitial lung diseases (ILD) are complex incurable lung scarring conditions, which cause distressing breathlessness, fatigue, and poor quality of life. It is the second most common cause of death due to chronic lung disease in Australia. My program will allow us to predict how the disease worsens over time, to understand how sleep and drug complexity affect health outcomes, and to better treat debilitating shortness of breath and low oxygen levels in people with ILD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008276</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Gregory Dore</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Improving health outcomes for people who inject drugs: hepatitis C and drug dependence</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,827,015.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Infectious Diseases</Field_s__of_Research>
        <Res_KW1>antiviral agents</Res_KW1>
        <Res_KW2>hepatitis C virus</Res_KW2>
        <Res_KW3>clinical trial</Res_KW3>
        <Res_KW4>clinical epidemiology</Res_KW4>
        <Res_KW5>injecting drug use</Res_KW5>
        <Plain_Description>People who inject drugs are a vulnerable population within society. Recent advances in treatment of hepatitis C have provided optimism for improved health outcomes for people who inject drugs. Addressing other areas, particularly management of drug dependency, is essential to improving the lives of people who inject drugs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008287</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Ranjeny Thomas</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Immunotherapy to prevent and cure autoimmune disease</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,127,015.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Autoimmunity</Field_s__of_Research>
        <Res_KW1>rheumatoid arthritis</Res_KW1>
        <Res_KW2>type 1 diabetes mellitus (insulin-dependent diabetes mellitus)</Res_KW2>
        <Res_KW3>immunotherapy</Res_KW3>
        <Res_KW4>immunological tolerance</Res_KW4>
        <Res_KW5>disease prevention</Res_KW5>
        <Plain_Description>Autoimmune diseases such as rheumatoid arthritis (RA) are incurable, inflammatory diseases, causing disability and early death. Building on early phase immunotherapy trials, my program develops ground-breaking immunotherapy research and technology to deliver: 1) tools to identify people at risk; and 2) preventive immunotherapy and lifestyle interventions to halt disease progression. My program will build pipeline drug development and delivery opportunities with industry to transform healthcare.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008300</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Claire Wakefield</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Maximising health and wellbeing for children with serious illness in countries with the most, through to the least, resources.</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,248,555.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Health, Clinical and Counselling Psychology</Field_s__of_Research>
        <Res_KW1>health psychology</Res_KW1>
        <Res_KW2>paediatric</Res_KW2>
        <Res_KW3>psycho-oncology</Res_KW3>
        <Res_KW4>quality of life</Res_KW4>
        <Res_KW5>quality of care</Res_KW5>
        <Plain_Description>More than 10% of all children have a serious/chronic illness. My research aims to maximise their health and wellbeing by rolling out interventions to support families of seriously ill children across Australia. My new interventions will improve mental health in families undergoing paediatric precision medicine and improve quality of life, resilience, physical activity and diet in child cancer survivors. The program will also expand to low resource settings to reach those with the greatest need.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008313</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Susanna Cramb</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>PLACE (Prioritising Location-based Analysis and Consumer Engagement) for Change</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$575,740.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Epidemiology</Field_s__of_Research>
        <Res_KW1>health inequalities</Res_KW1>
        <Res_KW2>cancer epidemiology</Res_KW2>
        <Res_KW3>injury epidemiology</Res_KW3>
        <Res_KW4>data linkage</Res_KW4>
        <Res_KW5>applied statistics</Res_KW5>
        <Plain_Description>Location plays a key role in Australia’s health inequities, yet is usually ignored or aggregated to large regions. This hinders identifying appropriate, localised solutions. This fellowship uniquely incorporates both complex spatial analyses and lived consumer experience to identify priority areas and propose actionable solutions to help reduce health inequities for cancer, diabetes and injuries.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008317</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Daniel Steinfort</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Improving survival in lung cancer using novel minimally invasive bronchoscopic techniques </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,235,060.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Cancer Therapy (excl. Chemotherapy and Radiation Therapy)</Field_s__of_Research>
        <Res_KW1>non-small cell lung cancer</Res_KW1>
        <Res_KW2>minimal intervention</Res_KW2>
        <Res_KW3>cancer immunology</Res_KW3>
        <Res_KW4>lung cancer</Res_KW4>
        <Res_KW5>bronchoscopy</Res_KW5>
        <Plain_Description>I will develop novel techniques to achieve tumour destruction via bronchoscopy for non-surgical cure of early stage lung cancer. I will explore the immune system response to tumour destruction, and determine the efficacy of combining tumour ablation (to enhance immune system recognition of tumour cells) with immunotherapy in patients with metastatic lung cancer to increase the proportion of patients who respond to immunotherapy, and increase the duration that responses are maintained.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008339</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Sudarshini Ramanathan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Defining pathogenic mechanisms to improve diagnosis and treatment of antibody-associated neurological disorders</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,551,688.72</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Central Nervous System</Field_s__of_Research>
        <Res_KW1>neuroimmunology</Res_KW1>
        <Res_KW2>demyelinating disease</Res_KW2>
        <Res_KW3>encephalitis</Res_KW3>
        <Res_KW4>immunotherapy</Res_KW4>
        <Res_KW5>biomarkers</Res_KW5>
        <Plain_Description>Autoimmune neurological disorders have recently been identified, and can result in severe disability including blindness, paralysis, and seizures. If diagnosed early and treated with specific immune therapy, brain injury can be reversed and patients can have a normal life.  My program will identify how frequent these disorders are, increase our understanding of underlying disease processes to identify new treatment targets, and develop diagnostic and therapeutic guidelines to improve outcomes. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008341</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Tracy Josephs</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>A personalised pharmacogenomic approach to inform autosomal dominant hypocalcaemia treatment</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Basic Pharmacology</Field_s__of_Research>
        <Res_KW1>membrane protein</Res_KW1>
        <Res_KW2>structural biology</Res_KW2>
        <Res_KW3>molecular pharmacology</Res_KW3>
        <Res_KW4>drug discovery</Res_KW4>
        <Res_KW5>endocrine disease</Res_KW5>
        <Plain_Description>Autosomal dominant hypocalcemia (ADH) is a rare disorder caused by genetic mutations that disrupt the body’s ability to retain calcium. There is no treatment for ADH. Developing new therapies has been difficult as potential drugs behave differently depending on the underlying mutation. My research is characterising how mutations in ADH can change drug behaviour. I am using this information to design new therapies resistant to these effects, providing treatment options for ADH sufferers.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008344</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Leigh Walker</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Sex differences in alcohol use disorders: harnessing reverse translation for target discovery</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$600,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Basic Pharmacology</Field_s__of_Research>
        <Res_KW1>sex differences</Res_KW1>
        <Res_KW2>amygdala</Res_KW2>
        <Res_KW3>alcohol use disorders</Res_KW3>
        <Res_KW4>neurochemistry</Res_KW4>
        <Res_KW5>anxiety</Res_KW5>
        <Plain_Description>Alcohol use disorders are a major socioeconomic burden on society and treatment options are inadequate. One of the major hurdles in treatment development is translation from preclinical to clinical models, which in part is underpinned by a lack of appropriate examination in both male and female research subjects. My research will identify and characterise new targets for the treatment of alcohol use disorder in both men and women.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008347</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Qi Cao</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Developing novel therapeutic approaches by using innate lymphoid cells in chronic kidney disease</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Nephrology and Urology</Field_s__of_Research>
        <Res_KW1>nephropathy</Res_KW1>
        <Res_KW2>chronic renal failure</Res_KW2>
        <Res_KW3>innate immunity</Res_KW3>
        <Res_KW4>immunotherapy</Res_KW4>
        <Res_KW5>inflammation</Res_KW5>
        <Plain_Description>Chronic kidney disease is a major cause of death and morbidity in Australia. Current strategies that delay progression of kidney disease are limited. Innate lymphoid cells (ILC) are a newly identified family of immune cells and include two protective subsets of ILC: regulatory ILC (ILCreg) and type 2 ILC (ILC2), which have been shown to suppress inflammation and promote tissue repair. The project will explore therapeutic potential of ILCreg and ILC2 in kidney disease. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008356</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Robert Brink</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Germinal centres, antibodies and immunological disease</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,927,015.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Cellular Immunology</Field_s__of_Research>
        <Res_KW1>antibody production</Res_KW1>
        <Res_KW2>autoimmunity</Res_KW2>
        <Res_KW3>germinal centre</Res_KW3>
        <Res_KW4>B cells</Res_KW4>
        <Res_KW5>genetic engineering</Res_KW5>
        <Plain_Description>Antibodies that latch strongly onto foreign pathogens provide us with immunological protection. They are produced by lymphocytes called B cells participating in the germinal centre phase of the immune response. Autoantibodies that attack the body’s own tissues are an unwanted by-product of the germinal centre. The aim of this study is to identify the processes by which B cells producing desirable protective antibodies versus autoantibodies are identified and controlled in the germinal centre.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008359</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Scott Ayton</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Investigating new targets and treatments for Alzheimer’s disease: from biochemistry through to clinical trial</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,098,844.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Neurology and Neuromuscular Diseases</Field_s__of_Research>
        <Res_KW1>Alzheimer disease</Res_KW1>
        <Res_KW2>biomarkers</Res_KW2>
        <Res_KW3>clinical trial</Res_KW3>
        <Res_KW4>iron</Res_KW4>
        <Res_KW5>disease mechanisms</Res_KW5>
        <Plain_Description>Alzheimer’s disease is a major disease of the elderly that causes profound impairment to cognition. This disease has proven difficult to diagnose and treat. Over the next 5 years I will take advantage of our new laboratory research to test new drugs and diagnostics for Alzheimer’s disease. I will test in a clinical trial of Alzheimer’s patients whether a drug candidate slows disease progression, and test whether new technologies can be used to diagnose Alzheimer’s disease. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008375</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Kimberley Haines</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Co-designed Critical Care Recovery</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$520,592.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Physiotherapy</Field_s__of_Research>
        <Res_KW1>critical care</Res_KW1>
        <Res_KW2>recovery</Res_KW2>
        <Res_KW3>survivorship</Res_KW3>
        <Res_KW4>health outcomes</Res_KW4>
        <Res_KW5>patient outcomes</Res_KW5>
        <Plain_Description>This research aims to improve patient and family outcomes following critical illness by developing and evaluating a novel and promising intervention - peer support delivered virtually, where survivors can support each other to recover. The outcomes from this research will include two co-designed peer support interventions that can be delivered virtually. This will reduce inequities in access to recovery programs following critical illness in Australia, and will have global impact.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008376</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Enzo Porrello</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Harnessing the regenerative potential of the newborn heart.</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,548,555.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Cardiology (incl. Cardiovascular Diseases)</Field_s__of_Research>
        <Res_KW1>regeneration</Res_KW1>
        <Res_KW2>regenerative medicine</Res_KW2>
        <Res_KW3>stem cells</Res_KW3>
        <Res_KW4>heart development</Res_KW4>
        <Res_KW5>transcriptional regulation</Res_KW5>
        <Plain_Description>Heart failure is a massive and growing public health problem affecting over 25 million people worldwide. In contrast to the extremely limited regenerative capacity of the adult heart, we have discovered that the newborn mammalian heart retains a robust capacity for regeneration for a short period after birth. This Investigator Grant seeks to unlock the regenerative potential of the newborn heart for cardiac repair in children and adults with heart failure.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008379</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Loai Albarqouni</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Optimising the uptake of effective underused evidence-based non-drug interventions in primary care</Grant_Title>
        <Admin_Institution>Bond University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Primary Health Care</Field_s__of_Research>
        <Res_KW1>primary care</Res_KW1>
        <Res_KW2>general practice</Res_KW2>
        <Res_KW3>evidence-based clinical practice</Res_KW3>
        <Res_KW4>shared clinical decision making</Res_KW4>
        <Res_KW5>clinical practice guidelines</Res_KW5>
        <Plain_Description>Non-drug treatments, such as exercise for low back pain or behavioural therapy for depression, can be equally or more effective than drugs - with fewer side effects. Despite clinicians’ and patients’ growing interest in non-drug treatments, they are less known and used. My research program will develop evidence-based guides for effective non-drug treatments and provide world-first evidence on the best way to improve the uptake of non-drug treatments by clinicians and patients in primary care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008382</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Zhichao Wu</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Preventing Irreversible Vision Loss from Age-Related Macular Degeneration </Grant_Title>
        <Admin_Institution>Centre for Eye Research Australia</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,570,120.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Ophthalmology</Field_s__of_Research>
        <Res_KW1>macular degeneration</Res_KW1>
        <Res_KW2>eye disease</Res_KW2>
        <Res_KW3>diagnostic imaging</Res_KW3>
        <Res_KW4>visual function</Res_KW4>
        <Res_KW5>artificial neural networks</Res_KW5>
        <Plain_Description>Age-related macular degeneration (AMD) is the leading cause of irreversible central vison loss in people over 50 years old. No treatments are available to slow or prevent degeneration of the tissue responsible for vision from the more common “dry” form of AMD. This project will use state-of-the-art imaging, vision testing and artificial intelligence to substantially improve our assessment of new treatments, and to gain critical insights into disease mechanisms, needed for treatment discovery.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008392</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Brett Mitchell</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Building evidence for strategies to prevent healthcare acquired infections</Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,570,120.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Public Health and Health Services not elsewhere classified</Field_s__of_Research>
        <Res_KW1>infection control</Res_KW1>
        <Res_KW2>nosocomial infections</Res_KW2>
        <Res_KW3>nursing practice</Res_KW3>
        <Res_KW4>infectious diseases</Res_KW4>
        <Res_KW5>health services research</Res_KW5>
        <Plain_Description>Despite being common and affecting 160,000 Australians a year, strategies to prevent infection acquired healthcare are underpinned by low quality evidence.  The proposed research program consists of three discrete, inter-related projects. The work will provide evidence for practical measures to reduce common infections – urinary tract infection, pneumonia as well as improving cleaning in healthcare. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008408</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Sammy Bedoui</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Understanding how DC-T cell interactions regulate human disease</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,297,570.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Cellular Immunology</Field_s__of_Research>
        <Res_KW1>CD8 T cells</Res_KW1>
        <Res_KW2>innate immunity</Res_KW2>
        <Res_KW3>viral infection</Res_KW3>
        <Res_KW4>dendritic cell</Res_KW4>
        <Res_KW5>adaptive immunity</Res_KW5>
        <Plain_Description>My research has played a significant role in understanding how certain immune cells instruct the body to eliminate infections. Building on this expertise, my team and I will address fundamental question of immune cell function that will be vital for understanding immunity and to develop better therapies against virus infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008426</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Julieann Coombes</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>A new systems approach to discharge and follow up care models for chronic conditions in Aboriginal and Torres Strait Islander children.</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$550,740.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Aboriginal and Torres Strait Islander Health</Field_s__of_Research>
        <Res_KW1>Aboriginal health</Res_KW1>
        <Res_KW2>Aboriginal child</Res_KW2>
        <Res_KW3>burn injury</Res_KW3>
        <Res_KW4>quality improvement</Res_KW4>
        <Res_KW5>access to health care</Res_KW5>
        <Plain_Description>A program providing culturally safe discharge planning for Aboriginal children with a burn injury will be trailed in Darwin and Townsville. It includes a component ‘Building Cultural Capabilities’ an educational program for health workers to develop cultural capacity improving healthcare for Aboriginal and Torres Strait Islander patients. This project will improve the quality and safety of healthcare for Aboriginal children in Darwin and Townsville and will improving burn injury outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008436</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Dinh Bui</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Reducing the burden of chronic obstructive pulmonary disease (COPD): novel phenotypes, risk factors and biomarkers</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Epidemiology</Field_s__of_Research>
        <Res_KW1>epidemiology</Res_KW1>
        <Res_KW2>chronic obstructive pulmonary disease (COPD)</Res_KW2>
        <Res_KW3>prevention</Res_KW3>
        <Res_KW4>risk factors</Res_KW4>
        <Res_KW5>phenotype</Res_KW5>
        <Plain_Description>Chronic Obstructive Pulmonary Disease (COPD) is a major public health issue around the world. At present, the only known way to prevent COPD and lessen its severity is tobacco smoking avoidance. However, not everyone who gets COPD smokes and patients with COPD often have different forms of the disease. I will determine the different types and causes of COPD and develop tools to identify who is most at risk. My research will help develop interventions to prevent and better treat COPD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008447</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Alisa Higgins</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Healthcare resource utilisation and long term outcomes following critical illness</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$613,240.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Health Economics</Field_s__of_Research>
        <Res_KW1>critical care</Res_KW1>
        <Res_KW2>health outcomes</Res_KW2>
        <Res_KW3>health economics</Res_KW3>
        <Res_KW4>randomised controlled trial (RCT)</Res_KW4>
        <Res_KW5>health care utilisation</Res_KW5>
        <Plain_Description>Patients admitted to intensive care units (ICU) are the sickest patients in hospital but little is known about what happens to these patients after they are discharged. This project will evaluate long-term outcomes such as disability, quality of life, anxiety and depression after ICU, along with ongoing healthcare use (including readmission to hospital). It will also conduct health economic analyses to determine which interventions provide the greatest value for money.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008450</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Alexander Loukas</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Next-generation therapeutics inspired by parasitic helminths</Grant_Title>
        <Admin_Institution>James Cook University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$3,327,015.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Medical Biotechnology Diagnostics (incl. Biosensors)</Field_s__of_Research>
        <Res_KW1>helminth infection</Res_KW1>
        <Res_KW2>biological therapy</Res_KW2>
        <Res_KW3>hookworms</Res_KW3>
        <Res_KW4>schistosomiasis</Res_KW4>
        <Res_KW5>vaccines</Res_KW5>
        <Plain_Description>Billions of people in developing countries are infected with parasitic worms, but they have been eradicated from industrialised nations. Humans co-evolved with worms, so their recent removal has deprived us of signals required to keep inflammation in check. My research focuses on worm molecules that can be used as: (1) vaccines and diagnostics to combat parasitic infections in developing countries, and (2) a novel platform of anti-inflammatory therapeutics for use in industrialised nations.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008454</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Anne Cust</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Tailored approaches to improve prevention and early detection of melanoma and other skin cancers </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,023,555.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Preventive Medicine</Field_s__of_Research>
        <Res_KW1>cancer screening</Res_KW1>
        <Res_KW2>melanoma</Res_KW2>
        <Res_KW3>skin cancer</Res_KW3>
        <Res_KW4>cancer prevention</Res_KW4>
        <Res_KW5>cancer epidemiology</Res_KW5>
        <Plain_Description>This proposal will evaluate ways to tailor melanoma and skin cancer prevention and early detection strategies to a person’s individual risk. It will help us understand the overall benefits and harms of different approaches, how to implement good national strategies, and measure the value for money for the health system. This research will improve skin cancer outcomes for the community and patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008460</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Jo Robinson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Using social media to reduce suicide and self-harm in young people</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,248,555.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Mental Health</Field_s__of_Research>
        <Res_KW1>suicide prevention</Res_KW1>
        <Res_KW2>suicide</Res_KW2>
        <Res_KW3>internet</Res_KW3>
        <Res_KW4>young adults</Res_KW4>
        <Res_KW5>adolescent</Res_KW5>
        <Plain_Description>This program will address the role of social media on youth suicide and self-harm. It will lead to increased understanding of the harms and benefits of online communication from the perspective of young people, parents, professionals and the social media industry. Outputs include evidence-based guidance plus co-designed social media campaign targeting young people. If effective, this work will directly translate into increased online safety for at-risk young people in Australia and overseas.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008462</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Jiawen Li</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Developing more accurate cardiovascular disease detection with a cellular-resolution imaging catheter</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$588,308.31</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Biomedical Instrumentation</Field_s__of_Research>
        <Res_KW1>diagnostic imaging</Res_KW1>
        <Res_KW2>acute myocardial infarction (AMI)</Res_KW2>
        <Res_KW3>instrumentation</Res_KW3>
        <Res_KW4>plaque rupture</Res_KW4>
        <Res_KW5>atherosclerosis</Res_KW5>
        <Plain_Description>Most heart attacks are caused by high-risk plaques. The holy grail in cardiology would be to reliably detect high-risk plaques before they are life-threatening. This research program will deliver a clinically applicable device to detect high-risk plaques, helping cardiologists determine the most efficient treatment on an individual basis. The imaging device will be the first-of-its-kind worldwide, holding great hope of significantly reducing cost and complications in cardiovascular diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008488</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Vicki Anderson</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Optimising outcomes from child concussion from sidelines to recovery: improving diagnostic precision, effective treatment and community knowledge</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$3,198,056.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Clinical Sciences not elsewhere classified</Field_s__of_Research>
        <Res_KW1>concussion</Res_KW1>
        <Res_KW2>child</Res_KW2>
        <Res_KW3>youth</Res_KW3>
        <Res_KW4>biomarkers</Res_KW4>
        <Res_KW5>early intervention</Res_KW5>
        <Plain_Description>In the context of wide media attention, child concussion is of increasing community concern, despite limited empirical evidence regarding its real consequences. My research will identify mechanisms underlying persistent symptoms and link these predictive markers to individual recovery profiles and to treatment responses to optimise outcomes for children with concussion.       </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008501</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Richard Price</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Interventions to eliminate Plasmodium vivax malaria</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,897,045.75</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Infectious Diseases</Field_s__of_Research>
        <Res_KW1>clinical malaria</Res_KW1>
        <Res_KW2>clinical trial</Res_KW2>
        <Res_KW3>health economics</Res_KW3>
        <Res_KW4>molecular biology</Res_KW4>
        <Res_KW5>pharmacology</Res_KW5>
        <Plain_Description>Malaria affects more 230 million people each year. In Asia, the Americas and the Horn of Africa malaria due to Plasmodium vivax accounts for more than half of these cases. I will work with partners in malaria endemic countries to develop better, safer and more effective treatment strategies and design better surveillance to identify populations at greatest risk of infection. The ultimate aim of my program is to change policy, impact on health outcomes and eliminate vivax malaria globally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008523</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Adam Culvenor</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Reducing the burden of knee osteoarthritis in young adults</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,432,688.31</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Physiotherapy</Field_s__of_Research>
        <Res_KW1>knee osteoarthritis</Res_KW1>
        <Res_KW2>rehabilitation</Res_KW2>
        <Res_KW3>exercise therapy</Res_KW3>
        <Res_KW4>physiotherapy</Res_KW4>
        <Res_KW5>sports injury</Res_KW5>
        <Plain_Description>In young people (&lt;40 years), arthritis commonly occurs after knee injury, forcing them to live with old knees and reducing their quality of life. This program of research leverages established resources to address the urgent need to prevent arthritis in young adults by: i) understanding why some people are more likely to get knee arthritis; ii) enhancing the care of knee injuries to prevent arthritis; and iii) uniting international efforts with a world-first database of early arthritis outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008535</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Gary Sacks</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Enhancing policy implementation for healthy food environments</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,427,980.49</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Health Promotion</Field_s__of_Research>
        <Res_KW1>overweight/obesity</Res_KW1>
        <Res_KW2>health policy</Res_KW2>
        <Res_KW3>population health</Res_KW3>
        <Res_KW4>nutrition</Res_KW4>
        <Res_KW5>translational research</Res_KW5>
        <Plain_Description>This Investigator Grant aims to enhance the implementation of policies for creating healthy food environments. It is expected that the research program will provide new evidence to support effective policy action, and powerful mechanisms for holding governments and the food industry to account for their roles in improving population diets and preventing obesity. In so doing, the research will improve the policy response to the leading contributors to poor health in Australia and globally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008542</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Gabrielle Belz</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Harnessing immune cell programs to drive immune protection </Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,941,612.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Innate Immunity</Field_s__of_Research>
        <Res_KW1>transcription factor</Res_KW1>
        <Res_KW2>innate immunity</Res_KW2>
        <Res_KW3>mucosal immunity</Res_KW3>
        <Res_KW4>immune protection</Res_KW4>
        <Res_KW5>lymphocytes</Res_KW5>
        <Plain_Description>Immunity is essential for life. Harnessing the immune system to drive increased protection against disease has never been more urgent than now. Achieving this requires understanding the cues that regulate the activation of immune cells and the wiring needed for them to function efficiently and defeat pathogens. My work aims to unravel this complex network to harness the immune switches that will facilitate the future development of therapeutics and vaccines to treat world disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008546</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Mark White</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Novel oxygen sensing pathways in hypoxic disease</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$624,389.97</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Analytical Biochemistry</Field_s__of_Research>
        <Res_KW1>hypoxia</Res_KW1>
        <Res_KW2>oxygen</Res_KW2>
        <Res_KW3>protein characterisation</Res_KW3>
        <Res_KW4>protein degradation</Res_KW4>
        <Res_KW5>solid tumours</Res_KW5>
        <Plain_Description>Oxygen (O2) is a vital biological resource and sufficient concentrations are needed for normal metabolism. Reductions in O2 (hypoxia) can cause significant stress that subverts life and is a key feature of disorders such as cancer and cardiovascular disease. By understanding how cells respond to changes in O2 we can develop effective methods to treat these detrimental conditions. This project aims to increase knowledge of a new O2 sensing system to combat hypoxic cancers such as glioblastoma.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008565</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Elie Matar</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>From dreams to delirium and dementia: Cognitive fluctuations as a window into novel biomarkers and therapeutic targets for neurodegeneration</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$250,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Neurology and Neuromuscular Diseases</Field_s__of_Research>
        <Res_KW1>dementia with Lewy bodies</Res_KW1>
        <Res_KW2>Parkinson disease</Res_KW2>
        <Res_KW3>rapid eye movement (REM) sleep</Res_KW3>
        <Res_KW4>neurodegeneration</Res_KW4>
        <Res_KW5>biomarkers</Res_KW5>
        <Plain_Description>Lewy body dementias are characterized by marked swings in attention and arousal known as cognitive fluctuations. We aim to show that disturbances in the biology maintaining the normal balance between wakefulness and sleep underlie this core symptom and use this to identify new disease biomarkers and novel therapeutic targets of Lewy body disease. We apply this to recruit the first prodromal cohort of delirium-onset Lewy body dementia and to improve prediction and treatment of delirium generally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008572</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Tony Tiganis</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Phosphatases in the pathogenesis of obesity and cancer</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,927,015.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Signal Transduction</Field_s__of_Research>
        <Res_KW1>protein tyrosine phosphatase (PTP)</Res_KW1>
        <Res_KW2>insulin signalling</Res_KW2>
        <Res_KW3>immunotherapy</Res_KW3>
        <Res_KW4>liver cancer</Res_KW4>
        <Res_KW5>obesity</Res_KW5>
        <Plain_Description>Obesity has reached epidemic proportions and is major driver of chronic human diseases, including type 2 diabetes, cardiovascular disease, fatty liver disease and cancer. This proposal will define key molecular mechanisms contributing to the development of obesity and its co-morbidities, especially liver disease and cancer. We will thereon seek to develop novel therapeutic approaches for combating obesity and these insidious and recalcitrant diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008574</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Peter Azzopardi</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Defining effective health actions for adolescents globally</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$870,120.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Public Health and Health Services not elsewhere classified</Field_s__of_Research>
        <Res_KW1>adolescent health</Res_KW1>
        <Res_KW2>health inequalities</Res_KW2>
        <Res_KW3>intervention</Res_KW3>
        <Res_KW4>indigenous health</Res_KW4>
        <Res_KW5>regional health</Res_KW5>
        <Plain_Description>The world is now home to 1.8 billion adolescents, the largest population in human history. My earlier work has described the unmet health needs of these adolescents- the task now is to define how to best respond. Working in partnership with adolescents across Indigenous communities, Papua New Guinea and Myanmar, I will define the actions required to improve their health. I will define a package of actions that is informed by adolescents and can be implemented across health and education sectors.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008600</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Julie Hennegan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Measuring unmet menstrual health needs and their impacts on health and education</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Public Health and Health Services not elsewhere classified</Field_s__of_Research>
        <Res_KW1>menstruation</Res_KW1>
        <Res_KW2>developing countries</Res_KW2>
        <Res_KW3>social determinants</Res_KW3>
        <Res_KW4>reproductive health</Res_KW4>
        <Res_KW5>adolescent health</Res_KW5>
        <Plain_Description>Each day, over 300 million females are menstruating. Their menstrual health matters for gender equality, health, and education. My work will transform the way we measure women’s and girls’ menstrual health needs in low- and middle-income countries and advance evidence-based action in Southeast Asia and the Pacific. I will grow our understanding of how adolescent girls’ needs change over time and quantify the impacts of menstrual health on broader health and education outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008612</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Michael Breakspear</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Generative models of brain disorders</Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,872,570.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Central Nervous System</Field_s__of_Research>
        <Res_KW1>dynamic process modelling</Res_KW1>
        <Res_KW2>neuroimaging</Res_KW2>
        <Res_KW3>mathematical modelling</Res_KW3>
        <Res_KW4>schizophrenia</Res_KW4>
        <Res_KW5>dementia</Res_KW5>
        <Plain_Description>The management of many neurological and psychiatric disorders remains underwhelming, due in part to of our limited understanding of how the brain works. Consequently, clinical practice remains rooted in trial-and-error and expert opinion. To make progress, we need to improve our knowledge of the brain using tools that embrace its complexity. I will use advanced mathematical modelling to understand the rules that govern neural circuits in health and as they fail in common brain disorders.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008616</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof James McCluskey</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Immunity mediated by MHC class I-related protein (MR1)</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Cellular Immunology</Field_s__of_Research>
        <Res_KW1>cellular immunology</Res_KW1>
        <Res_KW2>antigen presentation</Res_KW2>
        <Res_KW3>immune protection</Res_KW3>
        <Res_KW4>tumour immunity</Res_KW4>
        <Res_KW5>innate immunity</Res_KW5>
        <Plain_Description>Immune T cells react to molecular changes in cells during infection revealed by antigen-presenting molecules that constantly sample molecular patterns. MR1 is a newly discovered Ag presentation molecule involved in microbial immunity, but new evidence indicates that MR1 can present unique molecules from cancer cells driving T cell immunity. This proposal seeks to understand this process to harness a new arm of immunity amenable to development of novel anti-tumour vaccines and immunotherapy. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008625</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Steven Taylor</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Achieving precision care in chronic lung disease</Grant_Title>
        <Admin_Institution>South Australian Health and Medical Research Institute</Admin_Institution>
        <State>SA</State>
        <Sector>Research Institutes</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Medical Microbiology not elsewhere classified</Field_s__of_Research>
        <Res_KW1>molecular microbiology</Res_KW1>
        <Res_KW2>chronic suppurative lung disorders</Res_KW2>
        <Res_KW3>asthma</Res_KW3>
        <Res_KW4>airway inflammation</Res_KW4>
        <Res_KW5>airway diseases</Res_KW5>
        <Plain_Description>Current treatment guidelines poorly manage up to 30% of all patients with a chronic lung disease (CLD). In order to improve this, we need to identify useful disease markers that inform treatment response. Using stored samples and data from thousands of CLD patients, I will meticulously measure markers of disease and identify patient characteristics that inform treatment response. This research will improve guidelines for the large number of patients with poor disease control.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008631</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Olga Kondrashova</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Improving outcomes for patients with homologous recombination deficient cancer</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Bioinformatics</Field_s__of_Research>
        <Res_KW1>ovarian cancer</Res_KW1>
        <Res_KW2>breast cancer</Res_KW2>
        <Res_KW3>DNA repair</Res_KW3>
        <Res_KW4>targeted therapy</Res_KW4>
        <Res_KW5>medical genomics</Res_KW5>
        <Plain_Description>Some cancers, including ovarian and breast, have faulty DNA repair, which makes them respond to powerful cancer drugs called PARP inhibitors. Unfortunately, many cancers eventually develop resistance to these drugs. I will use genomic technologies to study the portraits of cancers with faulty DNA repair. I will look at how we can prevent resistance to PARP inhibitors and to treat each cancer most effectively. This important work aims to improve the cancer survival rates.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008632</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Brendan McMullan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Improving antimicrobial  use and reducing harms in children</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$450,370.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Health Promotion</Field_s__of_Research>
        <Res_KW1>antimicrobial therapy</Res_KW1>
        <Res_KW2>infection</Res_KW2>
        <Res_KW3>paediatric</Res_KW3>
        <Res_KW4>health service decision making</Res_KW4>
        <Res_KW5>clinical epidemiology</Res_KW5>
        <Plain_Description>Antibiotics are often given to children in hospital incorrectly or for longer than needed. My program makes use of routinely collected Australian data, and introduces improved systems for managing antibiotics in hospital, including guidelines and policy. The program will improve the reporting of how antibiotics are used in Australian hospitals, improve management of those antibiotics in children, and lead to better outcomes for children and families, with less time spent in hospital. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008640</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Matthew Field</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Developing Bioinformatics Capability to Diagnose Infectious Diseases using Clinical Metagenomics </Grant_Title>
        <Admin_Institution>James Cook University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,420,530.96</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Genomics</Field_s__of_Research>
        <Res_KW1>bioinformatics</Res_KW1>
        <Res_KW2>DNA sequencing</Res_KW2>
        <Res_KW3>sequence analysis</Res_KW3>
        <Res_KW4>genetic variation</Res_KW4>
        <Res_KW5>computers</Res_KW5>
        <Plain_Description>Current methods to identify infectious pathogens are time-consuming, inaccurate, and unable to detect novel pathogens. This research will develop the bioinformatics and clinical tools needed to implement unbiased metagenomic sequencing as an improvement to current practice in pathogen diagnostics. This new approach can be implemented in remote and regional healthcare settings and will have enormous global impact on the world’s expanding tropical population, who have limited access to healthcare.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008645</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Enrico Coiera</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Bringing artificial intelligence into the real world of healthcare - the implementation challenge </Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,500,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Public Health and Health Services not elsewhere classified</Field_s__of_Research>
        <Res_KW1>implementation</Res_KW1>
        <Res_KW2>safety</Res_KW2>
        <Res_KW3>replication</Res_KW3>
        <Res_KW4>computer-based decision support</Res_KW4>
        <Res_KW5>artificial neural networks</Res_KW5>
        <Plain_Description>This research program focuses on three foundational challenges to bringing artificial intelligence (AI) into the clinical world. To ensure AI is safe, the 1st challenge, the program will research optimal mechanisms for surveillance and governance of AI safety. The 2nd challenge addressed is the lack of genuine independent testing of claims for the benefits of AI.  The 3rd challenge for clinical AI is that good performance in one setting may not be repeated in even closely related settings.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008648</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Ian Cockburn</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Understanding natural and vaccine-induced immunity to malaria</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$1,836,259.93</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Medical Parasitology</Field_s__of_Research>
        <Res_KW1>malaria</Res_KW1>
        <Res_KW2>B cells</Res_KW2>
        <Res_KW3>T cells</Res_KW3>
        <Res_KW4>vaccines</Res_KW4>
        <Res_KW5>innate immunity</Res_KW5>
        <Plain_Description>Malaria is responsible for the deaths of >400,000 individuals per year. Eradication of malaria will require a safe and effective vaccine. Vaccine development requires an understanding of the immune responses to malaria parasites and vaccines. The work here aims to understand the necessary components for a successful vaccine and to understand why our immune system struggles to make effective responses to malaria.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008649</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Maree Toombs</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Transforming Young Aboriginal and Torres Strait Islander Mental Health through New Knowledge and Co-designed Healings</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,000,625.46</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Traditional Aboriginal and Torres Strait Islander Medicine and Treatments</Field_s__of_Research>
        <Res_KW1>Aboriginal mental health</Res_KW1>
        <Res_KW2>Aboriginal child</Res_KW2>
        <Res_KW3>suicide prevention</Res_KW3>
        <Res_KW4>primary care</Res_KW4>
        <Res_KW5>disease prevalence</Res_KW5>
        <Plain_Description>Young Indigenous Australians have one of the highest rates of suicide in the world and this tragic situation is worsening. My research program will address this call to action through collaborating with Indigenous youth and experts in the field, including traditional healers, to co-design a scalable Youth Model of Mental Health Care to reduce the rates of inter-generational trauma leading to mental illness and suicide/self-harm in young Indigenous Australians. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008650</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Kerrie Wiley</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Integrating social science evidence into the fight against vaccine-preventable and vector-borne diseases in the Australasian, South East Asian and Pacific regions.</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Pacific Peoples Health</Field_s__of_Research>
        <Res_KW1>social and behavioural research</Res_KW1>
        <Res_KW2>vector-borne disease</Res_KW2>
        <Res_KW3>vaccine-preventable diseases</Res_KW3>
        <Res_KW4>behavioural intervention</Res_KW4>
        <Res_KW5>disease prevention</Res_KW5>
        <Plain_Description>Rejection of preventive health measures like vaccination is a global issue.  Knowing what drives it is crucial to how health authorities respond but they don’t currently have tools to measure these drivers . This research adds social / behavioural data and new analysis methods to health authorities’ toolkit, e allowing new understanding of how diseases behave in human populations, and how humans behave around those diseases, enabling  targeted public health interventions to reduce disease.   </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008652</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Edwin Hawkins</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>In situ visualisation of cell fate</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,598,844.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Biochemistry and Cell Biology not elsewhere classified</Field_s__of_Research>
        <Res_KW1>microenvironment</Res_KW1>
        <Res_KW2>imaging</Res_KW2>
        <Res_KW3>cancer cell biology</Res_KW3>
        <Res_KW4>blood diseases</Res_KW4>
        <Res_KW5>autoimmunity</Res_KW5>
        <Plain_Description>Maintaining millions of blood cells every day is crucial for health and development. When this process is compromised, we can develop a range of diseases including cancer and a compromised immune system. To understand how this complex system is regulated, we have developed technology to watch blood cell behaviour in living tissue. Using this approach, I aim to develop new ways of driving healthy blood cell production and eliminating cells that cause disease.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008692</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof James Vince</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Inflammatory Responses to Programmed Cell Death Signalling                                                    </Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,348,555.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Cell Development, Proliferation and Death</Field_s__of_Research>
        <Res_KW1>cell death</Res_KW1>
        <Res_KW2>inflammation</Res_KW2>
        <Res_KW3>signal transduction</Res_KW3>
        <Res_KW4>innate immunity</Res_KW4>
        <Res_KW5>ubiquitination</Res_KW5>
        <Plain_Description>Inflammatory cytokines are the alarms that cells in our body engage to protect us against infections. However, when made in excess cytokines contribute to diseases such as arthritis, heart disease and hereditary inflammatory syndromes. This project aims to define the molecular mechanisms by which inappropriate cell death induces damaging levels of cytokines to cause disease.  Understanding how inflammation is controlled at the molecular level will allow the design of new, targeted, therapies. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008697</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Kinley Wangdi</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Geospatial applications for the control of Tropical Infectious Diseases in the Asia-Pacific Region</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Epidemiology</Field_s__of_Research>
        <Res_KW1>tropical disease</Res_KW1>
        <Res_KW2>surveillance</Res_KW2>
        <Res_KW3>disease modelling</Res_KW3>
        <Res_KW4>prevention</Res_KW4>
        <Res_KW5>cost-effectiveness</Res_KW5>
        <Plain_Description>My research program will improve geographical mapping to better prevent, detect, and manage malaria, dengue, and intestinal worms in tropical countries. Projects include developing systems to rapidly map and report new cases of malaria to facilitate effective interventions, building an early warning system for dengue, and predicting high-risk areas for intestinal worms. The research will improve in the prediction, early warning, and rapid response to control and elimination of these diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008698</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Chun-Xia Zhao</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Novel nanotechnology strategies towards a new paradigm of precision nanomedicine</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$2,248,555.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Biomaterials</Field_s__of_Research>
        <Res_KW1>drug delivery systems</Res_KW1>
        <Res_KW2>nanotechnology</Res_KW2>
        <Res_KW3>biomaterials</Res_KW3>
        <Res_KW4>drug delivery</Res_KW4>
        <Res_KW5>biotechnology</Res_KW5>
        <Plain_Description>Nanotechnology offers exciting prospects for many devastating diseases such as cancer. Despite the clinical success of a few nanomedicines, the development of cancer nanomedicines for effective and targeted delivery to pathogenic areas has  been limited. This project aims to develop revolutionising nanomedicines capable of simultaneous administration of two or more drugs in targeted cancer disease for synergistic therapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008699</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Seth Masters</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Diagnosis and Therapy based on new Mechanisms of Autoinflammatory Disease</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,948,555.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Innate Immunity</Field_s__of_Research>
        <Res_KW1>innate immunity</Res_KW1>
        <Res_KW2>inflammation</Res_KW2>
        <Res_KW3>inflammatory diseases</Res_KW3>
        <Res_KW4>immunogenetics</Res_KW4>
        <Res_KW5>neuroinflammation</Res_KW5>
        <Plain_Description>Mutations of our genetic code can affect cells of our immune system, leading to a functional loss or gain that can cause recurrent infection, or in some cases, promote autoimmunity and autoinflammation. Our investigation of these inborn errors of immunity will advance our understanding of disease mechanisms, and the fundamental workings of our immune system, in order to identify and improve therapies that will potentially treat a range of inflammatory diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008702</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Gregore Mielke</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Moving beyond one-size-fits-all: Exploring the optimal doses of physical activity and sedentary behaviour across the lifespan for prevention of non-communicable chronic diseases</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Human Movement and Sports Science not elsewhere classified</Field_s__of_Research>
        <Res_KW1>behavioural epidemiology</Res_KW1>
        <Res_KW2>physical activity</Res_KW2>
        <Res_KW3>sedentary behaviour</Res_KW3>
        <Res_KW4>chronic diseases</Res_KW4>
        <Res_KW5>epidemiology</Res_KW5>
        <Plain_Description>It is well known that physical inactivity is a risk factor for the development of non-communicable chronic diseases. This research program will determine the optimal doses of physical activity and sedentary behaviour during childhood, adolescence, adulthood and old age to prevent mental and physical health conditions. This research program will inform the development of strategies to reduce the social and fiscal burden of non-communicable chronic diseases in Australia. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008715</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Andreas Kupz</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Towards elimination of tuberculosis</Grant_Title>
        <Admin_Institution>James Cook University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,170,120.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Medical Bacteriology</Field_s__of_Research>
        <Res_KW1>Mycobacterium tuberculosis</Res_KW1>
        <Res_KW2>vaccine</Res_KW2>
        <Res_KW3>pre-clinical studies</Res_KW3>
        <Res_KW4>indigenous Australians</Res_KW4>
        <Res_KW5>mucosal immunity</Res_KW5>
        <Plain_Description>The development of new safe and effective vaccines is necessary for the control of tuberculosis, the leading infectious cause of death globally. Bacillus Calmette-Guérin (BCG), the only licensed tuberculosis vaccine, prevents severe forms of tuberculosis in children, but fails to protect adults. This project aims to further develop a new tuberculosis vaccine, to perform pre-clinical efficacy studies and to increase BCG coverage in vulnerable children in Far North Queensland and Papua New Guinea.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008723</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Nicole Warrington</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Using genetics to identify optimal times to intervene on early life growth and reduce future risk of cardio-metabolic disease</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,570,120.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Quantitative Genetics (incl. Disease and Trait Mapping Genetics)</Field_s__of_Research>
        <Res_KW1>statistical genetics</Res_KW1>
        <Res_KW2>genetic association</Res_KW2>
        <Res_KW3>growth</Res_KW3>
        <Res_KW4>cardiovascular risk</Res_KW4>
        <Res_KW5>body mass index</Res_KW5>
        <Plain_Description>The prevalence of cardiovascular disease and diabetes is increasing and the financial burden on society is substantial. Children who have unfavourable growth through early life are at increased risk of these diseases. This study aims to perform the largest genetic study of fetal growth and body mass index over childhood, and then investigate the relationship between early life growth and future risk of diseases like diabetes. Knowledge gained will inform the design of public health initiatives.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008727</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Stuart Brierley</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Identifying the underlying causes and discovering novel therapeutic treatments for chronic visceral pain (CVP)</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$2,173,555.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Peripheral Nervous System</Field_s__of_Research>
        <Res_KW1>chronic pain</Res_KW1>
        <Res_KW2>irritable bowel syndrome (IBS)</Res_KW2>
        <Res_KW3>nociception</Res_KW3>
        <Res_KW4>ion channels</Res_KW4>
        <Res_KW5>sensory nerves</Res_KW5>
        <Plain_Description>Chronic visceral pain is a major but underappreciated clinical, social and economic challenge affecting >1.5 billion people globally. Leading forms of chronic visceral pain include irritable bowel syndrome, endometriosis and bladder pain syndrome, but all lack effective treatments. Using scientific models, human biospecimens and translational science my program will identify the causes of these prevalent forms of chronic pain and develop novel treatments for these debilitating conditions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008735</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Jenny Lee</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Real-time prediction and monitoring of head and neck cancer treatment</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$530,518.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Cancer Therapy (excl. Chemotherapy and Radiation Therapy)</Field_s__of_Research>
        <Res_KW1>cancer immunotherapy</Res_KW1>
        <Res_KW2>biomarkers</Res_KW2>
        <Res_KW3>clinical trial</Res_KW3>
        <Res_KW4>cancer biology</Res_KW4>
        <Res_KW5>cancer prognosis</Res_KW5>
        <Plain_Description>Survival in patients with advanced head and neck cancer remains &lt;12 months in the majority. Immunotherapy has durable response, however &lt;20% of patients derive benefit. My program of research uses the patient’s tumour to test responses to new drugs and select the best therapy. The research applied novel, innovative methods and detects cancer using blood samples. Novel clinical trials will be designed to improve patient outcomes and avoid unnecessary side effects and drive down health care cost.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008737</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Genevieve Rayner</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Phenotyping Neurobehavioural Disorders in People with Epilepsy</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$370,353.39</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Medical Genetics (excl. Cancer Genetics)</Field_s__of_Research>
        <Res_KW1>epilepsy</Res_KW1>
        <Res_KW2>neuropsychology</Res_KW2>
        <Res_KW3>phenotype-genotype correlation</Res_KW3>
        <Res_KW4>behaviour disorders</Res_KW4>
        <Res_KW5>cognitive dysfunction</Res_KW5>
        <Plain_Description>Neurobehavioural disorders like depression, psychosis, and cognitive impairment are common in people with epilepsy. Recent discoveries suggest there may be a shared genetic underpinning of the two. This project aims to identify whether there are distinct profiles of neurobehavioural disorders in families who carry epilepsy genes. Exploring the genetic basis of neurobehavioural disorders will improve detection and management of comorbid neurobehavioural disorders in epilepsy. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008743</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Richard Harvey</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>A single cell, single molecule and multi-omics approach to identifying novel targets in heart failure</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,027,015.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Developmental Genetics (incl. Sex Determination)</Field_s__of_Research>
        <Res_KW1>fibroblasts</Res_KW1>
        <Res_KW2>myofibroblast</Res_KW2>
        <Res_KW3>heart disease</Res_KW3>
        <Res_KW4>acute myocardial infarction (AMI)</Res_KW4>
        <Res_KW5>adult stem cells</Res_KW5>
        <Plain_Description>Heart failure (HF) is a significant problem in our society. Fibrosis is associated with virtually all forms of CV disease and leads to problems with heart contraction. We hypothesise that a deeper understanding of fibrosis will facilitate cardiac regenerative medicine. Our grant focuses on technologies that allow us to understand tissue complexity down to the level of single cells. Applying these methods, we hope to revolutionise our understanding of cardiac health, ageing and disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008774</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Ms Karine Manera</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Partnering with patients to assess and address loneliness in chronic kidney disease</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Public Health and Health Services not elsewhere classified</Field_s__of_Research>
        <Res_KW1>social and behavioural research</Res_KW1>
        <Res_KW2>kidney disease</Res_KW2>
        <Res_KW3>nephrology</Res_KW3>
        <Res_KW4>social networks</Res_KW4>
        <Res_KW5>health behaviours</Res_KW5>
        <Plain_Description>Strong social connections and healthy lifestyles are vital for the health of people with chronic kidney disease. This research program will establish world-first evidence of the predictors and impacts of loneliness in CKD. In partnership with consumers, it will identify patient and caregiver priorities for interventions to reduce loneliness and improve social connections, and implement these patient-prioritised interventions in a novel trial to improve patient-centred care and outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008781</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof David Bowtell</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Driving Improvements in Ovarian Cancer Survival through Molecular and Clinical Studies</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,427,015.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Cancer Cell Biology</Field_s__of_Research>
        <Res_KW1>ovarian cancer</Res_KW1>
        <Res_KW2>genomics</Res_KW2>
        <Res_KW3>cancer biology</Res_KW3>
        <Res_KW4>drug resistance</Res_KW4>
        <Res_KW5>targeted therapy</Res_KW5>
        <Plain_Description>The Investigator grant would support Professor Bowtell, one of the world’s leading ovarian cancer researchers. His work focuses on clinical problems of chemotherapy resistance, investigator of rare, exceptional survival patient cohorts, and the development of new therapeutic approaches. His studies are underpinned by the Australian Ovarian Cancer Study (AOCS), one of the world’s most sophisticated clinical cohort studies of ovarian cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008793</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Atul Malhotra</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Cell Therapies for Newborn Infants: Translating Promise to Benefits   </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$431,671.37</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Paediatrics and Reproductive Medicine not elsewhere classified</Field_s__of_Research>
        <Res_KW1>prematurity</Res_KW1>
        <Res_KW2>cell therapy</Res_KW2>
        <Res_KW3>neuroprotection</Res_KW3>
        <Res_KW4>early detection</Res_KW4>
        <Res_KW5>cerebral palsy</Res_KW5>
        <Plain_Description>Premature babies are at increased risk of brain injury and cerebral palsy. Stem cell therapies offer a paradigm shifting treatment strategy for preterm brain injury. Over the next five years, I will lead a world-first research program to evaluate umbilical cord blood derived cell therapies as an early treatment of brain injury in high-risk preterm infants. I will conduct three proof of concept studies that are crucial to progress my research pipeline of cell-based therapies for preterm infants. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008813</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Yuming Guo</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>New Knowledge and Research Capacity for Health Impacts of Global Environmental Change with Big Data, Novel Approach and New Technology</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,598,844.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Epidemiology</Field_s__of_Research>
        <Res_KW1>climate change</Res_KW1>
        <Res_KW2>air pollution</Res_KW2>
        <Res_KW3>environmental health</Res_KW3>
        <Res_KW4>environmental epidemiology</Res_KW4>
        <Res_KW5>environmental risk factors</Res_KW5>
        <Plain_Description>This Investigator Grant research program will produce extremely significant outputs, including transformative changes to guidelines on global environmental change (e.g., climate change adaptation strategy, air quality standard and extreme weathers’ early warning system), new information to ensure direct impacts on public health policy and practice, and development of novel research methods for environmental epidemiology and strengthening the Australia’s leadership in the field. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008839</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Jill Newby</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Improving outcomes for people with Illness Anxiety Disorder</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,570,120.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Psychology not elsewhere classified</Field_s__of_Research>
        <Res_KW1>anxiety disorders</Res_KW1>
        <Res_KW2>psychosomatics</Res_KW2>
        <Res_KW3>internet service delivery</Res_KW3>
        <Res_KW4>mental health</Res_KW4>
        <Res_KW5>mental health services</Res_KW5>
        <Plain_Description>Illness anxiety disorder emerges early in life, causing great distress and disability, but if we detect and treat it early, this can yield great benefits in quality of life, and improved mental and physical health. This program of research will discover the best ways to assess, diagnose, and detect Illness anxiety disorder, improve access to evidence-based treatment using technology-based solutions, and develop new and improved treatments for Illness Anxiety Disorder. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008853</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Roland Ruscher</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Age-associated properties of intraepithelial lymphocytes, and their relation to intestinal diseases</Grant_Title>
        <Admin_Institution>James Cook University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$600,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Cellular Immunology</Field_s__of_Research>
        <Res_KW1>immunology</Res_KW1>
        <Res_KW2>mucosal immunology</Res_KW2>
        <Res_KW3>T cells</Res_KW3>
        <Res_KW4>cellular immunology</Res_KW4>
        <Res_KW5>gut immunity</Res_KW5>
        <Plain_Description>Inflammatory bowel disease (IBD) and colorectal cancer are a severe burden to those affected. While the peak onset age of IBD lies in early adulthood, colorectal cancer predominantly affects people over 50 years of age. How gut immunity fails in the context of age is poorly understood. This program will establish cornerstones of the intestinal immune system over different stages in life, and thereby help to design better treatment strategies that are adjusted to an individual’s age.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008871</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Jay Rasmussen</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Repetitive DNA as a contributing factor to tauopathy</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Gene Expression (incl. Microarray and other genome-wide approaches)</Field_s__of_Research>
        <Res_KW1>genomics</Res_KW1>
        <Res_KW2>genomic instability</Res_KW2>
        <Res_KW3>neurodegeneration</Res_KW3>
        <Res_KW4>age-related</Res_KW4>
        <Res_KW5>dementia</Res_KW5>
        <Plain_Description>The genome contains many regions of repetitive DNA sequence, some of which, termed mobile elements, can "copy-and-paste" themselves into new segments of the host genetic material. While a lot is known about the molecular mechanism behind their mobility, less is known about how mobile elements contribute to diseased states such as neurodegeneration. This project will investigate how mobile elements are regulated in tau pathology and whether this is age- or cell-specific.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008887</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Michael Kamm</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Microbiome Manipulation to Treat and Cure Inflammatory Bowel Disease</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,927,015.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Gastroenterology and Hepatology</Field_s__of_Research>
        <Res_KW1>Crohn's disease</Res_KW1>
        <Res_KW2>inflammatory bowel disease (IBD)</Res_KW2>
        <Res_KW3>clinical microbiology</Res_KW3>
        <Res_KW4>translational research</Res_KW4>
        <Res_KW5>gastrointestinal disease</Res_KW5>
        <Plain_Description>Immunosuppressive therapies for inflammatory bowel disease cause side effects and often don’t achieve remission. Targeting gut bacteria, which cause these disorders, is a promising alternative strategy. My programs have shown that faecal transplantation (FMT) is effective in ulcerative colitis, and identified key causative &amp; protective bacteria. I will now assess FMT in Crohn’s disease, define how diet &amp; bacteria combined cause inflammation, and identify bacteria causing disease complications. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008909</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Peter De Cruz</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Improving Outcomes in Inflammatory Bowel Disease: A Multifaceted Program of Research</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,456,096.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Clinical Microbiology</Field_s__of_Research>
        <Res_KW1>chronic inflammatory disease</Res_KW1>
        <Res_KW2>inflammatory bowel disease (IBD)</Res_KW2>
        <Res_KW3>Crohn's disease</Res_KW3>
        <Res_KW4>ulcerative colitis</Res_KW4>
        <Res_KW5>drug treatment</Res_KW5>
        <Plain_Description>Inflammatory bowel diseases (IBD) are chronic disorders involving damage to the gut. IBD is thought to result from an inherited tendency to develop an exaggerated immune response to the gut bugs.  IBD adversely impacts patients’ quality of life, psychological and social functioning. This research program seeks to develop new treatments and use existing treatments more effectively, discover factors contributing to IBD development and explore cost-effective ways of optimally caring for patients. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008911</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Kirsten Perrett</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Reducing the food allergy epidemic through prevention and early intervention</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,306,096.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Paediatrics</Field_s__of_Research>
        <Res_KW1>food allergy</Res_KW1>
        <Res_KW2>clinical trial</Res_KW2>
        <Res_KW3>allergy prevention</Res_KW3>
        <Res_KW4>treatment strategies</Res_KW4>
        <Res_KW5>translational research</Res_KW5>
        <Plain_Description>One in ten Australian infants has food allergy. My research program aims to reduce this burden and give every child the best chance of going to school without food allergy. Using high-quality clinical trials, I will test strategies to prevent food allergy (e.g.: infant vitamin D drops), and early intervention strategies to treat young children newly diagnosed with food allergy. Through established national collaborations, I will ensure my research findings rapidly become standard clinical care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008913</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Dale Godfrey</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Unconventional T cells: Fundamental biology and therapeutic potential</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,927,015.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Tumour Immunology</Field_s__of_Research>
        <Res_KW1>immunity</Res_KW1>
        <Res_KW2>T cell immunity</Res_KW2>
        <Res_KW3>tumour immunity</Res_KW3>
        <Res_KW4>antiviral immunity</Res_KW4>
        <Res_KW5>innate immunity</Res_KW5>
        <Plain_Description>There are many cell types in the human immune system that we still do not understand, in particular, a group of white blood cells broadly known as unconventional T cells. These cells detect abnormalities in molecules such as lipids, signatures of microbial infection, and drug metabolites, and they play a unique role in infection, cancer, allergy, autoimmunity, and tissue maintenance. This project aims to better understand the development and function of these cells in health and disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008920</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Chien-Hsiung Yu</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Taking neuroinflammation out of TDP-43 proteinopathies</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$600,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Innate Immunity</Field_s__of_Research>
        <Res_KW1>neuroinflammation</Res_KW1>
        <Res_KW2>neurodegenerative disorders</Res_KW2>
        <Res_KW3>mitochondrial disease</Res_KW3>
        <Res_KW4>neuronal cell death</Res_KW4>
        <Res_KW5>type I interferon</Res_KW5>
        <Plain_Description>Abnormal accumulation of proteins inside cells of the central nervous system is a disease hallmark of ALS/FTLD. I have discovered that one protein in particular, TDP-43, triggers an inflammatory response that precedes overt disease symptoms. My investigation of this inflammatory pathway will define how it triggers cell death. Further, understanding how TDP-43 causes disease will aid drug development and advance our knowledge of the pathogenesis of these incurable conditions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008921</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Arthur Kitching</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Better treatments for autoimmune kidney disease and vasculitis</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,297,570.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Autoimmunity</Field_s__of_Research>
        <Res_KW1>glomerulonephritis</Res_KW1>
        <Res_KW2>kidney disease</Res_KW2>
        <Res_KW3>vasculitis</Res_KW3>
        <Res_KW4>autoimmune disease</Res_KW4>
        <Res_KW5>cellular immunity</Res_KW5>
        <Plain_Description>Severe kidney disease caused by autoimmune inflammation of small blood vessels has no cure, and treatments cause significant side effects. However, opportunities exist for therapies that target only the abnormal parts of the immune response. Work in this application will provide a pathway for the development and testing of these new approaches, by understanding how disease occurs and which parts of the critical proteins involved are the culprits in these damaging and debilitating diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008928</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Quan Nguyen</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>SPatially ACcurate Evaluation (SPACE) of Cancer Biopsies</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,353,726.56</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Cancer Genetics</Field_s__of_Research>
        <Res_KW1>bioinformatics</Res_KW1>
        <Res_KW2>differential gene expression</Res_KW2>
        <Res_KW3>computer-assisted diagnosis</Res_KW3>
        <Res_KW4>malignant skin melanoma</Res_KW4>
        <Res_KW5>cancer biology</Res_KW5>
        <Plain_Description>Almost all suspected cancer patients have tissue biopsies manually examined. For decades, histological images are essential for diagnosis and treatment-decision making. Such an image diagnosis, however, fails to identify many cell types and their molecular signatures that underpin cancer metastasis. This program aims to establish a paradigm-shifting approach that maps spatially defined molecular data to tissue images, allowing for mechanistic understandings and accurate prediction of metastasis.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008955</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Josefine Antoniades</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>CultureCare: Co-designing an aged care decision aid for the South Asian communities to empower informed and culturally safe decision making about aged care services</Grant_Title>
        <Admin_Institution>National Ageing Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Public Health and Health Services not elsewhere classified</Field_s__of_Research>
        <Res_KW1>aged care</Res_KW1>
        <Res_KW2>cross-cultural</Res_KW2>
        <Res_KW3>ageing population</Res_KW3>
        <Res_KW4>access to health care</Res_KW4>
        <Res_KW5>dementia care</Res_KW5>
        <Plain_Description>This program of work seeks to develop a decision aid to empower older people and their families from South Asian backgrounds to plan, navigate and appraise aged care services to ensure these meet the needs of the older person. In this work, members of the South Asian community will be involved at every step of the project to ensure that the decision aid is culturally relevant, meets the needs of the community and is useful in the decision making process.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008956</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Ada Cheung</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Improving the health and wellbeing of transgender Australians </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,570,120.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Endocrinology</Field_s__of_Research>
        <Res_KW1>gender differences</Res_KW1>
        <Res_KW2>gender</Res_KW2>
        <Res_KW3>testosterone</Res_KW3>
        <Res_KW4>estradiol</Res_KW4>
        <Res_KW5>suicide prevention</Res_KW5>
        <Plain_Description>Transgender Australians are arguably among the most marginalised and socioeconomically disadvantaged groups in our community with high rates of depression, suicidality and a lack of research to guide optimal gender-affirming hormone and surgical interventions. This project will provide robust evidence to improve the health and well-being of the transgender community to guide treatment guidelines, and health policy, to enable trans people to live a life without barriers and discrimination. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008971</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Wolfgang Marx</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Nutritional Psychiatry: Investigation and translation of personalised nutritional therapies for depression</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$551,268.65</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Nutrition and Dietetics not elsewhere classified</Field_s__of_Research>
        <Res_KW1>mental health</Res_KW1>
        <Res_KW2>nutrition</Res_KW2>
        <Res_KW3>diet</Res_KW3>
        <Res_KW4>depression</Res_KW4>
        <Res_KW5>treatment</Res_KW5>
        <Plain_Description>Mental disorders account for the leading cause of disability. Dietary interventions represent a novel efficacious treatment to avert this significant burden.  To advance the field of Nutritional Psychiatry, we need to establish how diet affects depression, who is most receptive to treatment, and design guidelines on how best to integrate diet into mental health care. My program of research will advance the evidence base and facilitate translation of this new knowledge into policy and practice.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008981</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Jamie Rossjohn</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>A molecular investigation into T cell antigen receptor function and dysfunction in humans</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$3,927,015.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Structural Biology (incl. Macromolecular Modelling)</Field_s__of_Research>
        <Res_KW1>cellular immunology</Res_KW1>
        <Res_KW2>innate immunity</Res_KW2>
        <Res_KW3>major histocompatibility complex (MHC)</Res_KW3>
        <Res_KW4>X-ray crystallography</Res_KW4>
        <Res_KW5>autoimmune disease</Res_KW5>
        <Plain_Description>I am a biomedical researcher who focuses on understanding processes central to infection and immunity. My research program covers the pathogenesis of infectious human diseases, adaptive and innate immunity and autoimmunity.  I use biochemical approaches and structural biology as my main research tool, and my research program, which involves an international network of basic, clinical and industrial collaborators, has considerable relevance to applied outcomes for human immunological diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008983</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Mohammed Eslam</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Leveraging human genetics to inform treatment in fatty liver disease</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,270,120.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Gastroenterology and Hepatology</Field_s__of_Research>
        <Res_KW1>fatty liver disease</Res_KW1>
        <Res_KW2>hepatic fibrosis</Res_KW2>
        <Res_KW3>liver</Res_KW3>
        <Res_KW4>hepatic</Res_KW4>
        <Res_KW5>liver cirrhosis</Res_KW5>
        <Plain_Description>Fatty liver disease affects 1 in 3 Australians and a quarter will develop liver failure or cancer; it has no drug treatments. The disease is characterized by tremendous variability in its clinical course, in part due to a lack of understanding of its genetic basis. To move towards personalised medicine, this program will undertake human and small animal studies to develop novel gene-based tests for diagnostics and risk classification and identify genes that are targets for drug development.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008990</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof David Tscharke</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Reducing the burden of DNA viruses on human health</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$2,072,570.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Medical Virology</Field_s__of_Research>
        <Res_KW1>virology</Res_KW1>
        <Res_KW2>antiviral immunity</Res_KW2>
        <Res_KW3>antigen presentation</Res_KW3>
        <Res_KW4>CD8 T cells</Res_KW4>
        <Res_KW5>Herpes simplex virus (HSV)</Res_KW5>
        <Plain_Description>I aim to improve health by understanding how viruses interact with our bodies. This includes processes inside cells that keep microbes like the cold sore virus dormant. Also the way in which the white blood cells that allow our immune system to remember and respond more quickly to an infection after vaccination choose the parts of a virus to target. Finally we will find ways to help people on some treatments for diseases like multiple sclerosis avoid a common virus that is dangerous for them.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009005</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Rachel Climie</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Primordial prevention of cardiovascular disease from childhood</Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Cardiovascular medicine and Haematology nec</Field_s__of_Research>
        <Res_KW1>cardiovascular disease prevention</Res_KW1>
        <Res_KW2>cardiovascular risk factors</Res_KW2>
        <Res_KW3>cardiovascular health</Res_KW3>
        <Res_KW4>child health</Res_KW4>
        <Res_KW5>arterial stiffness</Res_KW5>
        <Plain_Description>Cardiovascular disease (CVD) is the leading cause of death worldwide. The risk factors for CVD begin to develop in childhood. Given the increasing rates of poor health in children worldwide, my research program will identify factors contributing to cardiovascular health in childhood, establish new ways to detect children at risk of developing CVD, and will develop strategies to improve cardiovascular health in children that can be easily implemented into policy and practice. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009010</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Peter Croucher</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>The Dormant Cancer Cell Life Cycle</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,427,015.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Haematological Tumours</Field_s__of_Research>
        <Res_KW1>bone biology</Res_KW1>
        <Res_KW2>bone cancer</Res_KW2>
        <Res_KW3>bone cells</Res_KW3>
        <Res_KW4>multiple myeloma</Res_KW4>
        <Res_KW5>bone metastasis</Res_KW5>
        <Plain_Description>In many major cancers, tumour cells spread to the skeleton and hide there in a long-term ‘dormant’ state where they resist current therapies. When they are ‘woken up’, they cause cancer relapse, at which point prognosis is poor. My vision is to devise new treatments that eradicate these rare dormant cells, so as to cure cancers that spread to bone. I will achieve this by defining the cell and molecular pathways, in dormant cells and in the surrounding bone, that control dormancy and relapse.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009026</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Hamish Graham</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Hypoxaemia detection and management for at-risk newborns and children in Sub-Saharan Africa</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$570,592.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Paediatrics</Field_s__of_Research>
        <Res_KW1>pulse oximetry</Res_KW1>
        <Res_KW2>oxygen</Res_KW2>
        <Res_KW3>pneumonia</Res_KW3>
        <Res_KW4>premature infant</Res_KW4>
        <Res_KW5>hypoxaemia</Res_KW5>
        <Plain_Description>Low blood oxygen levels (hypoxaemia) are common in COVID-19, pneumonia, and many other illnesses. In low-resource settings, many patients who need oxygen will not receive it, and could die. My research aims to make oxygen more accessible and safe to patients, particularly small newborns, children, and people living in remote locations. I will test a new device to deliver oxygen to babies more safely, and test whether introducing pulse oximetry to small clinics saves lives.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009035</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Louise Baur</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Transforming the prevention and treatment of child and adolescent obesity</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,750,000.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Health Promotion</Field_s__of_Research>
        <Res_KW1>obesity</Res_KW1>
        <Res_KW2>adolescent health</Res_KW2>
        <Res_KW3>early childhood</Res_KW3>
        <Res_KW4>health promotion</Res_KW4>
        <Res_KW5>health services</Res_KW5>
        <Plain_Description>Obesity in children &amp; adolescents is a serious problem with immediate and future complications. My vision is to lead an interdisciplinary program of research in preventing obesity in childhood and providing safe, effective treatments to children and adolescents living with obesity. My work will result in recommendations for targeting early childhood obesity prevention, personalised approaches to obesity treatment, and models of care &amp; costings for paediatric obesity treatment in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009047</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Sant-Rayn Pasricha</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Alleviating anaemia in mothers and babies worldwide</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,398,844.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Public Health and Health Services not elsewhere classified</Field_s__of_Research>
        <Res_KW1>anaemia</Res_KW1>
        <Res_KW2>iron deficiency</Res_KW2>
        <Res_KW3>nutrition</Res_KW3>
        <Res_KW4>randomised controlled trial (RCT)</Res_KW4>
        <Res_KW5>translational research</Res_KW5>
        <Plain_Description>Anaemia can cause fatigue, lethargy, and impair health outcomes during pregnancy and in children, and affects over 1.7 billion people. I will develop and test innovative new solutions to reduce anaemia in children and pregnant mothers, and use samples from these studies to drive new discoveries that will inform development of next generation improved treatments. Finally, I lead the WHO Collaborating Centre on anaemia control, enabling our findings to be quickly translated into practice. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009050</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Molla Wassie</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Personalising colorectal cancer prevention strategies with a risk stratification tool</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Epidemiology</Field_s__of_Research>
        <Res_KW1>cancer epidemiology</Res_KW1>
        <Res_KW2>public health</Res_KW2>
        <Res_KW3>dietary lifestyle</Res_KW3>
        <Res_KW4>colorectal cancer prevention</Res_KW4>
        <Res_KW5>health surveillance</Res_KW5>
        <Plain_Description>Bowel cancer is the second leading cause of cancer death in Australia. People who are at increased risk for this cancer are recommended to have colonoscopies every 3-5 years, with minimal personalisation to the individual’s risk factors (such as age, diet and lifestyle). This study will develop a computerised risk factor tool to personalise cancer prevention strategies for this high-risk subgroup of the population thereby utilising colonoscopy resources more efficiently. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009062</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Peter Czabotar</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Mining the Molecular Machinery of Cell Death for Novel Drug Targets</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,472,570.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Structural Biology (incl. Macromolecular Modelling)</Field_s__of_Research>
        <Res_KW1>apoptosis</Res_KW1>
        <Res_KW2>cell death</Res_KW2>
        <Res_KW3>structural biology</Res_KW3>
        <Res_KW4>X-ray crystallography</Res_KW4>
        <Res_KW5>electron microscopy</Res_KW5>
        <Plain_Description>Programmed cell death is a process the body uses to kill cells that are no longer needed, damaged or dangerous, e.g. those that have become cancerous or infected with viruses. Our studies have shown that the pathways that control cell death are targets for therapy, e.g. in cancer. We will continue to uncover the molecular details of how these pathways are regulated to provide new strategies for the development of therapeutic agents to treat diseases characterised by cell death malfunction.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009075</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Kate Schroder</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Inflammasome inhibitors as new first-in-class anti-inflammatory therapies</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,872,570.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Innate Immunity</Field_s__of_Research>
        <Res_KW1>caspases</Res_KW1>
        <Res_KW2>anti-inflammatory agents</Res_KW2>
        <Res_KW3>innate immunity</Res_KW3>
        <Res_KW4>macrophage biology</Res_KW4>
        <Res_KW5>chronic inflammation</Res_KW5>
        <Plain_Description>Inflammation drives many devastating human diseases, and there are currently no effective treatments for many such diseases. My research program aims to leverage my validated discovery and development pipeline to deliver new first-in-class anti-inflammatory drugs to treat devastating diseases such as chronic liver disease and inflammatory bowel disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009079</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Alex Hewitt</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Harnessing genetics to halt the sneak thief of sight.</Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$2,072,570.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Genomics</Field_s__of_Research>
        <Res_KW1>glaucoma</Res_KW1>
        <Res_KW2>complex genetic disease</Res_KW2>
        <Res_KW3>adult stem cells</Res_KW3>
        <Res_KW4>genetic association</Res_KW4>
        <Res_KW5>genetic susceptibility</Res_KW5>
        <Plain_Description>Glaucoma is the leading cause of irreversible blindness worldwide. In the early stages it is asymptomatic, and as such many people present at advanced stages of the disease when irreversible vision loss has already occurred. This research will reduce blindness and visual impairment from glaucoma through an improved prediction of high-risk individuals for developing glaucoma, and by the development of new therapies stemming from a better understanding of the molecular mechanisms of this disease. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009096</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Stephen Lord</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Fall prevention: innovation and translation</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,352,015.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Geriatrics and Gerontology</Field_s__of_Research>
        <Res_KW1>accidental falls</Res_KW1>
        <Res_KW2>exercise</Res_KW2>
        <Res_KW3>aged health</Res_KW3>
        <Res_KW4>multiple sclerosis (MS)</Res_KW4>
        <Res_KW5>Parkinson disease</Res_KW5>
        <Plain_Description>Falls are a major health care problem for older adults and people with neurodegenerative disorders. This program will evaluate novel fall prevention interventions in older people and people with multiple sclerosis and Parkinson’s disease. By developing software, diagnostic tools and balance training systems, my program intends to improve the health and wellbeing of older people and clinical populations with balance impairments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009136</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Tatiane Yanes</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Personalised Melanoma Risk Score: Development and Evaluation of a Co-Designed Toolkit for Nation-Wide Implementation</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Genetics not elsewhere classified</Field_s__of_Research>
        <Res_KW1>genetic counselling</Res_KW1>
        <Res_KW2>genomics</Res_KW2>
        <Res_KW3>polygenic diseases</Res_KW3>
        <Res_KW4>melanoma</Res_KW4>
        <Res_KW5>communications/social research</Res_KW5>
        <Plain_Description>Personalised risk prediction models that combined the effects of several genetic and non-genetic factors are rapidly being implemented in clinical practice. However, there is little implementation research on personalised risk, and data on the patient reported outcomes and risk management behaviour is scarce. For this study, I will develop a framework that provides guidance regarding optimal risk communication and a pathway for the successful translation of personalised risk information.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009152</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Andrew Neal</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Stereo-EEG and precision neuropsychology: optimising epilepsy surgery and minimising neurocognitive risk</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Central Nervous System</Field_s__of_Research>
        <Res_KW1>epilepsy</Res_KW1>
        <Res_KW2>epilepsy surgery</Res_KW2>
        <Res_KW3>electroencephalogram (EEG)</Res_KW3>
        <Res_KW4>neuropsychology</Res_KW4>
        <Res_KW5>neurophysiology</Res_KW5>
        <Plain_Description>To guide safe and successful epilepsy surgery, many patients may require sensors to be placed in the brain to map seizures. Electrical impulses can also be delivered through these sensors to test the function of different brain regions so that important brain structures are not removed. However, we do not know the best way to test language and memory. This project will develop a new method to assess brain function in patients with epilepsy in order to improve surgical outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009163</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Margaret Lam</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Dissecting the impacts of the bacterial host versus plasmid on the AMR burden</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Medical Bacteriology</Field_s__of_Research>
        <Res_KW1>klebsiella</Res_KW1>
        <Res_KW2>plasmids</Res_KW2>
        <Res_KW3>antimicrobial resistance</Res_KW3>
        <Res_KW4>bacterial evolution</Res_KW4>
        <Res_KW5>genomics</Res_KW5>
        <Plain_Description>Plasmids, mobile DNA, transmit antimicrobial resistance (AMR). This project will use an innovative approach of experimental evolution and the latest DNA and RNA sequencing technology to study how AMR plasmids spread and evolve in multidrug-resistant Klebsiella pneumoniae strains within different clinical settings. Expected outcomes include enhanced knowledge in bacterial-plasmid co-evolution critically needed for targeted surveillance, detection and control strategies to curb the spread of AMR.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009177</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Jake Shortt</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Genetically defining and pharmacologically exploiting new oncogenic dependencies in Myc-driven lymphoid cancer</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,228,048.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Haematological Tumours</Field_s__of_Research>
        <Res_KW1>human malignant  B-cell  lymphoma</Res_KW1>
        <Res_KW2>c-myc</Res_KW2>
        <Res_KW3>multiple myeloma</Res_KW3>
        <Res_KW4>epigenetics</Res_KW4>
        <Res_KW5>targeted therapy</Res_KW5>
        <Plain_Description>I will develop new treatments for blood cancers like multiple myeloma (MM) and B-cell lymphoma that share biological features associated with resistance to conventional treatments. By genetically editing the cancer-causing genes in MM and B-cell lymphoma, I have identified new (non-chemotherapy) drug targets that can overcome treatment resistance. My research will validate such drug targets and devise new therapies to improve patient outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009203</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Bala Venkatesh</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Improving outcomes in patients with sepsis through precision medicine</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,870,806.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Intensive Care</Field_s__of_Research>
        <Res_KW1>intensive care medicine</Res_KW1>
        <Res_KW2>sepsis</Res_KW2>
        <Res_KW3>systemic infection</Res_KW3>
        <Res_KW4>genomics</Res_KW4>
        <Res_KW5>corticosteroids</Res_KW5>
        <Plain_Description>Patients with life threatening infections may die or have major residual health issues. Previous attempts to treat such patients have focussed mainly on the infecting agent. It is now recognized that the genetic and biological make-up of the patient also plays a major role in the response to treatment. This work will improve the understanding of life threatening illnesses which will then be used to personalise patient treatments for improving outcomes with life threatening infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009209</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Jake O'Brien</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>A National Wastewater Surveillance Program for Antimicrobial Resistance</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Public Health and Health Services not elsewhere classified</Field_s__of_Research>
        <Res_KW1>antimicrobial resistance</Res_KW1>
        <Res_KW2>population health</Res_KW2>
        <Res_KW3>epidemiology</Res_KW3>
        <Res_KW4>chemistry</Res_KW4>
        <Res_KW5>mass spectrometry</Res_KW5>
        <Plain_Description>This fellowship aims to provide a world-class surveillance method for antimicrobial use and antimicrobial resistance genes in Australia's general population through wastewater-based epidemiology. Expected outcomes include building capacity to objectively measure antimicrobial use and antimicrobial resistance in the general population. Significant benefits expected include a cost effective, rapid surveillance tool to meet the emergent needs of bacterial disease outbreaks.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009216</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Sailesh Kumar</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Novel approaches to preventing perinatal death and disability from birth asphyxia</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,174,514.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Foetal Development and Medicine</Field_s__of_Research>
        <Res_KW1>fetal distress</Res_KW1>
        <Res_KW2>fetal growth restriction</Res_KW2>
        <Res_KW3>caesarean section</Res_KW3>
        <Res_KW4>stillbirth</Res_KW4>
        <Res_KW5>placental function</Res_KW5>
        <Plain_Description>Fetal distress is often caused by lack of oxygen because the poorly functioning placenta limits oxygen and nutrient supply to the baby. Lack of oxygen can cause brain injury and death. Sildenafil increases blood flow to the placenta potentially reducing this risk. The proposed body of work will address this problem and will develop tools to identify at-risk babies and evaluate if Sildenafil reduces the risk of injury related to birth asphyxia and rates of emergency caesarean section.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009231</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Aleksandr Kakinen</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Inflammation and chronic infections in the pathogenesis of Alzheimer’s disease: the role of amyloid cross-seeding.</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$517,233.19</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Neurosciences not elsewhere classified</Field_s__of_Research>
        <Res_KW1>Alzheimer disease</Res_KW1>
        <Res_KW2>amyloid</Res_KW2>
        <Res_KW3>inflammation</Res_KW3>
        <Res_KW4>bacterial infection</Res_KW4>
        <Res_KW5>fungal infection</Res_KW5>
        <Plain_Description>This project seeks to evaluate the pathological role of inflammation and infections in the development and progression of Alzheimer’s disease, the most common cause of dementia. The knowledge generated in this study will guide future drug discovery and development approaches against Alzheimer’s disease, especially for people who have faced acute or chronic inflammations or have been affected by bacterial and fungal infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009237</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Cynthia Shannon Weickert</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Neuroinflammation in schizophrenia</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,427,015.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Central Nervous System</Field_s__of_Research>
        <Res_KW1>schizophrenia</Res_KW1>
        <Res_KW2>neuropsychiatric disorders</Res_KW2>
        <Res_KW3>molecular neuroscience</Res_KW3>
        <Res_KW4>molecular biology</Res_KW4>
        <Res_KW5>inflammation</Res_KW5>
        <Plain_Description>Schizophrenia is debilitating disorder in need of a cure. Inflammation along with macrophage invasion occurs in the brains of ~40-45% of the people with schizophrenia. I aim to block immune cell invasion and test if the symptoms of schizophrenia can be reversed. Through studies of the human brain, basic science studies and novel investigator initiated clinical trials, I will continue to develop strategies to dampen neuroinflammation and to prevent damaging immune cells entering the brain. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009253</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Xinyang Hua</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Strengthen the role of health economics in perinatal health to inform priority setting and funding decisions</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Health Economics</Field_s__of_Research>
        <Res_KW1>health economics</Res_KW1>
        <Res_KW2>burden of disease</Res_KW2>
        <Res_KW3>economic evaluation</Res_KW3>
        <Res_KW4>disease modelling</Res_KW4>
        <Res_KW5>cost-effectiveness</Res_KW5>
        <Plain_Description>My program will develop new health economics methods to guide government decisions and help achieve the best health outcomes for children through more efficient and fair health care services during pregnancy and the year after birth. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009254</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Ding Ding</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Creating an active Australia through active systems: Co-production of multi-sectoral population physical activity strategies </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,570,120.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Health Promotion</Field_s__of_Research>
        <Res_KW1>disease prevention</Res_KW1>
        <Res_KW2>population health</Res_KW2>
        <Res_KW3>health promotion</Res_KW3>
        <Res_KW4>public health policy</Res_KW4>
        <Res_KW5>physical activity</Res_KW5>
        <Plain_Description>To prevent chronic disease, Australians need to become more physically active. This proposed research examines the value of solutions that promote physical activity, including changes to urban planning and transport. The research combines scientific evidence and local expertise to develop a decision-making tool to help predict the health, economic and environmental impacts of different solutions. The findings will guide policymakers in adopting the best strategies to promote physical activity.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009264</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Matthew Pase</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Unravelling the Contributions of Sleep Dysfunction to Alzheimer’s Disease and Dementia</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,306,096.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Neurology and Neuromuscular Diseases</Field_s__of_Research>
        <Res_KW1>dementia</Res_KW1>
        <Res_KW2>Alzheimer disease</Res_KW2>
        <Res_KW3>neurodegenerative disorders</Res_KW3>
        <Res_KW4>sleep/wake patterns</Res_KW4>
        <Res_KW5>longitudinal cohort study</Res_KW5>
        <Plain_Description>My research program will determine whether poor sleep should be a therapeutic target for reducing dementia risk. Using longitudinal cohort studies, I will identify the changes in sleep that most strongly predict the risk of Alzheimer’s disease and dementia. Results will guide targeted sleep interventions to reduce dementia risk and help select at risk subjects for inclusion in dementia prevention trials. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009278</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Alexandra Hogan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Mathematical modelling to support policy decisions on COVID-19 vaccination in Australia</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Epidemiology</Field_s__of_Research>
        <Res_KW1>COVID-19</Res_KW1>
        <Res_KW2>vaccine strategy</Res_KW2>
        <Res_KW3>mathematical modelling</Res_KW3>
        <Res_KW4>population health</Res_KW4>
        <Res_KW5>infectious diseases</Res_KW5>
        <Plain_Description>Vaccination against COVID-19 is underway globally. However, even as the virus is controlled by vaccination, it will be very difficult to eliminate COVID-19 completely, and we will need additional vaccine doses to boost protection against current and variant strains. I will use mathematical models to estimate the health benefit of COVID-19 vaccines, and to inform policy planning for longer-term, sustainable COVID-19 vaccine programs in Australia and regionally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009280</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Thomas Oxley</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Endovascular Neuromodulation</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$443,109.73</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Central Nervous System</Field_s__of_Research>
        <Res_KW1>motor neuron disease (MND)</Res_KW1>
        <Res_KW2>paralysis</Res_KW2>
        <Res_KW3>artificial neural networks</Res_KW3>
        <Res_KW4>biomedical engineering</Res_KW4>
        <Res_KW5>stroke</Res_KW5>
        <Plain_Description>The blood vessels provide access to regions of brain and nerves in the body that enable treatment with implantable devices. Interventional techniques enable a method of implanting a device while avoiding open brain surgery. Building off of work already achieved over a 6 year period, this grant progresses a body of world-first research that is proving the safety and efficacy of the first applications in paralysis and epilepsy in this new field of medicine. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009283</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Mark Fitzgerald</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Reducing Resuscitation Errors</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Decision Making</Field_s__of_Research>
        <Res_KW1>resuscitation</Res_KW1>
        <Res_KW2>traumatic injury</Res_KW2>
        <Res_KW3>surgical procedures</Res_KW3>
        <Res_KW4>decision support techniques</Res_KW4>
        <Res_KW5>computer-based decision support</Res_KW5>
        <Plain_Description>Error-free decisions made during resuscitation are fundamental to the subsequent recovery of the critically ill.  A computer-assisted, resuscitation decision support system has already been shown to reduce clinical errors and improve outcomes during the resuscitation of the severely injured.  This project will research and develop the system to include cardiac, stroke, sepsis, pediatric, toxidrome and obstetric emergencies and ascertain the effectiveness in these domains as well..</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009287</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Georgia Atkin-Smith</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title> Defining a novel waste disposal mechanism that aids vascular homeostasis and prevents inflammation</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Cellular Interactions (incl. Adhesion, Matrix, Cell Wall)</Field_s__of_Research>
        <Res_KW1>autophagy</Res_KW1>
        <Res_KW2>inflammation</Res_KW2>
        <Res_KW3>endothelial cells</Res_KW3>
        <Res_KW4>cell biology</Res_KW4>
        <Res_KW5>inflammatory diseases</Res_KW5>
        <Plain_Description>The survival of our cellular building blocks is crucial to prevent disease. One way in which our cells maintain their health is through disposing of cellular waste. This project will investigate a new waste disposal system employed by key cells that line the vascular system. Through advanced mouse models and imaging techniques, this project will determine how our cells survive under healthy and disease conditions, and how disposing of their waste correctly can prevent harmful inflammation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009288</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Alexandra Hawkey</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Reproductive bodies across borders: Enhancing fertility management among culturally and linguistically diverse women in Australia.</Grant_Title>
        <Admin_Institution>University of Western Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Public Health and Health Services not elsewhere classified</Field_s__of_Research>
        <Res_KW1>refugee health</Res_KW1>
        <Res_KW2>migrant health</Res_KW2>
        <Res_KW3>contraception</Res_KW3>
        <Res_KW4>qualitative methods</Res_KW4>
        <Res_KW5>women's health</Res_KW5>
        <Plain_Description>This project will explore CALD women’s perception and experiences of fertility control, focusing on fertility decision-making, contraception, and management of unplanned pregnancies, areas that have previously been underexplored. It will address CALD women’s health literacy and fertility control support needs through the co-design and evaluation of an online health educational resource, a knowledge translation exhibition and recommendations for health promotion and healthcare provision.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009295</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Adrienne O'Neil</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Translating lifestyle-based mental health care into practice</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,567,933.24</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Mental Health</Field_s__of_Research>
        <Res_KW1>lifestyle</Res_KW1>
        <Res_KW2>mental disorder</Res_KW2>
        <Res_KW3>dietary factors</Res_KW3>
        <Res_KW4>exercise</Res_KW4>
        <Res_KW5>quality of care</Res_KW5>
        <Plain_Description>We now know that providing clinical care to people with mental health problems that improves their diet, physical activity and sleep, while reducing their smoking, drug and alcohol use is highly beneficial for their mental health as well as their physical health.  Yet this type of care is not typically offered as part of routine mental health care.  My research will produce evidence that addresses this gap to improve the lives of individuals with mental health concerns in Australia and beyond. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009303</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Yeoung-Jee Cho</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Improving outcomes in peritoneal dialysis through patient-centred clinical trials</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,342,072.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Nephrology and Urology</Field_s__of_Research>
        <Res_KW1>nephrology</Res_KW1>
        <Res_KW2>kidney disease</Res_KW2>
        <Res_KW3>consumers</Res_KW3>
        <Res_KW4>patient safety</Res_KW4>
        <Res_KW5>collaboration</Res_KW5>
        <Plain_Description>Globally, the number of people living with kidney disease requiring dialysis or transplantation is growing.  Peritoneal dialysis (PD), a form of home-based therapy, has been promoted by the international community as a solution to overcome this crisis. Yet, globally only 11% of patients on dialysis receive PD and the number of people choosing PD therapy for their kidney disease is declining. My research program is focussed on patient-important outcomes to directly address these deficiencies. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009306</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Amy Peden</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Safeguarding the next generation: Using data to map and address injury-related harm in adolescence</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Public Health and Health Services not elsewhere classified</Field_s__of_Research>
        <Res_KW1>accidental injury</Res_KW1>
        <Res_KW2>rural and remote health</Res_KW2>
        <Res_KW3>adolescence</Res_KW3>
        <Res_KW4>alcohol</Res_KW4>
        <Res_KW5>injury prevention</Res_KW5>
        <Plain_Description>Globally, injury is a preventable cause of harm. This research focuses on preventing injury among adolescents and aims to assess and benchmark data on adolescent injury in Australia and the Western Pacific region, while also expanding understanding of the impact of remoteness and alcohol on adolescent fatal and non-fatal injury in urban and rural New South Wales, informing a pilot co-design process to develop an alcohol and injury prevention intervention for rural dwelling adolescents. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009308</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Jennifer Juno</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Harnessing T cell immunity to boost vaccine efficacy</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,320,120.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Cellular Immunology</Field_s__of_Research>
        <Res_KW1>CD4</Res_KW1>
        <Res_KW2>vaccine</Res_KW2>
        <Res_KW3>antibody</Res_KW3>
        <Res_KW4>Coronavirus</Res_KW4>
        <Res_KW5>T cell response</Res_KW5>
        <Plain_Description>The recent SARS-CoV-2 pandemic has highlighted the need for rapid, large-scale vaccine development. This research program will study how specific types of T cells can be activated in order to improve the immune response to vaccines, with the goal of identifying new vaccine platforms that can be successfully deployed in future pandemics. This work will advance our knowledge of vaccine-related immunology and significantly improve human health. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009309</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Emily Wong</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Deciphering the impact of non-coding mutations in congenital heart disease </Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,570,120.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Gene Expression (incl. Microarray and other genome-wide approaches)</Field_s__of_Research>
        <Res_KW1>enhancer</Res_KW1>
        <Res_KW2>comparative genomics</Res_KW2>
        <Res_KW3>heart development</Res_KW3>
        <Res_KW4>functional genomics</Res_KW4>
        <Res_KW5>control of gene expression</Res_KW5>
        <Plain_Description>Enhancers are non-coding regions of genomic DNA that play a crucial role in determining cellular identity. They are over-represented at genetic variants associated with disease. The goal of this proposal is to identify enhancers causal to human disease using in vivo high-throughput imaging and quantitative biology. The focus is to uncover the functional consequences of human enhancer variants in congenital heart disease. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009322</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Britta Regli-von Ungern-Sternberg</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Safer anaesthesia for children - optimizing perioperative outcomes by advancing and translating knowledge into clinical practice using an international, interdisciplinary approach</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,874,277.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Anaesthesiology</Field_s__of_Research>
        <Res_KW1>anaesthesia</Res_KW1>
        <Res_KW2>paediatric</Res_KW2>
        <Res_KW3>patient outcomes</Res_KW3>
        <Res_KW4>complications</Res_KW4>
        <Res_KW5>adverse events</Res_KW5>
        <Plain_Description>One in 20 children in Australia undergoes surgery each year. Children are particularly at risk of breathing problems during and after anaesthesia. I am investigating methods to predict, prevent and treat these problems. I am investigating ways to minimise the effects of anaesthesia on the developing brains of babies and improving the clinical tools available to paediatric anaesthetists. My goal is to ensure that when a child needs a vital operation, it is as safe and pain-free as possible.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009323</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Fran BAUM</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Restoring the Fair Go: which policies and practices are likely to reverse growing health inequities in Australia post-COVID-19</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$2,245,987.59</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Health Promotion</Field_s__of_Research>
        <Res_KW1>equity</Res_KW1>
        <Res_KW2>social determinants of health</Res_KW2>
        <Res_KW3>policy analysis</Res_KW3>
        <Res_KW4>social disadvantage</Res_KW4>
        <Res_KW5>social justice</Res_KW5>
        <Plain_Description>Australia has become a less equal society. My ‘Restoring the Fair Go’ program will analyse the underlying economic and health inequity trends, assess the policies that have contributed to these inequalities and determine how these can be reversed. The program will explore Australian policymaker and citizens perspectives on inequality and draw comparisons to other OECD countries. Practical policy proposals will be developed to help Australia build back from COVID-19.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009324</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Ms Briana Lees</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Alcohol use during pregnancy: Understanding and improving health outcomes in offspring</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Epidemiology</Field_s__of_Research>
        <Res_KW1>fetal alcohol syndrome</Res_KW1>
        <Res_KW2>mental health</Res_KW2>
        <Res_KW3>multi-generation study</Res_KW3>
        <Res_KW4>alcohol</Res_KW4>
        <Res_KW5>brain development</Res_KW5>
        <Plain_Description>The aim of this research is to gain understanding of how small amounts of alcohol during pregnancy can impact child development across the first two decades of life and to test the effectiveness of a program that aims to reduce some of this burden. The world's largest datasets for examining prenatal alcohol exposure will be used to provide concrete evidence of the impacts. It is anticipated the findings will provide critical new insights important for families, practitioners, and policy-makers.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009326</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Helena Teede</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Implementation research: Delivering impact at the interface between reproductive and metabolic women’s health</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,870,806.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Public Health and Health Services not elsewhere classified</Field_s__of_Research>
        <Res_KW1>implementation</Res_KW1>
        <Res_KW2>women's health</Res_KW2>
        <Res_KW3>endocrine</Res_KW3>
        <Res_KW4>overweight/obesity</Res_KW4>
        <Res_KW5>public health</Res_KW5>
        <Plain_Description>As an active clinician, academic and leader, I bring an exemplary track record, team and research program aiming to generate and translate new knowledge to improve women's health internationally, during the reproductive years and beyond. My research program addresses patient and clinician priorities, links to international guidelines and has far reaching translation programs to directly improve women's health. Target conditions include polycystic ovary syndrome, early menopause and pregnancy. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009336</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Ajithkumar Vasanthakumar</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Harnessing tissue-resident regulatory T cells to fight cancer</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,570,120.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Cellular Immunology</Field_s__of_Research>
        <Res_KW1>regulatory T cells</Res_KW1>
        <Res_KW2>tissue factor</Res_KW2>
        <Res_KW3>adipose tissue</Res_KW3>
        <Res_KW4>cancer immunology</Res_KW4>
        <Res_KW5>stromal cells</Res_KW5>
        <Plain_Description>Specialised immune cells called regulatory T cells (Tregs) reside in almost all organs of the body where they play a central role in preventing autoimmunity and inflammation. Tregs, however, aggravate cancer by antagonising the activity of beneficial, cancer killing immune cells and limiting cancer immunotherapy. This proposal aims to discover mechanisms utilized by Tregs to populate distinct tissues and tumours. These mechanisms will be harnessed to target Tregs for the treatment of cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009339</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Laura Cook</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Harnessing CD4+ Regulatory T Cells to Enhance Formation of Protective Immunity Against Human Viruses</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Cellular Immunology</Field_s__of_Research>
        <Res_KW1>regulatory T cells</Res_KW1>
        <Res_KW2>cellular immunity</Res_KW2>
        <Res_KW3>viral immunology</Res_KW3>
        <Res_KW4>T cell memory</Res_KW4>
        <Res_KW5>gut immunity</Res_KW5>
        <Plain_Description>In order to fight off infection we need specialised white blood cells, called helper T cells, to activate immune responses. A specialised helper T cell, called a regulatory T cell, are key orchestrators of immune memory, which protect against re-infection. This study will explore the role for regulatory T cells in generating protective immunity, which is the foundation of vaccine efficacy. This information will aid the design of better treatments and vaccines for infectious diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009340</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Clare Collins</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Personalised Nutrition Support </Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,927,015.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Nutrition and Dietetics not elsewhere classified</Field_s__of_Research>
        <Res_KW1>nutrition</Res_KW1>
        <Res_KW2>nutritional support techniques</Res_KW2>
        <Res_KW3>dietary intervention</Res_KW3>
        <Res_KW4>dietary intake</Res_KW4>
        <Res_KW5>chronic diseases</Res_KW5>
        <Plain_Description>My research program in precision and personalised nutrition technologies will generate new knowledge on cost-effective models of care to reduce diet-related health risks, especially for under-served groups based on life-stage, socio-economic status or geographic location. My research findings will improve health and well-being for those at elevated diet-related chronic disease risk and be rapidly translated to lower the healthcare burden related to poor nutrition.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009380</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Lisa Whop</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Addressing racialised health inequities in cancer</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$1,581,120.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Aboriginal and Torres Strait Islander Health</Field_s__of_Research>
        <Res_KW1>cervical cancer</Res_KW1>
        <Res_KW2>equity</Res_KW2>
        <Res_KW3>cancer prevention</Res_KW3>
        <Res_KW4>cancer screening</Res_KW4>
        <Res_KW5>implementation</Res_KW5>
        <Plain_Description>Cervical cancer can be eliminated by vaccination, screening and treatment (three pillars of elimination). Aboriginal and Torres Strait Islander women experience rates of cervical cancer comparable with less developed regions of the world despite other Australian women having the lowest rates in the world.  This Indigenous led research program will focus on overcoming racial inequities via strategic culturally safe interventions focused on the three pillars of elimination.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009389</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Bruce Taylor</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Improving outcomes for people with Multiple Sclerosis</Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$2,335,378.22</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Central Nervous System</Field_s__of_Research>
        <Res_KW1>multiple sclerosis (MS)</Res_KW1>
        <Res_KW2>adult stem cells</Res_KW2>
        <Res_KW3>patient outcomes</Res_KW3>
        <Res_KW4>complex genetic disease</Res_KW4>
        <Res_KW5>clinical epidemiology</Res_KW5>
        <Plain_Description>Multiple sclerosis is a disabling neurological condition with a profound impact on the community. This proposal builds on years of successful MS research to develop a "human" model to study MS. Using advanced genetic techniques to understand why MS is more common in families. To understand how genes, the environment, and personal behaviours influence MS risk and progression. How information can be used to improve MS and how to translate discoveries into meaningful outcomes rapidly. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009408</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Nick Scott</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Using modelling to guide the control of hepatitis C as a public health threat</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,570,120.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Health Economics</Field_s__of_Research>
        <Res_KW1>mathematical modelling</Res_KW1>
        <Res_KW2>economic analysis</Res_KW2>
        <Res_KW3>population health</Res_KW3>
        <Res_KW4>hepatitis C virus</Res_KW4>
        <Res_KW5>infectious diseases</Res_KW5>
        <Plain_Description>During this grant I will use epidemic and economic modelling to guide health policy responses to hepatitis C in Australia and internationally. My findings will inform decisions by national governments and global health organisations on how to best find and cure people with hepatitis C. I will leverage my own and my collaborators’ memberships on global panels to ensure that lives are saved around the world because approaches to hepatitis C elimination are evidence-based and cost-effective.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009409</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Jennifer Zenker</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Mitochondria live imaging in mammalian preimplantation embryos</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,270,120.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Biochemistry and Cell Biology not elsewhere classified</Field_s__of_Research>
        <Res_KW1>embryonic development</Res_KW1>
        <Res_KW2>imaging</Res_KW2>
        <Res_KW3>confocal microscopy</Res_KW3>
        <Res_KW4>mitochondria</Res_KW4>
        <Res_KW5>microtubules</Res_KW5>
        <Plain_Description>One type of organelle, mitochondria, are in the spotlight to improve pregnancy success of women suffering reduced fertility. This project will provide insights into mitochondrial integrity using cutting-edge non-invasive live imaging of the preimplantation embryo. We will uncover in real-time how mitochondria move, being sorted in subpopulations and how the parental mitochondrial heritage plays a role. Our findings will open new ways to refine mitochondrial therapies in reproductive medicine.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009419</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Tessa Copp</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Reducing the harms of inappropriate medicalisation of women's reproductive health</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Public Health and Health Services not elsewhere classified</Field_s__of_Research>
        <Res_KW1>harm minimisation</Res_KW1>
        <Res_KW2>fertility</Res_KW2>
        <Res_KW3>public health costs</Res_KW3>
        <Res_KW4>assisted reproductive technology (ART)</Res_KW4>
        <Res_KW5>communication</Res_KW5>
        <Plain_Description>Women’s reproductive health is an under-researched area with many areas of uncertainty, increasing the risk of inappropriate medicalisation and harm. The recent explosion of technology-based products focused on women’s health is expanding this issue on a massive scale. Using mixed methods and involving key stakeholders, this research program aims to a) understand the impacts of three increasingly popular technologies on women and b) find ways to reduce inappropriate medicalisation and harm.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009432</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Anna Lene Seidler</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>NextGen evidence synthesis to maximise data utility and improve health outcomes</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$600,740.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Paediatrics</Field_s__of_Research>
        <Res_KW1>meta-analysis</Res_KW1>
        <Res_KW2>overweight/obesity</Res_KW2>
        <Res_KW3>neonatology</Res_KW3>
        <Res_KW4>databases</Res_KW4>
        <Res_KW5>epidemiological research methods</Res_KW5>
        <Plain_Description>To bring together results from different studies, researchers would traditionally extract results from journal articles. Often, not all required information is available in these articles. New methods bring together full datasets of previous studies. This research program will develop these methods, looking at how to 1) best share data and 2) find and exclude fraudulent or low-quality studies. The program will also apply these methods looking at 1) babies born too early and 2) childhood obesity.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009447</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Yan Zou</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Biomimetic nanoparticles as a gene delivery platform for combinational brain tumour treatment</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Nanomedicine</Field_s__of_Research>
        <Res_KW1>nanotechnology</Res_KW1>
        <Res_KW2>drug delivery systems</Res_KW2>
        <Res_KW3>brain tumours</Res_KW3>
        <Res_KW4>biomaterials</Res_KW4>
        <Res_KW5>controlled release</Res_KW5>
        <Plain_Description>Gene engineering shows exciting potential in biomedical applications including cancer therapies. However, effective therapies for brain tumour remain limited due to the cascade brain delivery challenges, which markedly limits their translational potential. This project aims to develop a new treatment strategy for the delivery of state-of-the-art gene therapies directly into the brain, which may provide a new effective and safe therapy for brain tumour patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009464</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Antonio Verdejo-Garcia</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Decoding the drivers of food choices towards sustainable self-management of obesity</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,248,555.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Nutrition and Dietetics not elsewhere classified</Field_s__of_Research>
        <Res_KW1>obesity</Res_KW1>
        <Res_KW2>decision making</Res_KW2>
        <Res_KW3>cognition</Res_KW3>
        <Res_KW4>behavioural intervention</Res_KW4>
        <Res_KW5>neuroimaging</Res_KW5>
        <Plain_Description>Excessive eating of caloric foods is increasing the number of people who suffer obesity. Available treatments focus too much on personal efforts to reduce eating, and do not pay enough attention to the joint role of mental states, attractive foods and overwhelming marketing. I will use new research tools, such as brain scans taken while eating, mathematical algorithms made to reveal subconscious aspects of behaviour and virtual reality to assist people with obesity to change food choices.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009476</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Alexander Menzies</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Predictive biomarkers of response, resistance and toxicity with immunotherapy in melanoma</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,342,072.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Cancer Therapy (excl. Chemotherapy and Radiation Therapy)</Field_s__of_Research>
        <Res_KW1>melanoma</Res_KW1>
        <Res_KW2>immunotherapy</Res_KW2>
        <Res_KW3>drug resistance</Res_KW3>
        <Res_KW4>biomarkers</Res_KW4>
        <Res_KW5>drug  toxicity</Res_KW5>
        <Plain_Description>Immunotherapy has activity across many cancers, none more so than melanoma where approximately half the patients with metastatic disease may be cured. Half the patients do not benefit, however, and the drugs can cause toxicity and are expensive. At present, clinicians have little ability to predict who will and will not respond to therapy or get toxicity, nor the mechanisms underlying this. Improving this understanding will improve patient outcomes and reduce costs to the healthcare system.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009504</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Ross Hannan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Ribosome biogenesis and disease</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$1,927,015.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Cancer Therapy (excl. Chemotherapy and Radiation Therapy)</Field_s__of_Research>
        <Res_KW1>Ribosome biogenesis</Res_KW1>
        <Res_KW2>cancer cell biology</Res_KW2>
        <Res_KW3>drug development</Res_KW3>
        <Res_KW4>chromatin structure</Res_KW4>
        <Res_KW5>cell growth</Res_KW5>
        <Plain_Description>Ribosomes are macromolecular machines that synthesise all cellular proteins and their catalytic core, the ribosomal RNAs, are synthesised from hundreds of ribosomal genes in a sub-nuclear body termed the nucleolus. This application continues my work on developing drugs that target the nucleolus for cancer therapies and ribosomopathies and investigate new non-ribosomal functions of the nucleolus that we believe are important for normal cellular development and which are dysregulated in disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009507</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Ollie Jay</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Heat and Health: Building resilience to a warming planet across the human lifespan</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,098,555.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Exercise Physiology</Field_s__of_Research>
        <Res_KW1>heat stress</Res_KW1>
        <Res_KW2>thermoregulation</Res_KW2>
        <Res_KW3>hyperthermia</Res_KW3>
        <Res_KW4>dehydration</Res_KW4>
        <Res_KW5>climate change</Res_KW5>
        <Plain_Description>Each year peak temperature records are repeatedly broken around the world. We already know the health effects of extreme heat can be potentially devastating, from pregnancy through to older age. This investigator grant will explore different ways to increase our resilience to a warming world across the entire lifespan in way that is sustainable for the future, protects the most vulnerable, and helps reduce the risk of other diseases that are aggravated by heat stress.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009529</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Patsy Yates</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Optimising palliative care services to deliver better value health care for older people</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,500,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Health and Community Services</Field_s__of_Research>
        <Res_KW1>palliative care</Res_KW1>
        <Res_KW2>health services</Res_KW2>
        <Res_KW3>outcomes research</Res_KW3>
        <Res_KW4>aged care</Res_KW4>
        <Res_KW5>nursing</Res_KW5>
        <Plain_Description>The recent report from the Royal Commission into Aged Care Quality and Safety in Australia highlighted substandard palliative care in Australia’s aged care system. This research will transform the way in which palliative care services are delivered for older people by designing and evaluating new approaches to ensure quality palliative and end of life services in the residential and community aged care system.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009548</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Joshua Osowicki</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Advancing Australian human challenge trials for priority pathogens</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Infectious Diseases</Field_s__of_Research>
        <Res_KW1>Streptococcus pyogenes</Res_KW1>
        <Res_KW2>group A streptococcal disease</Res_KW2>
        <Res_KW3>Streptococcus pneumoniae</Res_KW3>
        <Res_KW4>vaccine</Res_KW4>
        <Res_KW5>pharyngitis</Res_KW5>
        <Plain_Description>In human challenge models, healthy volunteers are given a carefully monitored infection, with healthcare support, to learn how diseases work and how to stop them. I built the world’s only strep throat human model and will use it to test vaccines to stop Strep A diseases, which affect ~1 billion people and kill >500,000 annually. I will build challenge models for other important diseases (like pneumonia) and work with the public and participants to maximise the impact of this kind of research.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009550</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Yen Ying Lim</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Risk and resilience in Alzheimer's pathogenesis, cognitive decline and clinical disease progression</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,306,096.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Biological Psychology (Neuropsychology, Psychopharmacology, Physiological Psychology)</Field_s__of_Research>
        <Res_KW1>Alzheimer disease</Res_KW1>
        <Res_KW2>cognitive assessment</Res_KW2>
        <Res_KW3>biomarkers</Res_KW3>
        <Res_KW4>risk factors</Res_KW4>
        <Res_KW5>resilience</Res_KW5>
        <Plain_Description>Alzheimer’s disease is the most common form of dementia, and the number of people living with it will triple by 2050. There is currently no cure for Alzheimer’s disease, and the only means of slow the growing epidemic is to delay onset. My research program aims to identify risk and resilience factors of Alzheimer’s disease. This will uncover novel disease-modifying strategies, improve clinical trial design, and develop algorithms that will predict individuals’ rate of disease progression. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009551</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof David Fairlie</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Modulating protein-protein interactions in disease</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$3,927,015.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Basic Pharmacology</Field_s__of_Research>
        <Res_KW1>medicinal chemistry</Res_KW1>
        <Res_KW2>peptides</Res_KW2>
        <Res_KW3>protease-activated receptors</Res_KW3>
        <Res_KW4>G protein-coupled receptors</Res_KW4>
        <Res_KW5>drug design</Res_KW5>
        <Plain_Description>Healthy lives are powered by countless interactions between proteins that induce normal body functions. Infections, mutations, physical/chemical damage wear down our immune defences and lead to disease. This program will create new knowledge and approaches to discover new medicines, larger than conventional drugs but smaller than antibodies. They will modulate protein-protein interactions on or in cells to suppress inflammatory/metabolic diseases in rodents, on a path to clinical trials. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009554</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Di Yu</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Targeting Follicular Helper T cells to Boost Protective Humoral Immunity</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$3,098,844.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Humoural Immunology and Immunochemistry</Field_s__of_Research>
        <Res_KW1>B cells</Res_KW1>
        <Res_KW2>T cells</Res_KW2>
        <Res_KW3>antibody production</Res_KW3>
        <Res_KW4>vaccination</Res_KW4>
        <Res_KW5>lymphocyte differentiation</Res_KW5>
        <Plain_Description>After vaccination, the immune system is activated and acquires the ability to secret antibodies that recognise and destroy pathogens. However, vaccines don’t always induce sufficient immunity. The interactions between different types of immune cells play an essential role in regulating the generation of high-quality antibody immunity. This research will investigate the mechanisms governing this process. The new knowledge will have broad applications for infection control or vaccine design.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009564</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof David Craik</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Advancing peptide-based drug design</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$3,177,015.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Proteins and Peptides</Field_s__of_Research>
        <Res_KW1>peptides</Res_KW1>
        <Res_KW2>structure-based drug design</Res_KW2>
        <Res_KW3>protein structure</Res_KW3>
        <Res_KW4>drug design</Res_KW4>
        <Res_KW5>drug discovery</Res_KW5>
        <Plain_Description>I will use molecules called peptides to make safer, more effective medicines. These next-generation drugs will have fewer side effects than existing drugs due to their highly specific interactions with their target sites in the body. In the past pharmaceutical companies have not been able to utilise peptides because of technical challenges associated with their synthesis and delivery. My work has led to solutions to these problems that will be exploited to develop new drugs for pain and cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009572</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Margarita Moreno-Betancur</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Novel methods for analysing causal pathways to disease in longitudinal studies</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,442,004.49</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Biostatistics</Field_s__of_Research>
        <Res_KW1>statistics</Res_KW1>
        <Res_KW2>biostatistics</Res_KW2>
        <Res_KW3>epidemiological research methods</Res_KW3>
        <Res_KW4>longitudinal study</Res_KW4>
        <Res_KW5>biomarkers</Res_KW5>
        <Plain_Description>Health research studies obtain increasingly detailed data from participant biosamples that could in principle provide key insights into disease causality. However, the analytical tools and expertise for realising this potential are lacking. This program aims to develop, disseminate and apply novel data analysis methods that address this gap, as well as building biostatistical capacity in this area. Program outcomes will be urgently needed tools, expertise and new knowledge for improving health.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009577</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Gita Mishra</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Tackling multimorbidity in women across the life course: Building the evidence for improved prevention strategies and care pathways</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,350,314.03</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Epidemiology</Field_s__of_Research>
        <Res_KW1>women's health</Res_KW1>
        <Res_KW2>chronic diseases</Res_KW2>
        <Res_KW3>comorbidity</Res_KW3>
        <Res_KW4>multiple risk factors</Res_KW4>
        <Res_KW5>reproductive health</Res_KW5>
        <Plain_Description>Multimorbidity, where a person has two or more chronic conditions, is increasing and is more common among women than men. Women also face different risks for multimorbidity, and some can have conditions that interact and require complex care plans. My research addresses gaps in our understanding of how multimorbidity develops in women and of the corresponding care plans. The new knowledge will inform more personalised and co-ordinated care for prevention and management of multimorbidity.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009612</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Joanne McKenzie</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Improving evidence synthesis methods to enhance decision making about public health and policy interventions</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,248,555.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Biostatistics</Field_s__of_Research>
        <Res_KW1>evidence-based health care</Res_KW1>
        <Res_KW2>meta-analysis</Res_KW2>
        <Res_KW3>intervention study</Res_KW3>
        <Res_KW4>statistics</Res_KW4>
        <Res_KW5>methodology</Res_KW5>
        <Plain_Description>Systematic reviews synthesize available research to determine whether policy, health service delivery, and public health interventions are effective. Statistical methods underpin the validity of the findings in systematic reviews. This research will evaluate and develop statistical methods for systematic reviews with the aim of improving the quality of reviews and ensuring healthcare decisions are based on reliable research syntheses.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009633</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Amanda Cross</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Reducing medication-related harm in people living with dementia in residential aged care </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Residential Client Care</Field_s__of_Research>
        <Res_KW1>dementia</Res_KW1>
        <Res_KW2>aged care</Res_KW2>
        <Res_KW3>residential care</Res_KW3>
        <Res_KW4>pharmacy</Res_KW4>
        <Res_KW5>adverse drug reactions</Res_KW5>
        <Plain_Description>People who live in aged care facilities, particularly those living with dementia, often take multiple medications and are at increased risk of medication-related harm. My research aims to reduce medication-related harm by addressing key steps in the medication-management cycle where errors and harm can occur. I will work with consumers, aged care providers and health care professionals to ensure my findings are translated into practice to improve quality of life for people living with dementia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009642</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Benjamin Parker</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Targeting skeletal muscle for the treatment of insulin resistance</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,470,120.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Systems Physiology</Field_s__of_Research>
        <Res_KW1>proteomics</Res_KW1>
        <Res_KW2>muscle physiology</Res_KW2>
        <Res_KW3>mouse models</Res_KW3>
        <Res_KW4>signal transduction</Res_KW4>
        <Res_KW5>muscle metabolism</Res_KW5>
        <Plain_Description>Insulin resistance is a condition that leads to high-blood glucose and poor muscle function. It is the fastest growing chronic disease in Australia and the major contributor to type-2 diabetes and sarcopenia. We urgently need new treatment strategies. We have identified a series of novel therapeutic targets for the treatment of insulin resistance. This project will analyse these therapeutic targets in preclinical models and improve our understanding of the molecular events of insulin resistance.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009670</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Chee Khoon Lee</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Improving outcomes in advanced lung and gynaecological cancers through innovations in clinical trials</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,799,422.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Solid Tumours</Field_s__of_Research>
        <Res_KW1>medical oncology</Res_KW1>
        <Res_KW2>molecular oncology</Res_KW2>
        <Res_KW3>lung cancer</Res_KW3>
        <Res_KW4>gynaecological cancers</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>Lung and ovarian cancers are major causes of cancer-related deaths in Australia and worldwide. Improving outcomes for these cancers is a national priority. The overall aim of this project is to better personalise patient treatment and improve their cancer outcomes. The specific objectives are to develop new therapies and strategies for combination treatment, identify new biomarkers, evaluate benefits and harms from treatments, and improve selection of patients for more appropriate therapies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009675</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Shalin Naik</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Using clonal multi-omics to better understand haematopoiesis</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,348,555.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Immunology not elsewhere classified</Field_s__of_Research>
        <Res_KW1>haematopoiesis</Res_KW1>
        <Res_KW2>dendritic cell lineages</Res_KW2>
        <Res_KW3>biotechnology</Res_KW3>
        <Res_KW4>haematopoietic stem cells</Res_KW4>
        <Res_KW5>monocyte/macrophage differentiation</Res_KW5>
        <Plain_Description>Our body must continually produce white blood cells to fight infection. When this production goes wrong it can lead to too few cells (immune deficiency) or too many (leukemia). We will examine this process using cutting edge single cell technologies to trace the developmental origins and pathways of individual cells as they mature. In this way, we will learn how to treat these diseases and inform new ways to boost immunity or treat immune and inflammatory diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009707</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Natalee Newton</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Reconstructing ancestral viruses to fight current and future flavivirus outbreaks</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Structural Biology (incl. Macromolecular Modelling)</Field_s__of_Research>
        <Res_KW1>molecular virology</Res_KW1>
        <Res_KW2>virology</Res_KW2>
        <Res_KW3>structural biology</Res_KW3>
        <Res_KW4>viral proteins</Res_KW4>
        <Res_KW5>viral vaccines</Res_KW5>
        <Plain_Description>I am a co-inventor of a powerful toolset combining advanced structural biology and rapid virus engineering that enables the investigation of flavivirus structure and immune response at the molecular level. This project integrates these approaches to resurrect ancient flaviviruses and explore the structural evolution of non-human primate flaviviruses, which will be used to understand viral evolution, improve outbreak preparedness and design safer and more effective vaccines.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009711</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Hyon Xhi Tan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Driving rational improvement of vaccines against respiratory viruses</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$600,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)</Field_s__of_Research>
        <Res_KW1>B cells</Res_KW1>
        <Res_KW2>vaccination immunology</Res_KW2>
        <Res_KW3>vaccine development</Res_KW3>
        <Res_KW4>respiratory viruses</Res_KW4>
        <Res_KW5>humoral immunity</Res_KW5>
        <Plain_Description>Respiratory viruses, such as influenza and human coronaviruses, impose a significant burden on human health and present major pandemic risks. There is a critical need for highly effective vaccines to protect susceptible human populations. This research program will expand our understanding of fundamental drivers of protective immunity against respiratory viruses and integrate these insights in the design and testing of novel vaccine concepts that produce durable and efficacious immunity.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009726</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Cheryl Carcel</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Reducing sex disparities in stroke through a deeper understanding of risks and management patterns</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$575,578.71</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Epidemiology</Field_s__of_Research>
        <Res_KW1>sex differences</Res_KW1>
        <Res_KW2>stroke</Res_KW2>
        <Res_KW3>clinical trial</Res_KW3>
        <Res_KW4>cohort study</Res_KW4>
        <Res_KW5>cost-effectiveness</Res_KW5>
        <Plain_Description>Each year, 11,000 Australians die from one of the biggest killers in Australia and globally, stroke. There is high demand for effective prevention and treatment strategies. However, published evidence suggests that women and men experience the disease and its medical care differently. My research aims to better understand why such differences exist and how to provide sex-specific, strategies to improve survival from stroke.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009727</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Simon Graham</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Developing a community-led coordination and response guide for a syphilis outbreak in Aboriginal communities</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,581,120.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Aboriginal and Torres Strait Islander Health</Field_s__of_Research>
        <Res_KW1>syphilis</Res_KW1>
        <Res_KW2>Aboriginal health</Res_KW2>
        <Res_KW3>surveillance</Res_KW3>
        <Res_KW4>community participation</Res_KW4>
        <Res_KW5>community health care</Res_KW5>
        <Plain_Description>My program of research has two phases. Phase 1 will evaluate the how the World Health Organization establishes and deploying outbreak teams to different countries. Phase 2 aims to 1) evaluate Australia National Notifiable Surveillance System with a focus on the identification of Aboriginal people and alerts for potential outbreaks and 2) to develop a community-based coordination guide for syphilis outbreaks that includes Aboriginal leadership, governance and our biggest strength, our culture.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009730</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Zohra Lassi</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Addressing evidence gaps to improve adolescent the sexual and reproductive health</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,560,435.77</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Paediatrics and Reproductive Medicine not elsewhere classified</Field_s__of_Research>
        <Res_KW1>adolescent health</Res_KW1>
        <Res_KW2>sexual health</Res_KW2>
        <Res_KW3>reproductive health</Res_KW3>
        <Res_KW4>evidence-based health care</Res_KW4>
        <Res_KW5>population health</Res_KW5>
        <Plain_Description>My research focuses on identifying opportunities to improve the sexual and reproductive health of adolescents living in Australia and other parts of the world. This involves working with adolescents and health services to co-design and test new strategies to deliver sexual and reproductive health that is specifically focussed on the needs of young people.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009732</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr David Stroud</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Developing a multi-omics platform for the diagnosis of mitochondrial disease</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,570,120.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Genomics</Field_s__of_Research>
        <Res_KW1>mitochondrial disease</Res_KW1>
        <Res_KW2>proteomics</Res_KW2>
        <Res_KW3>functional genomics</Res_KW3>
        <Res_KW4>mitochondrial function</Res_KW4>
        <Res_KW5>systems biology</Res_KW5>
        <Plain_Description>Mitochondrial Diseases (MDs) are the most common inherited metabolic disorders. They can be caused by changes in more than 300 different genes and affect any or all of our organ systems. New genomic (DNA) technologies have increased our ability to diagnose MDs from less than a quarter of patients to about a half. DNA is the blueprint for protein. This study seeks to further improve the diagnostic rate by using new “proteomic” technologies that can detect changes in thousands of proteins at once.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009736</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Jason Roberts</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Translating precision antibiotic dosing into better outcomes for severe infections</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,772,570.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Clinical Pharmacology and Therapeutics</Field_s__of_Research>
        <Res_KW1>antibiotic therapy</Res_KW1>
        <Res_KW2>sepsis</Res_KW2>
        <Res_KW3>pharmacokinetics</Res_KW3>
        <Res_KW4>antibiotic resistance</Res_KW4>
        <Res_KW5>critical care medicine</Res_KW5>
        <Plain_Description>Millions of people die from infections around the world each year, in part, from inadequate antimicrobial use. Antimicrobial dosing is an aspect of therapy which clinicians can control and improve if given sufficient information. My research program will explore the benefits of using a dose that is optimised for an individual patient, to ensure the patient is cured from that infection, and not contribute to the emergence of antimicrobial resistant bacteria. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009750</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof David Hume</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Macrophage Biology in Health and Disease</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$3,427,015.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Innate Immunity</Field_s__of_Research>
        <Res_KW1>macrophage biology</Res_KW1>
        <Res_KW2>colony stimulating factors (CSF)</Res_KW2>
        <Res_KW3>gene transcription</Res_KW3>
        <Res_KW4>transgenic animals</Res_KW4>
        <Res_KW5>regenerative medicine</Res_KW5>
        <Plain_Description>Macrophages are cells of the innate immune system.  They are found in every organ and act as the body's waste disposal system and contribute to repair of damaged tissue.  In many diseases, their functions are out of control and they contribute to injury and symptoms.  In this project we aim to understand how macrophages are made and controlled and to exploit that knowledge to develop new therapies in regenerative medicine. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009765</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Kirsten Palmer</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Mitigating the consequence of preeclampsia for mother and child</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,285,060.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Obstetrics and Gynaecology</Field_s__of_Research>
        <Res_KW1>pre-eclampsia</Res_KW1>
        <Res_KW2>antioxidant therapy</Res_KW2>
        <Res_KW3>biomarkers</Res_KW3>
        <Res_KW4>placental insufficiency</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>Preeclampsia, a condition unique to pregnancy, is a major cause for premature birth, death and disability for both mother and baby. No treatment exists that can control the disease to reduce these risks. This research assesses a promising new therapy derived from broccoli sprouts that could prolong pregnancy, reducing the risk of preterm birth. New approaches to diagnosing preeclampsia earlier and to prevent women from poor health outcomes in the years that follow will also be explored.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009767</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Rui Wang</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Improving assisted reproductive technology outcomes - a personalised approach</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Reproduction</Field_s__of_Research>
        <Res_KW1>infertility</Res_KW1>
        <Res_KW2>evidence-based health care</Res_KW2>
        <Res_KW3>individualising management</Res_KW3>
        <Res_KW4>in vitro fertilisation (IVF)</Res_KW4>
        <Res_KW5>assisted reproductive technology (ART)</Res_KW5>
        <Plain_Description>One in seven couples have problems conceiving. Assisted reproductive technology (ART) is the last resort for all couples with prolonged unresolved infertility. There is a lack of personalised evidence-based guidance on choosing the best treatment strategies during ART. I will systematically evaluate the effectiveness and safety of treatment options in multiple steps during ART and provide a personalised treatment pathway to improve ART outcomes in couples with infertility.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009771</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Julian Trollor</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Addressing Health Inequality Experienced by People with Intellectual Disability</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,372,570.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Care for Disabled</Field_s__of_Research>
        <Res_KW1>intellectual disability</Res_KW1>
        <Res_KW2>burden of disease</Res_KW2>
        <Res_KW3>neurodevelopmental disorders</Res_KW3>
        <Res_KW4>health service utilisation</Res_KW4>
        <Res_KW5>health services</Res_KW5>
        <Plain_Description>People with intellectual disability face stark health inequalities, die prematurely from potentially avoidable causes and experience poor access to preventative health care. This project will find out why there are gaps in health care for people with intellectual disability, determine how these gaps affect people and develop better responses in healthcare for people with intellectual disability.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009776</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Yohannes Adama Melaku</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Increasing the value of evidence from nutritional epidemiology</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Nutrition and Dietetics not elsewhere classified</Field_s__of_Research>
        <Res_KW1>nutrition</Res_KW1>
        <Res_KW2>epidemiology</Res_KW2>
        <Res_KW3>public health</Res_KW3>
        <Res_KW4>cardiovascular health</Res_KW4>
        <Res_KW5>methodology</Res_KW5>
        <Plain_Description>In nutrition research, observational studies are fundamental sources of evidence as it is often impossible or unethical to conduct randomized controlled trials. Unfortunately, many nutritional epidemiological studies fail to provide useful evidence due to poor data analysis methods. My research will improve the quality of evidence from nutritional epidemiology by developing practical solutions to the challenges of dietary data analysis by advancing analysis methods and tools.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009782</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Jennifer Nicholas</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Lost in translation: Accelerating the implementation of digital interventions in youth mental health</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Psychiatry (incl. Psychotherapy)</Field_s__of_Research>
        <Res_KW1>mental health</Res_KW1>
        <Res_KW2>internet service delivery</Res_KW2>
        <Res_KW3>implementation</Res_KW3>
        <Res_KW4>young adults</Res_KW4>
        <Res_KW5>intervention</Res_KW5>
        <Plain_Description>Mental ill-health affects one in four young Australians. Digital interventions can deliver high-quality accessible mental health care to those in need, however, they currently sit disconnected from our overburdened, antiquated mental health system. My research program will address this historic failure of research translation, by refining, evaluating, and disseminating a blueprint for digital mental health implementation – propelling Australian youth mental health care into the 21st century.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009783</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Clare Scott</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Super-Responders and Super-Survivors – how to dramatically improve cancer outcomes </Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,372,570.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Cancer Therapy (excl. Chemotherapy and Radiation Therapy)</Field_s__of_Research>
        <Res_KW1>translational research</Res_KW1>
        <Res_KW2>ovarian cancer</Res_KW2>
        <Res_KW3>immune response</Res_KW3>
        <Res_KW4>cancer biology</Res_KW4>
        <Res_KW5>genomics</Res_KW5>
        <Plain_Description>Ovarian cancer and other rare cancer types have low survival rates. My program will study women who achieve very long remissions (“Super-Responders”) following PARP inhibitor + immune therapy and “Super-survivors”, individuals who develop three or more cancers. The underlying genetic mechanisms for this are poorly understood. By studying both, we expect to discover key molecular and immune pathways that should underpin effective therapies to prevent cancer recurrence.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009798</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Andrew Steer</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Innovative public health interventions to control the global burden of Strep A disease </Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,299,438.96</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Public Health and Health Services not elsewhere classified</Field_s__of_Research>
        <Res_KW1>Streptococcus pyogenes</Res_KW1>
        <Res_KW2>scabies</Res_KW2>
        <Res_KW3>rheumatic heart disease</Res_KW3>
        <Res_KW4>clinical trial</Res_KW4>
        <Res_KW5>vaccine</Res_KW5>
        <Plain_Description>Strep A causes over 500,000 deaths in the world each year, especially due to rheumatic heart disease. Scabies is a major driver of Strep A skin infection in our region. I propose to tackle the problem with 2 innovative approaches. First, I will test new vaccines using a human model of Strep A infection and in a large clinical trial. Second, I will investigate how mass treatment for scabies can impact on Strep A skin infection and rheumatic heart disease, and I will test new drugs and diagnostics.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009800</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof John Simes</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Innovations in Clinical Trials Research: from personalised medicine to population health </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,727,015.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Clinical Sciences not elsewhere classified</Field_s__of_Research>
        <Res_KW1>clinical trial</Res_KW1>
        <Res_KW2>clinical epidemiology</Res_KW2>
        <Res_KW3>oncology</Res_KW3>
        <Res_KW4>cardiovascular disease</Res_KW4>
        <Res_KW5>perinatal</Res_KW5>
        <Plain_Description>Well-designed clinical trials including translational research are critical for real advances in healthcare. The proposed research involves major clinical trials evaluating new treatments and strategies in cancer, cardiovascular disease and perinatal medicine; novel methods for better trials; and integrating evidence for better decision-making in healthcare. The aim is to integrate clinical research into routine care and use translational science to optimise treatment for individual patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009808</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Giovanni Ferreira</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Improving back pain care in Australia</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Rheumatology and Arthritis</Field_s__of_Research>
        <Res_KW1>musculoskeletal disorders</Res_KW1>
        <Res_KW2>back pain</Res_KW2>
        <Res_KW3>health policy evaluation</Res_KW3>
        <Res_KW4>clinical trial</Res_KW4>
        <Res_KW5>health services research</Res_KW5>
        <Plain_Description>Over the next five years, this research program will improve the care provided for back pain in Australia, the number one cause of disability. To accomplish that goal, a series of health policy evaluations at the national and state level, a randomised trial to reduce unnecessary lumbar surgeries and improve return to work, and two studies to investigate barriers and enablers of the right care for back pain will be conducted.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009820</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Nady Braidy</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Nicotinamide adenine dinucleotide as a novel target for ageing and dementia</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,570,120.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Central Nervous System</Field_s__of_Research>
        <Res_KW1>Alzheimer disease</Res_KW1>
        <Res_KW2>oxidative stress</Res_KW2>
        <Res_KW3>nutritional therapy</Res_KW3>
        <Res_KW4>cognition</Res_KW4>
        <Res_KW5>bioenergetics</Res_KW5>
        <Plain_Description>A better understanding of novel molecular targets of disease to use in diagnostics and therapeutics for age-related cognitive impairment and dementia is urgently needed. My research program will test the hypothesis that raising intracellular NAD+ levels can (1) slow down the onset of dementia-related neuropathology; (2) alter dementia biomarker trajectories; and (3) moderate behavioural/cognitive deficits, in established in animal models and humans cohorts. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009840</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Susan Ramus</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Development of clinical tests to improve treatment for ovarian cancer patients</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,427,015.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Solid Tumours</Field_s__of_Research>
        <Res_KW1>ovarian cancer</Res_KW1>
        <Res_KW2>genomics</Res_KW2>
        <Res_KW3>prognostic markers</Res_KW3>
        <Res_KW4>differential gene expression</Res_KW4>
        <Res_KW5>clinical decision making</Res_KW5>
        <Plain_Description>The aim of this program is to improve ovarian cancer survival. In other cancers, tumour tests at diagnosis are used to guide treatment. I will utilise the resources of the international Ovarian Tumour Tissue Analysis (OTTA) consortium, that I lead, to develop tumour tests to determine the best treatment for each patient. This will include; if they should have surgery before chemotherapy, if they need an alternative to the commonly used chemotherapy, and predicting response to new treatments. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009843</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Nawaf Yassi</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Tau - A diagnostic and therapeutic target in Alzheimer's Disease</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,280,217.88</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Central Nervous System</Field_s__of_Research>
        <Res_KW1>Alzheimer disease</Res_KW1>
        <Res_KW2>biomarkers</Res_KW2>
        <Res_KW3>clinical trial</Res_KW3>
        <Res_KW4>dementia</Res_KW4>
        <Res_KW5>diagnosis</Res_KW5>
        <Plain_Description>Toxic forms of ‘tau’ protein in the brain are part of the cause of Alzheimer’s disease. This condition is difficult to diagnose, and there are no treatments to stop progression. My research focuses on developing a blood test measuring the levels of toxic tau in patients attending Australian memory clinics. The program will also undertake a world-first clinical trial of an oral drug (SAMe) that targets the tau protein to understand whether this can slow the progression of Alzheimer’s disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009852</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Hongyuan Yang</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Lipid trafficking and storage: from cell biology to novel therapies against diseases</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,927,015.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Cell Metabolism</Field_s__of_Research>
        <Res_KW1>cell biology</Res_KW1>
        <Res_KW2>membrane trafficking</Res_KW2>
        <Res_KW3>protein trafficking</Res_KW3>
        <Res_KW4>membrane lipids</Res_KW4>
        <Res_KW5>phospholipids</Res_KW5>
        <Plain_Description>Lipids represent a major class of molecules in life. They are associated with many common human diseases such as obesity, diabetes, heart disease and cancer. A major gap in knowledge is how our cells store and transport important lipids such as cholesterol. This proposal aims to investigate mechanisms governing the storage and trafficking of lipids, and to also apply the new knowledge to developing novel compounds/therapies against cancer and other diseases.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009866</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Shanshan Li</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Health Risk Assessment of Bushfire Smoke on Children and Pregnancy Outcomes</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,570,120.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Environmental and Occupational Health and Safety</Field_s__of_Research>
        <Res_KW1>environmental epidemiology</Res_KW1>
        <Res_KW2>air pollution</Res_KW2>
        <Res_KW3>climate change</Res_KW3>
        <Res_KW4>exposure assessment</Res_KW4>
        <Res_KW5>child</Res_KW5>
        <Plain_Description>This Investigator Grant program will fill the knowledge gaps in whether bushfire smoke have impacts on children and pregnancy outcomes using new technology, novel approaches and big data analyses. The outcomes will result in improved environmental exposure assessment and reduced hazard of bushfire smoke, leading to substantial gains in population and environmental health. Importantly, this work will enhance capacity building and advance the development of bushfire epidemiology. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009873</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Gulam Khandaker</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>A Global Programme on Epidemiology, Early Detection and Intervention for Children with Cerebral Palsy in Low- and Middle-Income Countries </Grant_Title>
        <Admin_Institution>Central Queensland University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,342,072.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Paediatrics</Field_s__of_Research>
        <Res_KW1>cerebral palsy</Res_KW1>
        <Res_KW2>cerebral palsy treatments</Res_KW2>
        <Res_KW3>early diagnosis</Res_KW3>
        <Res_KW4>early intervention</Res_KW4>
        <Res_KW5>disease prevention</Res_KW5>
        <Plain_Description>Cerebral palsy (CP) is the leading cause of childhood disability with an estimated 50 million people affected globally. However, majority of the children with CP living in low- and middle-income countries (LMICs) do not receive timely diagnosis and intervention. I propose a global research programme across Asia, Africa and South America to study the burden, causes and suitable approaches for early detection and intervention for children with CP in LMICs to improve their lives.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009878</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Michael Hofman</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Personalised medicine to improve outcomes for men with prostate cancer through seamless integration of novel imaging and targeted therapy (theranostics)</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,863,610.68</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Nephrology and Urology</Field_s__of_Research>
        <Res_KW1>prostate cancer</Res_KW1>
        <Res_KW2>nuclear medicine</Res_KW2>
        <Res_KW3>radiology</Res_KW3>
        <Res_KW4>medical oncology</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>This grant will enable me as a clinician-scientist to improve outcomes for men with prostate cancer, a disease resulting in more than 3000 deaths in Australia annually, by using a technology called theranostics. Theranostics uses radioactive tumour seeking molecules to integrate whole body imaging and a targeted treatment. I will develop clinical trials with global impact and use artificial intelligence image interpretation to better define patient prognosis and select optimal therapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009885</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof David Currow</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Deciphering the heterogeneity of chronic breathlessness: implications for more personalised management of the symptom</Grant_Title>
        <Admin_Institution>University of Technology Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,500,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Medical and Health Sciences not elsewhere classified</Field_s__of_Research>
        <Res_KW1>breathlessness</Res_KW1>
        <Res_KW2>palliative care</Res_KW2>
        <Res_KW3>assessment</Res_KW3>
        <Res_KW4>neurophysiology</Res_KW4>
        <Res_KW5>phenotype</Res_KW5>
        <Plain_Description>Chronic breathlessness is a debilitating symptom affecting >300,000 Australians with chronic, progressive conditions. This innovative program combines epidemiological, basic science and health services research to generate a world-first classification of clinical sub-types of chronic breathlessness. This will provide more personalised symptom management, and ultimately deliver improved health outcomes and independence, and directly inform clinical practice and reduce health service use. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009940</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Robert Gilchrist</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Translating oocyte biology discoveries to clinical practice</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,827,015.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Reproduction</Field_s__of_Research>
        <Res_KW1>reproductive biology</Res_KW1>
        <Res_KW2>in vitro maturation of oocytes</Res_KW2>
        <Res_KW3>assisted reproductive technology (ART)</Res_KW3>
        <Res_KW4>ovary</Res_KW4>
        <Res_KW5>translational research</Res_KW5>
        <Plain_Description>I am reproductive biologist studying factors that regulate the intrinsic quality of unfertilised eggs. I have produced and patented the use of unique growth factors produced by the egg that enhance egg quality in women. Bringing together industry and world-leading clinics, I am developing new forms of hormone-free infertility treatment for cancer and infertile patients, which I will apply in widespread clinical practice over the next 5 years.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009957</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Trent Woodruff</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Developing new therapies targeting innate immune mediated inflammation in neurodegenerative disease</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$3,372,570.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Innate Immunity</Field_s__of_Research>
        <Res_KW1>complement</Res_KW1>
        <Res_KW2>neurodegeneration</Res_KW2>
        <Res_KW3>motor neuron disease (MND)</Res_KW3>
        <Res_KW4>neuroinflammation</Res_KW4>
        <Res_KW5>drug development</Res_KW5>
        <Plain_Description>Brain diseases such as Parkinson’s disease and motor neuron disease remain a burden on society with few effective treatments. Recent studies have documented a key role for the immune system and inflammation in accelerating neurodegenerative disease progression. This project will identify new drugs that can tame the inflammation cascade in the brain, to help treat these diseases. It will assist in the progression of these drugs into human clinical trials to ultimately improve patient outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009965</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Peter Meikle</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Integrating lipidomic, metabolomic and genomic studies to define causal metabolic pathways in cardiometabolic disease: Delivering precision medicine solutions for Australia.</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,427,015.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Medical Biochemistry: Proteins and Peptides (incl. Medical Proteomics)</Field_s__of_Research>
        <Res_KW1>lipid metabolism</Res_KW1>
        <Res_KW2>genomics</Res_KW2>
        <Res_KW3>bioinformatics</Res_KW3>
        <Res_KW4>risk prediction</Res_KW4>
        <Res_KW5>population studies</Res_KW5>
        <Plain_Description>Our metabolism plays a central role in the development type 2 diabetes, cardiovascular disease, age related dementia and some cancers. We plan to use new technology (genomics and metabolomics) to understand how our genes and environment combine to influence our metabolism and our health.  We will use this new information to develop new tests for risk assessment and early detection and develop new treatments to maintain health and to prevent, attenuate or treat these common metabolic diseases. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009982</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Daniel MacArthur</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Building a foundation for equitable population-scale genomic medicine</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$3,427,015.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Genomics</Field_s__of_Research>
        <Res_KW1>genetics</Res_KW1>
        <Res_KW2>genomics</Res_KW2>
        <Res_KW3>sequencing</Res_KW3>
        <Res_KW4>bioinformatics</Res_KW4>
        <Res_KW5>population genetics</Res_KW5>
        <Plain_Description>Genomic technologies, such as whole-genome sequencing, are already transforming our ability to diagnose, predict, and treat many diseases. However, to ensure that genomic medicine is accessible and useful to everyone, we need more powerful tools for analysis, new databases representing all Australian communities, and new approaches to identify targets for therapeutic drugs. My program will develop methods and resources to establish the foundations for equitable population-scale genomic medicine.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009991</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Ibrahim Javed</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Role of Gut-Bacteria in Dementia and Implications for Future Nanomedicine</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Nanomedicine</Field_s__of_Research>
        <Res_KW1>amyloid beta-protein</Res_KW1>
        <Res_KW2>protein aggregation</Res_KW2>
        <Res_KW3>bacterial biofilm</Res_KW3>
        <Res_KW4>nanotechnology</Res_KW4>
        <Res_KW5>microbial pathogenesis</Res_KW5>
        <Plain_Description>My research and recent clinical evidence indicate the involvement of gut-bacteria in the early-onset and accelerated progression of dementia in Alzheimer's Disease. This project will investigate the molecular mechanisms for this toxic communication between gut-bacteria and the brain, and develop a nanotechnology-based approach to block this communication. It will open new therapeutic opportunities to control the progression and inhibit the early-onset of dementia in Alzheimer’s Disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009998</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Belinda Gabbe</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Harnessing the power of diverse data to model population impacts of injury and inform health and social policy</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,885,378.22</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Health Information Systems (incl. Surveillance)</Field_s__of_Research>
        <Res_KW1>injury epidemiology</Res_KW1>
        <Res_KW2>traumatic injury</Res_KW2>
        <Res_KW3>data linkage</Res_KW3>
        <Res_KW4>data analysis</Res_KW4>
        <Res_KW5>disability</Res_KW5>
        <Plain_Description>This investigator grant program will transform thinking about the long-term impacts of injury and the complex interplay between health and social sectors. The program will establish cross-sectoral data platforms with the real-world capacity to fundamentally change how we use data to characterise injury and its impacts. The findings will drive evidence-informed public health and social policy planning and investment to reduce the population impacts of injury. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010008</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Janni Leung</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Reducing the impact and burden of substance use on mental health</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Mental Health</Field_s__of_Research>
        <Res_KW1>epidemiology</Res_KW1>
        <Res_KW2>substance use</Res_KW2>
        <Res_KW3>substance use disorders</Res_KW3>
        <Res_KW4>alcohol use disorders</Res_KW4>
        <Res_KW5>comorbidity</Res_KW5>
        <Plain_Description>Substance use and mental health are both major public health issues that commonly occur together. The relationship between them is not well understood. This work will use advanced statistical models to quantify the relationship, predict how much harm substance use is causing to mental health, and identify how much harm could be prevented by better policy. The knowledge gained will inform policies on how to reduce disease burden caused by substance use on mental health in Australia and overseas.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010037</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Dustin Flanagan</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Defining the mechanisms that drive cell competition and plasticity in stomach cancer.</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Cancer Cell Biology</Field_s__of_Research>
        <Res_KW1>adult stem cells</Res_KW1>
        <Res_KW2>gastric cancer</Res_KW2>
        <Res_KW3>mesenchymal signals</Res_KW3>
        <Res_KW4>epithelial biology</Res_KW4>
        <Res_KW5>cell-cell communication</Res_KW5>
        <Plain_Description>Cancers of the upper digestive tract (stomach) are composed of a diverse mixture of cell types that function differently depending on the stage of cancer progression. Understanding exactly how the different cell types interact with each other to promote cancer growth at various stages of disease (early, intermediate and late-stage) is crucial in order to develop better cancer therapies to extend patient survival.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010051</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Freya Shearer</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Mitigating the impacts of infectious disease emergencies</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Epidemiology</Field_s__of_Research>
        <Res_KW1>informed decision making</Res_KW1>
        <Res_KW2>policy development</Res_KW2>
        <Res_KW3>disease transmission</Res_KW3>
        <Res_KW4>social epidemiology</Res_KW4>
        <Res_KW5>emerging diseases</Res_KW5>
        <Plain_Description>While public health and social measures have been central to the COVID-19 response and saved lives, many uncertainties remain as to their optimal use. Governments have been repeatedly required to balance the consequences of an uncontrolled outbreak against the social and economic costs of interventions. Over the next five years, I will use modelling and decision science to support the development of more tailored and adaptive response policies for COVID-19 and inevitable future pandemics. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010053</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Josephine Forbes</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Designing and translating novel therapies for diabetes and kidney disease</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,372,570.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Nephrology and Urology</Field_s__of_Research>
        <Res_KW1>type 1 diabetes mellitus (insulin-dependent diabetes mellitus)</Res_KW1>
        <Res_KW2>kidney disease</Res_KW2>
        <Res_KW3>type 2 diabetes mellitus (non-insulin dependent diabetes mellitus)</Res_KW3>
        <Res_KW4>drug therapy</Res_KW4>
        <Res_KW5>indigenous health</Res_KW5>
        <Plain_Description>Four million individuals die from diabetes each year and half of these are less than 50 years old. Individuals with earlier onset diabetes in Australia and their families are personally impacted by diabetes specific health issues such as kidney disease. During this five year program of research we aim to better understand the factors responsible, and to progress therapies which may reduce diabetes and kidney disease if made available to these individuals including Indigenous Australians.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010055</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Blake Angell</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Health workforce investment to incentivise universal health coverage </Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Health Economics</Field_s__of_Research>
        <Res_KW1>health economics</Res_KW1>
        <Res_KW2>economic analysis</Res_KW2>
        <Res_KW3>incentives</Res_KW3>
        <Res_KW4>workforce policy</Res_KW4>
        <Res_KW5>community health care</Res_KW5>
        <Plain_Description>Health workers including doctors, nurses and community health workers are crucial to population health and a major driver of healthcare costs. In low- and middle-income nations, there has been little attention to the most effective way to finance and organise health workers despite the large costs in lost health and wasted expenditure caused by investing in ineffective care. This Fellowship will generate economic evidence to drive rational healthcare investment in low- and middle-income nations.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010063</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Ashleigh Lin</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Improving the mental health of trans and gender diverse young people</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,570,120.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Mental Health</Field_s__of_Research>
        <Res_KW1>mental health</Res_KW1>
        <Res_KW2>gender</Res_KW2>
        <Res_KW3>youth</Res_KW3>
        <Res_KW4>psychological</Res_KW4>
        <Res_KW5>psychiatric</Res_KW5>
        <Plain_Description>The aim of this research program is to improve the mental health of trans and gender diverse (henceforth trans) children and young people. One stream will be dedicated to better understanding the experiences of trans young people where gaps in knowledge still exist. The other stream will focus on the development of novel interventions to improve the mental health of trans children and young people at the individual and family levels.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010064</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Ramon Landin-Romero</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 2 </Sub_Type>
        <Grant_Title>Bridging the clinico-pathological divide: improving neuroimaging analysis and applications in dementia</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,570,120.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Neurology and Neuromuscular Diseases</Field_s__of_Research>
        <Res_KW1>frontotemporal dementia</Res_KW1>
        <Res_KW2>neuroimaging</Res_KW2>
        <Res_KW3>differential diagnosis</Res_KW3>
        <Res_KW4>atrophy</Res_KW4>
        <Res_KW5>disease progression</Res_KW5>
        <Plain_Description>Dementias are a group of incurable and fatal disorders caused by progressive deterioration of the brain function. This program will identify the gradual brain changes that cause symptoms of dementia (e.g., problems with thinking, language, behaviour and everyday skills) to develop. Greater understanding of how the brain changes throughout the disease course will lead to better diagnosis of dementia and contribute to develop medical treatments to stop the progression of the underlying disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010070</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Prof Shahneen Sandhu</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Improving outcomes for men with advanced prostate cancer through innovative clinical trials and biomarker development.</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,023,988.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Cancer Therapy (excl. Chemotherapy and Radiation Therapy)</Field_s__of_Research>
        <Res_KW1>prostate cancer</Res_KW1>
        <Res_KW2>novel therapies</Res_KW2>
        <Res_KW3>radiopharmaceuticals</Res_KW3>
        <Res_KW4>immunotherapy</Res_KW4>
        <Res_KW5>biomarkers</Res_KW5>
        <Plain_Description>Prostate cancer (PC) is a common disease and the median survival advantage from novel androgen receptor targeted agents for men with castration resistant disease is measured in months and is not cumulative due to underlying cross-resistance. My research program aims to understand the biology of aggressive forms of PC, define new immune and molecular targets and undertake novel biomarker driven clinical trials that will co-develop new combinations and biomarkers for optimal patient selection. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010072</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Zhuoting Zhu</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>RetinaAGE as a novel biomarker for ageing and cardiovascular risk</Grant_Title>
        <Admin_Institution>Centre for Eye Research Australia</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Ophthalmology</Field_s__of_Research>
        <Res_KW1>retina</Res_KW1>
        <Res_KW2>ageing</Res_KW2>
        <Res_KW3>chronic diseases</Res_KW3>
        <Res_KW4>artificial neural networks</Res_KW4>
        <Res_KW5>risk prediction</Res_KW5>
        <Plain_Description>The back of the eye (retina) is a window to our blood vessels and nervous system and can be easily imaged. I have developed and pilot tested an AI algorithm that can accurately predict age using retinal photos. The gap between age predicted by the algorithm and chronological age, known as RetinaAGE, can predict premature death and cardiovascular events. This project will test RetinaAGE in individuals of different ethnicities and translate this AI into a system that will be tested in clinics.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010084</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Mandeep Singh</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Molecular and genomic profiling of rogue lymphocytes in autoimmune disease using single-cell genomics</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Autoimmunity</Field_s__of_Research>
        <Res_KW1>autoimmune disease</Res_KW1>
        <Res_KW2>genomics</Res_KW2>
        <Res_KW3>immune tolerance</Res_KW3>
        <Res_KW4>bioinformatics</Res_KW4>
        <Res_KW5>autoantibodies</Res_KW5>
        <Plain_Description>Autoimmune disease occurs when the immune system turns "rogue" and attacks tissues within the body. The exact cause of human autoimmune diseases are unknown. A major hurdle in autoimmune disease research is identifying the rogue disease-causing immune cells from normal immune cells. I have developed novel technology capable of identifying and characterising rogue immune cells which will advance our understanding of how these cells arise and persist, and help develop more targeted therapies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010088</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Aidan Cashin</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Tailoring implementation for forgotten populations in chronic disease management</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Clinical Sciences not elsewhere classified</Field_s__of_Research>
        <Res_KW1>implementation</Res_KW1>
        <Res_KW2>evidence-based health care</Res_KW2>
        <Res_KW3>mechanisms</Res_KW3>
        <Res_KW4>translational research</Res_KW4>
        <Res_KW5>chronic diseases</Res_KW5>
        <Plain_Description>Using evidence in clinical practice is challenging when the evidence does not describe how the treatment works or include participants from the population of interest. The aim of this fellowship is to extend research evidence by identifying how treatments for chronic conditions work, and whether they apply to under-served populations in Australia. This information will improve the use of evidence in clinical practice and the uptake of evidence-based treatments for forgotten populations. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010091</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Sanjay Jayasinghe Wadanambi Arachchige</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Research generating evidence to optimise pneumococcal disease prevention</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$450,370.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Epidemiology</Field_s__of_Research>
        <Res_KW1>vaccine</Res_KW1>
        <Res_KW2>epidemiology</Res_KW2>
        <Res_KW3>public health</Res_KW3>
        <Res_KW4>epidemiological research methods</Res_KW4>
        <Res_KW5>vaccine-preventable diseases</Res_KW5>
        <Plain_Description>This research program aims to develop an in-depth understanding of various streptococcus pneumoniae (SP) infections that could be serious and even life threatening. Antibiotic resistance and how COVID-19 and influenza could make people vulnerable to SP infections will be two key areas explored. This research is expected to feed directly in to practice and policy relating to pneumococcal disease surveillance and optimizing prevention using vaccinations during COVID-19 pandemic and beyond.   </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010100</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Yannan Yang</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Developing an Oral Nanoformulation for Preventing Cancer Recurrence</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Nanomedicine</Field_s__of_Research>
        <Res_KW1>anticancer drug</Res_KW1>
        <Res_KW2>nanotechnology</Res_KW2>
        <Res_KW3>breast cancer prevention</Res_KW3>
        <Res_KW4>copper transport</Res_KW4>
        <Res_KW5>chemoprevention</Res_KW5>
        <Plain_Description>Triple negative breast cancer (TNBC) is a highly aggressive disease with high recurrence rate following primary treatment. This project aims to develop an oral nanoformulation for preventing TNBC recurrence by reducing systemic copper level. This formulation is based on an advanced nanobiotechnology which is expected to enable primarily localised copper depletion in the intestine and reduce systemic exposure, thereby minimising adverse off-target effects and improving therapeutic outcomes. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010110</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Aidan Burrell</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Improving Outcomes after  Extracorporeal Membrane Oxygenation </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$450,370.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Intensive Care</Field_s__of_Research>
        <Res_KW1>critical care medicine</Res_KW1>
        <Res_KW2>heart failure</Res_KW2>
        <Res_KW3>acute respiratory distress syndrome (ARDS)</Res_KW3>
        <Res_KW4>mechanical ventilation</Res_KW4>
        <Res_KW5>critical illness</Res_KW5>
        <Plain_Description>Extracorporeal membrane oxygenation is a potentially lifesaving support for patients with severe cardiac or respiratory failure, but the underlying evidence base remains limited. Over the last 7 years, i have build leading program of research, which has led to the development of a national ECMO registry and a large RCT of ECMO for cardiac failure. With this fellowship, i will extend this work to generate new high quality knowledge in major evidence gaps, including a new clinical trial. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010124</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Douglas Blank</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Improving Neonatal Resuscitation</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$450,370.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Systems Physiology</Field_s__of_Research>
        <Res_KW1>neonatal intensive care (NICU)</Res_KW1>
        <Res_KW2>resuscitation</Res_KW2>
        <Res_KW3>neonatal respiratory distress syndrome</Res_KW3>
        <Res_KW4>perinatal</Res_KW4>
        <Res_KW5>neonatal survival</Res_KW5>
        <Plain_Description>Over 5% of all babies worldwide need help breathing in the seconds after birth. Failing to breath kills more than 1 baby every minute. My grant will investigate simple ideas that may make birth safer for the baby, including: understanding how the baby begins breathing air after birth, augmenting the respiratory drive of premature babies to spontaneously breathe after birth, and helping babies breathe before cutting the umbilical cord so that they are still being supported by their mother. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010128</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof James McAuley</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Improving care for low back pain</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,111,089.24</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Physiotherapy</Field_s__of_Research>
        <Res_KW1>low back pain</Res_KW1>
        <Res_KW2>chronic pain</Res_KW2>
        <Res_KW3>clinical research</Res_KW3>
        <Res_KW4>clinical trial</Res_KW4>
        <Res_KW5>implementation</Res_KW5>
        <Plain_Description>Low back pain is the number-one cause of disability worldwide, affecting an estimated 540 million people at any one time. The disease burden due to low back pain has increased by 54% since 1990, threatening the sustainability of health care systems globally. My research will address the growing burden of low back pain by providing new knowledge on the effect of analgesic medicines and on works to improve the research translation of evidence into care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010134</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Christopher Goodnow</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Revealing how tolerance checkpoints fail in human autoimmune diseases and how to target therapy</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,500,000.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Autoimmunity</Field_s__of_Research>
        <Res_KW1>autoimmune disease</Res_KW1>
        <Res_KW2>immunological tolerance</Res_KW2>
        <Res_KW3>cellular immunology</Res_KW3>
        <Res_KW4>somatic mutation</Res_KW4>
        <Res_KW5>differential gene expression</Res_KW5>
        <Plain_Description>Prof Goodnow will lead a program of research defining the root cause of human autoimmune diseases and using these discoveries to guide better targetted treatment for these important, chronic diseases.  The research employs new single cell genomic technologies to pinpoint the DNA and other molecular abnormalities that allow rare cells within the immune system to escape the body’s normal control processes, and instead attack one or other part of the body to cause autoimmunity.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010136</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Vicki Flenady</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Preventing stillbirths and improving care after loss</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$3,372,570.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Public Health and Health Services not elsewhere classified</Field_s__of_Research>
        <Res_KW1>antenatal care</Res_KW1>
        <Res_KW2>stillbirth</Res_KW2>
        <Res_KW3>prevention</Res_KW3>
        <Res_KW4>bereavement</Res_KW4>
        <Res_KW5>neonatal</Res_KW5>
        <Plain_Description>In Australia, over 2000 families suffer the tragedy of stillbirth each year. By building on my achievements in rapidly translating new research into maternity care, I will lead my outstanding team to reduce stillbirth rates by 20% and reconcile inequities in stillbirth rates by Australia by 2025. I also anticipate a reduction in adverse neonatal outcomes. When stillbirth or neonatal death does occur, my research aims to ensure all women and families receive optimal care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010141</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Jason Mattingley</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Understanding the role of predictive coding in visual processing: from neural circuits to whole brain systems</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,527,015.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Biological Psychology (Neuropsychology, Psychopharmacology, Physiological Psychology)</Field_s__of_Research>
        <Res_KW1>visual attention</Res_KW1>
        <Res_KW2>visual system</Res_KW2>
        <Res_KW3>neuropsychological impairments</Res_KW3>
        <Res_KW4>electroencephalogram (EEG)</Res_KW4>
        <Res_KW5>functional magnetic resonance imaging (fMRI)</Res_KW5>
        <Plain_Description>The simple act of perceiving an object in the world depends not only on the incoming sensory information, but also on the brain’s predictions about the object’s likely identity. This research will characterise the neural mechanisms responsible for predictive coding of visual information. I will combine brain imaging and analogous visual tasks in humans and animal models, and apply novel computational methods to reveal a common code for perception in whole brain systems and individual neurons.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010149</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Luke Formosa</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Understanding complex I assembly for better diagnosis and future treatment</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Cell Metabolism</Field_s__of_Research>
        <Res_KW1>mitochondria</Res_KW1>
        <Res_KW2>membrane protein</Res_KW2>
        <Res_KW3>protein complexes</Res_KW3>
        <Res_KW4>mitochondrial disease</Res_KW4>
        <Res_KW5>proteomics</Res_KW5>
        <Plain_Description>Almost all cells in the human body need to produce energy so they can survive and grow. This is achieved by tiny generators in the cell called Mitochondria. When Mitochondria are unable to produce the energy the cell needs it dies and this leads to Mitochondrial Disease, which affects 1 in 2000 people. This project aims to understand one of the biggest contributors to Mitochondrial Disease- called Complex I Deficiency. This will lead to better diagnosis of patients and treatments in the future.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010154</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Wenlong Cheng</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 1 </Sub_Type>
        <Grant_Title>Gold Electronic Skins for Remote Biodiagnostics</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,348,555.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Medical Biotechnology Diagnostics (incl. Biosensors)</Field_s__of_Research>
        <Res_KW1>biosensor</Res_KW1>
        <Res_KW2>biomonitoring</Res_KW2>
        <Res_KW3>remote</Res_KW3>
        <Res_KW4>diagnosis</Res_KW4>
        <Res_KW5>nanotechnology</Res_KW5>
        <Plain_Description>This interdisciplinary Eng-IT-Med research program aims to develop artificial intelligence-powered soft gold electronic skins for ‘health’ monitoring of living organisms, including cells, tissues, organoids whenever one wants wherever one wants by a wireless smartphone. It is expected that this program will generate groundbreaking knowledge/technologies in remote monitoring of biological systems, deliver translational outcomes in industries and train a large cohort of workforces. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010156</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Dr Ruth Pidsley</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Emerging Leadership 1 </Sub_Type>
        <Grant_Title>Decoding the epigenome of the tumour microenvironment for improved patient outcomes in prostate cancer</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$650,740.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Epigenetics (incl. Genome Methylation and Epigenomics)</Field_s__of_Research>
        <Res_KW1>epigenetics</Res_KW1>
        <Res_KW2>prostate cancer</Res_KW2>
        <Res_KW3>microenvironment</Res_KW3>
        <Res_KW4>DNA methylation</Res_KW4>
        <Res_KW5>clinical decision making</Res_KW5>
        <Plain_Description>Just as people in big cities rely on a complex infrastructure network for their daily lives, cancer cells depend on the surrounding tumour microenvironment. Studying the behaviour and interactions of the neighbouring cells is crucial to understanding how a tumour develops and progresses. I will scrutinize the molecular information in prostate tumour microenvironment cells to learn how they emerge and function to promote cancer, and to identify new molecular markers to guide treatment decisions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010203</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Bob Graham</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 3 </Sub_Type>
        <Grant_Title>Building heart muscle to treat cardiomyopathies</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,352,015.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Cardiology (incl. Cardiovascular Diseases)</Field_s__of_Research>
        <Res_KW1>congestive heart failure</Res_KW1>
        <Res_KW2>coronary artery disease</Res_KW2>
        <Res_KW3>cardiomyopathy</Res_KW3>
        <Res_KW4>regeneration</Res_KW4>
        <Res_KW5>cell cycle regulation</Res_KW5>
        <Plain_Description>Cardiovascular disease is our major societal and economic health burden. Many types of heart disease are due to a lack of functioning heart muscle cells either resulting from the massive loss of these cells following a heart attack or to the toxic effects of certain drugs in adults, or to inadequate heart growth in children; causing heart failure or death. This study aims to stimulate heart muscle cells to divide, thereby building heart muscle to improve heart function, well-being and survival. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010212</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>Prof Julie Leask</CIA_Name>
        <Grant_Type>Investigator Grants</Grant_Type>
        <Sub_Type>Leadership 2 </Sub_Type>
        <Grant_Title>Behavioural and social science to close gaps in vaccination coverage</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$2,372,570.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Health Promotion</Field_s__of_Research>
        <Res_KW1>behavioural intervention</Res_KW1>
        <Res_KW2>communications/social research</Res_KW2>
        <Res_KW3>vaccination policy</Res_KW3>
        <Res_KW4>implementation</Res_KW4>
        <Res_KW5>primary care</Res_KW5>
        <Plain_Description>COVID-19 has cost trillions in economic loss globally and devastated entire nations. The pandemic now has the capacity to be much better controlled with vaccination. But the best vaccines - those against COVID-19 and other diseases - are of no use if the public will not, or cannot, take them. This research will help countries to gather a better understanding of why people don't vaccinate and what to do about it. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2000367</APP_ID>
        <Date_Announced>2021-09-14T00:00:00</Date_Announced>
        <CIA_Name>A/Pr John Wentworth</CIA_Name>
        <Grant_Type>Clinical Trials and Cohort Studies Grants</Grant_Type>
        <Sub_Type>Clinical Trials and Cohort Studies Grants</Sub_Type>
        <Grant_Title>Combination immune therapy for type 1 diabetes</Grant_Title>
        <Admin_Institution>Melbourne Health</Admin_Institution>
        <State>VIC</State>
        <Sector>Health</Sector>
        <Total>$1,803,801.50</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Endocrinology</Field_s__of_Research>
        <Res_KW1>type 1 diabetes mellitus (insulin-dependent diabetes mellitus) </Res_KW1>
        <Res_KW2>autoimmune disease </Res_KW2>
        <Res_KW3>immune modulation </Res_KW3>
        <Res_KW4>metabolic control </Res_KW4>
        <Res_KW5>immune tolerance</Res_KW5>
        <Plain_Description>This clinical trial will test whether a combination of two safe therapies, abatacept and nasal insulin, can stop the immune attack that causes type 1 diabetes. Sixty-two children and young adults with recently-diagnosed type 1 diabetes will receive either abatacept and nasal insulin or abatacept and nasal placebo for one year to determine if combined immune therapy preserves pancreas function and decreases the need for insulin therapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009677</APP_ID>
        <Date_Announced>2021-10-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Kate Schroder</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>Synergy Grants</Sub_Type>
        <Grant_Title>Mining the host-pathogen interface to deliver a drug pipeline for treating intractable and emerging infections</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Medical Microbiology not elsewhere classified</Field_s__of_Research>
        <Res_KW1>drug discovery</Res_KW1>
        <Res_KW2>medicinal chemistry</Res_KW2>
        <Res_KW3>therapeutic agents</Res_KW3>
        <Res_KW4>innate immunity</Res_KW4>
        <Res_KW5>host/pathogen interaction</Res_KW5>
        <Plain_Description>Emerging viruses and antibiotic-resistant superbugs are the most important challenge to human health in the 21st century. New viruses such as SARS-CoV2 and Zika, as well as antibiotic resistant superbugs, emerge regularly and rapidly, urgently requiring new therapies. Our multidisciplinary Synergy team has demonstrated success in drug development and will create new drugs to avert the imminent global health disaster posed by emerging viruses and superbugs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009851</APP_ID>
        <Date_Announced>2021-10-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Paul Haber</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>Synergy Grants</Sub_Type>
        <Grant_Title>Linking clinical and basic science discovery to find new treatments for alcohol use disorder</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Clinical Sciences not elsewhere classified</Field_s__of_Research>
        <Res_KW1>alcohol dependence</Res_KW1>
        <Res_KW2>pharmacotherapy</Res_KW2>
        <Res_KW3>animal model</Res_KW3>
        <Res_KW4>neuroimaging</Res_KW4>
        <Res_KW5>alcohol use disorders</Res_KW5>
        <Plain_Description>More than a million Australians meet criteria for an alcohol use disorder, making it a leading cause of death, injury and many diseases. Current treatment is often ineffective and research receives limited attention with no new medications in 20 years. We will create a program for treatment development. We will test new medications and new behavioural treatment in experimental animals before moving to human trials. The approach links outstanding basic science and clinical research groups.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009923</APP_ID>
        <Date_Announced>2021-10-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Monika Janda</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>Synergy Grants</Sub_Type>
        <Grant_Title>Roadmap Options for Melanoma Screening in Australia (Melanoma-ROSA)</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Health Promotion</Field_s__of_Research>
        <Res_KW1>melanoma</Res_KW1>
        <Res_KW2>non-melanoma skin cancer</Res_KW2>
        <Res_KW3>behaviour change</Res_KW3>
        <Res_KW4>cancer screening</Res_KW4>
        <Res_KW5>early detection</Res_KW5>
        <Plain_Description>Melanoma is Australia’s third most common cancer and the earlier a melanoma is diagnosed the better the patient outcomes. Our program will co-design with consumers a blueprint for a NEW nationwide strategy for effective melanoma screening to inform practice and policy. We anticipate our program will generate evidence that will translate into a targeted melanoma screening program that is equitable in its reach, trustworthy for patients and clinicians, and cost-effective to the system.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010268</APP_ID>
        <Date_Announced>2021-10-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Mark Jenkins</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>Synergy Grants</Sub_Type>
        <Grant_Title>Tackling Australia’s low screening participation to prevent bowel cancer morbidity and deaths</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Preventive Medicine</Field_s__of_Research>
        <Res_KW1>bowel cancer screening</Res_KW1>
        <Res_KW2>participation</Res_KW2>
        <Res_KW3>colorectal cancer prevention</Res_KW3>
        <Res_KW4>controlled trial</Res_KW4>
        <Res_KW5>behaviour change</Res_KW5>
        <Plain_Description>Fifteen years after rollout, participation in our national bowel cancer screening program continues to lag behind comparable programs globally. We have not yet cracked even 50% participation despite the program’s world class free postal test kit and national registry. Current methods at getting people to screen are not working for most people.  We content this due to failure to assess novel interventions in randomised controlled trials within the NBCSP.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010275</APP_ID>
        <Date_Announced>2021-10-22T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Kate Sutherland</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>Synergy Grants</Sub_Type>
        <Grant_Title>Improving outcomes for lung cancer patients: Discovering targetable vulnerabilities in lung cancer</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Tumour Immunology</Field_s__of_Research>
        <Res_KW1>lung cancer</Res_KW1>
        <Res_KW2>mouse models</Res_KW2>
        <Res_KW3>cancer biology</Res_KW3>
        <Res_KW4>targeted therapy</Res_KW4>
        <Res_KW5>cancer immunotherapy</Res_KW5>
        <Plain_Description>Lung cancer is the leading cause of cancer-related mortality. One major hurdle faced in the clinic is that many patients fail to respond to currently available anti-cancer drugs. We will leverage the expertise of a diverse team of scientists and clinicians to tease apart the processes that can cause lung cancer to become refractory to current treatments. The discoveries made in this proposal will catalyse translational programs that will lead to improved ways to detect and treat lung cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010287</APP_ID>
        <Date_Announced>2021-10-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Philip Hansbro</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>Synergy Grants</Sub_Type>
        <Grant_Title>Defining the role and therapeutic manipulation of the gut-lung axis in respiratory disease</Grant_Title>
        <Admin_Institution>University of Technology Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Respiratory Diseases</Field_s__of_Research>
        <Res_KW1>respiratory diseases</Res_KW1>
        <Res_KW2>gastroenterology</Res_KW2>
        <Res_KW3>microbial ecology</Res_KW3>
        <Res_KW4>metabolites</Res_KW4>
        <Res_KW5>treatment</Res_KW5>
        <Plain_Description>Emphysema is an enormous clinical issue that needs effective treatment. Gut diseases cause lung inflammation. We show that gut bacteria (the microbiome) are altered and can be modified with targeted dietary interventions. We will define these changes and rapidly screen new diet for effectiveness in the lab and then test the most effective in clinical trials in patients. We will define how the new therapies work and progress new interventions to human treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010290</APP_ID>
        <Date_Announced>2021-10-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Anne Kavanagh</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>Synergy Grants</Sub_Type>
        <Grant_Title>Interventions for better life-time mental health outcomes for young Australians with disability</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Care for Disabled</Field_s__of_Research>
        <Res_KW1>disability</Res_KW1>
        <Res_KW2>young adults</Res_KW2>
        <Res_KW3>health sociology</Res_KW3>
        <Res_KW4>employment</Res_KW4>
        <Res_KW5>community participation</Res_KW5>
        <Plain_Description>This research program brings together academic researchers from multiple disciplines to address the entrenched social, economic and mental health disadvantage experienced by Australian youth with disability. In partnership with advocacy groups and government, we will generate new evidence about interventions, including policy reforms, that can reduce the gap in mental health and wellbeing between young people with disability and their non-disabled peers.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010562</APP_ID>
        <Date_Announced>2021-10-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Ingrid Scheffer</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>Synergy Grants</Sub_Type>
        <Grant_Title>"Integrative-omics" for precision medicine in the epilepsies</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Central Nervous System</Field_s__of_Research>
        <Res_KW1>epilepsy</Res_KW1>
        <Res_KW2>genetics</Res_KW2>
        <Res_KW3>paediatric</Res_KW3>
        <Res_KW4>data analysis</Res_KW4>
        <Res_KW5>molecular biology</Res_KW5>
        <Plain_Description>Epilepsy affects 4% of the population, with an estimated annual cost of $12.3 billion in Australia in 2019. This is largely due to devastating epilepsies known as Developmental and Epileptic Encephalopathies (DEEs). Patients have uncontrolled seizures, developmental impairment and a high risk of early death. We will bring computational expertise to integrate multiple biological measurements from patients with DEEs to reveal underlying disease dynamics and target new treatment approaches.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010716</APP_ID>
        <Date_Announced>2021-10-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Jonathan Carapetis</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>Synergy Grants</Sub_Type>
        <Grant_Title>STopping Acute Rheumatic Fever Infections to Strengthen Health (STARFISH)</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Public Health and Health Services not elsewhere classified</Field_s__of_Research>
        <Res_KW1>rheumatic fever</Res_KW1>
        <Res_KW2>aboriginal health</Res_KW2>
        <Res_KW3>streptococcal disease</Res_KW3>
        <Res_KW4>immunology</Res_KW4>
        <Res_KW5>environmental health</Res_KW5>
        <Plain_Description>Rheumatic Heart Disease (RHD) is a serious disease caused by preventable Strep A infections, disproportionately affecting Indigenous Australians. Knowledge gaps remain on how to eliminate RHD, and preventing acute rheumatic fever (ARF, the step before RHD) is key. In a global first STARFISH brings together a diverse team of experts to tackle the root causes – social determinants – providing evidence as to how environmental health and housing interventions can stop Strep A spread and prevent ARF.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010736</APP_ID>
        <Date_Announced>2021-10-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Roslyn Boyd</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>Synergy Grants</Sub_Type>
        <Grant_Title>Cerebral Palsy SYNERGY Network to Protect, Repair and improve Outcomes</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Central Nervous System</Field_s__of_Research>
        <Res_KW1>cerebral palsy treatments</Res_KW1>
        <Res_KW2>neuroplasticity</Res_KW2>
        <Res_KW3>neuroprotection</Res_KW3>
        <Res_KW4>consumer participation</Res_KW4>
        <Res_KW5>clinical trial</Res_KW5>
        <Plain_Description>Cerebral Palsy (CP) is a life-long condition that affects movement and learning due to early brain injury. Recent research has reduced the number of infants being born with CP by 30 percent and now 70 percent of children will now walk. Our CP Synergy Network will develop new early tests to detect CP, treatments to prevent CP and repair and rehabilitate those with early brain injury that leads to Cerebral Palsy guided by a national consumer network and a diverse multidisciplinary clinical team.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010766</APP_ID>
        <Date_Announced>2021-10-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Mark Parsons</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>Synergy Grants</Sub_Type>
        <Grant_Title>SERPICO Stroke: Synergistic Enhancement of Research design with Precision analytics to Improve Clinical Outcomes in Stroke.</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Cardiology (incl. Cardiovascular Diseases)</Field_s__of_Research>
        <Res_KW1>stroke</Res_KW1>
        <Res_KW2>ischaemic stroke</Res_KW2>
        <Res_KW3>haemorrhage</Res_KW3>
        <Res_KW4>stroke outcome</Res_KW4>
        <Res_KW5>post-stroke dementia</Res_KW5>
        <Plain_Description>Our Stroke synergy brings a diverse and revitalised cross-disciplinary team to harness our data infrastructure and pursue a whole new research direction for stroke. We will conduct a suite of new clinical trials with advanced statistical designs to improve trial efficiency. We will also develop completely new brain function and physical frailty measures to predict stroke outcome with embed cost-effectiveness analysis across all our activities to identify new ways to help patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010849</APP_ID>
        <Date_Announced>2021-10-22T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Misty Jenkins</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>Synergy Grants</Sub_Type>
        <Grant_Title>Rational design of novel CARs for safe and effective brain cancer immunotherapy</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)</Field_s__of_Research>
        <Res_KW1>protein engineering</Res_KW1>
        <Res_KW2>t cell immunotherapy</Res_KW2>
        <Res_KW3>brain neoplasms</Res_KW3>
        <Res_KW4>cd8 t cells</Res_KW4>
        <Res_KW5>cancer immunotherapy</Res_KW5>
        <Plain_Description>Glioblastoma is a deadly brain cancer with &lt;5% survival, 5 years after diagnosis. There are no curative treatments so novel approaches are urgently required. This project will improve therapy options for brain cancer by using immunotherapy, an approach showing great clinical promise. Using genetically engineered blood cells designed to specifically kill cancer cells, this project will use cutting edge technology to make new cell therapies and test them in preclinical models of brain cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011100</APP_ID>
        <Date_Announced>2021-10-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Monica Slavin</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>Synergy Grants</Sub_Type>
        <Grant_Title>Improving patient outcomes through implementation of digital and diagnostic innovations for infections in cancer</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>Infectious Diseases</Field_s__of_Research>
        <Res_KW1>immunocompromised</Res_KW1>
        <Res_KW2>clinical patient management</Res_KW2>
        <Res_KW3>health information management</Res_KW3>
        <Res_KW4>surveillance</Res_KW4>
        <Res_KW5>infectious diseases</Res_KW5>
        <Plain_Description>Fever and sepsis complicate the management of cancer and occur in up to 90% of patients receiving treatment for certain types of cancer, and in some cases infection is the leading cause of early mortality. Gaps in the management of infection in cancer include lack of access to diagnostic tests and specialist care.  This project will incorporate new technologies to deliver life saving care pathways for these vulnerable patients on a national scale.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011139</APP_ID>
        <Date_Announced>2021-10-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Andrew Roberts</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>Synergy Grants</Sub_Type>
        <Grant_Title>Understanding and averting blood cancer resistance to therapy</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Haematological Tumours</Field_s__of_Research>
        <Res_KW1>acute leukaemia</Res_KW1>
        <Res_KW2>human malignant b-cell lymphoma</Res_KW2>
        <Res_KW3>chronic lymphocytic leukaemia (cll)</Res_KW3>
        <Res_KW4>drug resistance</Res_KW4>
        <Res_KW5>targeted therapy</Res_KW5>
        <Plain_Description>Blood cancers account for one-sixth of all cancer deaths. To substantially reduce this we need to establish why current treatments, including new targeted and immune therapies, fail. We are bringing together experts in different areas of science (biology, bioinformatics, imaging, immunology) and medicine (molecular diagnosis, treatment) to dissect why leukaemias and lymphomas become resistant to new therapies and design strategies to either prevent resistance occurring or to overcome it.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011204</APP_ID>
        <Date_Announced>2021-10-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Patrick Brennan</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>Synergy Grants</Sub_Type>
        <Grant_Title>IMPACT: IMplementation of x-ray PhAse-Contrast Tomography to transform cancer diagnosis</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Radiology and Organ Imaging</Field_s__of_Research>
        <Res_KW1>cancer detection</Res_KW1>
        <Res_KW2>diagnostic imaging</Res_KW2>
        <Res_KW3>computed tomography</Res_KW3>
        <Res_KW4>medical physics</Res_KW4>
        <Res_KW5>health services research</Res_KW5>
        <Plain_Description>Techniques used for breast and lung cancer imaging miss 20-40% of cancers and use unnecessary radiation. We will clinically implement a novel technique called propagation-based phase-contrast computed tomography (PB-CT) which will exploit X-ray refraction in addition to X-ray absorption. PB-CT increases image signal, offering significantly improved cancer detection and reduced radiation dose. This work will transform cancer diagnosis in Australia and internationally.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011277</APP_ID>
        <Date_Announced>2021-10-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Alex Brown</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>Synergy Grants</Sub_Type>
        <Grant_Title>Respecting the Gift - Empowering Indigenous Communities in Genomic Medicine</Grant_Title>
        <Admin_Institution>South Australian Health and Medical Research Institute</Admin_Institution>
        <State>SA</State>
        <Sector>Research Institutes</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>Medical Genetics</Field_s__of_Research>
        <Res_KW1>genetics</Res_KW1>
        <Res_KW2>aboriginal health</Res_KW2>
        <Res_KW3>community participation</Res_KW3>
        <Res_KW4>bioethics</Res_KW4>
        <Res_KW5>access to health care</Res_KW5>
        <Plain_Description>Genomic medicine represents a step change in medical sciences. Yet Indigenous Australians are not represented in, engaged with, nor have equitable access to the benefits of genomic research. Our national consortium will build Indigenous leadership in genomics through Empowering Communities; data sciences; understanding genomic variation; uncovering multi-omic signatures of disease; and translate these findings to health care, ensuring Indigenous peoples can lead genomic research on their terms.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011329</APP_ID>
        <Date_Announced>2021-10-22T00:00:00</Date_Announced>
        <CIA_Name>Prof Melissa Southey</CIA_Name>
        <Grant_Type>Synergy Grants</Grant_Type>
        <Sub_Type>Synergy Grants</Sub_Type>
        <Grant_Title>National Precision Health Research Translation for Breast and Prostate Cancer Prevention and Early Detection</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$5,000,000.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>Cancer Genetics</Field_s__of_Research>
        <Res_KW1>cancer genetics</Res_KW1>
        <Res_KW2>breast cancer prevention</Res_KW2>
        <Res_KW3>prostate cancer</Res_KW3>
        <Res_KW4>economic evaluation</Res_KW4>
        <Res_KW5>clinical genetics</Res_KW5>
        <Plain_Description>This program will make the next benchmark advance in saving lives from breast and prostate cancer by i) expanding our understanding of the genomic risk factors and improving individualised risk prediction, ii) extending our understanding of Australian attitudes, views and preferences on returning clinically actionable genomic information and iii) enabling an informed pilot study to demonstrate the feasibility of population genomic testing in the Australian setting.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010310</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Christopher Grainge</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Impaired mucociliary clearance drives Bronchiectasis progression</Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$909,817.40</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>cardiorespiratory medicine and heamatology | respiratory diseases | biochemistry and cell biology | cell development, proliferation and death | medical physiology | cell physiology | </Field_s__of_Research>
        <Res_KW1>bronchiectasis </Res_KW1>
        <Res_KW2>mucociliary clearance</Res_KW2>
        <Res_KW3>airway epithelium</Res_KW3>
        <Res_KW4>sequencing</Res_KW4>
        <Res_KW5>molecular biology</Res_KW5>
        <Plain_Description>How bronchiectasis develops and progresses in the lung remains a mystery. One of the key features of bronchiectasis is the inability to clear mucus from the airways which leads to mucus stagnation. We have a identified a defect in production of the cells critical to moving mucus in the airways in samples taken from patients with bronchiectasis. By identifying the causes of this defect we may be able to reverse it and restore healthy mucus clearance in patients that suffer with bronchiectasis.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010319</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Vicki Whitehall</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>OPN as an Immune Checkpoint in KRAS Mutant Colorectal Cancer</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$689,561.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | solid tumours | </Field_s__of_Research>
        <Res_KW1>colon cancer </Res_KW1>
        <Res_KW2>cancer therapy</Res_KW2>
        <Res_KW3>molecular oncology</Res_KW3>
        <Res_KW4>molecular pathology</Res_KW4>
        <Res_KW5>medical genomics</Res_KW5>
        <Plain_Description>Bowel cancer is a very common disease that will be diagnosed in 1/12 Australians living to age 85 and leads to over 4000 deaths annually. Subgrouping of colorectal cancers based on gene changes can predict response to therapy. Our research project specifically focuses on bowel cancers with a KRAS mutation that are usually resistant to currently available therapies. We are using cutting edge technology to identify novel approaches to therapy that will improve outcomes for these patients. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010330</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Thomas Cox</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>SPARC as a key regulator of breast cancer metastasis and resistance to therapy</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$798,196.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | cellular interactions (incl. adhesion, matrix, cell wall) | </Field_s__of_Research>
        <Res_KW1>extracellular matrix </Res_KW1>
        <Res_KW2>stroma</Res_KW2>
        <Res_KW3>cancer metastasis</Res_KW3>
        <Res_KW4>matrix proteins</Res_KW4>
        <Res_KW5>breast cancer metastases</Res_KW5>
        <Plain_Description>` The extracellular matrix or 'matrix' surrounds all cells and is very important in regulating cell behaviour. In cancer, the matrix is dramatically altered, typically making the cancer more aggressive. We recently developed new ways to study the matrix in breast cancer and in particular during cancer cell spread to other organs. We have uncovered exciting new matrix targets associated with breast cancer metastasis, and this project will validate their potential as novel therapeutic targets.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010332</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Aleksandra Filipovska</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Programmable correction of mitochondrial DNA mutations</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$760,442.50</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | biochemistry and cell biology not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>mitochondrial disease </Res_KW1>
        <Res_KW2>mitochondria</Res_KW2>
        <Res_KW3>mitochondrial function</Res_KW3>
        <Res_KW4>mitochondrial respiration</Res_KW4>
        <Res_KW5>gene expression</Res_KW5>
        <Plain_Description>Mitochondrial diseases (MD) may occur at any age, affect any body organ, and may result in severe disability and often death. The prognosis for children with mitochondrial disease is especially grim and devastating for families. There are no known cures and it is not possible to predict the future of a child with mitochondrial disease.  We have created unique RNA editing tools that can reverse mutations in cells and potentially improve energy metabolism in patient and in vivo models of MD. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010336</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Natkunam Ketheesan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title> Preclinical evaluation of a streptococcal peptide based specific diagnostic for rheumatic fever and the identification of proteins responsible for the pathogenesis of rheumatic heart disease</Grant_Title>
        <Admin_Institution>University of New England</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$485,134.90</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>medical microbiology | medical bacteriology | </Field_s__of_Research>
        <Res_KW1>rheumatic heart disease </Res_KW1>
        <Res_KW2>diagnostic test</Res_KW2>
        <Res_KW3>bacterial pathogenesis</Res_KW3>
        <Res_KW4>autoimmunity initiation</Res_KW4>
        <Res_KW5>indigenous health</Res_KW5>
        <Plain_Description>Rheumatic Heart Disease (RHD) is the commonest heart disease in children and young adults. While efforts have been made to control Strep infections that lead to RHD they are ineffective as NO SPECIFIC TEST for timely diagnosis is available. We have identified immune antibodies produced in RHD that can help the development of a new cost effective SPECIFIC test. During this project we will also identify the pathways that lead to heart damage and train and mentor three Indigenous Research Cadets.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010382</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Patrick Kwan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Machine learning models for personalised epilepsy management</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$781,017.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | central nervous system | </Field_s__of_Research>
        <Res_KW1>epilepsy </Res_KW1>
        <Res_KW2>antiepileptic drugs</Res_KW2>
        <Res_KW3>artificial neural networks</Res_KW3>
        <Res_KW4>risk prediction</Res_KW4>
        <Res_KW5>health service decision making</Res_KW5>
        <Plain_Description>We will use clinical and genetic information to develop machine learning models to help clinician to select the most effective drug for individual epilepsy patients, and to identify patients likely has drug-resistant epilepsy at the time of diagnosis. These models will be validated in a new multicentre cohort of patients with newly diagnosed epilepsy in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010384</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Brad Farrant</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Changing the paradigm to improve outcomes for Aboriginal children in out-of-home care</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,312,382.40</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | aboriginal and torres strait islander health | </Field_s__of_Research>
        <Res_KW1>indigenous health </Res_KW1>
        <Res_KW2>aboriginal child</Res_KW2>
        <Res_KW3>aboriginal health</Res_KW3>
        <Res_KW4>aboriginal mental health</Res_KW4>
        <Res_KW5>culturally appropriate methodology</Res_KW5>
        <Plain_Description>The evidence is clear that increasing the fit between service provision (research, policy, practice and resources), and the culture, values and needs of Aboriginal families and children is key to improving health and wellbeing outcomes. Building on the solid foundation of our previous work, this project will change the paradigm and co-design a personalised intervention support program to improve the health and wellbeing outcomes for Aboriginal children in out-of-home care and their families.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010390</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Philip Hugenholtz</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Dual-function ribonucleases: unexpected agents of antibiotic resistance</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$739,593.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | enzymes | genetics | molecular evolution | </Field_s__of_Research>
        <Res_KW1>antibiotic resistance </Res_KW1>
        <Res_KW2>enzymes</Res_KW2>
        <Res_KW3>molecular evolution</Res_KW3>
        <Res_KW4>bioinformatics</Res_KW4>
        <Res_KW5>genomics</Res_KW5>
        <Plain_Description>Bacterial pathogens use a group of enzymes called metallo-ß-lactamases (or MBLs) that enable them to be multi-drug resistant. Our project aims to determine how MBLs have evolved from harmless and widespread ribonucleases, both deep in the past and potentially very recently in response to modern use of antibiotics. These insights will provide valuable functional and structural information that will enable the development of urgently needed strategies to combat ß-lactam antibiotic resistance.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010400</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Christopher McDevitt</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Harnessing structural insights to block pneumococcal manganese uptake</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$998,822.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | biochemistry and cell biology not elsewhere classified | medical microbiology | medical bacteriology | </Field_s__of_Research>
        <Res_KW1>streptococcus pneumoniae </Res_KW1>
        <Res_KW2>manganese</Res_KW2>
        <Res_KW3>membrane transport</Res_KW3>
        <Res_KW4>metals</Res_KW4>
        <Res_KW5>ion transport</Res_KW5>
        <Plain_Description>Streptococcus pneumoniae is the world’s foremost bacterial pathogen. In Australia, bacterial infections are responsible for more than 9,000 deaths every year, and the economic burden associated with treating diseases due to S. pneumoniae infections is more than $1 billion annually. This proposal aims to define how manganese, an essential trace element, is scavenged by S. pneumoniae during infection and then use a novel antimicrobial therapeutic strategy to block this pathway and prevent disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010405</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Sathish Periyasamy</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Genotype Imputation Resources for Productive Genetic Disease Studies of Indigenous Oceanic Sub-Populations</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$2,512,857.80</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>genetics | genomics | genetics | population, ecological and evolutionary genetics | genetics | quantitative genetics (incl. disease and trait mapping genetics) | </Field_s__of_Research>
        <Res_KW1>population genetics </Res_KW1>
        <Res_KW2>genomics</Res_KW2>
        <Res_KW3>indigenous health</Res_KW3>
        <Res_KW4>human genome project</Res_KW4>
        <Res_KW5>genetic epidemiology</Res_KW5>
        <Plain_Description>Indigenous Oceanic sup-populations are perhaps the least-represented of any population in genetic studies. We are proposing productive applications to conduct genetic disease studies by deploying the Indigenous Oceanic genetic analysis resources to promote complex genetic disease studies in these sub-populations. The outcomes will lead to improved disease diagnosis, interventions, treatments, and understanding the interplay of genetic and environmental factors in diseases of IO sub-populations.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010464</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Boris Martinac</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>The role of Piezo1 and TRPM4 ion channels in pathophysiology of cardiac mechano-electric coupling</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,207,705.25</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | receptors and membrane biology | </Field_s__of_Research>
        <Res_KW1>mechanotransduction </Res_KW1>
        <Res_KW2>ion channels</Res_KW2>
        <Res_KW3>cardiac hypertrophy</Res_KW3>
        <Res_KW4>calcium imaging</Res_KW4>
        <Res_KW5>electrophysiology</Res_KW5>
        <Plain_Description>Heart hypertrophy is an important risk factor for premature death from a heart disease. In this project we propose to study a new cellular signalling pathway causing heart hypertrophy due to systemic increase in blood pressure. The biological molecules central to this new cellular pathway are the Piezo1 and TRPM4 ion channels underlying contractions of the heart muscle. This project aims to establish a novel paradigm in our understanding of the molecular origins of heart hypertrophy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010522</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Anand Ganesan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Using renewal theory to develop personalised classification and treatment for atrial fibrillation</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,166,529.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>cardiorespiratory medicine and heamatology | cardiology (incl. cardiovascular diseases) | biomedical engineering | biomedical engineering nec | </Field_s__of_Research>
        <Res_KW1>atrial fibrillation </Res_KW1>
        <Res_KW2>computer simulation</Res_KW2>
        <Res_KW3>cardiac electrophysiology</Res_KW3>
        <Res_KW4>applied statistics</Res_KW4>
        <Res_KW5>cardiovascular physiology</Res_KW5>
        <Plain_Description>Atrial fibrillation is the most common disorder of heart rhythm in the Australian community. It is characterised by  disordered electrical waves, and mini-tornadoes of electricity called rotors. We have recently developed equations which can accurately predict the number and population distribution of rotors. Here, we will harness this discovery to perform a combination of clinical, experimental, simulation and technology development projects to develop personalised approaches to AF treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010530</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Matthew Payne</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Prediction of preterm birth using vaginal microbiology</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$2,073,045.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>paediatrics and reproductive medicine | obstetrics and gynaecology | medical microbiology | medical bacteriology | paediatrics and reproductive medicine | foetal development and medicine | </Field_s__of_Research>
        <Res_KW1>very preterm birth </Res_KW1>
        <Res_KW2>diagnostic test</Res_KW2>
        <Res_KW3>molecular microbiology</Res_KW3>
        <Res_KW4>aboriginal health</Res_KW4>
        <Res_KW5>preventive medicine</Res_KW5>
        <Plain_Description>Recently, our team developed a vaginal microbial DNA test that successfully predicted up to 45% of spontaneous preterm birth (sPTB) cases in mid-gestation pregnant women, the majority of whom were Caucasian (75%). Our next steps are to maximise the tests’ ability to predict sPTB in Aboriginal women, whose vaginal microbiology differs, and to use pre-pregnancy vaginal microbiology to predict sPTB risk in all Australian women prior to conception.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010532</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Sean Coakley</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>A new model of ß-Spectrin function: understanding how the skin protects neurons from damage</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$682,448.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | cellular nervous system | </Field_s__of_Research>
        <Res_KW1>molecular neuroscience </Res_KW1>
        <Res_KW2>axonal degeneration</Res_KW2>
        <Res_KW3>cytoskeleton</Res_KW3>
        <Res_KW4>peripheral nerve damage</Res_KW4>
        <Res_KW5>neuroprotection</Res_KW5>
        <Plain_Description>The spectrin cytoskeleton is thought to function like a spring within neurons to allow them to bend and stretch – protecting them from damage induced by mechanical stress. Human mutations in spectrins cause severe neurological disorders with debilitating symptoms. We propose that spectrins function in tissue surrounding neurons to protect them from damage, and not within them as previously thought. This could revolutionise our understanding of disorders associated with spectrin dysfunction.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010551</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Vanessa Hayes</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Resolving prostate cancer health disparities through population-scale genomic interrogation </Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,314,996.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>genetics | genomics | </Field_s__of_Research>
        <Res_KW1>genomics </Res_KW1>
        <Res_KW2>prostate cancer</Res_KW2>
        <Res_KW3>population genetics</Res_KW3>
        <Res_KW4>mutation analysis</Res_KW4>
        <Res_KW5>bioinformatics</Res_KW5>
        <Plain_Description>Geography (environment) and ethnicity (genetics) are significant predictors of prostate cancer (PCa) mortality, specifically Africa or African ancestry. This project harnesses the power of whole genome interrogation and an intercontinental (Australia and Africa) and interethnic (European, African and Asian) study design, to distinguish the genetic and non-genetic factors contributing to PCa disparities. The hypothesis, non-genetic forces leave a ‘hallmark of DNA damage’ in the evolving tumour. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010571</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Christine Keenan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Heterochromatin instability as a molecular driver of haematopoietic ageing</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$949,007.90</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>genetics | genome structure and regulation | immunology | immunogenetics (incl. genetic immunology) | genetics | epigenetics (incl. genome methylation and epigenomics) | </Field_s__of_Research>
        <Res_KW1>chromatin structure </Res_KW1>
        <Res_KW2>ageing</Res_KW2>
        <Res_KW3>haematopoiesis</Res_KW3>
        <Res_KW4>immune dysfunction</Res_KW4>
        <Res_KW5>epigenetics</Res_KW5>
        <Plain_Description>Ageing of the blood and immune system leaves elderly people more susceptible to infections and blood cancers. Given our ageing population, strategies that can either rejuvenate or slow this process are urgently needed.  We have identified an epigenetic pathway that controls blood system ageing. This proposal will provide a comprehensive understanding of this epigenetic pathway in blood system ageing, and determine whether activating this pathway can slow-down or reverse the ageing process.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010593</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Christopher Degeling</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Preparing Australia for the next pandemic: Managing controversy; promoting trust.</Grant_Title>
        <Admin_Institution>University of Wollongong</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$840,775.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>applied ethics | bioethics (human and animal) | public health and health services | health promotion | public health and health services | environmental and occupational health and safety | </Field_s__of_Research>
        <Res_KW1>outbreak </Res_KW1>
        <Res_KW2>public health policy</Res_KW2>
        <Res_KW3>communications/social research</Res_KW3>
        <Res_KW4>communicable disease</Res_KW4>
        <Res_KW5>social and cultural issues</Res_KW5>
        <Plain_Description>This project addresses the question: how can we better prepare our institutions and Australian society for the next pandemic? COVID-19 has been characterised by uncertainties about transmission risks and the effectiveness of precautionary strategies, undermining confidence in experts and authorities. This project will develop guidance and practical resources to improve social preparedness for the next pandemic, and promote greater trust within and between expert groups and the broader community.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010600</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Peter Mount</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Targeting Renal Energy Metabolism in Kidney Injury and Disease </Grant_Title>
        <Admin_Institution>Institute for Breathing and Sleep</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$887,862.20</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | nephrology and urology | </Field_s__of_Research>
        <Res_KW1>kidney disease </Res_KW1>
        <Res_KW2>fatty acid metabolism</Res_KW2>
        <Res_KW3>amp-activated protein kinase</Res_KW3>
        <Res_KW4>kidney failure</Res_KW4>
        <Res_KW5>obesity</Res_KW5>
        <Plain_Description>Short-term acute kidney injury and permanent chronic kidney disease affects 1 in 10 Australians. It is unknown how these diseases are interlinked and related to obesity. A lack of energy supply in kidney cells could be the shared link and we will test this theory by targeting energy proteins in the kidney with a new drug O304. We anticipate knowledge generated by our innovative project will catalyse the development of new targeted treatments to improve kidney patient care and quality of life.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010610</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Joel Mackay</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>New approaches to cancer treatment through mRNA display</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$829,494.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | structural biology (incl. macromolecular modelling) | genetics | gene expression (incl. microarray and other genome-wide approaches) | medicinal and biomolecular chemistry | biologically active molecules | </Field_s__of_Research>
        <Res_KW1>gene regulation </Res_KW1>
        <Res_KW2>transcriptional regulation</Res_KW2>
        <Res_KW3>protein structure</Res_KW3>
        <Res_KW4>epigenetics</Res_KW4>
        <Res_KW5>drug discovery</Res_KW5>
        <Plain_Description>This proposal will pioneer the development of a new class of molecules that will block the activity of proteins that regulate gene expression and have been shown to be promising targets for a range of diseases, predominantly cancer. These molecules have the potential to be much more selective and potent than existing molecules and to also open up new directions for cancer therapy by allowing previously intractable molecular targets to be addressed.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010611</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Tracy Bryan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>A gene-editing strategy for telomere-related bone marrow failure</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$617,992.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical biotechnology | gene and molecular therapy | biochemistry and cell biology | enzymes | </Field_s__of_Research>
        <Res_KW1>telomeres </Res_KW1>
        <Res_KW2>telomerase</Res_KW2>
        <Res_KW3>haematological disorders</Res_KW3>
        <Res_KW4>gene therapy</Res_KW4>
        <Res_KW5>haematopoietic stem cells</Res_KW5>
        <Plain_Description>A subset of inherited bone marrow failure (BMF) syndromes is caused by mutations in genes that protect the ends of chromosomes, or telomeres. The only curative therapy for BMF is bone marrow transplant, which has a high rate of mortality and complications. We will use the latest developments in gene editing of bone marrow stem cells to develop a strategy for correcting mutations in telomere-related genes in the patient’s own cells, providing a potentially curative therapy for inherited BMF. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010632</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Des Richardson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Novel Hormone Analogues as an Innovative Endocrinological Intervention for the Anaemia of Chronic Disease</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$638,288.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | endocrinology | </Field_s__of_Research>
        <Res_KW1>hormones </Res_KW1>
        <Res_KW2>hormone action</Res_KW2>
        <Res_KW3>endocrine</Res_KW3>
        <Res_KW4>endocrine disease</Res_KW4>
        <Res_KW5>endocrine factors</Res_KW5>
        <Plain_Description>Anaemia of chronic disease (ACD) is a severe cause of morbidity &amp;amp; mortality in millions of people with cancer or inflammatory diseases.  ACD is due to excessive levels of hepcidin, a hormone that prevents gut iron uptake, which inhibits the use of iron for making red blood cells.  Thus, excessive hepcidin leads to debilitating anaemia.  This proposal will develop innovative Null Hepcidin Analogues that have no hormonal activity, but lead to excretion of excessive hepcidin, thereby curing the anaemia</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010647</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Justin Wong</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Alternative splicing: A novel target to improve outcomes in acute myeloid leukaemia</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,111,376.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>genetics | genetics not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>alternative splicing </Res_KW1>
        <Res_KW2>acute myeloid leukaemia (aml)</Res_KW2>
        <Res_KW3>cancer cell biology</Res_KW3>
        <Res_KW4>cancer genetics</Res_KW4>
        <Res_KW5>mouse models</Res_KW5>
        <Plain_Description>In 2013, we made a breakthrough discovery that certain parts of genes, previously considered “Junk DNA”, are actually carrying signals to control the amount of proteins produced in cells. Our preliminary work now suggests these signals controlling protein levels can be faulty in cancers. Here, we wish to determine if these faulty signals could be exploited to better manage a deadly blood cancer called acute myeloid leukaemia (AML). Our work will spur the development of novel therapy for AML.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010654</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Laura Jobson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Building an Evidence-Base to inform Post-Traumatic Stress Disorder (PTSD) Treatment for Culturally and Linguistically Diverse Communities </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$738,149.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>psychology | health, clinical and counselling psychology | </Field_s__of_Research>
        <Res_KW1>posttraumatic stress disorder (ptsd) </Res_KW1>
        <Res_KW2>mental health</Res_KW2>
        <Res_KW3>trauma</Res_KW3>
        <Res_KW4>culture</Res_KW4>
        <Res_KW5>cross-cultural</Res_KW5>
        <Plain_Description>How someone appraises trauma and deals with emotion is core to treating posttraumatic stress disorder (PTSD). Yet these treatments are based on research emphasising Western values. There is an urgent need to examine what appraisals and emotion regulation should be targeted in PTSD treatments for trauma survivors from other cultural backgrounds. This research examines cultural influences on appraisals and emotion regulation in PTSD to improve treatment outcomes for culturally diverse Australians.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010701</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Annmarie Hosie</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Driving quality in delirium care through a patient-centred monitoring system in palliative care</Grant_Title>
        <Admin_Institution>University of Notre Dame Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$503,477.30</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | clinical sciences not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>palliative care </Res_KW1>
        <Res_KW2>delirium</Res_KW2>
        <Res_KW3>health systems</Res_KW3>
        <Res_KW4>clinical practice</Res_KW4>
        <Res_KW5>psychological distress</Res_KW5>
        <Plain_Description>Delirium - sudden confusion and difficulty thinking related to illness, injury or medical treatment - is serious, distressing, and often not addressed for people in hospital at end of life. We will develop and test a new way to monitor delirium in palliative care that involves patients, their family, and staff. The system will align with national quality initiatives, tackle a complex and long-standing clinical issue, and be a key step forward for global quality improvement in palliative care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010704</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Alpha Yap</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Epithelial mechanics and the fate of cancer</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,187,084.40</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | cellular interactions (incl. adhesion, matrix, cell wall) | </Field_s__of_Research>
        <Res_KW1>epithelium </Res_KW1>
        <Res_KW2>cytoskeleton</Res_KW2>
        <Res_KW3>cell adhesion</Res_KW3>
        <Res_KW4>cell transformation</Res_KW4>
        <Res_KW5>cancer cell biology</Res_KW5>
        <Plain_Description>Many common cancers originate in epithelial tissues, such as the breast, lung, colon and skin. All such cancers first begin as one cancer (transformed) cell within its epithelial tissue of origin, and these can be potentially eliminated by the epithelium to protect against cancer. This research proposal tests how abnormal function of the host epithelium can increase the risk of a newly-transformed cell being retained in the body to progress into a clinically significant tumor.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010711</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Tim Thomas</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Modelling intellectual disability caused by mutations in chromatin-modifying enzymes to develop ameliorating treatments </Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$920,050.64</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>genetics | developmental genetics (incl. sex determination) | </Field_s__of_Research>
        <Res_KW1>epigenetics </Res_KW1>
        <Res_KW2>developmental genetics</Res_KW2>
        <Res_KW3>chromatin</Res_KW3>
        <Res_KW4>developmental disorders</Res_KW4>
        <Res_KW5>transcriptional regulation</Res_KW5>
        <Plain_Description>Intellectual disability is a condition that affects speech, motor-coordination and emotional interactions. In cases where it is caused by a reduction in enzyme activity, it may be possible to improve patient outcome by providing more substrate for the enzymatic reaction or by inhibiting the opposing enzymatic activity. We propose to model human genetic disorders in mice to study new treatment options.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010717</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Malcolm McConville</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Global analysis of metabolic targets in Leishmania parasites</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,224,328.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical microbiology | medical parasitology | </Field_s__of_Research>
        <Res_KW1>leishmania </Res_KW1>
        <Res_KW2>metabolomics</Res_KW2>
        <Res_KW3>microbial infections</Res_KW3>
        <Res_KW4>drug discovery</Res_KW4>
        <Res_KW5>cell metabolism</Res_KW5>
        <Plain_Description>There is an urgent need to develop new drugs to treat human leishmaniasis, a disease that causes debilitating and life-threatening diseases in millions of people worldwide. This project will systematically investigate the function of all metabolic enzymes in Leishmania pathogens using newly developed genetic and analytical tools. The findings of this study will be used to triage Leishmania metabolic enzymes for drug development, with the view of generating more effective anti-parasitics.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010743</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Mimi Tang</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Immune mechanisms underpinning remission of allergy</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$870,143.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>immunology | allergy | </Field_s__of_Research>
        <Res_KW1>food allergy </Res_KW1>
        <Res_KW2>specific allergen immunotherapy</Res_KW2>
        <Res_KW3>paediatric</Res_KW3>
        <Res_KW4>systems biology</Res_KW4>
        <Res_KW5>immunological intervention</Res_KW5>
        <Plain_Description>There is no cure for food allergy. Treatments in development have been shown to induce remission of allergy. This can be transient or long-lasting. We will employ state-of-the-art approaches to characterise the immune changes underpinning remission, particularly whether remission is persistent (long-lasting) or transient. This knowledge would enable the development of more effective long-term treatments for food allergy by providing new targets for intervention, possibly offering a cure.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010757</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Emma Gordon</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>COVID-19-induced vascular complications: mechanisms and potential therapies</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$717,305.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | biochemistry and cell biology not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>endothelial dysfunction </Res_KW1>
        <Res_KW2>vascular pathologies</Res_KW2>
        <Res_KW3>inflammatory cytokines</Res_KW3>
        <Res_KW4>covid-19</Res_KW4>
        <Res_KW5>coagulation</Res_KW5>
        <Plain_Description>The coronavirus SARS-CoV-2 is responsible for the disease COVID-19, which causes significant lung dysfunction. Importantly, reports have observed COVID-19 symptoms that are not associated with the lungs, such as blood clots, vessel inflammation and leakage of fluid from vessels into tissues. These virus-induced vessel defects can lead to the death of patients. Here, we aim to understand exactly how these vessel defects occur to develop treatments for patients with acute and long term disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010763</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Sandy Shultz</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Brain injury in intimate partner violence: Insight into a silent pandemic</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,924,134.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | neurology and neuromuscular diseases | </Field_s__of_Research>
        <Res_KW1>mild traumatic brain injury </Res_KW1>
        <Res_KW2>domestic violence</Res_KW2>
        <Res_KW3>biomarkers</Res_KW3>
        <Res_KW4>brain trauma</Res_KW4>
        <Res_KW5>brain imaging</Res_KW5>
        <Plain_Description>Intimate partner violence (IPV) is a worldwide problem that primarily affects women. Although &amp;gt;90% of IPV survivors report symptoms consistent with traumatic brain injury (mTBI), how IPV-related TBI contributes to the lived experience of IPV victims has been remarkably understudied. This translational project will characterise the effects of IPV-related TBI. By doing this, we will be able to development interventions, and change practice and policy, to improvement the well-being of IPV victims.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010778</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Alys Havard</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Are nicotine replacement therapy and varenicline safe and effective for women trying to quit smoking during pregnancy?</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$904,422.30</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | preventive medicine | </Field_s__of_Research>
        <Res_KW1>smoking cessation </Res_KW1>
        <Res_KW2>pregnancy</Res_KW2>
        <Res_KW3>pharmacoepidemiology</Res_KW3>
        <Res_KW4>drug safety</Res_KW4>
        <Res_KW5>effectiveness</Res_KW5>
        <Plain_Description>This project will measure the safety and effectiveness of two quit smoking medicines during pregnancy. It will use routinely collected data from Australia, New Zealand and the Nordic countries, for over 400,000 women who smoked during pregnancy. Women who used nicotine replacement therapy or varenicline during pregnancy will be compared to women who smoked but did not use these medicines in relation to quitting and adverse birth outcomes and neurodevelopmental problems among their children.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010781</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof John Wade</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Engineering of novel insulin analogues for improved management of diabetes</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,098,388.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medicinal and biomolecular chemistry | proteins and peptides | </Field_s__of_Research>
        <Res_KW1>peptides </Res_KW1>
        <Res_KW2>peptide synthesis</Res_KW2>
        <Res_KW3>synthetic peptides</Res_KW3>
        <Res_KW4>insulin</Res_KW4>
        <Res_KW5>type 1 diabetes mellitus (insulin-dependent diabetes mellitus)</Res_KW5>
        <Plain_Description>Diabetes is a major global health condition affecting nearly 0.5 billion people. Insulin is an essential treatment for Type 1 and, increasingly, Type 2 diabetes. However, it is difficult to both manufacture and handle as it aggregates rapidly in solution making storage and accurate dosing difficult. We will develop novel modified insulins that are biologically active, long-acting, aggregate-free and which self-respond to increases in glucose levels therefore greatly improving diabetes therapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010784</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Ashraful Haque</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Mapping B-cell fate to improve humoral immunity to malaria </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,548,906.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>immunology | cellular immunology | </Field_s__of_Research>
        <Res_KW1>b cells </Res_KW1>
        <Res_KW2>t cells</Res_KW2>
        <Res_KW3>cellular interactions</Res_KW3>
        <Res_KW4>genomics</Res_KW4>
        <Res_KW5>humoral immunity</Res_KW5>
        <Plain_Description>Malaria killed half a million people in 2019. While ~60 vaccines exist against viral or bacterial diseases, no effective vaccines exist against malaria-causing parasites. Immunity to malaria can be mediated by antibodies. This depends on immune cells called B- and T-cells, conducting a choreographed series of interactions in immune organs. This process appears defective in malaria for reasons unknown.  We will determine these reasons, and provide new ways for boosting immunity to malaria.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010795</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Ankur Sharma</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Oncofetal ecosystem in advanced Hepatocellular Carcinoma: Implications for Identifying Immunotherapy response</Grant_Title>
        <Admin_Institution>Curtin University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,195,455.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | gastroenterology and hepatology | immunology | tumour immunology | </Field_s__of_Research>
        <Res_KW1>liver cancer </Res_KW1>
        <Res_KW2>hepatocellular carcinoma</Res_KW2>
        <Res_KW3>cancer immunotherapy</Res_KW3>
        <Res_KW4>genomics</Res_KW4>
        <Res_KW5>macrophages</Res_KW5>
        <Plain_Description>Each year ~1800 Australians succumb to hepatocellular carcinoma (HCC). The lack of effective treatment options is a major contributing factor to the poor outcomes. A new immunotherapy treatment which activates the body's immune system, has demonstrated significant efficacy. However, this treatment does not work for all patients. Therefore, we will identify which patients will benefit from this treatment and provide biomarkers, with the overall purpose of guiding clinical decision making.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010804</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Timothy Sargeant</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Measuring healthy ageing: finding an autophagy biomarker for a scalable clinical test</Grant_Title>
        <Admin_Institution>South Australian Health and Medical Research Institute</Admin_Institution>
        <State>SA</State>
        <Sector>Research Institutes</Sector>
        <Total>$818,964.40</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | cell metabolism | </Field_s__of_Research>
        <Res_KW1>autophagy </Res_KW1>
        <Res_KW2>biomarkers</Res_KW2>
        <Res_KW3>plasma proteins</Res_KW3>
        <Res_KW4>lysosome biology</Res_KW4>
        <Res_KW5>ageing</Res_KW5>
        <Plain_Description>The cells of our bodies possess a powerful recycling system that removes damaged material that accumulates with age and causes diseases such as dementia and atherosclerosis. Although scientists know how to increase this recycling system in laboratory models, we cannot easily measure this function in humans. This study aims to develop easy methods to measure cell recycling in humans so that we can increase the activity of this recycling system to support healthy ageing. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010812</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Ostoja Vucic</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Mechanisms underlying cortical hyperexcitability in amyotrophic lateral sclerosis</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,009,316.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | neurology and neuromuscular diseases | </Field_s__of_Research>
        <Res_KW1>amyotrophic lateral sclerosis </Res_KW1>
        <Res_KW2>motor cortex</Res_KW2>
        <Res_KW3>motor neuron disease (mnd)</Res_KW3>
        <Res_KW4>transcranial magnetic stimulation (tms)</Res_KW4>
        <Res_KW5>dementia</Res_KW5>
        <Plain_Description>The current research grant will use novel neurophysiological tools to study brain activity in patients with motor neuron disease/amyotrophic lateral sclerosis.  We anticipate that excessive brain activity, called cortical hyperexcitability, will be caused by reduction in activity of cortical inhibitory nerves, increase in activity of cortical excitatory nerves and increase in persistent sodium currents. Treatments, targeting the abnormal brain processes, are likely to be developed.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010813</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Steven Zuryn</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Metabolic and molecular protection against mtDNA mutations</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$782,369.60</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | cell metabolism | </Field_s__of_Research>
        <Res_KW1>dna damage </Res_KW1>
        <Res_KW2>cell metabolism</Res_KW2>
        <Res_KW3>mitochondrial dna (mtdna)</Res_KW3>
        <Res_KW4>mitochondria</Res_KW4>
        <Res_KW5>cell biology</Res_KW5>
        <Plain_Description>Mitochondria are powerhouses of the cell. Their assembly and function are encoded by a small mitochondrial genome. Mutations in the mitochondrial genome can cause devastating metabolic disorders and have been linked to many common age-related diseases. This project will reveal how cells invoke protective measures to overcome these mutations, thus revealing new mechanisms that can be exploited to combat mitochondria-associated disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010841</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Hayley Newton</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Coxiella pathogenesis and Effector-Effector Interplay</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$572,643.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical microbiology | medical bacteriology | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>bacterial virulence factors </Res_KW1>
        <Res_KW2>coxiella burnetii</Res_KW2>
        <Res_KW3>bacterial pathogenesis</Res_KW3>
        <Res_KW4>autophagy</Res_KW4>
        <Res_KW5>protein interactions</Res_KW5>
        <Plain_Description>Coxiella causes the human infection Q fever. Coxiella has a cohort of virulence proteins that interfere with the human cell. This research will uncover how these proteins function, and interact with each other, to cause disease. This will contribute important new knowledge of pathogenesis that will highlight novel intervention targets. We will also learn how these virulence proteins manipulate human cell functions which are involved in a range of human diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010899</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Mark Bellgrove</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Neuropharmacology of decision-making: causal brain network modelling across species </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$2,018,154.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>psychology | biological psychology (neuropsychology, psychopharmacology, physiological psychology) | neurosciences | neurosciences not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>decision making </Res_KW1>
        <Res_KW2>electroencephalogram (eeg)</Res_KW2>
        <Res_KW3>functional magnetic resonance imaging (fmri)</Res_KW3>
        <Res_KW4>neuropharmacology</Res_KW4>
        <Res_KW5>dopamine</Res_KW5>
        <Plain_Description>Decision making is a critical aspect of human cognition that is frequently impaired in clinical disorders. This project will identify the fundamental brain processes governing decision making by studying both monkeys and humans while they perform the same cognitive task. We will identify the critical brain networks that allow organisms to efficiently make decisions and the chemicals which modulate these networks. Our knowledge will inform treatment of clinical disorders of decision making.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010901</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Frederic Meunier</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Investigating myristic acid as key mediator of memory via myristoylation</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$978,361.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | central nervous system | neurosciences | cellular nervous system | </Field_s__of_Research>
        <Res_KW1>memory </Res_KW1>
        <Res_KW2>lipid</Res_KW2>
        <Res_KW3>mass spectrometry</Res_KW3>
        <Res_KW4>synaptic plasticity</Res_KW4>
        <Res_KW5>phospholipases</Res_KW5>
        <Plain_Description>Despite the fact the that human brain is made of nearly 60 percent fat, the vast majority of studies on the mechanism of memory and neurodegeneration primarily focused on protein and genetic changes. Here, we discovered that myristic acid production derived from brain cell phospholipids correlates with memory acquisition.  Using state-of-the-art mass spectrometry and super-resolution microscopy, we will establish the role of myristic acid in learning and how it is affected during ageing.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010917</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Frederic Meunier</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Targeting neuropilin in SARS-Cov-2 neuronal uptake and transport</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$904,308.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | cellular nervous system | neurosciences | central nervous system | </Field_s__of_Research>
        <Res_KW1>covid-19 </Res_KW1>
        <Res_KW2>sars-cov-2</Res_KW2>
        <Res_KW3>endocytosis</Res_KW3>
        <Res_KW4>axonal transport</Res_KW4>
        <Res_KW5>central nervous system (cns) diseases</Res_KW5>
        <Plain_Description>COVID-19 is associated with a variety of neurological symptoms, ranging from a transient loss of smell and taste to headaches to severe ischaemic damage in fatal cases. The long-term consequences of potential interactions of the causative virus, SARS-CoV-2, with brain cells are currently unknown but could be linked to intractable neuronal degeneration as previously found with the 1918 influenza pandemic. We will investigate the uptake and transport of the virus and find ways to block infection.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010919</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Mojtaba Golzan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Detecting Referable Glaucoma Using Artificial Intelligence</Grant_Title>
        <Admin_Institution>University of Technology Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$379,061.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>ophthalmology and optometry | ophthalmology | </Field_s__of_Research>
        <Res_KW1>glaucoma </Res_KW1>
        <Res_KW2>artificial neural networks</Res_KW2>
        <Res_KW3>computer-assisted diagnosis</Res_KW3>
        <Res_KW4>retinal vessels</Res_KW4>
        <Res_KW5>image analysis</Res_KW5>
        <Plain_Description>Glaucoma is a leading cause of blindness worldwide affecting over 300,000 Australians. While treatments are available to delay vision loss, no cure for glaucoma exists, making early identification of at-risk individuals an utmost priority. We have developed a model that can accurately detect early glaucoma-specific changes in the eye. In this project, we will evaluate the performance of our model in comparison to assessments made by glaucoma specialists to determine its efficacy. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010939</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Michael Ryan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Molecular mechanisms underlying the pathogenesis of complex I dysfunction and mitochondrial disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,370,808.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | cell metabolism | biochemistry and cell biology | enzymes | medical biochemistry and metabolomics | medical biochemistry: proteins and peptides (incl. medical proteomics) | </Field_s__of_Research>
        <Res_KW1>mitochondria </Res_KW1>
        <Res_KW2>mitochondrial disease</Res_KW2>
        <Res_KW3>mitochondrial respiration</Res_KW3>
        <Res_KW4>protein complexes</Res_KW4>
        <Res_KW5>molecular basis of disease</Res_KW5>
        <Plain_Description>Mitochondria are the powerhouses of our cells that produce the chemical ATP for functions such as muscle contraction and triggering of nerves. Mitochondrial Complex I is a molecular motor that helps to make this ATP and defects in this motor cause mitochondrial disease, resulting in early childhood death. In this project we will study how Complex I is assembled and determine how defects in this assembly pathway leads to disease. New insights into therapeutic approaches will be investigated. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010955</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Sih Min Tan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Investigating complement C5a receptor 2 as a therapeutic target for diabetic kidney disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$855,469.60</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>other medical and health sciences | medical and health sciences not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>diabetic complications </Res_KW1>
        <Res_KW2>diabetic nephropathy</Res_KW2>
        <Res_KW3>complement activation</Res_KW3>
        <Res_KW4>complement c5a</Res_KW4>
        <Res_KW5>kidney disease</Res_KW5>
        <Plain_Description>Kidney disease is a serious and common complication of diabetes and the leading cause of kidney failure worldwide. We have found that the complement system, which is a normal part of the immune system, is overactivated in diabetes and leads to kidney injury. We propose studies to not only understand how complement leads to kidney disease in diabetes, but also to identify novel therapeutic targets to enable the development of new treatments for diabetic kidney disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010979</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Hamsa Puthalakath</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>A novel antibody-based treatment for polymicrobial sepsis.</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$653,115.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | cell development, proliferation and death | </Field_s__of_Research>
        <Res_KW1>apoptosis </Res_KW1>
        <Res_KW2>acute inflammation</Res_KW2>
        <Res_KW3>bacterial infection</Res_KW3>
        <Res_KW4>receptors</Res_KW4>
        <Res_KW5>biomarkers</Res_KW5>
        <Plain_Description>Sepsis or blood poisoning kills more than 7000 Australians every year and there is no cure for this disease. Using the CRISPR gene editing technology, we identified and characterized the receptor protein responsible death during sepsis in mice. We also have developed antibodies against the human counterparts of this receptor. We propose to test these antibodies in mice and human sepsis patients. We also propose to test a diagnostic marker for sepsis-associated mortality in sepsis patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010992</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Tatiana Soboleva</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Targeting a novel epigenetic regulator of Hodgkin lymphoma, H2A.B, for treament of cancer</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$1,041,337.40</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical biotechnology | medical molecular engineering of nucleic acids and proteins | biochemistry and cell biology | enzymes | genetics | gene expression (incl. microarray and other genome-wide approaches) | </Field_s__of_Research>
        <Res_KW1>drug discovery </Res_KW1>
        <Res_KW2>tumour-specific targeting</Res_KW2>
        <Res_KW3>nuclear transport</Res_KW3>
        <Res_KW4>protein targeting</Res_KW4>
        <Res_KW5>enzyme inhibition</Res_KW5>
        <Plain_Description>We have identified a novel key regulator of Hodgkin Lymphoma, epigenetic factor, histone H2A.B. This proposal aims to develop novel therapeutic tools that would target H2A.B and potentially provide a more specific and less toxic treatment for Hodgkin Lymphoma patients. We will use Modular Nanotransporters, a highly specific intracellular delivery system, to target H2A.B for degradation and we will use the small molecule kinase inhibitors for functional inactivation of H2A.B.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010998</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Kyle Hoehn</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Targeting metabolism to improve healthy ageing</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$858,203.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical biochemistry and metabolomics | metabolic medicine | </Field_s__of_Research>
        <Res_KW1>mitochondria </Res_KW1>
        <Res_KW2>healthy ageing</Res_KW2>
        <Res_KW3>ageing</Res_KW3>
        <Res_KW4>metabolism</Res_KW4>
        <Res_KW5>longevity</Res_KW5>
        <Plain_Description>Ageing is the largest risk factor for chronic diseases that account for most of the financial burden of disease and 90% of deaths in Australia. The goal of this project is to test a new small molecule drug in mouse models of ageing to test the hypothesis that it will improve healthy ageing by decreasing age-related organ deterioration. Success of this project would provide support for clinical translation that could benefit individuals and society by decreasing disease incidence.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011004</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Kyle Hoehn</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Targeting caloric efficiency to treat obesity-related diabetes</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$586,751.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical biochemistry and metabolomics | metabolic medicine | </Field_s__of_Research>
        <Res_KW1>diabetes mellitus </Res_KW1>
        <Res_KW2>obesity</Res_KW2>
        <Res_KW3>glucose homeostasis</Res_KW3>
        <Res_KW4>insulin resistance</Res_KW4>
        <Res_KW5>endocrinology</Res_KW5>
        <Plain_Description>Diabetes is a major unmet medical need in Australia. We have recently discovered a new class of drug that reverses obesity and pre-diabetes in mice.  The objectives of this project are to determine whether this drug is effective in a mouse model of very severe obesity-related diabetes, and to determine if new drug coatings will improve drug exposure so that it can be taken orally once per day. Success of this project will provide vital data needed to support clinical translation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011010</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Anna Roujeinikova</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Elucidating the function of host-derived cysteine in bacterial virulence</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$300,922.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical microbiology | medical bacteriology | biochemistry and cell biology | structural biology (incl. macromolecular modelling) | </Field_s__of_Research>
        <Res_KW1>helicobacter pylori </Res_KW1>
        <Res_KW2>oxidative stress</Res_KW2>
        <Res_KW3>x-ray crystallography</Res_KW3>
        <Res_KW4>host colonisation</Res_KW4>
        <Res_KW5>molecular microbiology</Res_KW5>
        <Plain_Description>Our immune system responds to stomach infection with Helicobacter pylori by producing high levels of defence molecules called reactive oxygen species (ROS). However, H. pylori can withstand ROS, and they fail to clear the infection, but in the long term, ROS damage the stomach lining resulting in disease. This project tests the hypothesis that H. pylori uses amino acids cysteine and cystine available in the stomach lining to combat ROS.  The outcomes will aid future design of new antimicrobials.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011020</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Ilia Voskoboinik</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Cytotoxic T cell granules – a matter of life and death</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,386,960.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | biochemistry and cell biology not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>lysosome biology </Res_KW1>
        <Res_KW2>lysosomal storage disorder</Res_KW2>
        <Res_KW3>cytotoxic t lymphocytes (ctl)</Res_KW3>
        <Res_KW4>protein trafficking</Res_KW4>
        <Res_KW5>apoptosis</Res_KW5>
        <Plain_Description>Humans are protected from infections and cancer by a subset of immune cells called cytotoxic lymphocytes, which can recognised and kill rogue cells. Despite an enormous clinical interest, how these cells mature from a naive inactive to a fully activated state is poorly understood. The aim of the current proposal is to investigate that process, and thus provide a better understanding of how the immune system works and how it can be better utilised to treat cancer and other diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011033</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Mitchell Lawrence</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>ComBATing lethal prostate cancer with combination Bipolar Androgen Therapy</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$952,194.20</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | cancer cell biology | </Field_s__of_Research>
        <Res_KW1>testosterone </Res_KW1>
        <Res_KW2>steroid hormones</Res_KW2>
        <Res_KW3>androgen receptor</Res_KW3>
        <Res_KW4>hormone-dependent cancers</Res_KW4>
        <Res_KW5>prostate</Res_KW5>
        <Plain_Description>For 80 years, the main way to treat advanced prostate cancer has been to cut off the supply of male hormones. Unfortunately, this only works temporarily and it compromises quality of life. Surprisingly, new clinical trials show that the opposite approach – supplying excess testosterone – is effective and improves quality of life. Our novel idea is to boost the efficacy of testosterone therapy, and ensure more patients benefit, by combining it with a second drug. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011042</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Gerald Atkins</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Establishing a new bone pathologic pathway and solving problems of diagnosis in chronic orthopaedic infections</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$893,115.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | clinical microbiology | clinical sciences | infectious diseases | clinical sciences | orthopaedics | </Field_s__of_Research>
        <Res_KW1>chronic infection </Res_KW1>
        <Res_KW2>orthopaedic surgery</Res_KW2>
        <Res_KW3>antibiotic therapy</Res_KW3>
        <Res_KW4>medicinal chemistry</Res_KW4>
        <Res_KW5>staphylococcus</Res_KW5>
        <Plain_Description>Orthopaedic and other bone infections are difficult to diagnose, treat and cure. Hard bone is a unique niche for host-pathogen interaction that provides both serious treatment challenges and new opportunities for improving patient outcomes. Using analysis of human patients, unique animal and human models of bone infection, our proposal will revolutionise diagnosis and understanding of complex infections such as periprosthetic joint infection and diabetic foot infection.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011044</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Manisha Pandey</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>COMBAT - A Combination B-and T-Cell Epitope Vaccine to Futureproof COVID-19 Vaccine</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,211,033.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | infectious diseases | clinical sciences | clinical microbiology | medical microbiology | medical virology | </Field_s__of_Research>
        <Res_KW1>covid-19 </Res_KW1>
        <Res_KW2>vaccine</Res_KW2>
        <Res_KW3>synthetic peptides</Res_KW3>
        <Res_KW4>humoral immunity</Res_KW4>
        <Res_KW5>cellular immunity</Res_KW5>
        <Plain_Description>We are proposing a vaccine that contains only safe components of the SARS-CoV-2 virus, yet effectively elicits protective immunity. The vaccine works by inducing antibodies capable of preventing the virus from attaching to lung cells, and killer T cells that destroy virus-infected cells. This highly innovative approach will generate a much needed safe and prophylactic 2nd generation modular vaccine, ideal for “vaccine update” that will have a major impact on health and society more generally. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011047</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Nadeem Kaakoush</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Immunoglobulin A degradation by the gut microbiome</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$647,333.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical microbiology | medical bacteriology | </Field_s__of_Research>
        <Res_KW1>microbial ecology </Res_KW1>
        <Res_KW2>immunoglobulin a (iga)</Res_KW2>
        <Res_KW3>ulcerative colitis</Res_KW3>
        <Res_KW4>protease</Res_KW4>
        <Res_KW5>microbial pathogenesis</Res_KW5>
        <Plain_Description>The antibody immunoglobulin A (IgA) plays an important role in the immune response to microbial species at mucosal surfaces. Pathogenic bacterial species are known to degrade IgA in the gut to aid their virulence; however, little is known about this activity in commensal bacteria. Here, we aim to study a novel protein identified in a gut commensal bacterium that can potentially degrade IgA, and determine if this protein activity has downstream consequences to disease susceptibility.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011083</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Sean Humphrey</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Mapping the Beneficial Effects of Exercise in humans using Personalised Phosphoproteomics</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,348,941.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical biochemistry and metabolomics | medical biochemistry: proteins and peptides (incl. medical proteomics) | biochemistry and cell biology | signal transduction | </Field_s__of_Research>
        <Res_KW1>exercise </Res_KW1>
        <Res_KW2>cell signalling</Res_KW2>
        <Res_KW3>insulin action</Res_KW3>
        <Res_KW4>glucose metabolism</Res_KW4>
        <Res_KW5>muscle metabolism</Res_KW5>
        <Plain_Description>Exercise has major health benefits and can prevent many diseases. For example, it is very effective in diabetes by improving insulin action. However, exercise is poorly tolerated by many creating a need to define the mechanism for these benefits. Using cutting-edge technologies we have identified a new lead that might underpin exercise effects on insulin action. This project will characterise this novel pathway in humans, bringing us a step closer to finding a drug that mimics exercise.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011115</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Tony Kenna</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Defining the inflammatory T cell landscape in ankylosing spondylitis</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$986,267.20</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | rheumatology and arthritis | immunology | autoimmunity | immunology | cellular immunology | </Field_s__of_Research>
        <Res_KW1>rheumatic diseases </Res_KW1>
        <Res_KW2>musculoskeletal disorders</Res_KW2>
        <Res_KW3>chronic inflammation</Res_KW3>
        <Res_KW4>cd8 t cells</Res_KW4>
        <Res_KW5>antigen</Res_KW5>
        <Plain_Description>Ankylosing spondylitis, or AS for short, is a common inflammatory arthritis that affects joints of the spine and pelvis. There is no cure for AS. Cells of the immune system called T cells are known to be important in AS but the details of how these cells work in the disease are unclear. Our work will define exactly how T cells work in AS. This world-first knowledge will permit design of new treatments focused specifically on preventing harmful aspects of T cell function that contribute to AS.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011119</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Laura Edgington-Mitchell</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Legumain at the cutting edge of oral cancer</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$588,593.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | enzymes | oncology and carcinogenesis | molecular targets | </Field_s__of_Research>
        <Res_KW1>protease </Res_KW1>
        <Res_KW2>protease inhibitors</Res_KW2>
        <Res_KW3>cancer metastasis</Res_KW3>
        <Res_KW4>cancer pain</Res_KW4>
        <Res_KW5>head and neck cancer</Res_KW5>
        <Plain_Description>Oral cancer patients suffer from profound pain and the survival rate is low due to the spread of the cancer. Effective therapies to treat oral cancer pain and prevent its spread are currently lacking. We have identified an enzyme that promotes cancer pain, and drugs that block its activity are effective at relieving pain. We will test the contribution of this enzyme to cancer spread and determine whether drugs blocking its activity are effective at preventing spread and alleviating pain. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011120</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Kelly Williams</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>When sporadic disease is not sporadic - exploiting cryptic relatedness to unravel MND genetics</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,165,925.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>genetics | genomics | </Field_s__of_Research>
        <Res_KW1>motor neuron disease (mnd) </Res_KW1>
        <Res_KW2>genetic linkage</Res_KW2>
        <Res_KW3>phenotype-genotype correlation</Res_KW3>
        <Res_KW4>genomics</Res_KW4>
        <Res_KW5>gene discovery</Res_KW5>
        <Plain_Description>Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with a significant genetic component underlying both the hereditary and sporadic forms of disease. Using a global cohort of ~10,000 ALS cases, we aim to uncover unrecognised ancestral relationships between patients in order to detect new genes that cause ALS or influence the progression of the disease. We will also harness the power of artificial intelligence to predict prognosis and inform clinical care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011129</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof David Lynn</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Vaccine nonspecific effects of live and non-live vaccines: understanding the mechanisms and potential consequences.</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$883,314.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | systems biology | genetics | genomics | immunology | innate immunity | </Field_s__of_Research>
        <Res_KW1>systems biology </Res_KW1>
        <Res_KW2>genomics</Res_KW2>
        <Res_KW3>innate immunity</Res_KW3>
        <Res_KW4>vaccine biology</Res_KW4>
        <Res_KW5>bacterial infection</Res_KW5>
        <Plain_Description>Increasing evidence suggests that in addition to protecting us against specific diseases, vaccines can also confer nonspecific effects that are defined as effects on health unrelated to the disease targeted by the vaccine. In this proposal, we will investigate how different vaccines may shape how our innate immune system responds to subsequent infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011143</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Cecilia Prele</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Evaluating anti-fibrotic drugs for intracochlear fibrosis</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,108,813.80</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | cellular interactions (incl. adhesion, matrix, cell wall) | clinical sciences | otorhinolaryngology | </Field_s__of_Research>
        <Res_KW1>fibrosis </Res_KW1>
        <Res_KW2>transforming growth factor beta (tgf-beta)</Res_KW2>
        <Res_KW3>fibroblasts</Res_KW3>
        <Res_KW4>cochlear implant</Res_KW4>
        <Res_KW5>animal model</Res_KW5>
        <Plain_Description>Cochlear implantation is currently the best method for hearing restoration and has been shown to improve speech understanding in the majority of patients. The acute and long-term outcomes of cochlear implantation remain variable and can be unpredictable. One reason for this variability is the formation of scar tissue around the electrode which, in some cases can lead to device failure. In this study we will determine if anti-fibrotic drugs can reduce the formation of this scar tissue.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011172</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Francine Marques</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>A new role for gut pH in blood pressure regulation </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$998,801.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>cardiorespiratory medicine and heamatology | cardiology (incl. cardiovascular diseases) | </Field_s__of_Research>
        <Res_KW1>blood pressure </Res_KW1>
        <Res_KW2>heart disease</Res_KW2>
        <Res_KW3>intestine</Res_KW3>
        <Res_KW4>g protein-coupled receptors</Res_KW4>
        <Res_KW5>nutritional therapy</Res_KW5>
        <Plain_Description>High blood pressure continues to be a major, poorly controlled but modifiable risk factor for cardiovascular death. Diets high in fibre are associated with lower blood pressure via the production of substances as a result of fibre digestion by gut microbes. We found that these same substances lower gut pH. This new mechanism could have major implications for the management of hypertension in the future.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011193</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Dusan Matusica</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Development of a nociceptive measuring device capable of differentiating chronic pain states</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$777,495.20</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | peripheral nervous system | biomedical engineering | medical devices | </Field_s__of_Research>
        <Res_KW1>peripheral nervous system (pns) diseases </Res_KW1>
        <Res_KW2>pain measurement</Res_KW2>
        <Res_KW3>dorsal root ganglia</Res_KW3>
        <Res_KW4>calcium imaging</Res_KW4>
        <Res_KW5>transcriptional regulation</Res_KW5>
        <Plain_Description>Pain measurement is an essential element in any medical assessment, including diagnosis, monitoring of disease progress and evaluation of treatment effectiveness, but there is no common or easy method of objective pain measurement. This study aims to create an biosensor "neuron-on-chip" cell-based device with the machine learning driven capacity to measure and discriminate between various chronic types by analysing serum samples from animal models of chronic pain and human patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011200</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Kirstan Vessey</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Novel therapies for slowing vision loss caused by retinal degeneration</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$735,066.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | sensory systems | ophthalmology and optometry | ophthalmology | </Field_s__of_Research>
        <Res_KW1>retinal degeneration </Res_KW1>
        <Res_KW2>autophagy</Res_KW2>
        <Res_KW3>proteasome</Res_KW3>
        <Res_KW4>photoreceptors</Res_KW4>
        <Res_KW5>drug screening</Res_KW5>
        <Plain_Description>Death of the light sensitive cells of the eye, the photoreceptors, is one of the leading causes of visual impairment in Australia. Our data indicate accumulation of intracellular waste within photoreceptors is a critical driver of their death. The aims of this project are to define the molecular pathways causing waste accumulation and find treatments that enhance waste recycling in photoreceptors to slow the devastating progression of vision loss.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011209</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Rachel Huxley</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Mapping sex differences in the journey of an individual with coronary heart disease through the healthcare system</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$843,258.40</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | public health and health services not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>coronary heart disease (chd) </Res_KW1>
        <Res_KW2>data linkage</Res_KW2>
        <Res_KW3>sex differences</Res_KW3>
        <Res_KW4>health service utilisation</Res_KW4>
        <Res_KW5>health outcomes</Res_KW5>
        <Plain_Description>A general practice visit is often the first point of contact with the health system and a gateway to other specialist health services. However, data from different services are not easily ‘joined up’ making it difficult to look across the patient’s care journey. This project will join all health attendances for patients with heart related symptoms. This high-quality ‘joined up’ research will contribute to improvements in the provision of health services and patient outcomes in Australia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011217</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Maria del Pilar Dominguez Rodriguez</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>TARGETING DEREGULATED EPIGENETIC MECHANISMS IN LYMPHOMA</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,111,760.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | haematological tumours | </Field_s__of_Research>
        <Res_KW1>lymphoma </Res_KW1>
        <Res_KW2>epigenetics</Res_KW2>
        <Res_KW3>b cells</Res_KW3>
        <Res_KW4>dna targeted drugs</Res_KW4>
        <Res_KW5>immune modulation</Res_KW5>
        <Plain_Description>Diffuse large B-cell lymphomas (DLBCL) are aggressive tumors, with 40% patients not responding to the conventional chemotherapy treatment or relapsing after treatment. In this proposal, we will evaluate new epigenetic therapies to treat these lymphomas, targeting the non-inherited environmental factors that control the function of genes. We predict that the results from this project will drive new clinical trials for DLBCL patients with TET2 or CREBBP mutations, which represent 1 in 3 patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011220</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Geraldine Mitchell</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Regenerative surgery for liver disease using human iPSC-derived liver organoids</Grant_Title>
        <Admin_Institution>St Vincents Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,184,911.50</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical biotechnology | regenerative medicine (incl. stem cells and tissue engineering) | </Field_s__of_Research>
        <Res_KW1>liver regeneration </Res_KW1>
        <Res_KW2>stem cell therapy</Res_KW2>
        <Res_KW3>stem cells</Res_KW3>
        <Res_KW4>liver disease</Res_KW4>
        <Res_KW5>tissue engineering</Res_KW5>
        <Plain_Description>This project will develop a new treatment for liver disease. Using a patient’s own stem cells, we will generate the key components of liver tissue and combine this into mini-liver units called organoids. Organoids will be transplanted into the body (in the groin), for initial development around a major artery/vein, forming a “second liver” in the body. We will then remove diseased liver tissue and replace this with the second liver, in a surgical procedure similar to liver transplantation. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011299</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Wayne Crismani</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Deciphering incomplete penetrance of subfertility</Grant_Title>
        <Admin_Institution>St Vincents Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,360,955.20</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>genetics | quantitative genetics (incl. disease and trait mapping genetics) | genetics | population, ecological and evolutionary genetics | genetics | cell and nuclear division | </Field_s__of_Research>
        <Res_KW1>meiosis </Res_KW1>
        <Res_KW2>recombination</Res_KW2>
        <Res_KW3>sexual recombination</Res_KW3>
        <Res_KW4>dna repair</Res_KW4>
        <Res_KW5>dna replication</Res_KW5>
        <Plain_Description>Infertility is one of the most common chronic health issues involving young adults. Infertility has many causes and is associated with other conditions including elevated risk of type 2 diabetes, heart disease and mental health issues such as anxiety and depression. The goal of the project is to discover genes that influence female fertility levels. This work is crucial to bridge the gap between accurately predicting who is at risk of infertility and how best to treat patients as individuals. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011314</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Melissa Little</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Generating a higher order kidney by understanding and controlling nephron connectivity</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,455,804.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical biotechnology | regenerative medicine (incl. stem cells and tissue engineering) | genetics | developmental genetics (incl. sex determination) | </Field_s__of_Research>
        <Res_KW1>kidney development </Res_KW1>
        <Res_KW2>stem cell biology</Res_KW2>
        <Res_KW3>regenerative medicine</Res_KW3>
        <Res_KW4>kidney disease</Res_KW4>
        <Res_KW5>tissue engineering</Res_KW5>
        <Plain_Description>Engineering replacement kidney tissue for the treatment of chronic kidney disease has the potential to revolutionise kidney disease treatment. We previously used human stem cells to generate many nephrons, the filtering units of the kidney. In this project, we will focus on how to induce connections between these nephrons to ensure a common path for urine exit. This will bring us one stem closer to a stem-cell derived replacement kidney.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011334</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Claire Foldi</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Can psychedelics treat anorexia nervosa? Insights into the therapeutic effects of psilocybin in an animal model</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$770,855.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | central nervous system | </Field_s__of_Research>
        <Res_KW1>anorexia nervosa </Res_KW1>
        <Res_KW2>animal model</Res_KW2>
        <Res_KW3>novel therapeutic agents</Res_KW3>
        <Res_KW4>cognitive behaviour</Res_KW4>
        <Res_KW5>serotonin</Res_KW5>
        <Plain_Description>Anorexia nervosa (AN) is a debilitating disorder which is currently untreatable. Phase 1 clinical trials of psilocybin are underway in patients with AN, however the biological mechanisms of psilocybin remain inadequately understood. This project, which will inform patient selection to avoid unfavourable effects, utilises the activity-based anorexia rat model combined with sophisticated techniques to furnish an understanding of psilocybin’s actions on weight loss, cognition and brain function.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011342</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Alison Hayes</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Novel modelling of childhood obesity to improve decision making and close the gap</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$367,556.20</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>applied economics | health economics | </Field_s__of_Research>
        <Res_KW1>overweight/obesity </Res_KW1>
        <Res_KW2>modelling</Res_KW2>
        <Res_KW3>health economics</Res_KW3>
        <Res_KW4>early prevention</Res_KW4>
        <Res_KW5>indigenous health</Res_KW5>
        <Plain_Description>Children from Aboriginal and Torres Strait Islander, other culturally and linguistically diverse groups, and socioeconomically disadvantaged groups are most affected by obesity. We will use novel modelling methods to assess childhood obesity prevention programs for future savings in healthcare costs, improvements in quality of life and impacts on inequalities. We will work with relevant stakeholders to ensure that resources are prioritised for the best and fairest obesity prevention programs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011344</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Georgia Kafer</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Elucidating the impact of oxidative stress on the early development of human placental villi using human stem cell derived placentoids</Grant_Title>
        <Admin_Institution>University of the Sunshine Coast</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$393,481.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>paediatrics and reproductive medicine | foetal development and medicine | </Field_s__of_Research>
        <Res_KW1>trophoblast </Res_KW1>
        <Res_KW2>placenta</Res_KW2>
        <Res_KW3>embryonic stem cells</Res_KW3>
        <Res_KW4>fetal growth restriction</Res_KW4>
        <Res_KW5>oxidative stress</Res_KW5>
        <Plain_Description>The placenta supports the life of the baby. Nutrients, waste and oxygen cross special placental cells (trophoblasts) at the boundary between fetal and maternal circulation. Early in pregnancy, trophoblasts may experience premature rises in oxygen levels that can damage the placenta and risk maternal and fetal health. A newly developed experimental system will be used to study how oxygen fluxes impact trophoblast health to better understand the cause of placental defects at the cellular level.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011355</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Zhonglin Chai</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>New strategy to safely and effectively reduce diabetic kidney disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,162,198.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | endocrinology | </Field_s__of_Research>
        <Res_KW1>renal fibrosis </Res_KW1>
        <Res_KW2>tubulointerstitial inflammation</Res_KW2>
        <Res_KW3>transforming growth factor beta (tgf-beta)</Res_KW3>
        <Res_KW4>protein interactions</Res_KW4>
        <Res_KW5>peptide inhibitors</Res_KW5>
        <Plain_Description>Diabetic kidney disease (DKD) is a catastrophic disease with no effective treatment to reduce scarring and inflammation, the major pathological features of DKD. We have found a new target and generated a prototype drug, CHA-061, to safely inhibit this target, which led to concurrent inhibition of inflammation and fibrosis in animal models of DKD. This grant will study the structure-activity relationship of this prototype inhibitor in order to generate a more effective therapy to combat DKD. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011391</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Renea Taylor</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Developing novel CAR T cell therapy approaches to treat prostate cancer</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,744,586.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Field_s__of_Research>
        <Res_KW1>prostate cancer </Res_KW1>
        <Res_KW2>cancer therapy</Res_KW2>
        <Res_KW3>pre-clinical studies</Res_KW3>
        <Res_KW4>cancer cell biology</Res_KW4>
        <Res_KW5>immunotherapy</Res_KW5>
        <Plain_Description>Prostate cancer is the most common cancer in Australian men and second leading cause of death. The major clinical challenge is to offer more effective treatments for men with advanced prostate cancer, particularly those who have failed all available therapies. This project will provide preclinical evidence that CAR T cell immunotherapy is effective for prostate cancer and will inform future clinical trial development. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011398</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof David Harrich</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Development of a defective interfering RNA based antiviral approach to treat infections by SARS-CoV-2 and emerging variants</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$815,219.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical microbiology | medical virology | </Field_s__of_Research>
        <Res_KW1>viral infection </Res_KW1>
        <Res_KW2>virus-like particle</Res_KW2>
        <Res_KW3>nanotechnology</Res_KW3>
        <Res_KW4>rna</Res_KW4>
        <Res_KW5>antiviral agents</Res_KW5>
        <Plain_Description>Specific therapy for severe disease caused by SARS-CoV-2 is limited. The ability of viruses to become resistant to a therapy may be obstacle for antiviral development. This project develops a unique platform, using virus-specific antiviral RNA, as a unique and possibly “antiviral-resistance” proof approach that could be deployed as a therapeutic for COVID-19 and also help to solve the challenge of viral pandemics from known and unknown viruses, especially other human pathogenic coronaviruses.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011447</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Harshal Nandurkar</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>A novel single treatment for two serious complications of allogeneic stem cell transplantation: acute graft-versus-host disease and sinusoidal obstruction syndrome.</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,863,376.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>cardiorespiratory medicine and heamatology | haematology | </Field_s__of_Research>
        <Res_KW1>graft versus host disease (gvhd) </Res_KW1>
        <Res_KW2>allogeneic transplantation</Res_KW2>
        <Res_KW3>novel therapeutic agents</Res_KW3>
        <Res_KW4>liver disease</Res_KW4>
        <Res_KW5>antibody therapy</Res_KW5>
        <Plain_Description>Acute graft versus host disease (GVHD) is a frequent and devastating complication of allogeneic stem cell transplantation, which is the use of stem cells from a donor related or unrelated to the patient who is the recipient. It is mediated by immune activation and inflammation. We have developed a new drug (Anti-VCAM-CD39) that has anti-inflammatory and immune suppressive properties. We will test the efficacy of this drug to simultaneously treat GVHD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011462</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Lucy Palmer</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>The role of memory engrams in the cortex</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$996,007.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | cellular nervous system | </Field_s__of_Research>
        <Res_KW1>memory </Res_KW1>
        <Res_KW2>memory disorders</Res_KW2>
        <Res_KW3>neuron</Res_KW3>
        <Res_KW4>dendrites</Res_KW4>
        <Res_KW5>synaptic plasticity</Res_KW5>
        <Plain_Description>Memory formation is one of the great mysteries of the brain. Memories are not only crucial for survival, but they make us who we are. This project will address where, and how, memories are formed in the brain and provide insight into new targets to treat disorders of memory.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011467</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Emer Prof Warwick Britton</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Defining the impact of chronic lung disease on COVID-19 and developing effective therapies</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$896,784.20</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>immunology | immunology not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>covid-19 </Res_KW1>
        <Res_KW2>lung inflammation</Res_KW2>
        <Res_KW3>chronic obstructive pulmonary disease (copd)</Res_KW3>
        <Res_KW4>tuberculosis</Res_KW4>
        <Res_KW5>anti-inflammatory agents</Res_KW5>
        <Plain_Description>COVID-19 disease is driven by virus-induced, hyper-inflammation that damages the lungs. Patients with chronic lung disease, such as chronic obstructive pulmonary disease (COPD) and tuberculosis (TB), have increased severity of COVID-19 disease. Using our models of TB and smoking-induced COPD, we will define how chronic lung disease increases the severity of COVID-19, how CoV2 infection exacerbates TB and COPD, and identify effective drugs that suppress this inflammatory damage to the lung.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011471</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Matthew Simunovic</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Optogenetic restoration of high-sensitivity vision with ChRmine, a novel Type I opsin</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$634,081.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>ophthalmology and optometry | ophthalmology | medical physiology | cell physiology | genetics | genetics not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>gene therapy </Res_KW1>
        <Res_KW2>retinal degeneration</Res_KW2>
        <Res_KW3>retina</Res_KW3>
        <Res_KW4>vision</Res_KW4>
        <Res_KW5>retinal dystrophy</Res_KW5>
        <Plain_Description>Inherited retinal disease (IRD) is the commonest cause of blindness in people of working age. Sight loss in IRD is due to the loss of light-sensitive cells inside the eye called the rods and cones. However, the light-insensitive nerve cells in the eye, which normally relay information from the rods and cones to the brain, persist. This project aims to introduce a new, highly light-sensitive protein called ChRmine into these cells to make them light-sensitive, thereby restoring vision.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011481</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof SEO-KYUNG CHUNG</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Characterisation of novel genetic variants in Hyperekplexia and Dravet Syndrome: Identifying the Unknown Knowns</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$585,714.50</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | medical genetics (excl. cancer genetics) | neurosciences | neurology and neuromuscular diseases | genetics | neurogenetics | </Field_s__of_Research>
        <Res_KW1>clinical diagnosis </Res_KW1>
        <Res_KW2>neurodevelopmental disorders</Res_KW2>
        <Res_KW3>epilepsy</Res_KW3>
        <Res_KW4>clinical genetics</Res_KW4>
        <Res_KW5>gene mutations</Res_KW5>
        <Plain_Description>All people carry 3 million points-of-variation (variants) in their individual genetic code which can be accurately read but only partially interpreted. This study, with collective world-wide efforts of neurologists and scientists, will enhance our interpretation of variants that are overlooked in routine clinical genetic testing. Outcomes of this study will improve our understanding of neurological disorders and provide a methodological pathway to rapidly detect the splicing variant defects. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011513</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Ole Tietz</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Intraneuronal Immunotherapy to treat Alzheimer’s Disease</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$972,072.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | neurosciences not elsewhere classified | medicinal and biomolecular chemistry | molecular medicine | </Field_s__of_Research>
        <Res_KW1>molecular neuroscience </Res_KW1>
        <Res_KW2>dementia</Res_KW2>
        <Res_KW3>drug development</Res_KW3>
        <Res_KW4>antibody therapy</Res_KW4>
        <Res_KW5>antibody engineering</Res_KW5>
        <Plain_Description>Dementia is the single greatest cause of disability in older Australians and the second leading cause of death. At present, dementia can only be managed through symptomatic treatment with limited therapeutic effects. Current immunotherapies for dementia are limited to the small amount of toxic protein accessible outside neurons. This project will develop new immunotherapeutics that clear problematic proteins inside neurons in order to halt and reverse the course of dementia.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011540</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Magdalene Montgomery</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Development of multifaceted glucose-plus therapies - A focus on Hexosaminidase A (HEXA)</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,087,328.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | cell metabolism | biochemistry and cell biology | receptors and membrane biology | biochemistry and cell biology | systems biology | </Field_s__of_Research>
        <Res_KW1>type 2 diabetes mellitus (non-insulin dependent diabetes mellitus) </Res_KW1>
        <Res_KW2>fatty liver disease</Res_KW2>
        <Res_KW3>endocrine factors</Res_KW3>
        <Res_KW4>lipid bilayers</Res_KW4>
        <Res_KW5>lipid metabolism</Res_KW5>
        <Plain_Description>Type 2 diabetes (T2D) is a cause of heart attacks, stroke, and kidney failure. Patients with T2D also commonly suffer from liver disease and increased blood lipids. We have recently identified Hexosaminidase A (HEXA) as a protein secreted by the liver that reduces high blood glucose levels and blood lipids, and improves insulin sensitivity and liver disease in diabetic mice. This project will investigate if HEXA is a useful therapeutic target for the treatment of metabolic disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011547</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Graham Neely</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Human pain genes as a window into pain mechanisms and modern pain management</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$832,476.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | sensory systems | </Field_s__of_Research>
        <Res_KW1>pain </Res_KW1>
        <Res_KW2>epigenetics</Res_KW2>
        <Res_KW3>chronic pain</Res_KW3>
        <Res_KW4>cell biology</Res_KW4>
        <Res_KW5>molecular basis of disease</Res_KW5>
        <Plain_Description>Chronic pain affects ~20% of the adult population at any one time, most people will suffer from chronic pain at some stage in their lives, and available pain treatments do not help the majority of pain patients. In this project we use new genomic knowledge and techniques to gain basic insight into pain biology and develop new gene editing therapies to treat extreme untreatable chronic pain. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011557</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Anandwardhan Hardikar</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>A microRNA NanoChip Technology for Predicting Childhood Type 1 Diabetes Risk</Grant_Title>
        <Admin_Institution>University of Western Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$390,166.90</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>medicinal and biomolecular chemistry | molecular medicine | </Field_s__of_Research>
        <Res_KW1>microrna </Res_KW1>
        <Res_KW2>nanotechnology</Res_KW2>
        <Res_KW3>risk prediction</Res_KW3>
        <Res_KW4>autoantibodies</Res_KW4>
        <Res_KW5>diabetes</Res_KW5>
        <Plain_Description>Type 1 diabetes (T1D) involves destruction of insulin-producing cells. Current clinical tests, although useful to diagnose T1D, cannot accurately predict future T1D as they measure blood-based molecules that arise following the destruction of insulin producing cells.  Through this study, we use a novel test (like a pregnancy test) that offers the capacity to measure a different class of blood-based molecules, which can help identifying T1D progression. Early detection can help prevent diabetes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011558</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Lisa Mielke</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Investigation of novel immune pathways for improving cancer immunotherapy</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$781,419.40</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>immunology | tumour immunology | immunology | cellular immunology | </Field_s__of_Research>
        <Res_KW1>colorectal cancer </Res_KW1>
        <Res_KW2>mucosal immunity</Res_KW2>
        <Res_KW3>gastrointestinal disease</Res_KW3>
        <Res_KW4>cytokine biology</Res_KW4>
        <Res_KW5>transcriptional regulation</Res_KW5>
        <Plain_Description>The epithelium of the gastrointestinal tract separates our body from the intestinal content. Its barrier function is crucially promoted by immune cells named intraepithelial lymphocytes (IELs) that sense cellular stress and recognise microbial agents. We show that IELs play a critical role in preventing bowel cancer progression. We will discover new genes and molecular pathways that promote the anti-cancer functions of IELs, leading to discovery of novel drug targets to treat bowel cancer. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011560</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Robin Anderson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Breast Cancer Dormancy - Mechanisms and Development of Rational New Therapies</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$768,784.40</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | cancer cell biology | </Field_s__of_Research>
        <Res_KW1>breast cancer </Res_KW1>
        <Res_KW2>metastatic progression</Res_KW2>
        <Res_KW3>minimal residual disease</Res_KW3>
        <Res_KW4>targeted therapy</Res_KW4>
        <Res_KW5>cancer immunotherapy</Res_KW5>
        <Plain_Description>Over 85% of breast cancer deaths are caused by the spread of the cancer cells to vital organs, leading to organ failure and death. Once these secondary tumours establish, our current therapies are not effective, at best, they delay the growth and further spread of the cancer.  Tumour cells can lie dormant for up to 20 years before relapse. The aim of this project is to test novel therapies for their ability to kill these dormant tumour cells before they can grow into new tumours. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011584</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Joanne Hildebrand </CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Targeting necroptosis in the race to treat acute and chronic inflammation</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,237,965.20</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | cell development, proliferation and death | immunology | innate immunity | </Field_s__of_Research>
        <Res_KW1>cell death </Res_KW1>
        <Res_KW2>pro-inflammatory alleles</Res_KW2>
        <Res_KW3>inflammatory diseases</Res_KW3>
        <Res_KW4>sepsis</Res_KW4>
        <Res_KW5>animal model</Res_KW5>
        <Plain_Description>Necroptosis, a form of programmed cell death, is an important weapon used by our bodies to prevent the spread of viruses, bacteria and even cancer. We have discovered that many populations have developed genetic changes that may enhance necroptosis and increase inflammation in the body. We propose that these changes are the key to understanding why only some people develop severe life threatening symptoms to infections, and the key to designing more effective therapies for inflammatory diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011590</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Mastura Monif</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Glioblastoma - inhibition of P2X7R as a potential therapeutic target for treatment of this aggressive cancer. </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$842,094.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | clinical sciences not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>glioma </Res_KW1>
        <Res_KW2>brain</Res_KW2>
        <Res_KW3>anticancer drug</Res_KW3>
        <Res_KW4>purinergic receptors</Res_KW4>
        <Res_KW5>drug therapy</Res_KW5>
        <Plain_Description>Glioblastoma is a highly fatal human brain cancer generally affecting young adults, with survival time of only 12 months after diagnosis despite treatment. Our work is showing very promising results where inhibiting a particular cell membrane protein, P2X7R (with a particular drug AZ10606120) can significantly reduce tumour proliferation. AZ10606120 was better than the currently available chemotherapy, Temozolomide. This is very exciting and warrants urgent further study via this Ideas grant.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011592</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Andrew Zalesky</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Normative reference ranges for brain phenotypes in psychiatry</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$596,602.80</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>cognitive science | neurocognitive patterns and neural networks | clinical sciences | psychiatry (incl. psychotherapy) | </Field_s__of_Research>
        <Res_KW1>magnetic resonance imaging (mri) </Res_KW1>
        <Res_KW2>neuroimaging</Res_KW2>
        <Res_KW3>neuropsychiatry</Res_KW3>
        <Res_KW4>brain imaging</Res_KW4>
        <Res_KW5>psychiatry</Res_KW5>
        <Plain_Description>Psychiatry is one of the few remaining fields in medicine where biological tests are seldom used to inform treatments and guide diagnoses. We aim to improve the utility of brain imaging in psychiatry through the development and provision of healthy reference ranges for measurements of brain structure extracted from a patient's MRI scan. This project charts a way forward towards personalised brain medicine in psychiatry.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011595</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Lachlan Harris</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Prolonging survival in glioblastoma through quiescence inhibition</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$571,687.60</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | cancer cell biology | </Field_s__of_Research>
        <Res_KW1>adult stem cells </Res_KW1>
        <Res_KW2>glioma</Res_KW2>
        <Res_KW3>combination therapy</Res_KW3>
        <Res_KW4>cell proliferation</Res_KW4>
        <Res_KW5>chemotherapy</Res_KW5>
        <Plain_Description>Most people diagnosed with the brain cancer glioblastoma die within 15-months. The cancer is so deadly because it rapidly returns after therapy. Glioblastoma returns because of slowly dividing cancer stem cells that resist treatment. Our strategy is to eliminate these cells by forcing them to divide quickly during chemotherapy. This project will test targeted molecules in organoid and pre-clinical animal models of the disease to establish an evidence base for Phase 1 trials.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011627</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof John Pimanda</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>The Single Cell Basis for the Emergence of Drug Resistance during Azacitidine Therapy in Myelodysplastic Syndromes and Acute Myeloid Leukemia</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,200,569.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | haematological tumours | </Field_s__of_Research>
        <Res_KW1>myelodysplasia </Res_KW1>
        <Res_KW2>haematopoietic stem cells</Res_KW2>
        <Res_KW3>epigenetics</Res_KW3>
        <Res_KW4>bone marrow stroma</Res_KW4>
        <Res_KW5>immune modulation</Res_KW5>
        <Plain_Description>Myelodysplasia and acute myeloid leukemia are blood cancers that arise in abnormal blood stem cells in the bone marrow. Azacitidine (AZA) is a drug that helps re-establish blood cell production in ~50% of patients. It is ineffective in the remainder. We will test whether AZA works in responders by improving the fitness of abnormal blood stem cells and their surrounding cells and modulating immune cells that help eliminate abnormal blood cells. This will guide drug discovery for non-responders. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011633</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Gavan McNally</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Novel pathways to abstinence from alcohol seeking</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,104,880.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>psychology | biological psychology (neuropsychology, psychopharmacology, physiological psychology) | </Field_s__of_Research>
        <Res_KW1>drug relapse </Res_KW1>
        <Res_KW2>neural pathways</Res_KW2>
        <Res_KW3>brain</Res_KW3>
        <Res_KW4>alcohol and behaviour</Res_KW4>
        <Res_KW5>animal model</Res_KW5>
        <Plain_Description>Relapse to drinking after a period of treatment remains a fundamental problem for sufferers of alcohol-use disorders. This project uses a suite of state of the art technologies in a well validated pre-clinical animal model to identify how the brain gates this propensity to relapse. It will provide critical new knowledge on which cells in which brain circuits to target as well as when to target them in order to prevent relapse and promote abstinence from drinking.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011634</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Craig Phillips</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Understanding Brain Cleaning in Obstructive Sleep Apnoea</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$658,233.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>cardiorespiratory medicine and heamatology | respiratory diseases | neurosciences | neurosciences not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>obstructive sleep apnoea </Res_KW1>
        <Res_KW2>sleep disturbance</Res_KW2>
        <Res_KW3>amyloid beta-protein</Res_KW3>
        <Res_KW4>haemodynamics</Res_KW4>
        <Res_KW5>dynamic process modelling</Res_KW5>
        <Plain_Description>During deep sleep, blood pressure falls and the brain rests. Production of toxic waste also slows while its removal increases. This brain cleaning process during sleep is thought to be crucial for preventing dementia. Obstructive Sleep Apnoea (OSA) is a common condition characterised by marked sleep and blood pressure disturbances. People with OSA have an increased risk for dementia. This study aims to investigate how sleep and blood pressure disturbances affect brain cleaning in people with OSA</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011728</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof David Croucher</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Targeting metastatic triple-negative breast cancer with a selective oncogenic JNK inhibitor</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$674,218.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | signal transduction | </Field_s__of_Research>
        <Res_KW1>c-jun/jnk kinase </Res_KW1>
        <Res_KW2>protein-protein interaction</Res_KW2>
        <Res_KW3>signal transduction</Res_KW3>
        <Res_KW4>cytoskeleton</Res_KW4>
        <Res_KW5>breast cancer</Res_KW5>
        <Plain_Description>While JNK is a potent oncogene in TNBC, there are no effective JNK-targeting therapies due to the fact that this signalling pathway regulates numerous cellular functions. Leveraging a recent screen of 114,000 compounds, we have identified a novel molecule, called K12, that specifically inhibits the tumour promoting activity of JNK. Now, we will further the preclinical evaluation of K12, to generate a world-first drug capable of preventing metastatic outgrowth in TNBC</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011730</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Natalie Hannan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Improving the pipeline for translation of therapies for serious complications of pregnancy</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$965,933.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>paediatrics and reproductive medicine | obstetrics and gynaecology | </Field_s__of_Research>
        <Res_KW1>pregnancy complications </Res_KW1>
        <Res_KW2>fetal growth restriction</Res_KW2>
        <Res_KW3>pre-eclampsia</Res_KW3>
        <Res_KW4>drug therapy</Res_KW4>
        <Res_KW5>placental insufficiency</Res_KW5>
        <Plain_Description>Preeclampsia and fetal growth restriction are deadly complications of pregnancy, without current therapies for either. Development of treatments is seriously limited, pregnant women are excluded from drug trials, due to concerns for both mother and baby. We have developed a dedicated pipeline for drug discovery for pregnancy; we will thoroughly test promising drug candidates and advanced delivery strategies. This proposal paves the way for much needed development of therapies for pregnant women.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011733</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Farshad Mansouri</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>The effects of early exposure to bushfires on adult brain structure and function</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,326,234.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | cellular nervous system | </Field_s__of_Research>
        <Res_KW1>monkey </Res_KW1>
        <Res_KW2>bushfire</Res_KW2>
        <Res_KW3>brain function</Res_KW3>
        <Res_KW4>brain development</Res_KW4>
        <Res_KW5>social and behavioural research</Res_KW5>
        <Plain_Description>The effects of bushfire smoke inhalation on brain structure and function remain unknown. We will conduct the first systematic study of this issue, based on a cohort of monkeys born during the 2019-2020 bushfire season. The effects of pre- and post-natal bushfire exposure will be investigated in adult brain, using functional and structural MRI, cognitive tests, and neuropathological examination. This project will gain vital scientific data that may help guide future government action.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011747</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Magdalena Plebanski</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Enabling early ovarian cancer diagnosis and prediction of platinum resistance  </Grant_Title>
        <Admin_Institution>RMIT University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$999,428.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>immunology | tumour immunology | medical biotechnology | medical biotechnology diagnostics (incl. biosensors) | genetics | epigenetics (incl. genome methylation and epigenomics) | </Field_s__of_Research>
        <Res_KW1>ovarian cancer </Res_KW1>
        <Res_KW2>early diagnosis</Res_KW2>
        <Res_KW3>cisplatin resistance</Res_KW3>
        <Res_KW4>biosensor</Res_KW4>
        <Res_KW5>nanotechnology</Res_KW5>
        <Plain_Description>Ovarian cancer often gets diagnosed late, and at that stage survival outcomes are poor. Here, we propose to use a simple drop of blood, to detect combinations of proteins and changes in genetic material originating from cancer and immune cells, to support earlier, more accurate diagnosis and predict platinum resistance to avoid delay of personalised treatment. We also develop easy-to-use, low-cost Lab-on-a Chip devices to enable routine testing and monitoring at the point-of-care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011753</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Stuart McDougall</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Infiltrating central command to selectively alter autonomic function</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$705,188.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | autonomic nervous system | </Field_s__of_Research>
        <Res_KW1>vagus nerve </Res_KW1>
        <Res_KW2>amygdala</Res_KW2>
        <Res_KW3>hypothalamus</Res_KW3>
        <Res_KW4>central autonomic control</Res_KW4>
        <Res_KW5>autonomic dysfunction</Res_KW5>
        <Plain_Description>The brain controls blood pressure and other internal organ functions that are necessary for life. In disease, this control does not work properly. This can be the cause of diseases like hypertension, but it also seems to happen in neurological conditions. It is not known why. Using a genetically modified virus that we made, we hope to find out exactly which neurons control organ function and then modify their activity.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011761</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Sandra Nicholson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>A novel regulator of interferon signalling</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$646,916.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | signal transduction | </Field_s__of_Research>
        <Res_KW1>interferon (ifn) </Res_KW1>
        <Res_KW2>suppressor of cytokine signalling (socs)</Res_KW2>
        <Res_KW3>cytokine signalling</Res_KW3>
        <Res_KW4>jak/stat pathway</Res_KW4>
        <Res_KW5>innate immunity</Res_KW5>
        <Plain_Description>We have identified a new role for a protein called ARAP2 in regulating the immune response to infection. We have generated unique experimental models and have access to immune cells from 25 patients carrying ARAP2 mutations which will enable us to understand the role of ARAP2 in infectious diseases such as TB or Covid-19. This project offers the potential to identify and treat individuals at high risk of life-threatening infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011763</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Shane Grey</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Harnessing a novel immune check point for cancer killing</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$924,922.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | molecular targets | immunology | tumour immunology | oncology and carcinogenesis | cancer genetics | </Field_s__of_Research>
        <Res_KW1>cancer genetics </Res_KW1>
        <Res_KW2>cancer immunotherapy</Res_KW2>
        <Res_KW3>mouse models</Res_KW3>
        <Res_KW4>nuclear factor kappa-b (nf-kb)</Res_KW4>
        <Res_KW5>cancer immunology</Res_KW5>
        <Plain_Description>The Project Team aims to test the idea that a patients T cells can be ‘tuned’ to increase the ability of their own immune system to find, infiltrate, and kill pancreatic cancer cells.This may be beneficial as a stand alone therapy or most likely, work in synergy with emerging immune therapies. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011767</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Chen Davidovich</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Rewriting the dogma of chromatin compaction: a new pathway for polycomb-mediated gene repression in development and disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$849,323.50</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | structural biology (incl. macromolecular modelling) | genetics | genome structure and regulation | genetics | epigenetics (incl. genome methylation and epigenomics) | </Field_s__of_Research>
        <Res_KW1>chromatin structure </Res_KW1>
        <Res_KW2>epigenetics</Res_KW2>
        <Res_KW3>structural biology</Res_KW3>
        <Res_KW4>chromatin</Res_KW4>
        <Res_KW5>gene regulation</Res_KW5>
        <Plain_Description>Polycomb repressive complexes are enzymatic complexes that safeguard the genome by preventing repressed genes from becoming active. The proposed study aimed at identifying how different types of polycomb repressive complexes work together to maintain genes in a compacted state that prevent their expression. The project aims to determine the cascade of molecular events that lead to chromatin compaction and to visualize this process in high resolution.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011768</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Daniel Johnson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Understanding and Treating Videogame Addiction in Young People</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,048,250.70</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>psychology | health, clinical and counselling psychology | </Field_s__of_Research>
        <Res_KW1>addiction treatment </Res_KW1>
        <Res_KW2>behavioural intervention</Res_KW2>
        <Res_KW3>randomised controlled trial (rct)</Res_KW3>
        <Res_KW4>addictive behaviours</Res_KW4>
        <Res_KW5>prospective cohort study</Res_KW5>
        <Plain_Description>Excessive videogame play is causing harm to individuals and conflict among families. In the most severe cases players develop Internet Gaming Disorder. We will identify the factors that lead to addiction and based on this we will work with videogame players to design an intervention that will help people overcome IGD. The intervention will be based in software that videogame players are already using. We will evaluate the intervention and translate the knowledge we gain for use by others.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011770</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Samir Taoudi</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Upending the platelet paradigm: Targeting actin-driven membrane budding to modulate platelet production in health and disease</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,953,814.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | cell development, proliferation and death | </Field_s__of_Research>
        <Res_KW1>platelets </Res_KW1>
        <Res_KW2>thrombocytopenia</Res_KW2>
        <Res_KW3>electron microscopy</Res_KW3>
        <Res_KW4>bone marrow</Res_KW4>
        <Res_KW5>actin cytoskeleton</Res_KW5>
        <Plain_Description>Platelets are the cells in the blood responsible for blood clotting and also contribute to wound healing and fighting infection. In a world first, we discovered how the body produces platelets, overturning a 100-year-old dogma. We will capitalise on our breakthrough to understand the diseases of platelet production, develop new therapies to control platelet levels, and generate new knowledge to overcome scalability problems preventing laboratory-based production of platelets for clinical use.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011806</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Ruiting Lan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Transforming genomic surveillance of foodborne Salmonella infections with SalmonellaTracker: a standardised, high resolution and scalable platform</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$865,336.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical microbiology | medical bacteriology | </Field_s__of_Research>
        <Res_KW1>salmonella </Res_KW1>
        <Res_KW2>food safety</Res_KW2>
        <Res_KW3>bacterial pathogen</Res_KW3>
        <Res_KW4>bacterial gastroenteritis</Res_KW4>
        <Res_KW5>molecular typing</Res_KW5>
        <Plain_Description>Salmonella infections are a major health burden with over 50,000 cases each year in Australia. Control of this disease requires rapid and accurate strain typing and tracking. In this project we will develop tools for national and international Salmonella genomic surveillance. These tools will facilitate the tracking, control and characterisation of Salmonella in both the human population and in the food production chain, reducing their global health burden.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011845</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Wendy Ingman</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>A paradigm shift in lactational mastitis</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$946,417.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>paediatrics and reproductive medicine | reproduction | </Field_s__of_Research>
        <Res_KW1>lactation </Res_KW1>
        <Res_KW2>breastfeeding</Res_KW2>
        <Res_KW3>breast development</Res_KW3>
        <Res_KW4>breast milk</Res_KW4>
        <Res_KW5>milk synthesis</Res_KW5>
        <Plain_Description>Lactation mastitis is a debilitating inflammatory breast disease occurring in 1 in 5 Australian breastfeeding women. The disease causes lactation insufficiency, localised pain and rapid onset of fever, muscle aches, chills and fatigue, leading many women to use supplementary formula or cease breastfeeding altogether. This project will address key gaps in our understanding of the biological causes of mastitis and lead to improved prevention and treatment of this disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011853</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Paul Donnelly</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Illumination of Immune Checkpoint Therapy of Cancer: Molecular Imaging of Immunity with Copper Radiopharmaceuticals</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$515,103.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical biochemistry and metabolomics | medical biochemistry: inorganic elements and compounds | </Field_s__of_Research>
        <Res_KW1>chemistry </Res_KW1>
        <Res_KW2>copper</Res_KW2>
        <Res_KW3>molecular imaging</Res_KW3>
        <Res_KW4>radiopharmaceuticals</Res_KW4>
        <Res_KW5>diagnostic imaging</Res_KW5>
        <Plain_Description>Exciting developments in the treatment of cancer have involved developing ways to reinvigorate a patient’s own immune system to attack their disease. This type of therapy, called immune checkpoint therapy, produces remarkable outcomes for some patients but some do not respond. This research will develop the chemistry required to produce imaging agents to enable clinicians to identify patients suitable for immune checkpoint therapies using non-invasive Positron Emission Tomography (PET) imaging. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011883</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Angela Dawson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Creating Health in a New Home: A transformative approach to building evidence for refugee health across generations</Grant_Title>
        <Admin_Institution>University of Technology Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$919,116.30</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | health promotion | public health and health services | epidemiology | public health and health services | public health and health services not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>refugee health </Res_KW1>
        <Res_KW2>health status</Res_KW2>
        <Res_KW3>social determinants of health</Res_KW3>
        <Res_KW4>ethnic health promotion</Res_KW4>
        <Res_KW5>health services research</Res_KW5>
        <Plain_Description>Refugees experience serious health issues on arrival that demand specialised services. Little is known about refugee health after settlement and over generations and if tailored healthcare is needed. This study will deliver new evidence to plan appropriate cost-effective health services and programs. A roadmap will be designed with refugees to achieve health and evaluate outcomes. This innovative approach will empower refugees, placing them at the centre of their health decision making.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011912</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Mr Gregory Pratt</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Communication training for mental health professionals: developing cultural sensitivity and capability to improve Aboriginal and Torres Strait Islander people mental health outcomes</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,813,401.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | aboriginal and torres strait islander health | </Field_s__of_Research>
        <Res_KW1>patient/professional communication </Res_KW1>
        <Res_KW2>aboriginal mental health</Res_KW2>
        <Res_KW3>clinical practice</Res_KW3>
        <Res_KW4>social and cultural issues</Res_KW4>
        <Res_KW5>capacity building</Res_KW5>
        <Plain_Description>This interventional study will be led by Indigenous researchers and mental health professionals and engage with Indigenous consumers, communities, services providers and policy makers to co-design, deliver and evaluate a communication training package for non-Indigenous mental health professionals. The goal is to improve health outcomes for Indigenous patients and build an accountable, more knowledgeable and culturally sensitive mental health workforce.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011940</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Marcus Stoodley</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>CHIARI MALFORMATION: DEFINING PATHOPHYSIOLOGY AND TREATMENT GOALS</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$729,270.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | surgery | neurosciences | central nervous system | </Field_s__of_Research>
        <Res_KW1>cerebellar disorders </Res_KW1>
        <Res_KW2>headache</Res_KW2>
        <Res_KW3>neurosurgery</Res_KW3>
        <Res_KW4>cognition</Res_KW4>
        <Res_KW5>magnetic resonance imaging (mri)</Res_KW5>
        <Plain_Description>Chiari I malformation is a complex neurological disorder that has a significant impact on a patient’s quality of life. We do not understand what causes many of the symptoms (debilitating headache &amp;amp; cognitive deficits) and complications (spinal cysts). Indications for surgery and surgical goals are also controversial. This project addresses these knowledge gaps using integrated human studies and machine learning and is expected to develop imaging guidelines for surgical indications and success. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011953</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Andrew Zannettino</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Development of a novel glucose lowering medication targeting mTORC1 in osteoblasts.</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$649,347.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical physiology | cell physiology | </Field_s__of_Research>
        <Res_KW1>glucoregulation </Res_KW1>
        <Res_KW2>insulin resistance</Res_KW2>
        <Res_KW3>osteoblast</Res_KW3>
        <Res_KW4>obesity</Res_KW4>
        <Res_KW5>bone biology</Res_KW5>
        <Plain_Description>New medications to lower blood sugar levels are desperately needed to help treat the many millions of people at risk of developing chronic diseases associated with obesity and Type 2 diabetes (T2DM). Our group has identified a new drug target in bone forming cells. This target becomes over-activated in obesity and decreases the ability of insulin to stimulate sugar uptake. In this proposal, we will develop a novel inhibitor and test the inhibitor in a model system of diet-induced T2DM.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011958</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Carrington Shepherd</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>New insights for reducing Aboriginal stillbirth: Community-led, integrated evidence for change</Grant_Title>
        <Admin_Institution>Curtin University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,462,378.90</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | aboriginal and torres strait islander health | </Field_s__of_Research>
        <Res_KW1>aboriginal child </Res_KW1>
        <Res_KW2>stillbirth</Res_KW2>
        <Res_KW3>perinatal</Res_KW3>
        <Res_KW4>health inequalities</Res_KW4>
        <Res_KW5>indigenous health</Res_KW5>
        <Plain_Description>This project will work in partnership with Aboriginal Elders, communities and service providers to undertake the first large-scale examination of stillbirth among Aboriginal peoples. It aims to enhance our understanding of the risks to Aboriginal stillbirth, explore Aboriginal community knowledge and awareness of stillbirth risks, and progress Aboriginal-specific intervention strategies to support stillbirth education and awareness.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011959</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Charles Bond</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>A FRET-based protein sensor for RNA detection, localisation and analysis</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$765,196.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | structural biology (incl. macromolecular modelling) | medicinal and biomolecular chemistry | characterisation of biological macromolecules | </Field_s__of_Research>
        <Res_KW1>rna binding proteins </Res_KW1>
        <Res_KW2>protein structure</Res_KW2>
        <Res_KW3>biophysics</Res_KW3>
        <Res_KW4>molecular biology</Res_KW4>
        <Res_KW5>molecular design</Res_KW5>
        <Plain_Description>The ability to detect specific RNA molecules is a key aspect of diagnosis and pathogenesis of a variety of diseases. Recent developments from synthetic biology have provided us with robust designer RNA-binding proteins which can be used as sophisticated tools for detecting specific RNA molecules to understand the molecular basis of numerous diseases. Applying cutting edge “single-molecule” techniques to prototype molecules we will develop these tools for application as RNA detecting biosensors.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011963</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Angus Johnston</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Improving therapeutic delivery of RNA</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$834,328.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>nanotechnology | nanomedicine | </Field_s__of_Research>
        <Res_KW1>nanotechnology </Res_KW1>
        <Res_KW2>messenger rna (mrna)</Res_KW2>
        <Res_KW3>endosomes</Res_KW3>
        <Res_KW4>targeting</Res_KW4>
        <Res_KW5>trafficking</Res_KW5>
        <Plain_Description>RNA based therapies show tremendous promise for treating many important diseases, however an effective method of delivering these drugs to the correct compartment of cells has not yet been discovered. This project will investigate the barriers existing at the cellular level that hinder RNA delivery. This knowledge will be used to engineer nanoparticles to help translate RNA technologies from the laboratory into the clinic.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011969</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Sara Howden</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Modelling polycystic kidney disease in vitro</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$861,834.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | biochemistry and cell biology not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>disease modelling </Res_KW1>
        <Res_KW2>drug screening</Res_KW2>
        <Res_KW3>kidney disease</Res_KW3>
        <Res_KW4>stem cells</Res_KW4>
        <Res_KW5>cell biology</Res_KW5>
        <Plain_Description>Autosomal Recessive Polycystic Kidney Disease (ARPKD) causes kidney and liver failure in babies and children. One quarter of babies born with ARPKD will not survive after birth. We have recently developed a method to recreate human kidney tissue from stem cells.  We will generate stem cells using patient blood samples and use these to make a model of the patient’s ARPKD disease in the laboratory. We will use these patient models to screen for new, personalised treatments for patients with ARPKD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011978</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Daniel Scott</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>α1-adrenoceptor protein structures and selective tools: towards novel treatments for heart failure and Alzheimer’s disease</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,551,582.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | receptors and membrane biology | pharmacology and pharmaceutical sciences | basic pharmacology | pharmacology and pharmaceutical sciences | pharmacology and pharmaceutical sciences not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>adrenoceptors </Res_KW1>
        <Res_KW2>rational drug design</Res_KW2>
        <Res_KW3>antibody engineering</Res_KW3>
        <Res_KW4>protein structure</Res_KW4>
        <Res_KW5>protein engineering</Res_KW5>
        <Plain_Description>Heart failure and dementia are the top and fifth leading disease burdens in Australia respectively, highlighting the urgent need to identify new ways to treat and relieve the symptoms of these devastating diseases. Adrenaline receptors in our body called a1-adrenoceptors, have been implicated as playing an important role in heart failure and Alzheimer’s disease, but no suitable drugs exist to explore this further. This project will develop such tools using innovative approaches.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011990</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Marie-Isabel Aguilar</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Pathogenic membranes as therapeutic drug targets</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,269,456.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | cellular interactions (incl. adhesion, matrix, cell wall) | </Field_s__of_Research>
        <Res_KW1>antimicrobial resistance </Res_KW1>
        <Res_KW2>membrane lipids</Res_KW2>
        <Res_KW3>peptides</Res_KW3>
        <Res_KW4>antimicrobial therapy</Res_KW4>
        <Res_KW5>biophysics</Res_KW5>
        <Plain_Description>Resistance of pathogens to drugs continues to emerge and intensify. While host defence peptides (HDPs) are a promising alternative to current drugs, many pathogens have also evolved resistance mechanisms through changes in their cell membrane. This application will apply a range of analytical tools to understand how bacteria change their cell walls in response to HDPs. The results will allow us to design new combination therapies to treat pathogenic infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012006</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Julie Atkin</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Characterising the unique functional and pathological properties of a novel extracellular RNA binding protein in Amyotrophic Lateral Sclerosis</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$810,299.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | cellular nervous system | </Field_s__of_Research>
        <Res_KW1>amyotrophic lateral sclerosis </Res_KW1>
        <Res_KW2>motor neuron disease (mnd)</Res_KW2>
        <Res_KW3>alternative splicing</Res_KW3>
        <Res_KW4>neurodegeneration</Res_KW4>
        <Res_KW5>rna binding proteins</Res_KW5>
        <Plain_Description>'FUS' is an important protein that causes aggressive, juvenile types of motor neuron disease (MND). FUS is also implicated in the most common sporadic forms of MND (90% of cases), but the mechanisms involved are unclear. We have found a new form of FUS that is unique because it exists outside the cell, unlike all other MND proteins. Importantly we have found that in MND patients this protein is abnormal. Here we will examine its normal function outside the cell and its role in MND.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012013</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Melissa Call</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Improving the safety and efficacy of chimeric antigen receptor (CAR)-T cell therapies</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,106,418.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | structural biology (incl. macromolecular modelling) | biochemistry and cell biology | signal transduction | immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | </Field_s__of_Research>
        <Res_KW1>receptor signalling </Res_KW1>
        <Res_KW2>cell surface receptor</Res_KW2>
        <Res_KW3>t cell activation</Res_KW3>
        <Res_KW4>t cell immunotherapy</Res_KW4>
        <Res_KW5>cancer immunotherapy</Res_KW5>
        <Plain_Description>Immunotherapy is the ‘fourth pillar’ of cancer treatment, alongside surgery, radiation and chemotherapy. We are investigating the manipulation of human immune cells to generate new and improved cancer treatments that ‘train’ a patient’s own immune cells to kill tumours. Preliminary results show potential for improved efficacy and patient safety compared to current immunotherapies. This grant will support further development of suitable ‘trained’ cells for potential use in human clinical trials.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012029</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Elisabeth Lambert</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Identifying brain pathways regulating sympathetic nervous outflow in human hypertension</Grant_Title>
        <Admin_Institution>Swinburne University of Technology</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$683,535.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>cardiorespiratory medicine and heamatology | cardiology (incl. cardiovascular diseases) | </Field_s__of_Research>
        <Res_KW1>sympathetic nervous system </Res_KW1>
        <Res_KW2>hypertension</Res_KW2>
        <Res_KW3>brain imaging</Res_KW3>
        <Res_KW4>central nervous system (cns)</Res_KW4>
        <Res_KW5>obesity</Res_KW5>
        <Plain_Description>Hypertension is characterised by an increase in the activity of the sympathetic nerves. We will use magnetoencephalography, which records the magnetic field generated by brain neurones, coupled with simultaneous direct nerve recording to reveal which neurones in the brain are responsible for the generation of excess nervous activity in individuals with hypertension.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012051</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Allison Cowin</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Development of a diagnostic platform for preventative wound management</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,256,874.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>biomedical engineering | medical devices | clinical sciences | dermatology | </Field_s__of_Research>
        <Res_KW1>wound healing </Res_KW1>
        <Res_KW2>diagnostic</Res_KW2>
        <Res_KW3>diabetic complications</Res_KW3>
        <Res_KW4>delayed wound repair</Res_KW4>
        <Res_KW5>prognosis</Res_KW5>
        <Plain_Description>Early diagnosis, accurate evaluation, and appropriate wound management are vital to prevent the progression of a diabetic foot ulcer to the stage where amputation is required. Currently there are no effective biochemical tools to predict whether a patient will develop a chronic wound. We aim to develop a simple blood-based diagnostic/prognostic device that will provide an early indication of wound risk for people living with diabetes. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012072</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Susan Clark</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>3D Nuclear Re-organisation Potentiates Genomic Structural Variations in Prostate Cancer</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$838,167.20</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>genetics | epigenetics (incl. genome methylation and epigenomics) | </Field_s__of_Research>
        <Res_KW1>epigenetics </Res_KW1>
        <Res_KW2>dna methylation</Res_KW2>
        <Res_KW3>chromatin structure</Res_KW3>
        <Res_KW4>dna replication</Res_KW4>
        <Res_KW5>cancer cell biology</Res_KW5>
        <Plain_Description>When the cell divides not only does the DNA (genome) need to be replicated but so do the chemical modifications on top of the DNA called the ‘epigenome’. Here we ask how the genome and epigenome talk to each other during cell division and how this can go wrong in cancer. We will demonstrate that progressive alterations to our epigenome when the cell divides result in an increased risk of DNA rearrangements and the development of cancer. Our results will open new approaches for cancer strategies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012074</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Timothy Inglis</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>The ADEPT study: Adaptive Diagnostics for Emerging Pandemic Threats in regional Australia</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$3,434,419.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>medical microbiology | medical microbiology not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>covid-19 </Res_KW1>
        <Res_KW2>influenza</Res_KW2>
        <Res_KW3>bacterial sepsis</Res_KW3>
        <Res_KW4>diagnostic assay</Res_KW4>
        <Res_KW5>regional health</Res_KW5>
        <Plain_Description>This project will develop regional diagnostic tests for serious infections, using technical advances made against COVID-19. We will apply these rapid, simple to operate technologies in regional Western Australia. This project will involve regional indigenous communities to reduce the physical, mental and cultural harm done when people are shipped out of country to run diagnostic tests for conditions that could be treated with confidence locally when an early, specific diagnosis is available.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012119</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Kevin Man</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Understanding the biology of adipose tissue regulatory T cells to treat metabolic disease</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$760,853.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>immunology | cellular immunology | immunology | immunology not elsewhere classified | biochemistry and cell biology | cell metabolism | </Field_s__of_Research>
        <Res_KW1>regulatory t cells </Res_KW1>
        <Res_KW2>adipose tissue</Res_KW2>
        <Res_KW3>inflammatory cytokines</Res_KW3>
        <Res_KW4>obesity</Res_KW4>
        <Res_KW5>dietary intervention</Res_KW5>
        <Plain_Description>Our lab has identified a unique population of immune cell found in abdominal fat (Tregs) that functions to regulate glucose metabolism and are anti-inflammatory.  In this proposal we aim to characterize the genes and signals found in fat that influence the function of these cells and understand how these signals differ between sexes.  We also aim to understand how Tregs communicate with other cells found in fat, which will help us formulate new therapies for obesity and metabolic diseases. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012140</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Carlie Cullen</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Myelin: wrapping up neural circuit function and behaviour</Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$794,211.30</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | central nervous system | </Field_s__of_Research>
        <Res_KW1>myelin </Res_KW1>
        <Res_KW2>oligodendrocytes</Res_KW2>
        <Res_KW3>neural plasticity</Res_KW3>
        <Res_KW4>behaviour</Res_KW4>
        <Res_KW5>neurobiology</Res_KW5>
        <Plain_Description>Almost half of all Australians aged 16-85 will experience mental illness in their life, yet we do not understand the underlying biological processes that contribute to mental ill health. This project aims to show how brain insulation adapts to and regulates brain function and learn how inappropriate insulation could underpin symptoms of mental health disorders.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012142</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof David Laybutt</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Type 2 diabetes relief by UPR-mediated beta cell protection</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,000,959.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | endocrinology | </Field_s__of_Research>
        <Res_KW1>type 2 diabetes mellitus (non-insulin dependent diabetes mellitus) </Res_KW1>
        <Res_KW2>insulin secretion</Res_KW2>
        <Res_KW3>pancreatic beta cell</Res_KW3>
        <Res_KW4>islets of langerhans</Res_KW4>
        <Res_KW5>obesity</Res_KW5>
        <Plain_Description>Type 2 diabetes (T2D) is caused by insulin deficiency, with obesity a strong risk factor. However, only a small fraction of obese individuals develops T2D. Usually the pancreatic ß-cells increase insulin release. This proposal will test the novel hypothesis that an adaptive response to stress helps ß-cells increase insulin release and protect against T2D by preventing the conversion of ß-cells to other pancreatic cell types. The studies are important for the development of novel therapy for T2D.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012166</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Andrew Sinclair</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Enhancers as a new target for diagnosing disorders of sex development.</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$756,178.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>genetics | developmental genetics (incl. sex determination) | genetics | gene expression (incl. microarray and other genome-wide approaches) | genetics | genome structure and regulation | </Field_s__of_Research>
        <Res_KW1>sex determination </Res_KW1>
        <Res_KW2>enhancer elements</Res_KW2>
        <Res_KW3>gene regulation</Res_KW3>
        <Res_KW4>functional genomics</Res_KW4>
        <Res_KW5>gonadal development</Res_KW5>
        <Plain_Description>Most human DNA is made up of regions that do not contain genes but instead carry important regulators that increase or decrease gene activity. Those that increase gene activity are called enhancers. This project aims to identify enhancers of genes that control testis or ovary development. We will determine whether disruption of these enhancers leads to a baby being born with a Disorder of Sex Development to improve diagnosis and clinical management of these patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012196</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Delphine Merino</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>A novel genetic barcoding approach to identify the vulnerabilities of lethal breast cancer clones</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$715,225.80</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>genetics | gene expression (incl. microarray and other genome-wide approaches) | </Field_s__of_Research>
        <Res_KW1>dna barcoding </Res_KW1>
        <Res_KW2>cell lineage</Res_KW2>
        <Res_KW3>sequencing</Res_KW3>
        <Res_KW4>cancer biology</Res_KW4>
        <Res_KW5>breast cancer metastases</Res_KW5>
        <Plain_Description>Metastasis is the primary cause of mortality for patients with breast cancer. There is an urgent need to better understand how breast cancer cells spread and resist standard therapy, to ?nd more effective ways to treat patients with metastatic disease. Our project aims at tracking the fate of thousands of human tumour cells during cancer progression to identify the genetic mechanisms responsible for the recurrence of the disease in vital organs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012211</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jason Ivanusic</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>On-Demand, Nanoparticle-Based Analgesia for Musculoskeletal Pain</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$893,856.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | sensory systems | neurosciences | peripheral nervous system | </Field_s__of_Research>
        <Res_KW1>chronic pain </Res_KW1>
        <Res_KW2>pain</Res_KW2>
        <Res_KW3>pain management</Res_KW3>
        <Res_KW4>musculoskeletal</Res_KW4>
        <Res_KW5>bone disease</Res_KW5>
        <Plain_Description>Chronic pain associated with musculoskeletal disease causes a major burden on individuals and health care systems. In this study, we will assay changes in whole-animal pain behavior, and pain signaling, in response to therapeutic delivery of designer nanoparticles in models of osteoarthritis and bone cancer pain. This project is exciting because it will provide proof-of-principle for the use of nanoparticles for on-demand, site-specific analgesia for osteoarthritis and bone cancer pain. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012225</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Melinda Hardy</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Uncovering the pathway between gluten immunity and adverse symptoms in coeliac disease and gluten sensitivity to define novel treatments and symptom biomarkers</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,100,483.60</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | gastroenterology and hepatology | </Field_s__of_Research>
        <Res_KW1>coeliac disease </Res_KW1>
        <Res_KW2>mucosal immunology</Res_KW2>
        <Res_KW3>gastrointestinal symptoms</Res_KW3>
        <Res_KW4>clinical research</Res_KW4>
        <Res_KW5>serotonin</Res_KW5>
        <Plain_Description>Coeliac disease and gluten sensitivity are common illnesses in Australia often associated with unpleasant symptoms after gluten is consumed. Symptoms in some patients can be severe and impair quality of life. How gluten causes this is poorly understood. This study aims to understand the pathways that are important in the development of symptoms, the true triggers, and how gluten immunity is involved. This will enable targeted treatments to manage symptoms improving patient health and well-being.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012233</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Anne Marie Thow</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Safeguarding health in International Investment Agreements</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$844,369.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | health promotion | public health and health services | public health and health services not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>public health policy </Res_KW1>
        <Res_KW2>policy analysis</Res_KW2>
        <Res_KW3>policy development</Res_KW3>
        <Res_KW4>preventive health</Res_KW4>
        <Res_KW5>access to health care</Res_KW5>
        <Plain_Description>The ‘post COVID-19 world’ will require striking a balance between economic recovery and protection of population health. It is essential that International Investment Agreements (IIAs) do not undermine comprehensive and effective health regulation. This project will generate new evidence on 'best practice' health safeguards in IIAs, to prevent challenge to public health policy, and provide resources for the health and investment policy sectors to increase inclusion of strong health safeguards.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012250</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Katie Ayers</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>USING HUMAN EMBRYONIC TESTIS ORGANOIDS TO MODEL REPRODUCTIVE DISORDERS </Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$953,527.80</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>genetics | developmental genetics (incl. sex determination) | </Field_s__of_Research>
        <Res_KW1>stem cells </Res_KW1>
        <Res_KW2>sex determination</Res_KW2>
        <Res_KW3>congenital urogenital abnormalities</Res_KW3>
        <Res_KW4>reproductive biology</Res_KW4>
        <Res_KW5>functional genomics</Res_KW5>
        <Plain_Description>Some babies are born with atypical reproductive organs meaning the sex of the baby is not clear. If the cause is unknown, doctors can be left guessing as to the best treatment. We have recently created a “human embryonic testis in a dish” model from stem cells. Here we will optimise its use to study genetic and environmental causes of reproductive disorders. Our findings will empower families and doctors to choose the right clinical care for these children, improving their health and wellbeing. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012257</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Marcus Kitchen</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Phase-Contrast Neuroimaging for Early Detection of Brain Injury at Birth</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,066,590.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>paediatrics and reproductive medicine | paediatrics | paediatrics and reproductive medicine | obstetrics and gynaecology | clinical sciences | radiology and organ imaging | </Field_s__of_Research>
        <Res_KW1>brain imaging </Res_KW1>
        <Res_KW2>diagnostic imaging</Res_KW2>
        <Res_KW3>brain development</Res_KW3>
        <Res_KW4>brain injury</Res_KW4>
        <Res_KW5>computed tomography</Res_KW5>
        <Plain_Description>Early detection of brain injury that can occur before, during and around the time of birth is critical for the prevention of lifelong intellectual and physical disabilities. However, current imaging techniques are not able to resolve these types of injuries whilst preventative actions can still be taken. We aim to develop novel imaging technologies that will enable subtle brain injuries to be detected early and accurately in order to improve lifelong outcomes for many infants.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012263</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Paul Neeson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>TARGETING COLD TUMOURS WITH TRIPLE THERAPY</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,624,510.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Field_s__of_Research>
        <Res_KW1>t cells </Res_KW1>
        <Res_KW2>tumour cells</Res_KW2>
        <Res_KW3>radiation</Res_KW3>
        <Res_KW4>adeno-associated virus</Res_KW4>
        <Res_KW5>gene therapy</Res_KW5>
        <Plain_Description>Patients with advanced metastatic disease have a very poor clinical outcome and are the main group of patients with an unmet clinical need. We know that very advanced cancers are resistant to the patient's immune system, and immune based therapies. In my program I will address these issues by (1) revealing how the patient's cancer avoids the immune system (2) create new types of T cells which will be resistant to the tumour immune evasion mechanisms (3) translate my findings into the clinic.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012271</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Kelly Rogers</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>A molecular and biophysical characterisation of host cell contribution to invasion by the Apicomplexan parasites</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$799,667.10</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical microbiology | medical parasitology | </Field_s__of_Research>
        <Res_KW1>plasmodium falciparum </Res_KW1>
        <Res_KW2>membrane biology</Res_KW2>
        <Res_KW3>invasion biology</Res_KW3>
        <Res_KW4>cytoskeleton</Res_KW4>
        <Res_KW5>cryptosporidium</Res_KW5>
        <Plain_Description>Disease causing Apicomplexan parasites, such as those causing malaria or cryptosporidiosis, must overcome the membrane barrier to infect their host cells. We have developed a novel 4D microscopy method to determine how these human pathogens penetrate the host membrane and how the host cell contributes to this process. Identifying which key factors are essential will improve current treatment strategies and give rise to a novel class of host directed therapies against this group of pathogens. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012273</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Lee Smith</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Adrenal-Targeted Nanobiotechnology: A Novel Therapy for Adrenal Disease</Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$733,194.50</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>nanotechnology | nanobiotechnology | </Field_s__of_Research>
        <Res_KW1>adrenal endocrinology </Res_KW1>
        <Res_KW2>androgens</Res_KW2>
        <Res_KW3>congenital adrenal hyperplasia</Res_KW3>
        <Res_KW4>nanotechnology</Res_KW4>
        <Res_KW5>gene therapy</Res_KW5>
        <Plain_Description>The adrenal gland produces hormones essential for life-long health. Conditions related to the disruption of these hormones affect 4 million Australians annually, at a cost of $2 Billion. Adrenal conditions require life-long drug replacement therapy, with no possibility of a cure. Through the use of a new adrenal specific delivery technology, we aim to develop novel drug treatments and single-injection cures for adrenal disease. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012285</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Barbara de Graaff</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Eliminating hepatitis B in remote Indigenous settings: generating health economic evidence</Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$750,736.60</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | aboriginal and torres strait islander health | applied economics | health economics | </Field_s__of_Research>
        <Res_KW1>indigenous health </Res_KW1>
        <Res_KW2>hepatitis b infection</Res_KW2>
        <Res_KW3>health services</Res_KW3>
        <Res_KW4>health economics</Res_KW4>
        <Res_KW5>disease modelling</Res_KW5>
        <Plain_Description>Chronic infection with hepatitis B (CHB), which can cause liver disease including liver cancer, is common across NT Indigenous communities. Many people are unaware they have CHB and few engage in care. To address this, the NHMRC funded the HEP B PAST Project (2017) which aims to eliminate CHB from NT Indigenous communities. Results show a highly effective model of care. This new project will generate health economic evidence that is required to embed the HEP B PAST model into standard practice.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012286</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Paul Horwood</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Understanding the establishment and persistence of community associated methicillin-resistant Staphylococcus aureus (CA-MRSA) in resource-limited, high-burden settings: How can we reduce the burden of disease?</Grant_Title>
        <Admin_Institution>James Cook University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$603,908.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>medical microbiology | medical bacteriology | </Field_s__of_Research>
        <Res_KW1>staphylococcus aureus </Res_KW1>
        <Res_KW2>skin infections</Res_KW2>
        <Res_KW3>papua new guinea</Res_KW3>
        <Res_KW4>antimicrobial resistance</Res_KW4>
        <Res_KW5>multiply-resistant staphylococci</Res_KW5>
        <Plain_Description>Methicillin resistant Staphylococcus aureus (MRSA) strain ST93 is a potentially dangerous pathogen of particular concern in resource-limited settings. Our research team has recently identified the highlands of Papua New Guinea as a hotspot for MRSA ST93 bone infections. Through this study we will determine the factors that enable the spread and persistence of ST93 in these settings and identify interventions to reduce the impact of ST93 in resource-limited communities.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012287</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Michael Hildebrand</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Using Cerebrospinal Fluid Liquid Biopsy for Detection of Mosaic Brain Mutations</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$909,172.80</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | cellular nervous system | </Field_s__of_Research>
        <Res_KW1>neurogenetics </Res_KW1>
        <Res_KW2>somatic mutation</Res_KW2>
        <Res_KW3>focal epilepsy</Res_KW3>
        <Res_KW4>seizures</Res_KW4>
        <Res_KW5>cerebrospinal fluid</Res_KW5>
        <Plain_Description>Seizures can occur in patients with or without abnormalities in their brain. We have collected spinal fluid from a subset of these patients and we will use this precious resource to determine the contribution of genetic defects to the development of their seizures. The overall contribution of different types of genetic defects to seizures is not completely understood and this knowledge will improve outcomes for patients by ending their diagnostic odyssey and promoting new therapies. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012290</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Tracy Heng</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>The mesenchymal stromal cell paradox – living cell therapy or dying therapeutic cell?</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$957,031.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical biotechnology | regenerative medicine (incl. stem cells and tissue engineering) | </Field_s__of_Research>
        <Res_KW1>cell therapy </Res_KW1>
        <Res_KW2>cell death</Res_KW2>
        <Res_KW3>macrophages</Res_KW3>
        <Res_KW4>immunomodulation</Res_KW4>
        <Res_KW5>mechanism of action</Res_KW5>
        <Plain_Description>Mesenchymal stromal cells (MSCs) can dampen inflammation and aid tissue repair, but efforts to improve their clinical utility are hampered by our poor understanding of how they work. We have found that the therapeutic effects of MSCs depend on their cell death, which triggers immune suppression. Instead of focussing on viable MSCs, we will investigate how dying MSCs modify immune responses. Our discoveries will enable more effective cell therapies for a wide range of diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012301</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Sarah Lockie</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Targeting the brain and sympathetic nervous system to improve outcomes in cancer cachexia</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$878,451.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | peripheral nervous system | medical physiology | systems physiology | </Field_s__of_Research>
        <Res_KW1>cachexia </Res_KW1>
        <Res_KW2>sympathetic nervous system</Res_KW2>
        <Res_KW3>appetite regulation</Res_KW3>
        <Res_KW4>hypothalamus</Res_KW4>
        <Res_KW5>energy balance</Res_KW5>
        <Plain_Description>Cancer cachexia is the wasting of fat and muscle that occurs in late stages of a number of cancers. It is particularly prevalent in pancreatic cancer. One of the known causes for this wasting is increased activity of the sympathetic nervous system (SNS), also responsible for the 'fight or flight' response to danger. The SNS is under control of the brain, and this project will look at specific brain cells as therapeutic targets for treating cachexia in a mouse model of pancreatic cancer. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012313</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Kristin Brown</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Investigating the role of cellular metabolism in regulating antigen presentation and tumour immune escape</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$994,327.50</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | cell metabolism | </Field_s__of_Research>
        <Res_KW1>cell metabolism </Res_KW1>
        <Res_KW2>cancer cell biology</Res_KW2>
        <Res_KW3>antigen presentation</Res_KW3>
        <Res_KW4>immune evasion</Res_KW4>
        <Res_KW5>molecular mechanisms</Res_KW5>
        <Plain_Description>In order to develop and progress, tumours must avoid elimination by the immune system. Understanding the mechanisms that allow tumours to evade the immune system is critical for developing strategies to overcome immune escape and enhance the efficacy of currently existing immunotherapies. This research will investigate the fundamental mechanisms by which aberrant cell metabolism contributes to immune evasion in cancer and identify strategies to restore tumour elimination by the immune system.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012330</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Anatoly Rozenfeld</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Enabling next generation radiotherapy for cancer: Development of novel Quality Assurance instrumentation for Proton Therapy</Grant_Title>
        <Admin_Institution>University of Wollongong</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$758,040.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | radiation therapy | other physical sciences | medical physics | biomedical engineering | medical devices | </Field_s__of_Research>
        <Res_KW1>radiotherapy </Res_KW1>
        <Res_KW2>proton therapy</Res_KW2>
        <Res_KW3>instrumentation</Res_KW3>
        <Res_KW4>quality assurance</Res_KW4>
        <Res_KW5>medical physics</Res_KW5>
        <Plain_Description>Proton Therapy is a new form of radiotherapy that has many benefits over conventional radiotherapy and is particularly useful for childhood cancers.  To maximise the benefits of proton therapy, we need to develop instruments called microdosimeters to accurately measure the physical and biological dose of radiation received by the patient. Our research will develop and test a novel microdosimeter for proton therapy to coincide with the opening of the new Australian Bragg Centre for Proton Therapy</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012342</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Karla Hutt</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Does Chlamydia infection damage the ovary and compromise fertility?</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,057,446.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>paediatrics and reproductive medicine | reproduction | </Field_s__of_Research>
        <Res_KW1>ovary </Res_KW1>
        <Res_KW2>fertility</Res_KW2>
        <Res_KW3>bacterial infection</Res_KW3>
        <Res_KW4>oocyte</Res_KW4>
        <Res_KW5>inflammation</Res_KW5>
        <Plain_Description>The ability of Chlamydia to infect and damage the ovary has never been investigated. We will determine exactly how Chlamydia infects and damages ovarian tissues by studying aspects of ovarian function including hormone production, egg health, and fertility in our unique mouse model, and a cohort of human samples. We will also assess whether antibiotics, and our newly developed Chlamydia vaccine, can protect against ovary damage.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012351</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Yiping Wang</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Exploring the therapeutic potential of genetically engineering macrophages with a Chimeric Signaling Switch Receptor in kidney diseases</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$753,039.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | nephrology and urology | </Field_s__of_Research>
        <Res_KW1>kidney disease </Res_KW1>
        <Res_KW2>anti-inflammatory</Res_KW2>
        <Res_KW3>cell therapy</Res_KW3>
        <Res_KW4>immunology</Res_KW4>
        <Res_KW5>macrophage biology</Res_KW5>
        <Plain_Description>Kidney diseases are a major cause of death and morbidity worldwide. Current treatments to delay progression of kidney diseases are few and largely ineffective, so that new therapies are urgently needed. We have recently developed an innovative approach to genetically engineer immune cells (macrophages) to treat kidney diseases. This study will determine the effectiveness of this new cell therapy in kidney disease models and whether it can be used to treat human kidney diseases. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012362</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Peter Houweling</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>IS THE EVOLUTIONARY LOSS OF ACTN3 DETRIMENTAL IN MODERN SOCIETY?</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,215,355.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | cell metabolism | genetics | gene expression (incl. microarray and other genome-wide approaches) | genetics | population, ecological and evolutionary genetics | </Field_s__of_Research>
        <Res_KW1>muscle </Res_KW1>
        <Res_KW2>performance</Res_KW2>
        <Res_KW3>overweight/obesity</Res_KW3>
        <Res_KW4>genetic influences</Res_KW4>
        <Res_KW5>knockout mouse</Res_KW5>
        <Plain_Description>Do you feel the cold or are you happiest in the depths of winter? A common null polymorphism in the skeletal muscle gene ACTN3 (R577X) has been described as a key gene during modern evolution due to its ability to improve muscle function and metabolism following cold exposure. We will explore the impacts of this gene further in modern humans by studying muscles from healthy and obese ACTN3 R577X mice and humans to determine how our ACTN3 genotype influences life in todays modern society.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012370</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Nicholas Eyre</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Development and mechanistic analysis of novel inhibitors of the dengue virus NS1 protein</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$783,440.40</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical microbiology | medical virology | </Field_s__of_Research>
        <Res_KW1>dengue virus </Res_KW1>
        <Res_KW2>antiviral agents</Res_KW2>
        <Res_KW3>drug discovery</Res_KW3>
        <Res_KW4>viral replication</Res_KW4>
        <Res_KW5>proteomics</Res_KW5>
        <Plain_Description>Mosquito-borne flaviviruses such as dengue virus (DENV) cause significant morbidity and mortality in tropical and sub-tropical areas worldwide. The DENV NS1 protein is critical to multiple aspects of the viral life cycle and DENV pathogenesis, making it an appealing target of future antiviral therapies. In this project we will apply a rational multi-disciplinary approach to identify and mechanistically characterise unique NS1-targeting antiviral drugs and future NS1-related drug targets. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012371</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Jennifer Devlin</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Targeting dysregulated transcription in cancer through Cyclin-Dependent-Kinase 11</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$849,454.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | cancer cell biology | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>gene regulation </Res_KW1>
        <Res_KW2>cancer cell biology</Res_KW2>
        <Res_KW3>gene transcription</Res_KW3>
        <Res_KW4>anticancer drug action</Res_KW4>
        <Res_KW5>rna processing</Res_KW5>
        <Plain_Description>Many proteins cooperate to carefully control which genes are ‘on’ or ‘off’ in our cells. Defects in gene control that cause cells to grow faster and to live longer than normal give rise to cancer. I will investigate the activity of a group of proteins called Cyclin-dependent-kinases (CDKs), that are essential for ensuring proper gene control and are essential for cancer cells to survive. This will allow us to design better strategies to block the activity of CDKs to kill cancer cells.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012373</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Janni Petersen</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Determining the role of Target of Rapamycin Complex 2 (TORC2) in cancer cell proliferation</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$491,420.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | signal transduction | genetics | cell and nuclear division | </Field_s__of_Research>
        <Res_KW1>cell signalling </Res_KW1>
        <Res_KW2>cell biology</Res_KW2>
        <Res_KW3>cell growth</Res_KW3>
        <Res_KW4>cell division</Res_KW4>
        <Res_KW5>cancer cell biology</Res_KW5>
        <Plain_Description>In normal cells, proliferation depends on the availability of nutrients. Tumour cells are usually ‘nutritionally stressed’ but survive despite this. This project aims to study the cell’s nutrient sensor — TOR Complex 2 — in order to  elucidate how it facilitates cell division under nutrient stress. Better understanding of TORC2 signalling will improve future treatment strategies for patients with solid tumours.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012382</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Sarah Jones</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Achieving benefit without harm: a next-generation glucocorticoid replacement</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,076,432.80</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>immunology | autoimmunity | </Field_s__of_Research>
        <Res_KW1>glucocorticoids </Res_KW1>
        <Res_KW2>rheumatology</Res_KW2>
        <Res_KW3>chronic inflammation</Res_KW3>
        <Res_KW4>drug discovery</Res_KW4>
        <Res_KW5>systemic lupus erythematosus (sle)</Res_KW5>
        <Plain_Description>Over 2% of the world’s population takes long-term steroid therapy to control unwanted immune system activity, despite the predictable, harmful side effects of steroids. A natural anti-inflammatory protein, GILZ, is increased as a result of steroid treatment, which is an important way that steroids work. Our studies will lead to a strategy to develop a drug that increases GILZ without the use of steroids, bringing about the protective effects of steroids without the harmful side effects.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012393</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Damien Keating</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>The contribution of the gut to bipolar disorder</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$844,809.80</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | psychiatry (incl. psychotherapy) | </Field_s__of_Research>
        <Res_KW1>bipolar disorder </Res_KW1>
        <Res_KW2>serotonin</Res_KW2>
        <Res_KW3>gut peptides</Res_KW3>
        <Res_KW4>visceral afferents</Res_KW4>
        <Res_KW5>mental health</Res_KW5>
        <Plain_Description>Bipolar disorder is a severe mental illness affecting many Australians. We provide evidence that specific gut cells may trigger the mood fluctuations that are central in bipolar disorders. Activation of these cells can alter brain activity via a pathway called the gut brain axis. This project will focus on understanding how serotonin release from these cells affects brain function in bipolar disorder and how we can target these cells to create new treatments for this disease. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012404</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Nigel Beebe</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Removing mosquito populations by releasing incompatible males: a species specific biocontrol for urban arbovirus vectors</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,047,634.80</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | public health and health services not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>arbovirus diseases </Res_KW1>
        <Res_KW2>mosquito-borne disease</Res_KW2>
        <Res_KW3>vector control</Res_KW3>
        <Res_KW4>vector-borne disease</Res_KW4>
        <Res_KW5>arbovirus</Res_KW5>
        <Plain_Description>Two mosquitoes, Aedes aegypti and Aedes albopictus, drive the global expansion of arboviruses such as dengue and Zika; both threaten Australia. With no effective vaccines and extensive insecticide resistance, new mosquito control tools are vital. By releasing reproductively incompatible males (males don’t bite), we have successfully reduced aegypti populations in some Queensland towns by over 80% . We will now develop this technology into an efficient deployable product for Australia and beyond.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012418</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Anne Grunseit</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Applying reverse translation to the parkrun phenomenon to identify effective, sustainable methods for scaling-up public health interventions</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$569,798.90</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | health promotion | </Field_s__of_Research>
        <Res_KW1>physical activity </Res_KW1>
        <Res_KW2>dissemination</Res_KW2>
        <Res_KW3>preventive</Res_KW3>
        <Res_KW4>social networks</Res_KW4>
        <Res_KW5>social epidemiology</Res_KW5>
        <Plain_Description>parkrun is a free, weekly organised grass-roots mass physical activity event, which has spread across 23 countries with over six million registrants. It has succeeded where most researcher and government-led physical activity interventions have failed in terms of high participation, accessibility and sustainability. Our proposal analyses how parkrun has disseminated and been sustained throughout Australia and will derive models and principles to inform future public health interventions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012427</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Bobbi Fleiss</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Studying the persisting glial dysfunction occurring after preterm brain injury to uncover new therapeutic targets</Grant_Title>
        <Admin_Institution>RMIT University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$845,926.42</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>paediatrics and reproductive medicine | paediatrics and reproductive medicine not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>neuroinflammation </Res_KW1>
        <Res_KW2>very preterm birth</Res_KW2>
        <Res_KW3>microglia</Res_KW3>
        <Res_KW4>glucocorticoids</Res_KW4>
        <Res_KW5>novel therapies</Res_KW5>
        <Plain_Description>We cannot treat brain damage in prematurely born babies despite it often leading to permanent brain injury and disability. Cells called glia are vital for building the brain and keeping it healthy. After early-life brain injury, we are learning that glia cannot perform these tasks as they should for many months. In this project, we will test if helping glia 'get back to work’ in the weeks or months after injury might be a way to repair the damaging effects of preterm birth.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012443</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Stuart Hooper</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Improving respiratory support for preterm infants at birth</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,098,188.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>paediatrics and reproductive medicine | foetal development and medicine | </Field_s__of_Research>
        <Res_KW1>very preterm birth </Res_KW1>
        <Res_KW2>neonatal respiratory distress syndrome</Res_KW2>
        <Res_KW3>birth</Res_KW3>
        <Res_KW4>fetal physiology</Res_KW4>
        <Res_KW5>respiratory physiology</Res_KW5>
        <Plain_Description>In Australia, 92% of babies born very preterm need help to breathe at birth, which can injure their lungs and brains. While providing respiratory support with a face mask is the gentlest approach, it often fails because the baby’s vocal cords reflexly close if they stop breathing, which prevents air from entering their lungs. Our research focuses on helping these babies breathe at birth to improve the success of providing gentle respiratory support.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012453</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Tatiana Soboleva</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Communication via epigenetic mechanisms: cell cross-talk and male fertility</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$962,786.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | cell development, proliferation and death | genetics | gene expression (incl. microarray and other genome-wide approaches) | biochemistry and cell biology | biochemistry and cell biology not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>spermatogenesis </Res_KW1>
        <Res_KW2>cell-cell communication</Res_KW2>
        <Res_KW3>control of gene expression</Res_KW3>
        <Res_KW4>epigenetics</Res_KW4>
        <Res_KW5>sertoli cell</Res_KW5>
        <Plain_Description>Male infertility is on the rise in Western society but the processes that drive sperm production are still poorly understood. We discovered a new epigenetics-based process that involves the transfer of important information between different cell types in the testis that is critical for the production of viable sperm. We aim to uncover the molecular mechanism of this process, which will provide new insights into the causes of male infertility.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012454</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Paul Beavis</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Engineering chimeric antigen receptor (CAR) T cells that induce host anti-tumour immunity</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$984,101.60</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | </Field_s__of_Research>
        <Res_KW1>t cell immunotherapy </Res_KW1>
        <Res_KW2>t cell immunity</Res_KW2>
        <Res_KW3>cd8 t lymphocytes</Res_KW3>
        <Res_KW4>cancer immunotherapy</Res_KW4>
        <Res_KW5>cancer immunology</Res_KW5>
        <Plain_Description>This project will further enhance the therapeutic application of a gene-engineering based immune therapy involving a patients' own cells. To date this form of therapy has been effective in blood cancers but not solid tumours. We will aim to overcome this by developing technological and scientific advances which will make the immune cells more effective against solid tumours. These findings have the potential to provide treatment options for late stage solid tumour cancer patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012463</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Brad Gilbertson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Investigation of the structure of the influenza A virus genome and how it directs reassortment to generate novel strains</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$745,583.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | infectious diseases | </Field_s__of_Research>
        <Res_KW1>influenza </Res_KW1>
        <Res_KW2>influenza virus</Res_KW2>
        <Res_KW3>viral replication</Res_KW3>
        <Res_KW4>viral proteins</Res_KW4>
        <Res_KW5>viral infection</Res_KW5>
        <Plain_Description>Pandemic influenza viruses acquire new properties through the swapping of gene segments known as reassortment. We will investigate the structure of the influenza A virus genome to dissect the molecular mechanism that enables specific genes to interact and be co-selected during reassortment. Our work will provide key insights into the probability of viruses with particular gene constellations emerging in the future, that will greatly benefit pandemic assessment and planning.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012471</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Anna Hearps</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Eliminating HIV-infected macrophages; a neglected problem in HIV cure research</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$708,501.10</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical microbiology | medical virology | </Field_s__of_Research>
        <Res_KW1>human immunodeficiency virus (hiv) </Res_KW1>
        <Res_KW2>macrophages</Res_KW2>
        <Res_KW3>latency</Res_KW3>
        <Res_KW4>cytotoxicity</Res_KW4>
        <Res_KW5>envelope protein</Res_KW5>
        <Plain_Description>HIV cannot currently be cured due to the persistence of ‘silent’ sources of HIV hidden within certain cells which are not sensitive to anti-HIV drugs. One type of immune cell that HIV hides in are called macrophages, and these cells are very hard for the immune system to destroy.  We will study HIV infection in macrophages and identify ways to ‘wake up’ silent HIV in these cells and weaken them so that they can be eliminated from the body.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012474</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Susann Beier</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Opening the pathway to large data-driven patient-specific diagnostics using novel coronary angiogram analysis</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$459,117.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biomedical engineering | biomechanical engineering | </Field_s__of_Research>
        <Res_KW1>haemodynamics </Res_KW1>
        <Res_KW2>biomedical engineering</Res_KW2>
        <Res_KW3>medical imaging</Res_KW3>
        <Res_KW4>modelling</Res_KW4>
        <Res_KW5>blood flow</Res_KW5>
        <Plain_Description>This work will reform the medical practice of risk assessment for coronary artery disease and acute coronary artery syndrome by delivering the next generation of rapid, patient-specific, and high accuracy medical image-based risk assessment. Using innovative state-of-the-art engineering methods, including machine learning, large-scale computational modelling and image analysis, we will  reveal new markers of cardiovascular risk in individuals for improved standard clinical care.   </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012475</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Paul Beavis</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>CRISPR Engineering of CAR T Cells to Enhance Efficacy in Solid Tumours</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$897,551.80</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>immunology | tumour immunology | </Field_s__of_Research>
        <Res_KW1>immunology </Res_KW1>
        <Res_KW2>t cell immunotherapy</Res_KW2>
        <Res_KW3>cellular immunology</Res_KW3>
        <Res_KW4>gene regulation</Res_KW4>
        <Res_KW5>cd8 t lymphocytes</Res_KW5>
        <Plain_Description>This project will further enhance the therapeutic application of a gene-engineering based immune therapy involving a patients' own cells. To date this form of therapy has been effective in blood cancers but not solid tumours. We will aim to overcome this by developing technological and scientific advances which will make the immune cells more effective against solid tumours. These findings have the potential to provide treatment options for late stage solid tumour cancer patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012498</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Anselm Enders</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Pursuing IRF4 as a therapeutic opportunity for lymphoid malignancies </Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$1,434,231.80</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>immunology | cellular immunology | </Field_s__of_Research>
        <Res_KW1>b cells </Res_KW1>
        <Res_KW2>lymphocyte differentiation</Res_KW2>
        <Res_KW3>transcription factor</Res_KW3>
        <Res_KW4>chronic lymphocytic leukaemia (cll)</Res_KW4>
        <Res_KW5>structural immunology</Res_KW5>
        <Plain_Description>The molecule IRF4 is essential to the function of the immune system. In this application we investigate mouse models with mutations in IRF4 that are identical to those found in patients with cancers of the immune system. We will investigate how these mutations affect binding of IRF4 to the DNA and how changes in the IRF4-DNA binding domain lead to formation of tumours and how this interaction can be targeted therapeutically.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012500</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Leon Hugo</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Mosquito-specific viruses: novel agents to control the transmission of arboviral pathogens</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$807,376.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical microbiology | medical virology | </Field_s__of_Research>
        <Res_KW1>arbovirus </Res_KW1>
        <Res_KW2>mosquito transmission</Res_KW2>
        <Res_KW3>mosquito-borne disease</Res_KW3>
        <Res_KW4>flavivirus</Res_KW4>
        <Res_KW5>ross river virus</Res_KW5>
        <Plain_Description>Insect-specific viruses are benign viruses that infect only insects and are transmitted from the insect to their offspring. We and others have shown that infection of mosquitoes with these benign viruses can inhibit infection of these mosquitoes by other viruses that cause human disease. In this grant, we plan to produce one or more strains of mosquitoes harboring these benign viruses for use in biological control programs against mosquito-borne diseases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012505</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Luke Grzeskowiak</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Using population-based data to improve maternal asthma management and offspring health and development</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$979,886.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | epidemiology | paediatrics and reproductive medicine | obstetrics and gynaecology | paediatrics and reproductive medicine | paediatrics | </Field_s__of_Research>
        <Res_KW1>asthma </Res_KW1>
        <Res_KW2>pregnancy</Res_KW2>
        <Res_KW3>pharmacoepidemiology</Res_KW3>
        <Res_KW4>child development</Res_KW4>
        <Res_KW5>data linkage</Res_KW5>
        <Plain_Description>Asthma affects more than 30,000 Australian pregnancies each year and has been associated with a range of adverse pregnancy outcomes. This project will utilise population-based data to examine the effects of maternal asthma, as well as the use of individual asthma treatments during pregnancy, on child health and development from birth to 14-years of age and will provide direct evidence to support improvements in policy and practice related to optimising asthma management during pregnancy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012513</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Reginald Lord</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Improving the Diagnosis of Barrett’s Oesophagus with Dysplasia</Grant_Title>
        <Admin_Institution>University of Notre Dame Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,001,895.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | gastroenterology and hepatology | </Field_s__of_Research>
        <Res_KW1>barrett's oesophagus </Res_KW1>
        <Res_KW2>histopathology</Res_KW2>
        <Res_KW3>lower oesophageal adenocarcinoma</Res_KW3>
        <Res_KW4>endoscopy</Res_KW4>
        <Res_KW5>biomarkers</Res_KW5>
        <Plain_Description>Some patients with Barrett’s oesophagus are at greatly increased risk of developing oesophageal adenocarcinoma, the most common form of oesophageal cancer in Australia. Unfortunately, the current examination method is unreliable for diagnosing these patients prior to cancer, or for accurately predicting cancer risk. We will investigate a molecular test and the potential to develop an antibody test to improve diagnosis and prediction of cancer risk, and possibly reduce healthcare costs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012523</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Guiying Nie</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>A new way to see endometriosis</Grant_Title>
        <Admin_Institution>RMIT University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,197,867.40</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>paediatrics and reproductive medicine | obstetrics and gynaecology | </Field_s__of_Research>
        <Res_KW1>endometriosis </Res_KW1>
        <Res_KW2>uterus</Res_KW2>
        <Res_KW3>menstruation</Res_KW3>
        <Res_KW4>embryo implantation</Res_KW4>
        <Res_KW5>endometrium</Res_KW5>
        <Plain_Description>Endometriosis, a chronic and painful condition, affects ~10% women of reproductive age, and is characterized by growth of uterine-like cells outside the uterus such as the pelvis. However, why cells of the uterus end up in other parts of the body, and how they cause pain and other symptoms, are not well understood. This project will address these questions by studying the fundamental biology and function of uterine cells and exploring new diagnostic and therapeutic options for endometriosis. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012530</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Briony Forbes</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Harnessing a novel insulin receptor binding mechanism to therapeutic benefit</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$727,642.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | receptors and membrane biology | </Field_s__of_Research>
        <Res_KW1>insulin </Res_KW1>
        <Res_KW2>insulin receptor</Res_KW2>
        <Res_KW3>insulin signalling</Res_KW3>
        <Res_KW4>peptides</Res_KW4>
        <Res_KW5>structure-function</Res_KW5>
        <Plain_Description>We aim to develop new insulin molecules that provide better blood glucose control to Type 1 and late stage Type 2 diabetic patients. A fascinating discovery from investigations of marine cone snail venom has provided the basis to develop a new class of diabetes therapeutics built on a cone snail derived "mini" insulin scaffold. This proposal outlines the steps required to translate our findings into the development of ultra fast acting insulin analogues for diabetes treatment.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012535</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Andrew Elefanty</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>iHSCs, repopulating haematopoietic stem cells derived from human pluripotent stem cells</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,375,597.60</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical biotechnology | regenerative medicine (incl. stem cells and tissue engineering) | </Field_s__of_Research>
        <Res_KW1>haematopoietic stem cells </Res_KW1>
        <Res_KW2>stem cell biology</Res_KW2>
        <Res_KW3>embryonic stem cells</Res_KW3>
        <Res_KW4>developmental biology</Res_KW4>
        <Res_KW5>cell differentiation</Res_KW5>
        <Plain_Description>The ability to make blood stem cells from human pluripotent stem cells would be beneficial for patients with leukaemia or bone marrow failure who cannot find a matched donor. We will compare the blood stem cells that we can now make in the laboratory with stem cells present in umbilical cord blood and we will use these comparisons to inform improvements in our methods. Success in this project will accelerate the translation of these human stem cell derived blood therapies to the clinic.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012552</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Kate Denton</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Sex-differences in cellular aging and cardiovascular disease: Role of the AngIV/IRAP axis</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,189,392.20</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>cardiorespiratory medicine and heamatology | cardiology (incl. cardiovascular diseases) | </Field_s__of_Research>
        <Res_KW1>hypertension </Res_KW1>
        <Res_KW2>senescence</Res_KW2>
        <Res_KW3>end organ damage</Res_KW3>
        <Res_KW4>pregnancy</Res_KW4>
        <Res_KW5>kidney disease</Res_KW5>
        <Plain_Description>High blood pressure and ageing increase the risk of heart disease. Young women are protected from heart disease, but lose this protection with age. Senolytics are a new class of drug that remove damaged (senescent) cells from the body.  Senescent cells lose the ability to self-repair and trigger a cascade of reactions to promote disease. We will determine if a novel enzyme insulin-regulated aminopeptidase (IRAP) causes cell damage and disease, and test the efficacy of IRAP inhibitors. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012560</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Chamindie Punyadeera</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Multi-analyte liquid biopsy-based biomarkers for oropharyngeal cancer</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$763,417.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>medical biotechnology | medical biotechnology diagnostics (incl. biosensors) | </Field_s__of_Research>
        <Res_KW1>saliva </Res_KW1>
        <Res_KW2>biomarkers</Res_KW2>
        <Res_KW3>biosensor</Res_KW3>
        <Res_KW4>biomedical engineering</Res_KW4>
        <Res_KW5>cancer prognosis</Res_KW5>
        <Plain_Description>Throat cancer affects individuals at a relatively young age, who often go on to suffer from long-term treatment related morbidities. In addition, 20% of throat cancers reoccur. There is a desire to reduce the intensity of treatment to lessen severe side effects as well as to monitor response to treatment . We propose to use non-invasive, novel biomarkers to address these unmet clinical needs, thereby improving quality of life for cancer patients and significantly cutting healthcare costs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012567</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Orazio Vittorio </CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Pioneering novel therapeutic strategies to enhance an anti-tumour immune response in Neuroblastoma</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$721,983.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | oncology and carcinogenesis | solid tumours | </Field_s__of_Research>
        <Res_KW1>neuroblastoma </Res_KW1>
        <Res_KW2>antibody cancer therapy</Res_KW2>
        <Res_KW3>paediatric</Res_KW3>
        <Res_KW4>adaptive immunity</Res_KW4>
        <Res_KW5>metals</Res_KW5>
        <Plain_Description>Neuroblastoma has one of the lowest survival rates of all childhood cancers. Immunotherapy stimulates an immune response against cancer cells yet still works poorly in neuroblastoma. This suggests that understanding how neuroblastoma evade immune system is critical to improving such therapies. Our research has found that copper plays a key role in tumours to evade the immune response. We are currently developing new strategies to reduce copper and activate the anti-tumour immune responses.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012569</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Leonie Heilbronn</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Only a matter of time? A comparison of caloric restriction versus time restriction of food intake.</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,189,927.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>nutrition and dietics | nutritional physiology | </Field_s__of_Research>
        <Res_KW1>circadian rhythms </Res_KW1>
        <Res_KW2>obesity</Res_KW2>
        <Res_KW3>feeding and nutrition</Res_KW3>
        <Res_KW4>type 2 diabetes mellitus (non-insulin dependent diabetes mellitus)</Res_KW4>
        <Res_KW5>healthy ageing</Res_KW5>
        <Plain_Description>The proposed study will compare the health benefits of limiting “when” vs “how much” is eaten on health in individuals at high risk of developing type 2 diabetes. The concept that marked improvements in health can be achieved by aligning food intake with circadian rhythms, without weight loss, is game changing. But we do not yet clearly understand how one performs against the other, or if both are required, in humans, since no trials have been performed. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012579</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Martin Stone</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Defining Chemotactic Signalling Networks to Identify New Anti-inflammatory Targets</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,152,153.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | signal transduction | </Field_s__of_Research>
        <Res_KW1>chemokine receptor </Res_KW1>
        <Res_KW2>chemokines</Res_KW2>
        <Res_KW3>signal transduction</Res_KW3>
        <Res_KW4>proteomics</Res_KW4>
        <Res_KW5>functional genomics</Res_KW5>
        <Plain_Description>A key feature of inflammatory diseases is infiltration of the affected tissues by white blood cells. White blood cell migration is controlled by “chemokine” proteins that are produced in the tissues and activate receptor proteins on the blood cells. This project will characterise the molecular events leading from receptor activation to white blood cell migration. The results will guide development of medicines to control inflammatory diseases, including atherosclerosis and rheumatoid arthritis.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012582</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Zanfina Ademi</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>A novel approach integrating genomics into the health economic modelling of therapeutics </Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$491,777.50</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | epidemiology | public health and health services | preventive medicine | </Field_s__of_Research>
        <Res_KW1>cost-effectiveness </Res_KW1>
        <Res_KW2>cardiovascular disease prevention</Res_KW2>
        <Res_KW3>modelling</Res_KW3>
        <Res_KW4>early prevention</Res_KW4>
        <Res_KW5>therapeutics</Res_KW5>
        <Plain_Description>Despite the increasing uptake of health economic models in practice, greater understanding of the impact of lifetime disease risk in costs and outcomes is fundamental for cardiovascular disease. This research project will utilise an innovative approach in health economic modelling that will provide evidence for the first time on the cost-effectiveness of new interventions. This in return will inform government policies, lead to efficient access to preventive therapeutics.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012583</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Jonathan Paul</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Targeted Delivery of Nucleic Acid Therapeutics for Preventing Preterm Birth</Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$732,334.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>paediatrics and reproductive medicine | obstetrics and gynaecology | </Field_s__of_Research>
        <Res_KW1>pregnancy </Res_KW1>
        <Res_KW2>premature birth</Res_KW2>
        <Res_KW3>myometrium</Res_KW3>
        <Res_KW4>nanotechnology</Res_KW4>
        <Res_KW5>experimental therapeutics</Res_KW5>
        <Plain_Description>Thousands of babies could be saved each year with a timely intervention for preterm birth. Current approaches are hampered by a lack of drug specificity. To address this, we first developed uterine-targeted nanocarriers for targeting interventions to the pregnant uterus. We now seek to leverage this platform for the targeted delivery of nucleic acid therapeutics. This bold strategy aims to modulate cellular phenotype in order to block the premature uterine contractions that cause preterm birth.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012600</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Kirsten Coupland</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>New pathways to improved stroke outcome: the importance of managing intracranial pressure.</Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$497,265.58</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>cardiorespiratory medicine and heamatology | cardiology (incl. cardiovascular diseases) | medical physiology | medical physiology not elsewhere classified | medical biochemistry and metabolomics | medical biochemistry and metabolomics not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>ischaemic stroke </Res_KW1>
        <Res_KW2>intracranial pressure</Res_KW2>
        <Res_KW3>cerebrospinal fluid</Res_KW3>
        <Res_KW4>molecular mechanisms</Res_KW4>
        <Res_KW5>cardiovascular physiology</Res_KW5>
        <Plain_Description>Stroke is caused by a loss of blood supply that results in brain tissue death leading to disability. Delayed expansion of stroke injury can occur in the 24-48 hours after stroke. What causes this was previously unknown. We found that an increase in cerebrospinal fluid pressure that affects blood flow to the injury site is likely to blame. We have evidence that a change in the composition of cerebrospinal fluid drives this increase in pressure and we aim to design therapies to prevent it. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012601</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Andrew Zannettino</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Leveraging innovative multi-omic approaches to understand and predict myeloma disease development</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$943,074.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | haematological tumours | </Field_s__of_Research>
        <Res_KW1>multiple myeloma </Res_KW1>
        <Res_KW2>proteomics</Res_KW2>
        <Res_KW3>biomarkers</Res_KW3>
        <Res_KW4>microenvironment</Res_KW4>
        <Res_KW5>cancer biology</Res_KW5>
        <Plain_Description>Multiple myeloma is a fatal bone marrow cancer which is universally preceded by a pre-cancerous stage known as MGUS. We currently have no way of identifying which MGUS patients will develop myeloma and no treatments to prevent this process. This study will develop clinical tools to identify which MGUS patients are at high risk of developing myeloma, and will identify new therapeutic targets, to revolutionise how we treat MGUS and myeloma and improve outcomes for these patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012620</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Richard Ferrero</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Defining a protective role for NLRC5 signalling in Helicobacter pylori disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,172,064.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical microbiology | medical microbiology not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>helicobacter pylori </Res_KW1>
        <Res_KW2>pathogenesis</Res_KW2>
        <Res_KW3>host/pathogen interaction</Res_KW3>
        <Res_KW4>chronic infection</Res_KW4>
        <Res_KW5>mucosal inflammation</Res_KW5>
        <Plain_Description>Helicobacter pylori infects the stomach of half the world’s population and is a major cause of human disease. The body fights H. pylori infection by mobilising white blood cells to the stomach lining, but these responses can lead to lymphoma. We have identified a host protein, NLRC5, as being important in the generation of immune responses that protect against the development of this disease. The project will determine how NLRC5 protects against stomach lymphoma due to H. pylori infection.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012622</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Tri Phan</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Location! Location! Location! Geospatial control of memory B cell reactivation in vaccine-induced immunity</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$684,360.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>immunology | humoural immunology and immunochemistry | </Field_s__of_Research>
        <Res_KW1>immunologic memory </Res_KW1>
        <Res_KW2>vaccine</Res_KW2>
        <Res_KW3>b cells</Res_KW3>
        <Res_KW4>germinal centre</Res_KW4>
        <Res_KW5>humoral immunity</Res_KW5>
        <Plain_Description>Vaccines are one of the great public health achievements in the modern era. However, vaccinology remains an empirical art and there is an urgent need to advance the science to realize its full potential, particularly in the face of pandemics such as COVID-19 and the emergence of virus variants that require booster injections. Here we propose to track the cell fate trajectories of memory B cells to determine the factors that are critical to generating a potent immune response to vaccination.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012657</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Sebastian Furness</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>A new frontier in receptor biology relevant to treatment of disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$699,712.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | receptors and membrane biology | pharmacology and pharmaceutical sciences | basic pharmacology | neurosciences | autonomic nervous system | </Field_s__of_Research>
        <Res_KW1>g protein-coupled receptors </Res_KW1>
        <Res_KW2>molecular pharmacology</Res_KW2>
        <Res_KW3>cell biology</Res_KW3>
        <Res_KW4>gastrointestinal motility</Res_KW4>
        <Res_KW5>autonomic nervous system</Res_KW5>
        <Plain_Description>Disorders of colorectal function, especially constipation, are poorly responsive to drug therapy and are a substantial medical problem. This project should provide insights into the molecular basis for the voluntary defecation response that could provide the basis for novel therapeutic approaches to treat disorders of colorectal function. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012661</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Richard Clark</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Making peptide drugs orally bioavailable</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$689,721.20</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medicinal and biomolecular chemistry | proteins and peptides | medicinal and biomolecular chemistry | biologically active molecules | </Field_s__of_Research>
        <Res_KW1>peptides </Res_KW1>
        <Res_KW2>drug design</Res_KW2>
        <Res_KW3>drug delivery</Res_KW3>
        <Res_KW4>oral administration</Res_KW4>
        <Res_KW5>drug absorption</Res_KW5>
        <Plain_Description>Bioactive peptides have exciting therapeutic potential however they are limited by the fact that that they generally can't be taken orally and they don't last very long in the body. The goal of this project is to develop an approach that solves both of these problems and to develop new drug leads for the treatment of chronic pain.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012674</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Wayne Phillips</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Submucosal glands as the origin of Barrett’s oesophagus and oesophageal adenocarcinoma</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,115,454.40</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | cancer cell biology | </Field_s__of_Research>
        <Res_KW1>barrett's oesophagus </Res_KW1>
        <Res_KW2>progenitor cells</Res_KW2>
        <Res_KW3>epithelial biology</Res_KW3>
        <Res_KW4>oesophageal cancer</Res_KW4>
        <Res_KW5>gastrointestinal tumourigenesis</Res_KW5>
        <Plain_Description>Barrett’s oesophagus is a relatively common benign condition that arises as a consequence of acid reflux. In some patients, Barrett’s progresses to oesophageal cancer, for which treatments are largely ineffective and thus outcomes are poor. This project addresses a vital gap in our knowledge regarding the cell of origin of Barrett’s oesophagus, which will enable the future development of effective strategies for early intervention or prevention of oesophageal cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012689</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Erin Symonds</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Do patients with symptoms need a colonoscopy? A novel panel of non-invasive biomarkers to determine need for diagnostic investigation.</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$881,020.40</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | gastroenterology and hepatology | </Field_s__of_Research>
        <Res_KW1>colorectal cancer risk </Res_KW1>
        <Res_KW2>colorectal cancer prevention</Res_KW2>
        <Res_KW3>colonoscopy</Res_KW3>
        <Res_KW4>biomarkers</Res_KW4>
        <Res_KW5>gastrointestinal symptoms</Res_KW5>
        <Plain_Description>Gastrointestinal symptoms can raise concern for bowel cancer, but as they are often non-specific, it is difficult to determine what type of further clinical investigations are needed. There is a need for simple tests to determine the need for colonoscopy. Our study will establish the use of blood and stool tests for identifying disease risk. This will ensure that all symptomatic patients are reviewed for bowel cancer risk with tests that are independent of their symptoms.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012701</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof William Heath</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>The role of resident and circulating CD8 T cell memory in the control of liver infections</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$920,958.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>immunology | cellular immunology | </Field_s__of_Research>
        <Res_KW1>t cells </Res_KW1>
        <Res_KW2>hepatocytes</Res_KW2>
        <Res_KW3>infectious diseases</Res_KW3>
        <Res_KW4>cytotoxic t lymphocytes (ctl)</Res_KW4>
        <Res_KW5>memory t-cells</Res_KW5>
        <Plain_Description>CD8+ tissue-resident memory T (Trm) cells are a specialized population of immune cells that act as front-line defenders against pathogens in organs such as the liver. In this study we will investigate how these and other T cells recognise and destroy pathogens like malaria that infect liver cells, without damaging the remaining liver tissue, with the aim of designing better vaccines against liver infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012704</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Corneel Vandelanotte</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Applying machine learning to develop a smart and engaging chatbot to increase physical activity and improve health</Grant_Title>
        <Admin_Institution>Central Queensland University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,497,468.80</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | health promotion | </Field_s__of_Research>
        <Res_KW1>physical activity </Res_KW1>
        <Res_KW2>health promotion</Res_KW2>
        <Res_KW3>behavioural intervention</Res_KW3>
        <Res_KW4>internet</Res_KW4>
        <Res_KW5>behaviour change</Res_KW5>
        <Plain_Description>As high levels of physical inactivity lead to a high disease burden in Australia, cost-effective population-based strategies are needed to increase activity levels. The main aim of this project is to develop a very sophisticated chatbot that applies artificial intelligence and machine learning to provide highly personalised physical activity advice, delivered just-in-time, based on real-time data (e.g., Fitbit, GPS, weather). Our project will enable 'precision medicine' for behavioural health.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012718</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Suzi Edwards</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Effectiveness of empirically based tackle technique intervention to reduce the in-game risk of concussion</Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,026,166.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>human movement and sports science | biomechanics | human movement and sports science | sports medicine | neurosciences | neurosciences not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>concussion </Res_KW1>
        <Res_KW2>sports injury</Res_KW2>
        <Res_KW3>indigenous australians</Res_KW3>
        <Res_KW4>biomechanics</Res_KW4>
        <Res_KW5>neurophysiology</Res_KW5>
        <Plain_Description>Concussion in collision sports, is a prominent community health concern, occurring mostly during tackles. To make the sport safer for all players, our research will reveal how a rugby players’ tackles alters their head forces and how retraining their tackle technique can reduce their concussion risk. Our tackle coaching program will have an Indigenous focus as many players identify as Indigenous/Pasifika. We will use this information to develop new coaching guidelines to make the sport safer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012764</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Lee Wong</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Chromatin defects in histone mutated brain cancers: from basic mechanisms to novel therapeutic strategies</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$853,016.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>genetics | cell and nuclear division | </Field_s__of_Research>
        <Res_KW1>chromatin </Res_KW1>
        <Res_KW2>chromatin structure</Res_KW2>
        <Res_KW3>telomeres</Res_KW3>
        <Res_KW4>chromosomal anomalies</Res_KW4>
        <Res_KW5>atrx syndrome - alpha thalassemia-mental retardation of the x</Res_KW5>
        <Plain_Description>Paediatric glioblastoma (pGBM) is the most aggressive kind of brain cancer affecting children. To develop treatments for this disease, the underlying molecular mechanisms leading to disease formation must first be understood. This study will investigate how mutations in two key regulators of the genome change DNA integrity and gene activity, leading to the development of pGBM. It will thereby identify new targets for therapeutic intervention strategies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012769</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Nicole Messina</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Harnessing the beneficial off-target effects of BCG vaccination to boost protection against SARS-CoV-2 </Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,085,524.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | infectious diseases | cardiorespiratory medicine and heamatology | respiratory diseases | immunology | immunology not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>vaccination </Res_KW1>
        <Res_KW2>vaccination immunology</Res_KW2>
        <Res_KW3>sars-cov-2</Res_KW3>
        <Res_KW4>immunomodulation</Res_KW4>
        <Res_KW5>antiviral immunity</Res_KW5>
        <Plain_Description>Bacillus Calmette–Guérin(BCG), the vaccine that protects against tuberculosis, also protects against other diseases. This is thought to be because BCG can boost immunity. We will investigate how BCG boosts immune responses to SARS-CoV-2 and if this improves protection against COVID-19 and the effectiveness of COVID-19 vaccines. We will combine use of mouse models with use of samples from BRACE, our 6800 participant trial testing if BCG vaccination protects against COVID-19 in healthcare workers.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012772</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Denuja Karunakaran</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Inflammatory Cell Death, Circadian Rhythm &amp; Obesity: A Surprising Triad</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,274,091.08</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | cell metabolism | biochemistry and cell biology | signal transduction | biochemistry and cell biology | cell development, proliferation and death | </Field_s__of_Research>
        <Res_KW1>overweight/obesity </Res_KW1>
        <Res_KW2>metabolic disorders</Res_KW2>
        <Res_KW3>adipose tissue</Res_KW3>
        <Res_KW4>macrophages</Res_KW4>
        <Res_KW5>circadian rhythms</Res_KW5>
        <Plain_Description>Obesity rates continue to soar despite decades of efforts to promote lifestyle changes. Our work points to an important role for the RIPK1 gene in obesity through adipose tissue inflammation and circadian clock disruption. Using unique mouse models, nanoparticle therapies and novel technologies to map genetic reprogramming, we will explore how RIPK1 pathways drive these processes in obesity and provide proof-of-concept for novel anti-obesity therapies. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012793</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Katharine Irvine</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Macrophage-driven lipid metabolism in health and disease – mechanisms and therapeutic opportunities</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$656,972.40</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>immunology | innate immunity | </Field_s__of_Research>
        <Res_KW1>macrophage biology </Res_KW1>
        <Res_KW2>energy metabolism</Res_KW2>
        <Res_KW3>fatty liver disease</Res_KW3>
        <Res_KW4>adipose tissue</Res_KW4>
        <Res_KW5>muscle</Res_KW5>
        <Plain_Description>Macrophages are cells of the immune system that are abundant in every organ. We discovered that treating animals with a macrophage growth factor, Colony Stimulating Factor 1 (CSF1), reduces body fat mass and increases lean mass. This indicates that macrophages responding to CSF1 influence the cross-talk between metabolic tissues that controls energy metabolism and body composition. In this project we will investigate how this occurs and test CSF1 as a therapy for obesity-related complications.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012805</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof John Bekkers</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Novel roles for NMDA receptors in cortical processing</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$552,737.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | cellular nervous system | </Field_s__of_Research>
        <Res_KW1>cerebral cortex </Res_KW1>
        <Res_KW2>n-methyl-d-aspartic acid (nmda) receptors</Res_KW2>
        <Res_KW3>olfaction</Res_KW3>
        <Res_KW4>patch clamp</Res_KW4>
        <Res_KW5>calcium imaging</Res_KW5>
        <Plain_Description>Major psychiatric disorders, like schizophrenia and depression, are thought to arise from subtle changes in brain circuits.  A key player in these changes is a protein called the NMDA receptor, which is important for electrical signalling in the brain.  This project will study how NMDA receptors normally work in mouse brains to enable the animal to make sense of its environment.  The findings will help guide the development of new NMDA receptor-targeting drugs with fewer side-effects.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012809</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Alexander Khromykh</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>How the synergy between flavivirus protein and noncoding RNA defeats antiviral response</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$783,516.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical microbiology | medical virology | </Field_s__of_Research>
        <Res_KW1>flavivirus </Res_KW1>
        <Res_KW2>rna</Res_KW2>
        <Res_KW3>jak/stat pathway</Res_KW3>
        <Res_KW4>host/pathogen interaction</Res_KW4>
        <Res_KW5>molecular virology</Res_KW5>
        <Plain_Description>Flaviviruses represent a persistent threat with a devastating impact on human health. They have sophisticated mechanisms to subvert and control human antiviral response. One of them is by producing a noncoding RNA. In this project we will obtain an understanding of how these RNAs determine the ability of flaviviruses to evade immune response and establish infection in humans. The outcome will advance our understanding of flavivirus pathogenesis and inform future design of novel antivirals.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012828</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Bei Bei</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Circadian clock, sleep, and depression in adolescence: Modelling a novel pathway</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,239,303.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>psychology | biological psychology (neuropsychology, psychopharmacology, physiological psychology) | psychology | health, clinical and counselling psychology | clinical sciences | psychiatry (incl. psychotherapy) | </Field_s__of_Research>
        <Res_KW1>sleep </Res_KW1>
        <Res_KW2>depression</Res_KW2>
        <Res_KW3>mood disorders</Res_KW3>
        <Res_KW4>circadian rhythms</Res_KW4>
        <Res_KW5>adolescence</Res_KW5>
        <Plain_Description>Body clock and sleep undergo significant changes during adolescence, a critical phase for the development of depression. In a large sample of adolescents, we propose to test how later timing of the body clock, shorter sleep duration, and irregular sleep timing, are associated with increased depressive symptoms. We will also test how light exposure patterns affect the shift in timing of the body clock. The study will inform the development of evidence-based sleep interventions for adolescents.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012837</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr David Herrmann</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Single-cell intravital imaging guides anti-fibrotic therapy to improve standard-of-care treatment in triple negative breast cancer</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$599,808.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | signal transduction | </Field_s__of_Research>
        <Res_KW1>cell biology </Res_KW1>
        <Res_KW2>cancer cell biology</Res_KW2>
        <Res_KW3>imaging</Res_KW3>
        <Res_KW4>biosensor</Res_KW4>
        <Res_KW5>cancer chemotherapy</Res_KW5>
        <Plain_Description>Tissue fibrosis is a well-known risk factor for breast cancer initiation, progression and prognosis. It is commonly found in aggressive cancers, such as triple negative breast cancer (TNBC). Fibrosis is also known to protect cancer cells from treatment including chemotherapy, which is the standard-of-care in TNBC. In this proposal we will test the hypothesis that reducing tissue fibrosis can improve standard-of-care performance and outcomes in pre-clinical models of TNBC.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012848</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Therese Becker</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Revolutionising immunotherapy response prediction in non-small cell lung cancer via longitudinal single-cell proteomic analysis of liquid biopsy derived cancer and immune cells</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,356,196.80</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | cancer cell biology | </Field_s__of_Research>
        <Res_KW1>cancer cell biology </Res_KW1>
        <Res_KW2>computer-assisted diagnosis</Res_KW2>
        <Res_KW3>non-small cell lung cancer</Res_KW3>
        <Res_KW4>biomarkers</Res_KW4>
        <Res_KW5>immunocytochemistry</Res_KW5>
        <Plain_Description>Lung cancer is leading personalised medicine (replacing “one medicine for all” with drugs targeting unique cancer characteristics), but that only applies to a small subset of lung cancers with certain characteristics (biomarkers). This proposal uses innovative methods to apply and thourougly test novel biomarkers for lung cancer patients, predicting response to immunotherapy, improving treatment and preventing deadly side-effects. This will transform treatment of Australia’s most deadly cancer.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012860</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Helen Rizos</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Restoring anti-tumour immunity in melanoma</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,134,001.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | cancer cell biology | immunology | tumour immunology | </Field_s__of_Research>
        <Res_KW1>cutaneous melanoma </Res_KW1>
        <Res_KW2>cancer immunotherapy</Res_KW2>
        <Res_KW3>drug resistance</Res_KW3>
        <Res_KW4>melanoma antigens</Res_KW4>
        <Res_KW5>major histocompatibility complex (mhc)</Res_KW5>
        <Plain_Description>Melanoma is a major Australian health problem and a common cause of cancer death in young adults. Two recent types of therapies have revolutionised the treatment of patients with melanoma, and although patient survival has improved, most patients will eventually become resistant to treatment. This research explores how cancer cells evade treatment and reveals cancer vulnerabilities that can be exploited to re-sensitize melanoma to current and new therapies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012863</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Cynthia Munier</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Dissecting the healthy and immunosuppressed, primary and secondary immune responses within human lymph nodes following COVID-19 vaccination</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$982,669.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>immunology | cellular immunology | immunology | immunogenetics (incl. genetic immunology) | </Field_s__of_Research>
        <Res_KW1>covid-19 </Res_KW1>
        <Res_KW2>vaccine efficacy</Res_KW2>
        <Res_KW3>lymph node</Res_KW3>
        <Res_KW4>t cell response</Res_KW4>
        <Res_KW5>germinal centre</Res_KW5>
        <Plain_Description>The dynamics of the immune response to vaccines in human lymph nodes are important in determining eventual vaccine responses but are poorly characterised. We will investigate the critical components of the immune response in human lymph nodes that lead to an effective neutralising antibody response to novel COVID-19 vaccines. Our findings will provide insights into the critical responses required for a successful vaccine and will inform the rational design of future vaccines.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012882</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Petra Karlsson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>MY Voice Library</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,092,492.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>biomedical engineering | biomechanical engineering | cognitive science | linguistic processes (incl. speech production and comprehension) | cognitive science | knowledge representation and machine learning | </Field_s__of_Research>
        <Res_KW1>motor speech disorders </Res_KW1>
        <Res_KW2>cerebral palsy</Res_KW2>
        <Res_KW3>dysarthria</Res_KW3>
        <Res_KW4>communication</Res_KW4>
        <Res_KW5>young children</Res_KW5>
        <Plain_Description>For children with cerebral palsy and speech impairment access to a communication device is imperative. Today, accessing their communication device is often challenging, resulting in 15-20 times slower communication rates compared to those who can speak. This application seeks funding to support the development of a world-first data-driven MY Voice Library, a foundation for research and development of innovative engineering of real-time communication solutions for children with cerebral palsy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012883</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Alexander Khromykh</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Predicting and preparing for the unfolding evolution of SARS-CoV-2</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$999,836.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical microbiology | medical virology | </Field_s__of_Research>
        <Res_KW1>covid-19 </Res_KW1>
        <Res_KW2>molecular virology</Res_KW2>
        <Res_KW3>host/pathogen interaction</Res_KW3>
        <Res_KW4>viral vaccines</Res_KW4>
        <Res_KW5>antiviral</Res_KW5>
        <Plain_Description>One year on from the emergence of the COVID-19 pandemic, variants of SARS-CoV-2 have evolved to be more transmissible, pathogenic and less susceptible to immune responses from infection or vaccination. We propose utilising the deep mutational scanning method to examine the molecular pathogenesis and vaccine escape of SARS-CoV-2 at a single amino acid residue resolution and towards developing a universal vaccine candidate to neutralise all potential future SARS-CoV-2 variants. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012895</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Angela Laird</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Exploiting the neuroprotective effects of the gut microbiome for the treatment of spinocerebellar ataxia-3 and related neurodegenerative diseases</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$708,204.40</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical microbiology | medical bacteriology | neurosciences | neurology and neuromuscular diseases | medical biochemistry and metabolomics | medical biochemistry and metabolomics not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>molecular microbiology </Res_KW1>
        <Res_KW2>trinucleotide repeat disorder</Res_KW2>
        <Res_KW3>metabolites</Res_KW3>
        <Res_KW4>neurodegenerative disorders</Res_KW4>
        <Res_KW5>autophagy</Res_KW5>
        <Plain_Description>Spinocerebellar ataxia-3 (SCA3, also known as Machado Joseph disease) is a fatal neurodegenerative disease that causes coordination and mobility problems, leading to paralysis. There is currently no treatment for SCA3. This project will investigate whether the gut microbiome, bacteria that inhabit the gut, and levels of chemicals produced by these microbes are altered in SCA3 patients. We will also investigate a therapeutic strategy to correct the gut microbiome and its products to treat SCA3. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012915</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Shalini Amukotuwa</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Artificial Intelligence to Understand and Predict Chronic Subdural Haematoma Evolution</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,236,630.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | radiology and organ imaging | </Field_s__of_Research>
        <Res_KW1>brain imaging </Res_KW1>
        <Res_KW2>intracerebral haemorrhage</Res_KW2>
        <Res_KW3>neurosurgery</Res_KW3>
        <Res_KW4>computed tomography</Res_KW4>
        <Res_KW5>artificial neural networks</Res_KW5>
        <Plain_Description>This project tackles chronic subdural haematoma, a disease caused by bleeding on the brain’s surface that is increasing in incidence due to our ageing population. Artificial intelligence and advanced brain imaging will be used to predict and identify earlier those patients who are likely to need and benefit from treatment.  This will personalize patient care, allowing proactive treatment to prevent progression and decrease the burden of disease. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012929</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Robyn Brown</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Why do women overeat? Understanding the neural circuits driving stress-related eating</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$793,515.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | central nervous system | </Field_s__of_Research>
        <Res_KW1>binge eating </Res_KW1>
        <Res_KW2>sub-clinical eating disorders</Res_KW2>
        <Res_KW3>binge eating disorder</Res_KW3>
        <Res_KW4>healthy eating</Res_KW4>
        <Res_KW5>psychoemotional stress</Res_KW5>
        <Plain_Description>For women negative emotions such as stress and loneliness are more likely to drive overeating compared to men. There is a dearth of literature detailing the brain circuits driving stress-induced binge eating, particularly in female subjects, as to date no suitable animal model exists. We have developed a highly translational model of stress-induced binge eating in female subjects, which enables us to determine for the first time the neurobiology underlying this specific form of eating behaviour.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012936</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Elizabeth Ng</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Making a Niche: an in vitro human bone marrow organoid factory for blood</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,122,736.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical biotechnology | regenerative medicine (incl. stem cells and tissue engineering) | </Field_s__of_Research>
        <Res_KW1>haematopoietic stem cells </Res_KW1>
        <Res_KW2>embryonic stem cells</Res_KW2>
        <Res_KW3>bone marrow</Res_KW3>
        <Res_KW4>bone development</Res_KW4>
        <Res_KW5>stem cell biology</Res_KW5>
        <Plain_Description>The bone marrow is the ‘factory’ where blood cells are made. The ability to recreate a human bone marrow organ from pluripotent stem cells in the laboratory would improve our ability to make blood stem cells for patients with leukaemia or bone marrow failure who cannot find a matched donor. We can now make all the individual components– blood cells, bone, cartilage, blood vessels and stromal cells. In this project we will assemble these into a functioning human bone marrow organ.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012941</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof David Gallego Ortega</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>High-fidelity tumouroids: accelerating next generation personalised medicine</Grant_Title>
        <Admin_Institution>University of Technology Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$510,388.50</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | molecular targets | </Field_s__of_Research>
        <Res_KW1>tissue engineering </Res_KW1>
        <Res_KW2>cancer therapy</Res_KW2>
        <Res_KW3>drug sensitivity</Res_KW3>
        <Res_KW4>molecular oncology</Res_KW4>
        <Res_KW5>expression profiling</Res_KW5>
        <Plain_Description>Anti-cancer drug testing using in vitro models are unable to recapitulate the complexity of human tumours, hindering the application of more effective therapeutic strategies.  We have created ALTEN, a tissue-engineering system capable of preserving tumour biopsies maintaining their original environment. ALTEN allows parallel testing of different therapies on each patient’s biopsy, accurately identifying the most effective treatment for each patient, facilitating a personalised medicine approach.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012943</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Belinda Parker</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Boosting cellular immunogenicity to combat metastatic cancer</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$658,031.60</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | solid tumours | oncology and carcinogenesis | radiation therapy | immunology | tumour immunology | </Field_s__of_Research>
        <Res_KW1>breast cancer metastases </Res_KW1>
        <Res_KW2>hormone-refractory prostate cancer</Res_KW2>
        <Res_KW3>cancer immunotherapy</Res_KW3>
        <Res_KW4>immunogenicity</Res_KW4>
        <Res_KW5>interferon (ifn)</Res_KW5>
        <Plain_Description>Spread (metastasis) to bone in breast and prostate cancer is painful and very difficult to treat. We have discovered that cancers growing in bone have developed changes to allow them to go undetected and escape immune control. In this proposal, we will discover ways to reverse these changes and increase response to radiotherapy and immune therapies to target deadly metastatic cancers. This work will offer a new avenue of therapy for bone metastasis that is built on strong biological discoveries.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2012971</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Simon Jiang</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>A20 variants contribute to endemic kidney disease in Tiwi Islanders</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$453,680.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | nephrology and urology | genetics | genetic immunology | </Field_s__of_Research>
        <Res_KW1>kidney disease </Res_KW1>
        <Res_KW2>chronic inflammation</Res_KW2>
        <Res_KW3>cardiovascular disease</Res_KW3>
        <Res_KW4>indigenous australians</Res_KW4>
        <Res_KW5>immunology</Res_KW5>
        <Plain_Description>Kidney disease is endemic amongst the Tiwi Islanders with the highest reported rates worldwide. It is thought that 60% of this risk comes from genetics. We have identified six gene variants in a gene likely to be important in controlling progression of kidney disease. These variants impair the ability of the gene to prevent kidney disease and offers a novel treatment target for the Tiwi Islanders.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013024</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Catherine Blizzard</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Toward tailored excitation therapy for amyotrophic lateral sclerosis</Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$624,821.20</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | central nervous system | </Field_s__of_Research>
        <Res_KW1>motor neuron disease (mnd) </Res_KW1>
        <Res_KW2>excitotoxicity</Res_KW2>
        <Res_KW3>transcranial magnetic stimulation (tms)</Res_KW3>
        <Res_KW4>brain</Res_KW4>
        <Res_KW5>spinal cord</Res_KW5>
        <Plain_Description>Motor neuron disease and associated dementia are significantly debilitating Australians and we have no effective cures. Our work has discovered that the way brain cells communicate in these diseases is disrupted.  We propose to develop a new way of treating these diseases, tailored to the part of the brain that is affected. With this knowledge we will investigate new targeted therapies that could prevent brain cells from tipping over from proper brain function to too much excitation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013027</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Melanie White</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Revealing how junctional neural tube defects arise</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$582,341.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | cell development, proliferation and death | biochemistry and cell biology | cellular interactions (incl. adhesion, matrix, cell wall) | </Field_s__of_Research>
        <Res_KW1>neural tube defects </Res_KW1>
        <Res_KW2>embryo development</Res_KW2>
        <Res_KW3>tissue development</Res_KW3>
        <Res_KW4>tissue mechanics</Res_KW4>
        <Res_KW5>abnormal embryogenesis</Res_KW5>
        <Plain_Description>The brain and spinal cord control are formed early in development from a common precursor called the neural tube. Each end of the neural tube forms by a different process and how these are united to form a single tube is unknown. Failures in this critical process cause severe birth defects in humans. We will use live imaging of transgenic quail embryos to understand how cells arrange into a continuous neural tube and what goes wrong when genes linked to human neural tube defects are mutated.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013058</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Sarah Russell</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Understanding latent fate programming in T cells.</Grant_Title>
        <Admin_Institution>Swinburne University of Technology</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$802,328.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | cell development, proliferation and death | statistics | biostatistics | biochemistry and cell biology | systems biology | </Field_s__of_Research>
        <Res_KW1>differentiation </Res_KW1>
        <Res_KW2>cd8 t cells</Res_KW2>
        <Res_KW3>cell cycle</Res_KW3>
        <Res_KW4>developmental biology</Res_KW4>
        <Res_KW5>t cell response</Res_KW5>
        <Plain_Description>Our immune response to infections and cancer involves amplification of T cells. Each of us has trillions of T cells, with  only a handful specific for each infectious agent or cancer cell. What controls the effectiveness of their response is not yet known. In this project, we will use single cell approaches to describe what determines whether a T cell can yield an effective response. These studies will also provide a general framework to assess how fate is controlled in multicellular organisms.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013115</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Simranpreet Kaur</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Accelerating treatment for epilepsy in children with KIF1A-associated neurological disorders.</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$776,019.50</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | neurology and neuromuscular diseases | genetics | neurogenetics | neurosciences | central nervous system | </Field_s__of_Research>
        <Res_KW1>neurological diseases </Res_KW1>
        <Res_KW2>seizures</Res_KW2>
        <Res_KW3>genetic disorders</Res_KW3>
        <Res_KW4>brain development</Res_KW4>
        <Res_KW5>neurodegenerative disorders</Res_KW5>
        <Plain_Description>Epilepsies are life threatening, where approximately 40% patients do not respond to current medications. Mutations in the KIF1A gene lead to a devastating form of epilepsy where patients die within first 5 years of life. We will use extremely innovative and physiologically relevant models such as stem cells and bioinformatic algorithms to identify novel therapies for KIF1A-related epilepsies. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013129</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Thomas Riley</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>A One Health/System Dynamics approach to reducing Clostridioides difficile infection</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,284,890.50</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | environmental and occupational health and safety | clinical sciences | infectious diseases | medical microbiology | medical infection agents (incl. prions) | </Field_s__of_Research>
        <Res_KW1>antimicrobial resistance </Res_KW1>
        <Res_KW2>disease transmission</Res_KW2>
        <Res_KW3>public health impact</Res_KW3>
        <Res_KW4>molecular epidemiology</Res_KW4>
        <Res_KW5>zoonoses</Res_KW5>
        <Plain_Description>Clostridioides difficile infection is a major public health problem. While thought to be acquired in hospitals, evidence is growing that it can be acquired in the community. The bacteria have been found in food, households, farm animals and the environment, but we don’t understand what role this plays in human infection. We will use a novel approach using systems modelling to understand how people become exposed to C. difficile and, most importantly, what we can do to control the infection.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013158</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Brian Drew</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Polygenic mitochondrial dysfunction in heart failure and neurodegeneration</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,166,807.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical biochemistry and metabolomics | metabolic medicine | </Field_s__of_Research>
        <Res_KW1>mitochondrial function </Res_KW1>
        <Res_KW2>heart failure</Res_KW2>
        <Res_KW3>population genetics</Res_KW3>
        <Res_KW4>neurodegeneration</Res_KW4>
        <Res_KW5>ageing</Res_KW5>
        <Plain_Description>Mitochondria are the energy producing components of our cells. Genetics influences mitochondrial function, which influences risk for diseases such as heart failure and neurodegeneration. We don’t yet fully understand this genetic influence, however we propose that subtle, cumulative genetic (polygenic) differences may be liable. We will test this idea using unique mouse models, and use these findings to identify readily detectable measures for developing heart failure and neurodegeneration.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013180</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Guillermo Gomez</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Harnessing artificial intelligence, spatial-omics and patient-derived organoids to cure glioblastoma.</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,999,371.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | biochemistry and cell biology not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>metabolic stress </Res_KW1>
        <Res_KW2>cell adhesion</Res_KW2>
        <Res_KW3>microenvironment</Res_KW3>
        <Res_KW4>glioblastoma</Res_KW4>
        <Res_KW5>artificial neural networks</Res_KW5>
        <Plain_Description>This Proposal will investigate the mechanisms by which tumour cells reprogram healthy non-cancerous cells to support the tumour cells’ energy demands. Our results will lay the foundations of new anti-cancer approaches that will not only inhibit tumour cell source of energy (metabolism) but also prevent their metabolic compensation via recruitment and reprogramming of surrounding healthy cells.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013189</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Richard Mills</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Bioengineered skeletal muscle to discover therapies for age-related muscle weakness </Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$950,516.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical biotechnology | regenerative medicine (incl. stem cells and tissue engineering) | </Field_s__of_Research>
        <Res_KW1>skeletal muscle </Res_KW1>
        <Res_KW2>sarcopenia</Res_KW2>
        <Res_KW3>exercise</Res_KW3>
        <Res_KW4>skeletal muscle wasting</Res_KW4>
        <Res_KW5>epigenetics</Res_KW5>
        <Plain_Description>As we grow older the positive effects of exercise training in muscle are reduced. This project will use 1000s of lab made mini-muscles, which act and function like real human skeletal muscle to understand changes that occur when we get older and how muscle responds to training. By understanding these changes we aim to identify new therapies to treat age-related muscle weakness, so that every Australian can be active and healthy in their older years. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013215</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr David Jacques</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Understanding how viruses overcome the nuclear pore complex, the gatekeeper of genomic access</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$794,379.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | protein trafficking | </Field_s__of_Research>
        <Res_KW1>human immunodeficiency virus (hiv) </Res_KW1>
        <Res_KW2>nuclear transport</Res_KW2>
        <Res_KW3>encapsidation</Res_KW3>
        <Res_KW4>viral proteins</Res_KW4>
        <Res_KW5>antiviral agents</Res_KW5>
        <Plain_Description>HIV remains an incurable disease. New ways of treating HIV infection are needed if we are to be ready for emerging strains that are resistant to current treatments. The viral shell, the ‘capsid’, has proven to be a good target for new drugs. We aim to understand how the capsid tricks immune cells into allowing HIV to enter their nuclei where it establishes infection. Understanding how HIV enters the nucleus will not only inform HIV therapies but also virus-inspired gene therapy technologies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013237</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Yeesim Khew-Goodall</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Overcoming chemoresistance in triple negative breast cancer</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,121,242.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | signal transduction | </Field_s__of_Research>
        <Res_KW1>protein kinase c (pkc) </Res_KW1>
        <Res_KW2>protein phosphorylation</Res_KW2>
        <Res_KW3>molecular modelling</Res_KW3>
        <Res_KW4>breast cancer</Res_KW4>
        <Res_KW5>chemotherapy</Res_KW5>
        <Plain_Description>Triple negative breast cancer (TNBC) is the most challenging breast cancer to treat. There is no reliable targeted therapy available and chemotherapy is the standard of care. About 20-25% of patients will become chemoresistant. For these patients, there are few viable treatment options available and their median survival is about 12 months. In this study, we aim to better understand the pathways to chemoresistance and to use a novel paradigm to develop new drugs to circumvent chemoresistance.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013243</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Zane Andrews</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Top down cortical control of hypothalamic feeding circuits</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$895,804.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | central nervous system | medical physiology | systems physiology | neurosciences | neurosciences not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>appetite regulation </Res_KW1>
        <Res_KW2>neural pathways</Res_KW2>
        <Res_KW3>feeding disorders</Res_KW3>
        <Res_KW4>acute stress</Res_KW4>
        <Res_KW5>motivation</Res_KW5>
        <Plain_Description>Obesity continues to be a significant burden to public health shows no sign of slowing. A central part of the problem is the overconsumption calorically dense, highly palatable and innately rewarding foods. Although genetic evidence shows this overconsumption is driven by our brain, the precise way this occurs remain unknown. In this proposal, we will assess how the brain cortex communicates with the hypothalamus in order to control food intake, food motivation and the development of obesity.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013260</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Kerry-Anne Rye</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>A novel, dual-targeted therapeutic approach for reducing diabetes-accelerated atherosclerosis</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,566,077.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>cardiorespiratory medicine and heamatology | cardiology (incl. cardiovascular diseases) | </Field_s__of_Research>
        <Res_KW1>atherosclerosis </Res_KW1>
        <Res_KW2>type 2 diabetes mellitus (non-insulin dependent diabetes mellitus)</Res_KW2>
        <Res_KW3>inflammation</Res_KW3>
        <Res_KW4>myeloperoxidase</Res_KW4>
        <Res_KW5>peptides</Res_KW5>
        <Plain_Description>Patients with diabetes are in a pro-inflammatory state and many of them develop an aggressive form of heart disease. Blood levels of the pro-inflammatory enzyme myeloperoxidase (MPO) are also elevated in these patients. This project will determine whether treatment with peptides that have anti-diabetic and anti-inflammatory properties plus an MPO inhibitor reduces heart disease in these patients more effectively than the peptides alone or an MPO inhibitor alone. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013278</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Andrew Philp</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Enhancing mitochondrial energetics to prevent age-associated muscle weakness </Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$799,706.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | cell metabolism | </Field_s__of_Research>
        <Res_KW1>skeletal muscle </Res_KW1>
        <Res_KW2>skeletal muscle wasting</Res_KW2>
        <Res_KW3>mitochondria</Res_KW3>
        <Res_KW4>clinical pharmacology</Res_KW4>
        <Res_KW5>ageing</Res_KW5>
        <Plain_Description>Sarcopenia is a recognized disease of ageing, describing the progressive decline in skeletal muscle mass and strength that occurs from midlife in humans. Recent research suggests that a decline in mitochondrial function, the energy producing cells in our body, precedes the development of sarcopenia. This project will test whether increasing mitochondrial energetics in skeletal muscle with the pharmacological compound BAM15 can prevent sarcopenia in mouse and human models of ageing. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013281</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Jacob Gratten</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Understanding the pathophysiology of Parkinson’s disease using cellular genomics</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$837,064.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>genetics | gene expression (incl. microarray and other genome-wide approaches) | genetics | quantitative genetics (incl. disease and trait mapping genetics) | genetics | neurogenetics | </Field_s__of_Research>
        <Res_KW1>parkinson disease </Res_KW1>
        <Res_KW2>gene expression</Res_KW2>
        <Res_KW3>genetic association</Res_KW3>
        <Res_KW4>complex genetic disease</Res_KW4>
        <Res_KW5>neurogenetics</Res_KW5>
        <Plain_Description>Parkinson’s disease (PD) is a devastating neurodegenerative condition affecting 1% of Australians aged 60-years and over. Understanding the genetic basis of PD is critical to identifying new drug targets. We will apply powerful methods for measuring gene expression in single cells to identify specific genes that are altered in specific cell types in PD-related brain and gut regions. Our study will shed light on the cell type-specific molecular pathology of PD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013284</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Craig Harrison</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Transforming fertility treatment</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$846,531.50</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>paediatrics and reproductive medicine | reproduction | </Field_s__of_Research>
        <Res_KW1>ovary </Res_KW1>
        <Res_KW2>female infertility</Res_KW2>
        <Res_KW3>growth factor therapy</Res_KW3>
        <Res_KW4>protein engineering</Res_KW4>
        <Res_KW5>activin and inhibin</Res_KW5>
        <Plain_Description>It is estimated that worldwide 186 million individuals live with infertility. Depending on the cause of infertility, treatment ranges from medications to stimulate ovulation through to more complex procedures, such as in vitro fertilisation (IVF). These fertility treatments have been quite successful; however, they all rely on decades-old medications that promote or suppress hormone activity. We will develop a new set of drugs that target ovarian growth factors to treat or prevent infertility.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013285</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Gary Housley</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Bionic-array Directed Gene Electrotransfer for Treating Focal Brain Disorders</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,941,007.20</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biomedical engineering | biomedical instrumentation | neurosciences | central nervous system | </Field_s__of_Research>
        <Res_KW1>biomedical engineering </Res_KW1>
        <Res_KW2>gene delivery</Res_KW2>
        <Res_KW3>gene therapy</Res_KW3>
        <Res_KW4>focal epilepsy</Res_KW4>
        <Res_KW5>neurological disorders</Res_KW5>
        <Plain_Description>A platform for localized brain gene therapy, ‘Brain-BaDGE’, will be developed from proprietary UNSW electric field-focusing technology. This translational program will produce a first-for-human ‘needle-like’ medical device for electrotransfer of therapeutic DNA encoding a neuromodulator targeted to groups of neurons in the brain to suppress epileptic seizures of focal origin. This Brain-BaDGE platform will establish a translational pathway for gene therapies treating localized brain disorders.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013305</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Jan Kaslin</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Precursor neurons on standby fast track neural repair</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$814,423.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>genetics | developmental genetics (incl. sex determination) | neurosciences | cellular nervous system | biochemistry and cell biology | cell development, proliferation and death | </Field_s__of_Research>
        <Res_KW1>neurodevelopment </Res_KW1>
        <Res_KW2>adult neurogenesis</Res_KW2>
        <Res_KW3>zebrafish</Res_KW3>
        <Res_KW4>neural regeneration</Res_KW4>
        <Res_KW5>acute inflammation</Res_KW5>
        <Plain_Description>Brain and spinal cord injury are devastating events that has a life-long impact on the patient’s life with wide-reaching social and economic effects. This research program uses innovative regeneration models and screening approaches to identify how endogenous cells and molecules can be hoaxed to boost neural regeneration after injury or in disease. The work provides critical insight and hold keys to unlocking strategies for future restorative therapies in the brain or spinal cord.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013323</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Louisa Jorm</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Hospital trajectories for 15 million Australians</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$655,934.60</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | health information systems (incl. surveillance) | public health and health services | epidemiology | statistics | applied statistics | </Field_s__of_Research>
        <Res_KW1>data analysis </Res_KW1>
        <Res_KW2>applied statistics</Res_KW2>
        <Res_KW3>hospitalisation</Res_KW3>
        <Res_KW4>longitudinal study</Res_KW4>
        <Res_KW5>health service utilisation</Res_KW5>
        <Plain_Description>Patient segmentation, which divides a patient population into distinct groups with specific needs and characteristics, underpins a patient-centred approach to health care. We will use hospital records for the population of NSW and deep learning to identify clusters (segments) of patients who share patterns of hospital use, characterise and visualise these, and explore how they change over time. Our novel methods will have application in health service planning and delivery and research.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013349</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Rodrigo Suarez</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Building the mind: interplay of transcriptional and electrical activities in the self-assembly of cortical circuits in vivo</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$887,243.20</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | central nervous system | </Field_s__of_Research>
        <Res_KW1>early brain development </Res_KW1>
        <Res_KW2>cerebral cortex</Res_KW2>
        <Res_KW3>transcriptional regulation</Res_KW3>
        <Res_KW4>neural coding</Res_KW4>
        <Res_KW5>targeted gene delivery</Res_KW5>
        <Plain_Description>The early impact of nature and nurture influences in human brain wiring remains poorly understood due to a lack of ways to study embryonic development in naturalistic live models. We have established advanced new methods in an Australian marsupial that allow, for the first time, mechanistic studies of how genes and electrical activity interact to form precise circuits in the cerebral cortex. These unique opportunities can revolutionise the way we understand brain wiring in health and disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013362</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Rebecca Robker</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Remodelling the ovary to extend female fertility and health</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$1,449,102.60</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>paediatrics and reproductive medicine | reproduction | </Field_s__of_Research>
        <Res_KW1>ovary </Res_KW1>
        <Res_KW2>ageing</Res_KW2>
        <Res_KW3>fibrosis</Res_KW3>
        <Res_KW4>extracellular matrix</Res_KW4>
        <Res_KW5>monocyte/macrophage</Res_KW5>
        <Plain_Description>Female infertility is commonly caused by an inability to release an egg from the ovary, particularly in women who are middle-age or if they have obesity or PCOS. We discovered that these females also have fibrosis in the ovary; excess collagen deposited by cellular stress and inflammation that prevents the egg from being released. This project will identify strategies to combat the detrimental changes in the ovary that cause fibrosis in order to improve female health.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013384</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Paul Gleeson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Establishment of novel, neuronal-cell based, therapeutic screens for Alzheimer’s disease using patients stem cells</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$861,704.60</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | receptors and membrane biology | </Field_s__of_Research>
        <Res_KW1>stem cells </Res_KW1>
        <Res_KW2>alzheimer disease</Res_KW2>
        <Res_KW3>neurons</Res_KW3>
        <Res_KW4>secretory pathway</Res_KW4>
        <Res_KW5>golgi</Res_KW5>
        <Plain_Description>Alzheimer’s disease is the most common cause of dementia and a major cause of death in Australia.  There is no effective treatment for this disease and there is an urgent need to develop treatments to target the cause of the Alzheimer’s disease.  This project aims to use human neurons derived from patient’s stem cells to establish a powerful screening platform for the identification of targeted therapeutic drugs to rescue neuron defects to efficiently treat Alzheimer’s disease.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013404</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Andrew Currie</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>aSPOC – Commercialisable Aptamer-based Diagnostics for Sepsis Point of Care</Grant_Title>
        <Admin_Institution>Murdoch University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$1,043,133.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>medical biotechnology | medical biotechnology diagnostics (incl. biosensors) | clinical sciences | infectious diseases | clinical sciences | emergency medicine | </Field_s__of_Research>
        <Res_KW1>sepsis </Res_KW1>
        <Res_KW2>biotechnology</Res_KW2>
        <Res_KW3>diagnostic techniques</Res_KW3>
        <Res_KW4>molecular basis of disease</Res_KW4>
        <Res_KW5>biomarkers</Res_KW5>
        <Plain_Description>Sepsis - bacterial blood infection - is a common cause of disease in babies and adults. Current diagnostic tests are too slow and often miss the sepsis diagnosis. We have identified blood markers that can improve sepsis diagnosis. Our team have developed a powerful system for making the molecular tools needed to rapidly detect these blood markers. We are working with science and manufacturing experts to make new sepsis tests that can be used easily by frontline staff in hospitals and GP clinics.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013421</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Avril Robertson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Inhibiting ASC with small molecules for treatment of inflammatory diseases</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,061,883.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medicinal and biomolecular chemistry | biologically active molecules | immunology | innate immunity | </Field_s__of_Research>
        <Res_KW1>anti-inflammatory agents </Res_KW1>
        <Res_KW2>airway inflammation</Res_KW2>
        <Res_KW3>drug discovery</Res_KW3>
        <Res_KW4>cell biology</Res_KW4>
        <Res_KW5>viral immunology</Res_KW5>
        <Plain_Description>During flu infection inflammation causes significant morbidity there is therefore a need to reduce this inflammation while tackling the viral infection, we have special molecules that have this dual action. We will develop these molecules so they can become future drugs and explore their use in flu models combined with either asthma or obesity as these people are particularly vulnerable to the deadly effects of flu. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013427</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof David Bishop</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Do mitochondrial changes underlie insulin resistance induced by inadequate sleep, and can this be prevented by prescribed exercise?</Grant_Title>
        <Admin_Institution>Victoria University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$813,502.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>human movement and sports science | sports medicine | </Field_s__of_Research>
        <Res_KW1>mitochondria </Res_KW1>
        <Res_KW2>exercise</Res_KW2>
        <Res_KW3>sleep</Res_KW3>
        <Res_KW4>muscle metabolism</Res_KW4>
        <Res_KW5>exercise training</Res_KW5>
        <Plain_Description>More than 7.4 million Australians suffer from inadequate sleep. Sleep loss doesn't just make us tired; we have shown it also negatively affects mitochondria ("energy powerhouses") and glucose metabolism (increasing the risk of diabetes). Based on compelling data, this project will discover novel mechanisms responsible for the negative effects of sleep loss and test targeted exercise prescription as a cost-effective strategy to prevent metabolic problems arising from inadequate sleep.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013451</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Robyn Jamieson</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>ALPK1 dysfunction: revealing a novel pathogenic pathway in retinal diseases</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$747,501.80</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>ophthalmology and optometry | vision science | </Field_s__of_Research>
        <Res_KW1>retinal disease </Res_KW1>
        <Res_KW2>photoreceptors</Res_KW2>
        <Res_KW3>vision loss</Res_KW3>
        <Res_KW4>ocular disease</Res_KW4>
        <Res_KW5>blindness</Res_KW5>
        <Plain_Description>Genetic retinal diseases are caused by changes in many different genes and lack effective therapy. This proposal aims to characterise and modulate a newly identified disease pathway in the retina. This holds promise for development of novel approaches to preserve vision in genetic and other forms of blinding retinal degeneration.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013460</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Claudine Bonder</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Exploiting a novel cell surface biomarker to defeat multiple myeloma</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$908,658.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | cancer cell biology | </Field_s__of_Research>
        <Res_KW1>multiple myeloma </Res_KW1>
        <Res_KW2>cancer prognosis</Res_KW2>
        <Res_KW3>cell adhesion molecule</Res_KW3>
        <Res_KW4>bone marrow stroma</Res_KW4>
        <Res_KW5>inhibitors</Res_KW5>
        <Plain_Description>Multiple myeloma is an incurable aggressive cancer of the bone marrow. In Australia, ~2,500 new cases are diagnosed every year with a 5 year survival rate of ~50% and treatment costs exceeding $700,000 per patient. We have identified a single cell surface protein to be upregulated by ~20% of myeloma patients who are then 3 times more likely to die within 6 years of diagnosis. This study examines a new prognostic tool to rapidly identify poor prognosis patients and new a target to treat them. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013468</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Guillaume Méric</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Understanding the asymptomatic carriage of pathogens and antimicrobial resistance (AMR) in the human gut microbiota</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$546,216.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | infectious diseases | clinical sciences | clinical microbiology | biochemistry and cell biology | bioinformatics | </Field_s__of_Research>
        <Res_KW1>antimicrobial resistance </Res_KW1>
        <Res_KW2>bioinformatics</Res_KW2>
        <Res_KW3>microbiology</Res_KW3>
        <Res_KW4>microbial ecology</Res_KW4>
        <Res_KW5>microbial infections</Res_KW5>
        <Plain_Description>The rise of microbial antibiotic resistance (AMR) and the lack of novel antibiotic compounds could soon be cancelling the effectiveness of current infectious disease therapies. Understanding and controlling the spread of AMR is a major challenge for public health, but we currently do not understand well if and how healthy people can carry and spread AMR genes. Here, we propose to study AMR dynamics in the gut microbiome of &amp;gt;20,000 healthy people, linking it with health and prescription records.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013478</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof David Huang</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Identifying rational approaches to enhance the activity of BH3 mimetic drugs in blood cancers</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$992,305.40</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | haematological tumours | </Field_s__of_Research>
        <Res_KW1>bcl-2 </Res_KW1>
        <Res_KW2>leukaemia</Res_KW2>
        <Res_KW3>lymphoma</Res_KW3>
        <Res_KW4>apoptosis</Res_KW4>
        <Res_KW5>therapeutic target</Res_KW5>
        <Plain_Description>It is now appreciated that normal cell death prevents cancers from developing; however, this could be undermined in blood cancers (e.g., leukemias). This is often due to overactivity of BCL2 which allows the cancer cells to persist. Treating patients with a drug blocking BCL2 - venetoclax - is proving highly effective for such blood cancers. However, the disease will often eventually recur: this project seeks to understand why this is and to discover ways by which this can be prevented.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013500</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Edwina McGlinn</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>MicroRNA targeting to enhance haematopoietic stem cell function</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$992,474.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | cell development, proliferation and death | genetics | developmental genetics (incl. sex determination) | </Field_s__of_Research>
        <Res_KW1>mouse genetics </Res_KW1>
        <Res_KW2>haematopoietic stem cells</Res_KW2>
        <Res_KW3>microrna</Res_KW3>
        <Res_KW4>stem cell biology</Res_KW4>
        <Res_KW5>bone marrow transplantation</Res_KW5>
        <Plain_Description>The ability to transplant blood stem cells has dramatically improved outcomes for many blood diseases. However, there is a major limitation in the numbers of appropriate blood stem cells available for use. We have identified a gene family that represses the potential of blood stem cells to function after transplantation. Here, we aim to inhibit this gene family to enhance blood stem cell function.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013511</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Ozren Bogdanovic</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>The rogue germline: deciphering mechanisms of cancer testis antigen reactivation in cancer</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$791,930.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>genetics | epigenetics (incl. genome methylation and epigenomics) | </Field_s__of_Research>
        <Res_KW1>epigenetics </Res_KW1>
        <Res_KW2>germ cells</Res_KW2>
        <Res_KW3>carcinogenesis</Res_KW3>
        <Res_KW4>embryogenesis</Res_KW4>
        <Res_KW5>genomics</Res_KW5>
        <Plain_Description>Cancer testis antigens (CTAs) are proteins that are normally expressed in the germline of healthy individuals. During malignant transformation, CTAs become expressed in cancerous tissues, however their role in cancer formation is largely unknown. Given their tissue specificity, CTAs are being actively pursued as targets for cancer immunotherapy. This project aims to unravel the mechanisms of CTA reactivation and interrogate their contribution to cancer formation in vivo.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013538</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Allison Pettit</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Increasing hematopoietic stem cell niches post transplantation through enhancing bone marrow macrophage resilience and regeneration mechanisms</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$935,616.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>cardiorespiratory medicine and heamatology | haematology | </Field_s__of_Research>
        <Res_KW1>macrophages </Res_KW1>
        <Res_KW2>haematopoietic stem cell transplantation</Res_KW2>
        <Res_KW3>bone marrow reconstitution</Res_KW3>
        <Res_KW4>tissue regeneration</Res_KW4>
        <Res_KW5>bone marrow stroma</Res_KW5>
        <Plain_Description>Bone marrow transplantation, a potential cure for blood cancers and used to enable high dose therapy in treatment resistant cancers, has a high-risk profile preventing treatment progression and high mortality. We will investigate a novel treatment to alleviate transplantation risk by improving the recovery of the recipient's bone marrow environment.  It is expected that the efficiency of donor stem cell engraftment will be increased, and reconstitution of blood and immune cells accelerated.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013563</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Ashley Schram</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Evaluating Systems Change for Health Equity: A Case Study of Australia’s COVID-19 Policy Response</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$452,482.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | public health and health services not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>equity </Res_KW1>
        <Res_KW2>social determinants of health</Res_KW2>
        <Res_KW3>policy analysis</Res_KW3>
        <Res_KW4>policy evaluation</Res_KW4>
        <Res_KW5>policy making</Res_KW5>
        <Plain_Description>This project will build new resources to evaluate the impact of policy reforms on changes to the underlying societal structures that shape health inequity. Using systems science we will study Australia’s COVID-19 policy response and the impact it will have on the rules, norms, power dynamics, and resource flows that stratify society and shape people’s health. This new evidence will be used to advocate for policy reform that better targets the roots of health inequity in Australia and abroad. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013565</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Michael Sorich</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>MACHINE LEARNING OF RANDOMISED CONTROLLED TRIALS: A major emerging opportunity to advance precision oncology</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$560,598.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | pharmacology and pharmaceutical sciences | clinical pharmacology and therapeutics | </Field_s__of_Research>
        <Res_KW1>risk prediction </Res_KW1>
        <Res_KW2>cancer treatment</Res_KW2>
        <Res_KW3>biomarkers</Res_KW3>
        <Res_KW4>clinical epidemiology</Res_KW4>
        <Res_KW5>clinical pharmacology</Res_KW5>
        <Plain_Description>Individual patients can gain very different benefit from the same treatment. Immunotherapy for cancer is an important example of this - some patients have dramatic improvement in survival, whereas many others gain little or no benefit. Currently it is not possible to predict in advance who will benefit and who will not. We will evaluate of a new approach based on machine learning analysis of clinical trials to better distinguish patients who are unlikely to benefit from those who will benefit. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013574</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Christian Nefzger</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Reinforcing the cell identity network to improve the function of aged cells</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$777,899.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | biochemistry and cell biology not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>ageing </Res_KW1>
        <Res_KW2>transcription factor</Res_KW2>
        <Res_KW3>epigenetics</Res_KW3>
        <Res_KW4>chromatin structure</Res_KW4>
        <Res_KW5>gene regulation</Res_KW5>
        <Plain_Description>By 2055, one in four Australians will be aged over 65 and the frequency of age-related disorders will increase. In order to prevent unsustainable burdens for the health system and to reduce human suffering, innovative new therapies are needed to target the underlying causes of ageing. The proposal will provide the basis for new strategies to improve the function of aged cells by directly reinforcing youthful cell identity.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013580</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Nicole Verrills</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>A dual approach to activate a tumour suppressor for breast cancer therapy</Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$597,824.10</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | molecular targets | medical biochemistry and metabolomics | medical biochemistry: proteins and peptides (incl. medical proteomics) | </Field_s__of_Research>
        <Res_KW1>protein phosphatase </Res_KW1>
        <Res_KW2>tumour suppressor</Res_KW2>
        <Res_KW3>protein-protein interaction</Res_KW3>
        <Res_KW4>anticancer drug action</Res_KW4>
        <Res_KW5>cell signalling</Res_KW5>
        <Plain_Description>Cancer is characterised by inactivation of proteins that inhibit cell growth and survival, called tumour suppressors. A rational way to treat cancer is to re-activate the tumour suppressors. Until recently this was not possible. However, we have developed drugs that can do this. Here, we will fully characterise how these drugs function in breast cancer, and use this knowledge to develop new anti-cancer therapies that could have wide reaching applicability for many cancer patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013615</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Gordon Lynch</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Interrogating the therapeutic potential of slow muscle programming in cancer</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$943,864.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical physiology | medical physiology not elsewhere classified | medical physiology | cell physiology | medical physiology | systems physiology | </Field_s__of_Research>
        <Res_KW1>skeletal muscle </Res_KW1>
        <Res_KW2>basic science</Res_KW2>
        <Res_KW3>plasticity</Res_KW3>
        <Res_KW4>exercise intolerance</Res_KW4>
        <Res_KW5>cancer</Res_KW5>
        <Plain_Description>Physical activity can improve cancer prognosis, but many patients cannot exercise because of treatment complications. Slow muscle programming could confer exercise-like benefits but its therapeutic potential to improve muscle health in cancer has not been interrogated. These studies will determine whether this strategy can preserve and promote muscle health in different cancer settings. The outcomes will inform development of new therapies for cancer patients throughout the continuum of care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013620</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Adrian Lowe</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Do allergies start with the skin? A novel lipidomic analysis of early life skin to identify “high risk” children and potential targets for preventive interventions</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$299,752.80</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | dermatology | </Field_s__of_Research>
        <Res_KW1>atopic dermatitis </Res_KW1>
        <Res_KW2>allergic disease</Res_KW2>
        <Res_KW3>skin permeability</Res_KW3>
        <Res_KW4>lipids</Res_KW4>
        <Res_KW5>hypersensitivity</Res_KW5>
        <Plain_Description>Eczema and food allergy are common conditions that cause a substantial burden for individuals and families. Impaired skin barrier in early life is believe to be critical in the development of these conditions, and skin lipids (fats) are the ‘mortar’ that holds the bricks of the skin barrier together. Using a non-invasive technique, we will test if the skin lipids can identify children who will develop eczema and food sensitisation, which may lead to novel preventive strategies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013621</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr James Burchfield</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Treating Cardiometabolic Disease by Targeting Mitochondrial Defects</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,711,067.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | cell metabolism | biochemistry and cell biology | signal transduction | medicinal and biomolecular chemistry | molecular medicine | </Field_s__of_Research>
        <Res_KW1>mitochondrial function </Res_KW1>
        <Res_KW2>insulin resistance</Res_KW2>
        <Res_KW3>reactive oxygen species (ros)</Res_KW3>
        <Res_KW4>drug delivery</Res_KW4>
        <Res_KW5>antioxidant</Res_KW5>
        <Plain_Description>Cardiometabolic disease is the leading cause of death and disability in the world. We have discovered that depletion of Coenzyme Q10 (a molecule essential for energy production) occurs in people with pre-diabetes and that boosting CoQ10 is a potential treatment for cardiometabolic disease. Here we seek to understand the underlying cause of CoQ10 depletion and how depletion causes disease. Finally, we will use our newly acquired understanding of the disease process to develop new treatments.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013629</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Lauren May</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Positive allosteric modulation of anti-convulsant G protein-coupled receptor signalling to treat drug-resistant epilepsy.</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,982,356.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>pharmacology and pharmaceutical sciences | basic pharmacology | </Field_s__of_Research>
        <Res_KW1>g protein-coupled receptors </Res_KW1>
        <Res_KW2>adenosine receptors</Res_KW2>
        <Res_KW3>antiepileptic drugs</Res_KW3>
        <Res_KW4>receptor signalling</Res_KW4>
        <Res_KW5>drug discovery</Res_KW5>
        <Plain_Description>Epilepsy remains a significant health burden, with current antiseizure medications (ASM) providing inadequate seizure control for &amp;gt;30% of patients. Activation of adenosine A1 receptors, a protein expressed on neurons, can effectively abolish seizures animal models. We will apply multidisciplinary, innovative approaches to develop novel drug leads that can modulate adenosine A1 receptor activity in a more selective and efficacious manner, developing a unique path for ASM discovery.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013631</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Anthony Purcell</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Dominant classes of tumour specific antigens in Melanoma</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,026,825.20</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>immunology | tumour immunology | immunology | cellular immunology | medical biochemistry and metabolomics | medical biochemistry: proteins and peptides (incl. medical proteomics) | </Field_s__of_Research>
        <Res_KW1>cancer vaccine </Res_KW1>
        <Res_KW2>tumour antigens</Res_KW2>
        <Res_KW3>proteomics</Res_KW3>
        <Res_KW4>human leukocyte antigen (hla)</Res_KW4>
        <Res_KW5>antigen presentation</Res_KW5>
        <Plain_Description>We will explore new classes of antigens that can form targets of vaccines and immunotherapy in melanoma. In particular, we will compare the ability of small protein fragments that are generated via enzymatic modifications or through unusual proteolytic activities to stimulate patient immune responses to those protein fragments that contain cancer specific mutations. We anticipate that the inclusion of a broader variety of antigen classes will boost anti-cancer vaccines.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013641</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Dr Nigel Beebe</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>The development and potential of a malaria resistant mosquito for the Southwest Pacific</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$739,220.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | infectious diseases | </Field_s__of_Research>
        <Res_KW1>malaria </Res_KW1>
        <Res_KW2>mosquito-borne disease</Res_KW2>
        <Res_KW3>mosquito transmission</Res_KW3>
        <Res_KW4>population genetics</Res_KW4>
        <Res_KW5>gene transfer</Res_KW5>
        <Plain_Description>Malaria plagues the Southwest Pacific. With no vaccine, resistance to antimalarials growing, vector control is the mainstay in reducing malaria but mosquitoes are adapting to these tools. We are developing a malaria resistant mosquito in the lab with the capability to drive malaria resistant traits through populations. This project will permit the potential of this technology to be explored through population genomics and mathematical modelling to develop simulations of hypothetical releases.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013650</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Prof Leanne Delbridge</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Towards optimizing diabetes therapies for cardioprotection: Precision approaches for women</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,006,417.80</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>cardiorespiratory medicine and heamatology | cardiology (incl. cardiovascular diseases) | </Field_s__of_Research>
        <Res_KW1>diabetic cardiomyopathy </Res_KW1>
        <Res_KW2>diastolic dysfunction</Res_KW2>
        <Res_KW3>proteomics</Res_KW3>
        <Res_KW4>mechanotransduction</Res_KW4>
        <Res_KW5>cellular mechanisms</Res_KW5>
        <Plain_Description>Diabetes is an epidemic disease. A major cause of death in diabetic patients is due to heart damage &amp;amp; women are particularly vulnerable. No heart-specific therapies are available and current guidelines are not gender-targeted. The goal of this project is to understand why women have such high cardiac risk in diabetes, and to identify new treatment opportunities to maximise heart protection for diabetic women.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013757</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jack Chen</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Developing a real-time machine learning rapid response and risk stratification system for in hospital patients</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$768,889.20</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | public health and health services not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>health services research </Res_KW1>
        <Res_KW2>emergency medicine</Res_KW2>
        <Res_KW3>population health</Res_KW3>
        <Res_KW4>health care delivery</Res_KW4>
        <Res_KW5>health care evaluation</Res_KW5>
        <Plain_Description>We intend to develop and implement a scalable and accurate patient-centred AI system based on the information derived during the whole patient journey for patients in a normal and pandemic setting so as to provide a clinical triage system for patients that match critical resources to patient needs and augment the current rapid response system (RRS) through more accurate and tailored risk predicting. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013783</APP_ID>
        <Date_Announced>2021-11-04T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Simon Murray</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>Ideas Grants</Sub_Type>
        <Grant_Title>Promoting myelin repair in a refractory environment in vivo.</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,010,803.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | neurology and neuromuscular diseases | </Field_s__of_Research>
        <Res_KW1>brain-derived neurotrophic factor (bdnf) </Res_KW1>
        <Res_KW2>neurotrophins</Res_KW2>
        <Res_KW3>demyelinating disease</Res_KW3>
        <Res_KW4>oligodendrocytes</Res_KW4>
        <Res_KW5>remyelination</Res_KW5>
        <Plain_Description>Many nerve cells in the brain are ensheathed in myelin. Myelin is critical for optimal brain function as it supports nerve cell function and survival. Damage to myelin, as occurs in multiple sclerosis and other neurodegenerative diseases leaves nerve cells vulnerable to degeneration. This proposal aims to identify whether a molecular target we have identified that promotes myelin repair can be optimised and promote myelin repair in a novel and more complex model of brain injury.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008644</APP_ID>
        <Date_Announced>2021-11-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Anna Ralph</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2021 Partnership Projects - Peer Review Cycle 1</Sub_Type>
        <Grant_Title>The Communicate Study: partnership across the Top End to improve Aboriginal patients’ experience and outcomes of healthcare</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,499,896.70</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | aboriginal and torres strait islander health | </Field_s__of_Research>
        <Res_KW1>communication </Res_KW1>
        <Res_KW2>aboriginal health </Res_KW2>
        <Res_KW3>doctor-patient interaction </Res_KW3>
        <Res_KW4>patient/doctor communication </Res_KW4>
        <Res_KW5>clinical competence / skills </Res_KW5>
        <Plain_Description>Effective communication in healthcare improves patient outcomes. Aboriginal language interpreters should be used for around 50% of Aboriginal patients in Northern Territory Top End, but only around 18% of those in need are currently getting access. The Communicate Study, partnering Menzies with health and interpreter services aims to improve cultural safety in healthcare, focusing on improved uptake of Aboriginal interpreters and integration of Aboriginal Heath Practitioners into tertiary care. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010289</APP_ID>
        <Date_Announced>2021-11-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Yvette Roe</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2021 Partnership Projects - Peer Review Cycle 1</Sub_Type>
        <Grant_Title>To Be Born Upon a Pandanus Mat (Yothuw gayatha dhäwal’ guyaŋa’nharaw)</Grant_Title>
        <Admin_Institution>Charles Darwin University</Admin_Institution>
        <State>NT</State>
        <Sector>University</Sector>
        <Total>$1,497,855.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | aboriginal and torres strait islander health | </Field_s__of_Research>
        <Res_KW1>birth </Res_KW1>
        <Res_KW2>indigenous health </Res_KW2>
        <Res_KW3>midwifery </Res_KW3>
        <Res_KW4>maternal and child health </Res_KW4>
        <Res_KW5>health services research </Res_KW5>
        <Plain_Description>We will establish and evaluate, Australia’s ‘Birthing on Country’ very remote, demonstration site in Galiwin’ku, Elcho Island, Northern Territory. We will redesign maternal and infant health services for Yolŋu (Aboriginal) families who currently have one of the highest proportions of babies being born too soon (preterm) in Australia (22% versus 7% non-Indigenous Australians). Djäkamirrs’ (Indigenous doulas) will increase support for women to modify risk factors and reduce preterm birth by 50%. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010493</APP_ID>
        <Date_Announced>2021-11-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Sharon Goldfeld</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2021 Partnership Projects - Peer Review Cycle 1</Sub_Type>
        <Grant_Title>Development and evaluation of a Child and Family eHub to improve access, engagement and use of the existing community, social and mental health services system </Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$429,262.20</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | mental health | </Field_s__of_Research>
        <Res_KW1>community child health </Res_KW1>
        <Res_KW2>health care evaluation </Res_KW2>
        <Res_KW3>access to health care </Res_KW3>
        <Res_KW4>implementation </Res_KW4>
        <Res_KW5>child behaviour </Res_KW5>
        <Plain_Description>Most Australian children with mental health concerns don’t get the right care at the right time. With COVID-19 this will only get worse. This project aims to improve access and engagement of existing services to address problems early, especially for disadvantaged families. We will co-develop and test a Child and Family eHub, overlaying existing systems with an easily accessible digital entry point to seek information, connect with services, and provide a care navigator for those most in need.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2010866</APP_ID>
        <Date_Announced>2021-11-12T00:00:00</Date_Announced>
        <CIA_Name>Prof David Lubans</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2021 Partnership Projects - Peer Review Cycle 1</Sub_Type>
        <Grant_Title>Optimising the implementation of an evidence-based school program to engage adolescents in muscle-strengthening activities consistent with national guidelines </Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$709,054.50</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | health promotion | </Field_s__of_Research>
        <Res_KW1>physical activity </Res_KW1>
        <Res_KW2>implementation </Res_KW2>
        <Res_KW3>health promotion </Res_KW3>
        <Res_KW4>translational research </Res_KW4>
        <Res_KW5>school health promotion </Res_KW5>
        <Plain_Description>School-based physical activity interventions need to be ‘scaled-up’ to improve population health. The aim of this project is to study the effects of different implementation support models on the scale-up of an evidence-based physical activity program in NSW secondary schools. Expected outcomes include an optimal support model for scaling up school-based health promotion interventions, and population health benefits from participation in resistance training.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011157</APP_ID>
        <Date_Announced>2021-11-12T00:00:00</Date_Announced>
        <CIA_Name>Prof Catherine Sherrington</CIA_Name>
        <Grant_Type>Partnership Projects</Grant_Type>
        <Sub_Type>2021 Partnership Projects - Peer Review Cycle 1</Sub_Type>
        <Grant_Title>Promotion of evidence-based physical activity for older adults and people with disabilities by health professionals</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,440,374.50</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | public health and health services not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>disability </Res_KW1>
        <Res_KW2>ageing </Res_KW2>
        <Res_KW3>exercise therapy </Res_KW3>
        <Res_KW4>health promotion </Res_KW4>
        <Res_KW5>physical activity </Res_KW5>
        <Plain_Description>Promotion of physical activity by health services is part of the solution to global inactivity proposed in the WHO Global Action Plan on Physical Activity. Health professionals are an underutilised resource in the global fight against inactivity. This project aims to mobilise and empower Health professionals to encourage and support physical activity among patients by targeting implementation barriers identified at our Partnership health services.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>GNT1078523</APP_ID>
        <Date_Announced>2021-11-15T00:00:00</Date_Announced>
        <CIA_Name>Prof Bettina Meiser </CIA_Name>
        <Grant_Type>Research Fellowship</Grant_Type>
        <Sub_Type>Research Fellowship 6th Year Extension</Sub_Type>
        <Grant_Title>Psychosocial impact of genetic counselling and testing</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$131,769.60</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>genetics | genetics not elsewhere classified |</Field_s__of_Research>
        <Res_KW1>psychology </Res_KW1>
        <Res_KW2>public health </Res_KW2>
        <Res_KW3>genetics </Res_KW3>
        <Res_KW4>hereditary cancer </Res_KW4>
        <Res_KW5>health psychology </Res_KW5>
        <Plain_Description>Not applicable</Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008937</APP_ID>
        <Date_Announced>2021-11-16T00:00:00</Date_Announced>
        <CIA_Name>Prof Sotiris Vardoulakis</CIA_Name>
        <Grant_Type>Special Initiative</Grant_Type>
        <Sub_Type>Special Initiative in Human Health and Environmental Change</Sub_Type>
        <Grant_Title>Healthy Environments And Lives (HEAL) - National Research Network on Human Health and Environmental Change</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$10,000,000.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>psychology | social and community psychology</Field_s__of_Research>
        <Res_KW1>environmental health </Res_KW1>
        <Res_KW2>climate change adaption </Res_KW2>
        <Res_KW3>environmental intervention </Res_KW3>
        <Res_KW4>aboriginal health </Res_KW4>
        <Res_KW5>environmental epidemiology</Res_KW5>
        <Plain_Description>HEAL aims to strengthen the Australian community and health system’s resilience to changing environmental conditions, climate change and extreme weather events. This will be achieved by stimulating collaborative research that will improve the current understanding of the interactions between the climate, the natural and built environment and our health. HEAL will lead to more effective policies and measures that will protect and improve the health of the community and reduce inequalities.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2011289</APP_ID>
        <Date_Announced>2021-12-02T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Louise Cheng</CIA_Name>
        <Grant_Type>Ideas Grants</Grant_Type>
        <Sub_Type>2021 Ideas Grants</Sub_Type>
        <Grant_Title>Identification of metabolic alterations in cancer cachexia</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$894,806.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>genetics | developmental genetics (incl. sex determination) | biochemistry and cell biology | cell development, proliferation and death | biochemistry and cell biology | cell metabolism | </Field_s__of_Research>
        <Res_KW1>drosophila </Res_KW1>
        <Res_KW2>developmental biology </Res_KW2>
        <Res_KW3>cachexia </Res_KW3>
        <Res_KW4>wasting syndromes </Res_KW4>
        <Res_KW5>cell metabolism </Res_KW5>
        <Plain_Description>Cachexia is a metabolic disease where tumours cause muscle and fat to waste away.  We established a Drosophila (fruit fly) model of cachexia-like wasting, opening up a novel opportunity to use its powerful genetic tools to better understand  the genetic basis of cachexia-like wasting. This grant proposes to look at how organs can communicate with each other, and our findings will allow us to find potential new avenues for the development of treatment strategies for cachexia. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013881</APP_ID>
        <Date_Announced>2021-12-27T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Thomas Cox</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2021 Development Grants</Sub_Type>
        <Grant_Title>A First-In-Class Tumour Matrix Targeting Approach to Enhance Chemotherapy in Pancreatic Cancer</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$827,500.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | cancer cell biology | </Field_s__of_Research>
        <Res_KW1>extracellular matrix</Res_KW1>
        <Res_KW2>pancreatic cancer</Res_KW2>
        <Res_KW3>fibrosis</Res_KW3>
        <Res_KW4>stroma</Res_KW4>
        <Res_KW5>fibroblasts</Res_KW5>
        <Plain_Description>Chemotherapy is the standard-of-care for pancreatic cancer patients. Whilst chemotherapy initially works, it quickly becomes ineffective and patients go on to relapse. One reason for this failure is chemotherapy-induced scarring (fibrosis) in and around the tumour. This scarring blunts the effectiveness of subsequent rounds of treatment. Our preliminary data show that our novel compound can block this scar formation offering a novel stromal targeting approach to improve chemotherapy efficacy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013899</APP_ID>
        <Date_Announced>2021-12-27T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Anthony Dear</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2021 Development Grants</Sub_Type>
        <Grant_Title>Development of a Novel Photo-Angioplasty Device for the Treatment of Occlusive Peripheral Vascular Disease</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$808,505.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>cardiorespiratory medicine and heamatology | cardiology (incl. cardiovascular diseases) | </Field_s__of_Research>
        <Res_KW1>angioplasty</Res_KW1>
        <Res_KW2>artery bypass graft failure</Res_KW2>
        <Res_KW3>restenosis</Res_KW3>
        <Res_KW4>epigenetics</Res_KW4>
        <Res_KW5>photobiology</Res_KW5>
        <Plain_Description>We have designed and developed a new light-activated drug eluting balloon (DEB) angioplasty device termed Lumi-Solve, which targets drug delivery and activation specifically to the surface of a re-narrowed blood vessel, at the time of angioplasty balloon deployment, for the safer and more effective treatment of vascular disease. Our project aims to evaluate Lumi-Solve, in a large animal model with a view to commencing human trials shortly after completion of these studies.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013973</APP_ID>
        <Date_Announced>2021-12-27T00:00:00</Date_Announced>
        <CIA_Name>Prof Jonathan Baell</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2021 Development Grants</Sub_Type>
        <Grant_Title>Preventing reperfusion injury in stroke with an acutely dosed NK1R antagonist prodrug</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$653,527.20</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medicinal and biomolecular chemistry | biologically active molecules | </Field_s__of_Research>
        <Res_KW1>medicinal chemistry</Res_KW1>
        <Res_KW2>pharmaceutical treatment</Res_KW2>
        <Res_KW3>drug delivery</Res_KW3>
        <Res_KW4>pharmacokinetics</Res_KW4>
        <Res_KW5>ischaemic stroke</Res_KW5>
        <Plain_Description>Stroke represents a major clinical and societal burden (on individuals and society) and is the primary cause of adult disability, second-most common cause of dementia, and third-leading cause of death. We will develop a novel and effective intravenous form of a compound known to act beneficially in these clinical settings. This form of administration will act quickly and more effectively with beneficial stroke victim outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014002</APP_ID>
        <Date_Announced>2021-12-27T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Timothy Mercer</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2021 Development Grants</Sub_Type>
        <Grant_Title>Building Synthetic DNA Controls for Oxford Nanopore Sequencing.</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$786,252.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>genetics | genomics | </Field_s__of_Research>
        <Res_KW1>sequencing</Res_KW1>
        <Res_KW2>diagnosis</Res_KW2>
        <Res_KW3>genomics</Res_KW3>
        <Res_KW4>bioinformatics</Res_KW4>
        <Res_KW5>cancer</Res_KW5>
        <Plain_Description>The mutations that cause many cancers are often missed using current sequencing technologies because they are too large and complex. Our partner, Oxford Nanopore Technologies, developed a long-read sequencing method that can detect these complex mutations, but is too inaccurate and unreliable for use in clinical laboratories. We will build synthetic controls that improve the accuracy of long-read sequencing, and enable its use to diagnose mutations that are otherwise missed in cancer patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014063</APP_ID>
        <Date_Announced>2021-12-27T00:00:00</Date_Announced>
        <CIA_Name>Prof Matthias Ernst</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2021 Development Grants</Sub_Type>
        <Grant_Title>Developing HCK inhibitor drugs to improve immunotherapy</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$992,328.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Field_s__of_Research>
        <Res_KW1>immune modulation</Res_KW1>
        <Res_KW2>solid tumours</Res_KW2>
        <Res_KW3>therapy</Res_KW3>
        <Res_KW4>src-family tyrosine kinases</Res_KW4>
        <Res_KW5>inhibitors</Res_KW5>
        <Plain_Description>Anti-tumour immune responses are modulated by a cell type called macrophages, which suppress the effects of immunotherapy. We identified a molecule called HCK, which induces macrophages to inhibit the anti-tumour immune response. In collaboration with SYNthesis and the Cancer Therapeutics CRC we will develop inhibitors for HCK. We will test these compounds in preclinical cancer models to identify the most effective combination with immunotherapies to provide the greatest patient benefits.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014079</APP_ID>
        <Date_Announced>2021-12-27T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Kyle Hoehn</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2021 Development Grants</Sub_Type>
        <Grant_Title>Targeting metabolism to correct fatty liver disease</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$621,083.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | cell metabolism | </Field_s__of_Research>
        <Res_KW1>fatty liver disease</Res_KW1>
        <Res_KW2>energy metabolism</Res_KW2>
        <Res_KW3>mitochondria</Res_KW3>
        <Res_KW4>drug discovery</Res_KW4>
        <Res_KW5>mouse models</Res_KW5>
        <Plain_Description>The severe form of fatty liver disease steatohepatitis affects ~40 million people worldwide and has no approved treatment. This project aims to identify new drugs and test them in mouse models to establish proof-of-concept that they safely reverse steatohepatitis.  Success of this project will generate new drug candidates for human clinical testing.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014095</APP_ID>
        <Date_Announced>2021-12-27T00:00:00</Date_Announced>
        <CIA_Name>Prof Ricky O'Brien</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2021 Development Grants</Sub_Type>
        <Grant_Title>Lung Ventilation Imaging: A new device to protect the lungs for cancer treatment</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$1,075,714.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>other physical sciences | medical physics | </Field_s__of_Research>
        <Res_KW1>medical physics</Res_KW1>
        <Res_KW2>lung cancer</Res_KW2>
        <Res_KW3>radiation oncology</Res_KW3>
        <Res_KW4>medical imaging</Res_KW4>
        <Res_KW5>oncology</Res_KW5>
        <Plain_Description>We will develop a device that gives clinicians insight into how their patients lungs are functioning. The information our technology will provide will allow radiotherapy plans to be shaped to minimise side effects for each individual patient, and allow surgeons to assess suitability for surgery in marginal patients with greater confidence. We will leverage the proven track record of our industry partner in complementary technologies to develop our device into a commercially ready product.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014168</APP_ID>
        <Date_Announced>2021-12-27T00:00:00</Date_Announced>
        <CIA_Name>Dr Valerie Wasinger</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2021 Development Grants</Sub_Type>
        <Grant_Title>Development of a non-invasive mucosal integrity diagnostic and ingestible capsule sampling tool targeting IBD gut health.</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$345,635.20</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>medicinal and biomolecular chemistry | biologically active molecules | biochemistry and cell biology | analytical biochemistry | </Field_s__of_Research>
        <Res_KW1>diagnostic assay</Res_KW1>
        <Res_KW2>validation</Res_KW2>
        <Res_KW3>inflammatory bowel disease (ibd)</Res_KW3>
        <Res_KW4>proteome analysis</Res_KW4>
        <Res_KW5>gastrointestinal disease</Res_KW5>
        <Plain_Description>Inflammatory Bowel Disease (IBD) affects many Australians and is a chronic condition requiring life-long management and intervention. Current technologies to manage the disease include invasive colonoscopy or non-specific lab tests. There is a need for non-invasive methods to improve the health and well-being of people suffering from IBD. We wish to develop a non-invasive diagnostic and ingestible sampling capsule that can determine gut-health and guide treatment for the long-term patients. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014250</APP_ID>
        <Date_Announced>2021-12-27T00:00:00</Date_Announced>
        <CIA_Name>Prof Stuart Brierley</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2021 Development Grants</Sub_Type>
        <Grant_Title>Developing a first-in-class therapeutic for chronic visceral pain using venom derived peptides</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$998,858.88</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | peripheral nervous system | </Field_s__of_Research>
        <Res_KW1>chronic pain</Res_KW1>
        <Res_KW2>irritable bowel syndrome (ibs)</Res_KW2>
        <Res_KW3>nociception</Res_KW3>
        <Res_KW4>analgesia</Res_KW4>
        <Res_KW5>colon</Res_KW5>
        <Plain_Description>Irritable Bowel Syndrome (IBS) is a leading cause of chronic pain, both world-wide and in Australia, but is without treatment. Chronic pain arises from nerve fibres in the colon which fail to "reset" back to normal following inflammation. Targeting these nerve endings with drugs is a key advance in IBS treatment. This project will identify specific voltage-gated sodium channel analogues that act at the level of the colon to numb pain sensing nerve fibres, providing efficacious pain relief in IBS</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014380</APP_ID>
        <Date_Announced>2021-12-27T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Hamish Meffin</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2021 Development Grants</Sub_Type>
        <Grant_Title>Retinal Implant with Closed-loop, Multichannel Stimulation to Improve Visual Acuity</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$1,141,581.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>biomedical engineering | medical devices | ophthalmology and optometry | vision science | </Field_s__of_Research>
        <Res_KW1>biomedical engineering</Res_KW1>
        <Res_KW2>signal processing</Res_KW2>
        <Res_KW3>retinitis pigmentosa</Res_KW3>
        <Res_KW4>neuromodulation</Res_KW4>
        <Res_KW5>vision loss</Res_KW5>
        <Plain_Description>Previously we developed a retinal implant capable of restoring some vision to a group of patients blinded by the retinal disease, retinitis pigmentosa. However, the level of vision is relatively low. This project will develop a prototype retinal implant that aims to dramatically improve the level of vision provided. This would significantly increase the market of patients that could benefit from the implant.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014388</APP_ID>
        <Date_Announced>2021-12-27T00:00:00</Date_Announced>
        <CIA_Name>Prof Mark von Itzstein</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2021 Development Grants</Sub_Type>
        <Grant_Title>Targeting the Achille’s heel of multi-drug resistant Neisseria gonorrhoeae with drugs that disrupt metal homeostasis</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$1,116,524.60</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical microbiology | medical bacteriology | </Field_s__of_Research>
        <Res_KW1>neisseria gonorrhoeae</Res_KW1>
        <Res_KW2>antibiotic resistance</Res_KW2>
        <Res_KW3>treatment-resistant</Res_KW3>
        <Res_KW4>drug development</Res_KW4>
        <Res_KW5>microbiology</Res_KW5>
        <Plain_Description>Neisseria gonorrhoeae causes sexually transmitted disease gonorrhea. Most gonococcal infections are asymptomatic and can lead to pelvic disease, infertility and increasing risk of HIV co-transmission. Due to the recent emergence of multidrug resistant superbugs, N. gonorrhoeae is now classified as an immediate public-health threat. No vaccine is available. This ideas grant will generate new antibiotics to treat multidrug resistant gonorrhea infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014395</APP_ID>
        <Date_Announced>2021-12-27T00:00:00</Date_Announced>
        <CIA_Name>Prof Peter Leedman</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2021 Development Grants</Sub_Type>
        <Grant_Title>A novel RNA-based therapeutic for liver cancer</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$482,632.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | gastroenterology and hepatology | </Field_s__of_Research>
        <Res_KW1>microrna</Res_KW1>
        <Res_KW2>liver cancer</Res_KW2>
        <Res_KW3>toxicology</Res_KW3>
        <Res_KW4>mouse models</Res_KW4>
        <Res_KW5>novel therapeutic agents</Res_KW5>
        <Plain_Description>The outlook for patients with liver cancer is poor.   A new form of RNA-based treatment offers promise. An exciting development is the addition of a molecular hook to the RNA, which specifically targets the RNA-drug to the liver.   We have modified our drug, miR-7, to make it more effective in the body and also to specifically target the liver.   In this project we will evaluate how effective the new drug is and develop some of the essential data needed to progress it to a clinical trial. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014398</APP_ID>
        <Date_Announced>2021-12-27T00:00:00</Date_Announced>
        <CIA_Name>Prof Robert Casson</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2021 Development Grants</Sub_Type>
        <Grant_Title>RESCUING CONE PHOTORECEPTORS IN RETINITIS PIGMENTOSA WITH LASER-DELIVERED PHOTOBIOMODULATION</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$525,106.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>ophthalmology and optometry | ophthalmology | </Field_s__of_Research>
        <Res_KW1>photobiology</Res_KW1>
        <Res_KW2>retinitis pigmentosa</Res_KW2>
        <Res_KW3>photoreceptors</Res_KW3>
        <Res_KW4>laser</Res_KW4>
        <Res_KW5>neuroprotection</Res_KW5>
        <Plain_Description>This proposal develops a new laser to treat the blinding eye condition, retinitis pigmentosa. The low energy laser rescues the light-sensitive film at the back of the eye and preserves central vision preventing complete blindness.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014416</APP_ID>
        <Date_Announced>2021-12-27T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Mark Fear</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2021 Development Grants</Sub_Type>
        <Grant_Title>Development of a novel topical serine protease inhibitor for tissue repair and inflammatory skin disease </Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$590,264.40</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>pharmacology and pharmaceutical sciences | clinical pharmacology and therapeutics | </Field_s__of_Research>
        <Res_KW1>wound healing</Res_KW1>
        <Res_KW2>chronic inflammation</Res_KW2>
        <Res_KW3>skin disease</Res_KW3>
        <Res_KW4>burn injury</Res_KW4>
        <Res_KW5>atopic dermatitis</Res_KW5>
        <Plain_Description>Slow tissue repair, excessive scarring and many skin diseases are driven by the body’s inappropriate or excessive immune response to the injury or environmental trigger. A key enzyme that causes this excessive response is Granzyme B. We will develop a new drug that can target Granzyme B. We will generate the data to support the first in human trials of the drug at the end of this study to support translation to better treat patients with scarring, fibrosis and inflammatory skin disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014427</APP_ID>
        <Date_Announced>2021-12-27T00:00:00</Date_Announced>
        <CIA_Name>Dr Brad Sleebs</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2021 Development Grants</Sub_Type>
        <Grant_Title>Development of a potent and fast acting antimalarial that is orally efficacious in vivo</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,002,769.20</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medicinal and biomolecular chemistry | biologically active molecules | </Field_s__of_Research>
        <Res_KW1>malaria</Res_KW1>
        <Res_KW2>antimalarial</Res_KW2>
        <Res_KW3>drug discovery</Res_KW3>
        <Res_KW4>medicinal chemistry</Res_KW4>
        <Res_KW5>drug development</Res_KW5>
        <Plain_Description>Malaria is a devastating disease that causes 420,000 deaths worldwide annually. Critically malaria parasites have become resistant to nearly all currently used drug classes, and therefore there is an urgent need to develop new therapies.  We have identified a highly active antimalarial class with a known mechanism of action and all the prerequisites required to advance this antimalarial class into human clinic trials in partnership with Medicines for Malaria Venture and Janssen Pharmaceuticals.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014512</APP_ID>
        <Date_Announced>2021-12-27T00:00:00</Date_Announced>
        <CIA_Name>Prof David Craik</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2021 Development Grants</Sub_Type>
        <Grant_Title>Developing FXIIa inhibitors as next-generation anticoagulants</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$698,512.40</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medicinal and biomolecular chemistry | biologically active molecules | </Field_s__of_Research>
        <Res_KW1>thrombosis</Res_KW1>
        <Res_KW2>anticoagulants</Res_KW2>
        <Res_KW3>protease inhibitors</Res_KW3>
        <Res_KW4>synthetic lipopeptides</Res_KW4>
        <Res_KW5>drug development</Res_KW5>
        <Plain_Description>We have designed a new potential drug to inhibit disease-related blood clotting without interfering with normal clotting processes. The new molecule is promising because it is effective at stopping clotting, but to develop it into a drug we need to generate additional data confirming its safety and stability, then test it in animal models of thrombosis as a precursor to human trials. This project aims to generate these data and to optimise the lead molecule to make it suitable for such trials.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014538</APP_ID>
        <Date_Announced>2021-12-27T00:00:00</Date_Announced>
        <CIA_Name>Prof Barbara Fazekas de St Groth</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2021 Development Grants</Sub_Type>
        <Grant_Title>Development of a novel blood test that accurately predicts response to checkpoint therapy in cancer patients</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$571,216.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Field_s__of_Research>
        <Res_KW1>cancer immunotherapy</Res_KW1>
        <Res_KW2>lung cancer</Res_KW2>
        <Res_KW3>flow cytometry</Res_KW3>
        <Res_KW4>clinical test</Res_KW4>
        <Res_KW5>cancer immunology</Res_KW5>
        <Plain_Description>New cancer therapies that target the patient’s immune system can cure patients whose cancers are resistant to all other therapies. However these new immune targeting treatments are effective in only a minority of patients, can cause significant toxicity and are very expensive. This application will meet the urgent need for a blood test that can accurately predict which patients will respond before therapy is started.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014544</APP_ID>
        <Date_Announced>2021-12-27T00:00:00</Date_Announced>
        <CIA_Name>Dr Richard Clark</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2021 Development Grants</Sub_Type>
        <Grant_Title>Novel long-acting and orally delivered conotoxin-based peptides with both analgesic efficacy and disease modifying potential. </Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$948,644.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medicinal and biomolecular chemistry | proteins and peptides | </Field_s__of_Research>
        <Res_KW1>peptides</Res_KW1>
        <Res_KW2>peptide synthesis</Res_KW2>
        <Res_KW3>rational drug design</Res_KW3>
        <Res_KW4>chronic pain</Res_KW4>
        <Res_KW5>neuropathic pain</Res_KW5>
        <Plain_Description>Chronic pain is a common and debilitating condition and there is a significant need for new analgesics to treat this pain. We have designed conotoxin (small peptides from marine cone snail venom) analogues with potent analgesic effects and the objective of this project is the preclinical development of these molecules as novel long-acting treatments of chronic pain.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014584</APP_ID>
        <Date_Announced>2021-12-27T00:00:00</Date_Announced>
        <CIA_Name>Prof Marc Pellegrini</CIA_Name>
        <Grant_Type>Development Grants</Grant_Type>
        <Sub_Type>2021 Development Grants</Sub_Type>
        <Grant_Title>c-FIND: Diagnosis of infections in minutes</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$868,752.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | infectious diseases | </Field_s__of_Research>
        <Res_KW1>infectious diseases</Res_KW1>
        <Res_KW2>diagnostic</Res_KW2>
        <Res_KW3>molecular design</Res_KW3>
        <Res_KW4>antimicrobial resistance</Res_KW4>
        <Res_KW5>paediatric</Res_KW5>
        <Plain_Description>Diagnostic tests dictate treatment algorithms for infectious diseases which has become incredibly complex due antibiotic resistance. The inability to diagnose infections or lengthy delays in diagnosis result in patients being unable to access appropriate, timely or effective treatment. WEHI has been using a gene technology called CRISPR for over a decade and we have adapted this to accurately detect infections in patients within minutes to inform management at the point of care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013798</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Luke McLean</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Understanding response and resistance to immunotherapy in immunocompromised patients with cutaneous squamous cell carcinomas</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Field_s__of_Research>
        <Res_KW1>immunotherapy </Res_KW1>
        <Res_KW2>non-melanoma skin cancer</Res_KW2>
        <Res_KW3>immunocompromised</Res_KW3>
        <Res_KW4>molecular oncology</Res_KW4>
        <Res_KW5>drug resistance</Res_KW5>
        <Plain_Description>Cutaneous squamous cell carcinoma (CSCC) is common in those with impaired immune systems and these patients have been excluded from the major immunotherapy trials. This research looks at CSCC that has improved or worsened on immunotherapy so we can better understand why some tumours respond and others do not. This will help assess who will benefit from immunotherapy, how we can fight resistance and improve treatment outcomes for vulnerable immunosuppressed patients.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013800</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Yew Li Dang</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Using twin studies to investigate epilepsy aetiology and antiepileptic drug-induced birth defects</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | neurology and neuromuscular diseases | clinical sciences | medical genetics (excl. cancer genetics) | </Field_s__of_Research>
        <Res_KW1>epilepsy </Res_KW1>
        <Res_KW2>genetics</Res_KW2>
        <Res_KW3>twin studies</Res_KW3>
        <Res_KW4>antiepileptic drugs</Res_KW4>
        <Res_KW5>seizures</Res_KW5>
        <Plain_Description>By measuring and comparing the degree of similarity in a trait or disease between identical and non-identical twins, we can understand how much of the difference in a trait or disease between people is attributable to genes. This project will use twins to study the genetic contributions to epilepsy and to birth defects seen in babies born to mothers taking antiepileptic medications in pregnancy. The results will improve patient management and lead to the development of better treatments.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013809</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Lucy McGrath-Cadell</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Understanding the genetics and mechanisms of spontaneous coronary artery dissection</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$97,640.33</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>cardiorespiratory medicine and heamatology | cardiology (incl. cardiovascular diseases) | </Field_s__of_Research>
        <Res_KW1>acute coronary syndromes </Res_KW1>
        <Res_KW2>coronary heart disease (chd)</Res_KW2>
        <Res_KW3>transgenic animals</Res_KW3>
        <Res_KW4>women's health</Res_KW4>
        <Res_KW5>computed tomography</Res_KW5>
        <Plain_Description>SCAD occurs in young women as a bleed into the wall of an artery of the heart, resulting in a heart attack. Cause(s) are not known but there is a genetic link in some cases. I plan to: (1) use advanced heart imaging to define differences between heart arteries of affected and unaffected people; (2) use animal models to correlate the observed characteristics (phenotype) and genetics (genotype) of SCAD; (3) sequence DNA from people with SCAD and selected relatives to identify causative genes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013816</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Ralley Prentice</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>The Pregnancy in Crohn's and Colitis - Observations, Levels and Outcomes Extension (PICCOLO - X) study</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$101,376.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>immunology | cellular immunology | clinical sciences | gastroenterology and hepatology | paediatrics and reproductive medicine | foetal development and medicine | </Field_s__of_Research>
        <Res_KW1>inflammatory bowel disease (ibd) </Res_KW1>
        <Res_KW2>reproductive immunology</Res_KW2>
        <Res_KW3>reproductive health</Res_KW3>
        <Res_KW4>infant health</Res_KW4>
        <Res_KW5>biological therapy</Res_KW5>
        <Plain_Description>Poorly controlled IBD has been shown to negatively affect outcomes for mother and baby. As newer medications become available to treat IBD, it is increasingly important to determine: 1. How disease activity can be accurately and non-invasively monitored in pregnancy. 2. To what degree medications cross the placenta into the baby. 3. For how long medications remain detectable in the baby after delivery. 4. The effect on the baby’s brain and immune system development. PICCOLO-X will address these.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013817</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Julia Lai-Kwon</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Harnessing the power of Patient Reported Outcomes (PROs): demonstrating novel applications of PROs in the care of oncology patients </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | solid tumours | </Field_s__of_Research>
        <Res_KW1>melanoma </Res_KW1>
        <Res_KW2>health services research</Res_KW2>
        <Res_KW3>patient/doctor communication</Res_KW3>
        <Res_KW4>medical oncology</Res_KW4>
        <Res_KW5>patient outcomes</Res_KW5>
        <Plain_Description>Patient-reported outcomes (PROs) empower patients to communicate their symptoms and needs to clinicians.  Understanding the impact of treatment from a patient’s perspective is vital to ensure their concerns are addressed and to inform improvements to cancer care.  This study will examine new ways of using PROs to understand the patient experience, enable treatment side effects to be captured and communicated with patients, and promote the collection of PROs in clinical registries.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013821</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Michael Zhu</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Long-term Outcomes of Surgery for Diseases of the Aortic Valve in Children</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$116,321.17</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>cardiorespiratory medicine and heamatology | cardiology (incl. cardiovascular diseases) | clinical sciences | surgery | paediatrics and reproductive medicine | paediatrics | </Field_s__of_Research>
        <Res_KW1>congenital heart disease </Res_KW1>
        <Res_KW2>cardiac surgery</Res_KW2>
        <Res_KW3>aortic valve</Res_KW3>
        <Res_KW4>paediatric</Res_KW4>
        <Res_KW5>surgical outcomes research</Res_KW5>
        <Plain_Description>Over 2400 children in Australia are born with a heart defect annually. Up to 7% will have an abnormal aortic heart valve and need open-heart surgery in order to survive. Although surgery is often successful, affected children will need multiple heart operations throughout their life and face heart complications and premature death. This study will investigate the long-term outcomes of aortic valve surgery in children and aim to identify strategies to minimise complications and maximise survival.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013829</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Jayson Jeganathan</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Negative Symptoms of Psychosis</Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$93,904.17</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | central nervous system | </Field_s__of_Research>
        <Res_KW1>psychiatry </Res_KW1>
        <Res_KW2>neuroscience</Res_KW2>
        <Res_KW3>neuroimaging</Res_KW3>
        <Res_KW4>psychophysics</Res_KW4>
        <Res_KW5>functional magnetic resonance imaging (fmri)</Res_KW5>
        <Plain_Description>Impairments in facial expressivity, motivation, and sociality – the ‘negative symptoms’ - are the most debilitating features of psychotic disorders, yet they are inadequately treated. In this study, I will use facial emotion detection algorithms, functional brain imaging, and novel tasks including real-time facial feedback and heart rate feedback, to discover the changes in the brain’s emotional circuits that underlie negative symptoms. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013831</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Ouli Xie</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Evolution of Streptococcal pathovars</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$123,793.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | infectious diseases | genetics | genomics | biochemistry and cell biology | bioinformatics | </Field_s__of_Research>
        <Res_KW1>streptococcal disease </Res_KW1>
        <Res_KW2>bacterial genetics</Res_KW2>
        <Res_KW3>bacterial evolution</Res_KW3>
        <Res_KW4>bacterial virulence factors</Res_KW4>
        <Res_KW5>antigenic variation</Res_KW5>
        <Plain_Description>Streptococcus dysgalactiae subspecies equisimilis (group C/G Streptococcus) is a bacterium that is increasingly recognised as a cause of serious human disease. It shares genes and disease manifestations with the closely related bacteria, Streptococcus pyogenes (group A Streptococcus). We aim to analyse a global streptococcal genetic database to identify common drivers of disease and potential shared vaccine targets to inform public health and vaccine approaches to combat streptococcal disease.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013839</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Adrian Lee</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Towards the understanding of the immunopathogenesis of autoantibody-mediated systemic diseases: new approaches to old problems</Grant_Title>
        <Admin_Institution>Garvan Institute of Medical Research</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>immunology | autoimmunity | </Field_s__of_Research>
        <Res_KW1>autoantibodies </Res_KW1>
        <Res_KW2>autoimmune disease</Res_KW2>
        <Res_KW3>b cells</Res_KW3>
        <Res_KW4>diagnostic</Res_KW4>
        <Res_KW5>lupus</Res_KW5>
        <Plain_Description>Autoantibodies and white cells called B cells are found in systemic autoimmune diseases such as lupus. These are normally present in healthy individuals but a series of failed checkpoints enable them to go “rogue”, damage host tissue and cause debilitating symptoms. Understanding their molecular signatures will allow me to understand the processes that occur that lead to autoimmunity. This will help create personalised therapies for patients to “eliminate” these rogue populations.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013842</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Jessica Fairley</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Meeting an unmet need in systemic sclerosis: defining the burden of arrhythmia and sudden cardiac death </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | rheumatology and arthritis | </Field_s__of_Research>
        <Res_KW1>scleroderma </Res_KW1>
        <Res_KW2>muscle disease</Res_KW2>
        <Res_KW3>cardiomyopathy</Res_KW3>
        <Res_KW4>risk factors</Res_KW4>
        <Res_KW5>treatment</Res_KW5>
        <Plain_Description>Scleroderma is an autoimmune condition which damages multiple organs. Scleroderma patients are at risk of heart rhythm abnormalities which can result in sudden death. We do not understand why some people develop heart problems, or how to identify patients at greatest risk of rhythm abnormalities. We aim to determine how often heart rhythm problems occur in scleroderma, to understand how to predict risk of heart rhythm disturbances and potentially prevent them from occurring.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013844</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Michael Lim</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Randomised Evaluation of the Impact of Catheter Ablation versus Medical Therapy on Psychological Distress and Neurocognitive Function in Atrial Fibrillation</Grant_Title>
        <Admin_Institution>Melbourne Health</Admin_Institution>
        <State>VIC</State>
        <Sector>Health</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>cardiorespiratory medicine and heamatology | cardiology (incl. cardiovascular diseases) | </Field_s__of_Research>
        <Res_KW1>atrial fibrillation </Res_KW1>
        <Res_KW2>psychological distress</Res_KW2>
        <Res_KW3>cognitive dysfunction</Res_KW3>
        <Res_KW4>randomised controlled trial (rct)</Res_KW4>
        <Res_KW5>quality of life</Res_KW5>
        <Plain_Description>Atrial fibrillation (AF), a type of arrhythmia, is a risk factor for both psychological distress and cognitive decline. This study aims to determine if potentially curative catheter ablation procedures result in a greater improvement in markers of psychological distress and neurocognitive function compared to ongoing anti-arrhythmic drugs. We will also assess if catheter ablation procedures lead to reduced AF burden and hospitalisations as well as improved quality of life and cardiac function.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013845</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Tara Guckel</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Advancing the prevention and early intervention for co-occurring anxiety and alcohol use disorders</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$93,056.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | mental health | </Field_s__of_Research>
        <Res_KW1>alcohol abuse </Res_KW1>
        <Res_KW2>anxiety disorders</Res_KW2>
        <Res_KW3>youth</Res_KW3>
        <Res_KW4>cognitive behaviour therapy</Res_KW4>
        <Res_KW5>addiction prevention</Res_KW5>
        <Plain_Description>Alcohol use disorders often occur together with anxiety disorders, especially among youth. When these two occur together, individuals can have worse symptoms and treatment outcomes. This study will enhance the prevention and early intervention between anxiety and hazardous alcohol use by identifying key underlying mechanisms driving their relationship, and optimising interventions which address both conditions simultaneously.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013862</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Adithya Balasubramanian</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Targeting immune resistance mechanisms to enhance anti-tumour immunity in Non-Small Cell Lung Cancer</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$97,640.33</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | cancer cell biology | oncology and carcinogenesis | solid tumours | immunology | tumour immunology | </Field_s__of_Research>
        <Res_KW1>lung cancer </Res_KW1>
        <Res_KW2>immune surveillance</Res_KW2>
        <Res_KW3>cancer immunotherapy</Res_KW3>
        <Res_KW4>non-small cell lung cancer</Res_KW4>
        <Res_KW5>cancer immunology</Res_KW5>
        <Plain_Description>Lung cancer remains the leading cause of cancer related death globally. Treatments designed to unleash the immune system’s brakes (‘immunotherapy’) have resulted in significantly improved long-term survival in only a minority of patients. Tumour cells evolve to escape the immune system by silencing signals that allow their recognition by immune cells. We will identify means to reactivating these signals could enable immunotherapy to work in these otherwise resistant tumours.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013877</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Larissa Trease</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Risk factors for and burden of low back pain in elite athletes.</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>human movement and sports science | sports medicine | </Field_s__of_Research>
        <Res_KW1>sports medicine </Res_KW1>
        <Res_KW2>injury epidemiology</Res_KW2>
        <Res_KW3>injury prevention</Res_KW3>
        <Res_KW4>athlete training programs</Res_KW4>
        <Res_KW5>spinal health</Res_KW5>
        <Plain_Description>Despite being in peak physical condition, athletes experience low back pain (LBP) at a higher rate than other members of our community.  The reasons for this are not well understood and the advice to "keep active" that is given to non-athletic patients is less appropriate for athletes. This project will recruit and follow 300 elite athletes for one year to identify risk factors for athlete LBP. The project will also measure the cost of LBP in terms of episodes of pain and training time lost.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013894</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Lachlan Batty</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Young people with old knees: The role of matrix metalloproteinase 3 and type 2 collagen C-telopeptide fragments in predicting post traumatic osteoarthritis after anterior cruciate ligament reconstruction</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$101,376.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>biochemistry and cell biology | biochemistry and cell biology not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>knee reconstruction </Res_KW1>
        <Res_KW2>knee cartilage</Res_KW2>
        <Res_KW3>knee osteoarthritis</Res_KW3>
        <Res_KW4>cartilage</Res_KW4>
        <Res_KW5>ligament</Res_KW5>
        <Plain_Description>Anterior cruciate ligament (ACL) injuries are common in young and active people. The development of knee arthritis after ACL injury and ACL surgery is a concern because it can lead to a situation were a young patient has an "old knee". This scenario is a major cause of disability and is very challenging to treat. This research is important in identifying patients at risk of premature arthritis and to facilitate prevention, treatment and better outcomes for this young patient group.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013908</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Yi Chao Foong</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Validation and implementation of smartphone-based digital biomarkers in multiple sclerosis to define subclinical progression and treatment failure: the ACTIVE MS study</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | central nervous system | </Field_s__of_Research>
        <Res_KW1>multiple sclerosis (ms) </Res_KW1>
        <Res_KW2>biomarkers</Res_KW2>
        <Res_KW3>disease progression</Res_KW3>
        <Res_KW4>patient participation</Res_KW4>
        <Res_KW5>quantitative magnetic resonance imaging (mri)</Res_KW5>
        <Plain_Description>Multiple sclerosis (MS) is a leading cause of disability amongst young Australian adults. To date, only 2 effective treatments for progressive MS has been found. Current treatment is limited by the lack of accurate tools to detect disease progression, which leads to inefficient clinical trials for progressive MS. This project aims to establish smartphone-based apps as a tool to monitor disease activity and detect subtle clinical progression, thereby empowering patients in their own care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013928</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Miss Sophia Garlick Bock</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Comorbid Mental Health and Drug and Alcohol Use Among Sexuality and Gender Diverse Young People in Australia</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$93,056.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | mental health | public health and health services | health and community services | statistics | biostatistics | </Field_s__of_Research>
        <Res_KW1>sexuality </Res_KW1>
        <Res_KW2>gender</Res_KW2>
        <Res_KW3>adolescent</Res_KW3>
        <Res_KW4>substance use</Res_KW4>
        <Res_KW5>mental health</Res_KW5>
        <Plain_Description>This study aims to fill a gap in current literature around existing rates of comorbid mental ill-health and drug and alcohol use among young sexuality and gender diverse people (aged 14-25). Existing literature has demonstrated that this population have higher rates of mental ill-health and drug and alcohol use compared to their heterosexual and cisgender peers. I will examine the rates and risk and protective factors of comorbidity among this group, using nationally representative datasets. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013946</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Sonali Shah</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Hypertension with low renin - new insights into prevalence, pathophysiology and management</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | endocrinology | </Field_s__of_Research>
        <Res_KW1>hypertension </Res_KW1>
        <Res_KW2>aldosterone</Res_KW2>
        <Res_KW3>mineralocorticoid receptor</Res_KW3>
        <Res_KW4>renin-angiotensin system (ras)</Res_KW4>
        <Res_KW5>cardiovascular disease</Res_KW5>
        <Plain_Description>High blood pressure is a major cause of death affecting over 6 million Australians, yet two-thirds of patients have poor control. Many of these patients may have a type of hypertension that will respond well to a cheap and widely available medicine called an aldosterone blocker. We will test this drug against currently recommended hypertension treatments to find out if our approach will improve blood pressure control and the overall health of patients. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013949</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Desiree LaGrappe</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Maternal and Child Health Nursing: A golden opportunity to integrate screening for reproductive coercion and increase effective contraception use?</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$101,541.92</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>nursing | clinical nursing: primary (preventative) | public health and health services | primary health care | paediatrics and reproductive medicine | reproduction | </Field_s__of_Research>
        <Res_KW1>maternal and child health </Res_KW1>
        <Res_KW2>nursing</Res_KW2>
        <Res_KW3>reproductive health</Res_KW3>
        <Res_KW4>domestic violence</Res_KW4>
        <Res_KW5>contraception in female</Res_KW5>
        <Plain_Description>This research will create and test a short set of questions about behaviours used to control the pregnancy choices of another person. We aim to help health care workers talk to clients about making a safety plan and planning a pregnancy. The questions will be tested in the Victorian Maternal Child Health Service where nurses currently ask about domestic and family violence. Researchers will also review research papers and talk to nurses, their clients and experts to learn about their opinions.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013951</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Olivia Price</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Preventing infectious disease and reducing associated harms among people who inject drugs</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$93,056.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | epidemiology | clinical sciences | infectious diseases | public health and health services | public health and health services not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>injecting drug use </Res_KW1>
        <Res_KW2>vaccination</Res_KW2>
        <Res_KW3>blood-borne communicable diseases</Res_KW3>
        <Res_KW4>infectious diseases</Res_KW4>
        <Res_KW5>sexually-transmitted infections (sti)</Res_KW5>
        <Plain_Description>People who inject drugs (PWID) are an understudied population and there are gaps in our understanding of their experience with infectious disease. This project will produce crucial evidence on: 1) vaccination rates and barriers; 2) rates of infection; 3) service utilisation after infection; and 4) effect of drug dependence treatment on infectious disease-related outcomes. These data will inform interventions to prevent and treat infectious disease, improving health outcomes of PWID.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013953</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Isabelle Meulenbroeks</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>The impact of COVID-19 and associated health policies on access to allied healthcare, care quality, and health outcomes in Australian residential aged care facilities</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$101,541.92</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | aged health care | </Field_s__of_Research>
        <Res_KW1>aged care </Res_KW1>
        <Res_KW2>residential care</Res_KW2>
        <Res_KW3>health care utilisation</Res_KW3>
        <Res_KW4>covid-19</Res_KW4>
        <Res_KW5>health outcomes</Res_KW5>
        <Plain_Description>This PhD seeks to explore care quality, health outcomes, and allied healthcare delivery in residential aged care facilities pre and during COVID-19. This PhD uses electronic medical record data from a large aged care provider. Findings will be used to inform care practices and policy during future RACF lockdowns which occur regularly for conditions like influenza. The results also address key policy areas in care quality, e.g., falls, restraint use, and access to allied healthcare.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013961</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Katie Lee</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Dora Lush Basic Science Research</Sub_Type>
        <Grant_Title>Genomic architecture of skin in the vicinity of previous melanoma in photodamaged and non-photodamaged areas</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$77,630.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | dermatology | genetics | genomics | genetics | genome structure and regulation | </Field_s__of_Research>
        <Res_KW1>melanoma </Res_KW1>
        <Res_KW2>skin</Res_KW2>
        <Res_KW3>photocarcinogenesis</Res_KW3>
        <Res_KW4>genomics</Res_KW4>
        <Res_KW5>gene transcription</Res_KW5>
        <Plain_Description>UV damage is a cause of melanoma-associated mutations, but recent work shows that even normal skin is awash with mutations. Why do some sites become melanoma, but not in nearby, equally UV-damaged sites? I will identify genomic aberrations, that are markers of melanoma-prone sites, by assessing skin from UV-damaged sites near melanomas, UV-damaged sites away from melanomas, and sun-protected sites with spatial profiling technology that will enable a molecular map of aberrations across the skin.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013970</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Gemma Reynolds</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>High-risk lymphoproliferative malignancies in the era of novel therapies: Infection risk, surveillance and prophylaxis</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | infectious diseases | immunology | cellular immunology | library and information studies | informetrics | </Field_s__of_Research>
        <Res_KW1>antifungal </Res_KW1>
        <Res_KW2>fungal infection</Res_KW2>
        <Res_KW3>bacterial infection</Res_KW3>
        <Res_KW4>haematological malignancy</Res_KW4>
        <Res_KW5>novel therapies</Res_KW5>
        <Plain_Description>Opportunistic infection risk in lymphoma patients is incompletely understood, especially amongst heavily pre-treated patients receiving novel cellular therapies. This project will explore infection epidemiology, prediction and prophylaxis strategies amongst lymphoma patients. Retrospective cohort analysis, immune-profiling, multivariate analysis of infection risk and national audit of prophylaxis strategies will be conducted, informing future infection prevention and treatment strategies. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013981</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Elizabeth Armari</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Developing and evaluating an evidence-based training program for improving labour and childbirth care in India. </Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$101,376.50</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>paediatrics and reproductive medicine | obstetrics and gynaecology | </Field_s__of_Research>
        <Res_KW1>maternal health </Res_KW1>
        <Res_KW2>health care worker education</Res_KW2>
        <Res_KW3>public health impact</Res_KW3>
        <Res_KW4>labour</Res_KW4>
        <Res_KW5>program evaluation</Res_KW5>
        <Plain_Description>Prolonged labour is a major cause of stillbirth and maternal haemorrhage. The WHO Labour Care Guide (LCG) is a labour-monitoring tool which assists nurses, midwives and doctors provide early and effective interventions to prevent these complications. In my PhD, I will develop a LCG training program and evaluate its effects on LCG use within four hospitals in India. By optimizing LCG use, we expect the quality of maternity care and women's childbirth experiences to improve.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2013987</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Shania Liu</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Responsible pre-operative Opioid use for Hip and knee ArthropLasTy (OpioidHALT) study</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$81,985.42</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>pharmacology and pharmaceutical sciences | clinical pharmacy and pharmacy practice | </Field_s__of_Research>
        <Res_KW1>opioid analgesia </Res_KW1>
        <Res_KW2>total hip replacement</Res_KW2>
        <Res_KW3>knee replacement</Res_KW3>
        <Res_KW4>clinical trial</Res_KW4>
        <Res_KW5>qualitative study</Res_KW5>
        <Plain_Description>Opioids are medicines used to manage strong pain, but are associated with significant side effects. Opioids are often prescribed inappropriately for osteoarthritis and, when used before surgery, lead to worse pain and longer hospital stay. We propose an intervention where pharmacists educate patients on pain self-management and help with lowering opioid doses before surgery. This research is projected to save $5 million from safer opioid use and reduced hospital costs.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014022</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Anthony Hew</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Revolutionising System Reform in Mental Health: Addressing Gaps in the System through Big Data and Data Linkage</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$116,321.17</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | mental health | </Field_s__of_Research>
        <Res_KW1>mental health services </Res_KW1>
        <Res_KW2>health services research</Res_KW2>
        <Res_KW3>data analysis</Res_KW3>
        <Res_KW4>data linkage</Res_KW4>
        <Res_KW5>access to health care</Res_KW5>
        <Plain_Description>The current mental health system in Australia is not providing the care to those that need it the most. This program of research aims to understand how the mental health system is failing these individuals though an internationally unique approach of analysing population-level ambulance and healthcare records to provide insights into how to improve and re-develop the system. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014024</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Noa Amir</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Identifying and addressing the needs and priorities of patients with  genetic kidney disease and their families</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$97,640.33</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | epidemiology | public health and health services | health and community services | </Field_s__of_Research>
        <Res_KW1>kidney disease </Res_KW1>
        <Res_KW2>genetic disorders</Res_KW2>
        <Res_KW3>clinical epidemiology</Res_KW3>
        <Res_KW4>patient education</Res_KW4>
        <Res_KW5>service delivery</Res_KW5>
        <Plain_Description>Chronic kidney disease has a genetic cause in 10% of affected adults and up to 70% of children. A diagnosis of genetic kidney disease (GKD) can bring about a complex emotional response, this psychological burden if not addressed leads to frustration, and distress. I aim to describe patient and clinician experiences of genetic testing, and of GKD, determine patient priorities for genetic testing and models of care in GKD, and develop and implement patient resources to improve care in GKD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014035</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Aaron Kee Yee Wong</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Personalising Pain Relief for People With Cancer: The Right Opioid For the Right Person at the Right Time</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$93,904.17</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>pharmacology and pharmaceutical sciences | pharmacogenomics | </Field_s__of_Research>
        <Res_KW1>cancer pain </Res_KW1>
        <Res_KW2>pharmacogenomics</Res_KW2>
        <Res_KW3>palliative care</Res_KW3>
        <Res_KW4>clinical decision making</Res_KW4>
        <Res_KW5>biomarkers</Res_KW5>
        <Plain_Description>Cancer pain is common and distressing. There is no scientific method to predict which opioid will work for which person. The same opioid may treat one person’s pain well, but cause confusion, or be ineffective for another. This multi-phase project aims to transform pain management.It will consolidate the evidence, and evaluate the impact and feasibility of using gene testing to personalise opioid prescribing for cancer, so that the right opioid is prescribed to the right person at the right time</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014036</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Laura Eades</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Biomarker profiles in Indigenous Australians with systemic lupus erythematosus</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>immunology | autoimmunity | </Field_s__of_Research>
        <Res_KW1>systemic lupus erythematosus (sle) </Res_KW1>
        <Res_KW2>indigenous australians</Res_KW2>
        <Res_KW3>biomarkers</Res_KW3>
        <Res_KW4>genomics</Res_KW4>
        <Res_KW5>proteomics</Res_KW5>
        <Plain_Description>Lupus is a serious, incurable illness which reduces quality of life and life expectancy. Indigenous Australians have more frequent and severe lupus than the general population, although the reasons for this are unclear. I aim to analyse proteins in the blood of Indigenous and non-Indigenous lupus patients, to determine if there are biochemical differences which explain these disparities. This may help us select better treatments for Indigenous lupus patients in the future.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014037</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Edmund Chung</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Treatments to expand regulatory T cells and/or deplete autoantibody production in primary membranous nephropathy</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$97,640.33</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | nephrology and urology | immunology | autoimmunity | immunology | applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) | </Field_s__of_Research>
        <Res_KW1>experimental glomerulonephritis </Res_KW1>
        <Res_KW2>glomerulonephritis</Res_KW2>
        <Res_KW3>regulatory t cells</Res_KW3>
        <Res_KW4>cell therapy</Res_KW4>
        <Res_KW5>autoimmunity</Res_KW5>
        <Plain_Description>Primary membranous nephropathy (pMN) is a kidney disease caused by antibodies that attack the kidney (autoantibody) and is often difficult to treat. We propose research into treatments in a rat model of pMN that target autoantibody-producing immune cells or promote regulatory immune cells, using manufactured immune cells and protein vaccination. We will also compare the immune cells in humans with pMN and healthy individuals to identify specific immune cells targetable using our new treatments. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014038</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Hiu Tat Chan</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Dora Lush Basic Science Research</Sub_Type>
        <Grant_Title>Towards vaginal microbiota stability: new treatment paradigm for bacterial vaginosis</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$97,640.33</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical microbiology | medical microbiology not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>bacteriophage </Res_KW1>
        <Res_KW2>bacteria</Res_KW2>
        <Res_KW3>microbial ecology</Res_KW3>
        <Res_KW4>disease mechanisms</Res_KW4>
        <Res_KW5>gynaecology</Res_KW5>
        <Plain_Description>Bacterial vaginosis (BV) is very common in reproductive aged women. Current therapies are not very effective. However bacterial vaginosis is linked with poor reproductive health outcomes in women. New therapies are needed. Phages are viruses that attack bacteria, and CPR bacteria are a group of little-known bacteria that parasitise other bacteria. This research will investiage how phages and CPR bacteria affect vaginal health and develop new BV therapies based on phages and CPR bacteria.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014056</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Mr Dominic Delport</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Using mathematical models to generate evidence to support Australia’s COVID-19 responses and prepare for future pandemics</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$93,056.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | epidemiology | </Field_s__of_Research>
        <Res_KW1>epidemiology </Res_KW1>
        <Res_KW2>infectious diseases</Res_KW2>
        <Res_KW3>information systems/decision support systems</Res_KW3>
        <Res_KW4>health systems</Res_KW4>
        <Res_KW5>mathematical modelling</Res_KW5>
        <Plain_Description>My PhD will utilise mathematical modelling to generate evidence to support COVID-19 responses in Australia and prepare for future epidemics/pandemics. The main objectives are to address current COVID-19 policy questions (e.g. vaccination strategies), learn lessons from deep analysis of previous COVID-19 outbreaks in Australia, and produce generalisable and impactful guidelines for future pandemic responses.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014074</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Mr Karan Shah</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Economic evaluation of strategies to increase kidney donation and transplantation</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$80,201.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>applied economics | health economics | </Field_s__of_Research>
        <Res_KW1>health economics </Res_KW1>
        <Res_KW2>economic evaluation</Res_KW2>
        <Res_KW3>quality of life</Res_KW3>
        <Res_KW4>equity</Res_KW4>
        <Res_KW5>health policy evaluation</Res_KW5>
        <Plain_Description>I will investigate value and harm of changing the way organ donation is managed in Australia using health economic approaches. I will use data from a large trial to look at how quality of life changes over time as people wait for a transplant. By linking health datasets together I will look at whether the transplant program in Australia treats everyone fairly. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014086</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Yasmin Hughes</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Improving Syphilis diagnosis and management in the community</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | primary health care | </Field_s__of_Research>
        <Res_KW1>syphilis </Res_KW1>
        <Res_KW2>public health</Res_KW2>
        <Res_KW3>sexually-transmitted infections (sti)</Res_KW3>
        <Res_KW4>diagnosis</Res_KW4>
        <Res_KW5>clinical epidemiology</Res_KW5>
        <Plain_Description>Syphilis is an important global health problem. Rates of syphilis have climbed dramatically in Australia, with heterosexual populations increasingly affected and rises in congenital syphilis. This research project has three objectives: i) to optimize diagnosis of syphilis in general practice using new testing methods; ii) to design and evaluate clinic systems to improve screening for syphilis; and iii) to improve partner notification using internet based contact tracing.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014100</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Madeleine  Gill</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Understanding Cirrhotic Cardiomyopathy</Grant_Title>
        <Admin_Institution>Centenary Institute of Cancer Medicine and Cell Biology</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$123,793.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | gastroenterology and hepatology | </Field_s__of_Research>
        <Res_KW1>cirrhosis </Res_KW1>
        <Res_KW2>portal hypertension</Res_KW2>
        <Res_KW3>liver transplantation</Res_KW3>
        <Res_KW4>cardiomyopathy</Res_KW4>
        <Res_KW5>metabolomics</Res_KW5>
        <Plain_Description>Liver transplant is the only life-saving option for people with end-stage liver disease. People with liver disease can also have a type of heart failure that can be problematic with liver transplant because of the major stress on the body. This project aims to enrich our understanding of how often, and why this disease happens. We will use a new technique called "metabolomics" to look for specific bloods markers and also follow patients and the changes in their hearts before and after transplant</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014110</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Garry Hamilton</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Radial artery conduits in coronary artery bypass surgery: the impact of prior instrumentation with a focus on the vascular biology and clinical outcomes.</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>cardiorespiratory medicine and heamatology | cardiology (incl. cardiovascular diseases) | </Field_s__of_Research>
        <Res_KW1>coronary artery bypass surgery </Res_KW1>
        <Res_KW2>coronary artery disease</Res_KW2>
        <Res_KW3>vascular biology</Res_KW3>
        <Res_KW4>arterial flow dynamics</Res_KW4>
        <Res_KW5>angiography</Res_KW5>
        <Plain_Description>Certain patients with severely narrowed coronary arteries may require bypass (open heart) surgery, with the radial artery in the forearm frequently used as a bypass graft. Prior to surgery, this artery is also used to insert wires and plastic tubes which are fed up the arm to the heart to perform a coronary angiogram. This research aims to assess what damage a coronary angiogram does to the radial artery, and whether this impacts on its ability to be used as a coronary artery bypass graft.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014111</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Prianka Puri</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title> An integration of multi-omics and machine learning to stratify patients with lupus nephritis for precision medicine </Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$131,265.83</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>immunology | autoimmunity | </Field_s__of_Research>
        <Res_KW1>lupus nephritis </Res_KW1>
        <Res_KW2>gene transcription</Res_KW2>
        <Res_KW3>expression profiling</Res_KW3>
        <Res_KW4>metabolomics</Res_KW4>
        <Res_KW5>artificial neural networks</Res_KW5>
        <Plain_Description>This project will investigate genetic and metabolic changes associated with Lupus Nephritis (LN).  I will undertake transitional, genomic and metabolic profiling of patients to assess alterations associated with disease activity in LN. I will then analyse this data using machine learning to stratify patient disease class and generate non- invasive disease markers to predict LN activity and uncover new drug targets. This approach will provide personalised medicine for patients with LN.  </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014112</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Sean Tan</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Cardiovascular Screening in Cancer Patients Treated with Immune Checkpoint Inhibitors</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>cardiorespiratory medicine and heamatology | cardiology (incl. cardiovascular diseases) | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Field_s__of_Research>
        <Res_KW1>cancer immunotherapy </Res_KW1>
        <Res_KW2>cardiovascular disease</Res_KW2>
        <Res_KW3>cardiovascular disease prevention</Res_KW3>
        <Res_KW4>cardiovascular risk factors</Res_KW4>
        <Res_KW5>preventive screening</Res_KW5>
        <Plain_Description>Patients with cancer treated with immunotherapy are at higher risk of cardiovascular disease. As cancer survival with immunotherapy is improving, it is important to address cardiovascular risk and screening in cancer patients to reduce the burden of cardiovascular disease and improve overall survivorship. We aim to evaluate cardiovascular risk and guide screening policies that could help prevent cardiovascular disease in cancer patients receiving immunotherapy.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014114</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Alexandra Stewart</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>The role of cytochrome polymorphisms in primaquine metabolism and effects on its activity in radical cure of Plasmodium vivax infection</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | infectious diseases | </Field_s__of_Research>
        <Res_KW1>malaria </Res_KW1>
        <Res_KW2>antimalarial</Res_KW2>
        <Res_KW3>pharmacogenetics</Res_KW3>
        <Res_KW4>clinical pharmacology</Res_KW4>
        <Res_KW5>tropical medicine</Res_KW5>
        <Plain_Description>Malaria is a mosquito-borne infection that can be life threatening. Globally there were 228 million cases and 405,000 deaths in 2018. One species, vivax malaria, can cause recurrent infection due to a dormant stage in the liver. The drug primaquine kills this dormant stage. However, recent studies have shown that genetic variations may limit primaquine effectiveness. This research will investigate how genetic variations affect primaquine metabolism and the prevention of recurrent vivax malaria.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014122</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Tanya Ross</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Informing future recommendations for prevention and treatment of ovarian cancer using population data</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$90,168.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | epidemiology | </Field_s__of_Research>
        <Res_KW1>cancer epidemiology </Res_KW1>
        <Res_KW2>ovarian cancer</Res_KW2>
        <Res_KW3>survival analysis</Res_KW3>
        <Res_KW4>quality of life</Res_KW4>
        <Res_KW5>incidence</Res_KW5>
        <Plain_Description>Ovarian cancer is the eighth most commonly diagnosed cancer in females worldwide. Five-year survival remains below 50% and physical and psychological symptoms are common amongst survivors. I aim to assess: 1. Factors associated with ovarian cancer risk to inform prevention strategies 2. Survival, symptom and wellbeing outcomes associated with current care pathways to optimise future treatment 3. Lifestyle and genetic factors associated with survival, symptoms and wellbeing to improve outcomes</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014140</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Mr Samuel Tu</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Cardiometabolic, Genetic and Lifestyle Risk Factors for Arrhythmias</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$77,630.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>cardiorespiratory medicine and heamatology | cardiology (incl. cardiovascular diseases) | </Field_s__of_Research>
        <Res_KW1>atrial fibrillation </Res_KW1>
        <Res_KW2>arrhythmia</Res_KW2>
        <Res_KW3>cardiovascular risk factors</Res_KW3>
        <Res_KW4>lifestyle factors</Res_KW4>
        <Res_KW5>electrophysiology</Res_KW5>
        <Plain_Description>Abnormal heart rhythms are common conditions that cause debilitating symptoms and lead to poorer health outcomes. We have recently begun to appreciate the importance of managing lifestyle and other risk factors in these disorders; however, we still have an incomplete understanding of the role of alcohol consumption, healthy diet, and iron deficiency. This project will inform us of the optimal management of these risk factors, to provide the best care for patients with heart rhythm disorders. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014142</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Isobel Todd</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Perinatal and early childhood risk and protective factors for paediatric infection</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$93,056.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | epidemiology | paediatrics and reproductive medicine | foetal development and medicine | </Field_s__of_Research>
        <Res_KW1>pregnancy </Res_KW1>
        <Res_KW2>epidemiology</Res_KW2>
        <Res_KW3>maternal and child health</Res_KW3>
        <Res_KW4>birth</Res_KW4>
        <Res_KW5>risk prediction</Res_KW5>
        <Plain_Description>Infection is the most common reason for children needing healthcare. All children are exposed to viruses and bacteria that can cause them to become ill. However, some children are more likely to become ill or get a more severe illness than other children, and the reasons why are not known. This project looks at whether events or conditions during pregnancy, birth and the early years of life could change how likely children are to get sick, or how severe their illness is.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014147</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Melissa  Savaglio</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Developing a community-based psychosocial intervention for  young people with mental illness</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$67,346.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | mental health | </Field_s__of_Research>
        <Res_KW1>adolescent </Res_KW1>
        <Res_KW2>adolescent health</Res_KW2>
        <Res_KW3>community intervention</Res_KW3>
        <Res_KW4>psychosocial</Res_KW4>
        <Res_KW5>participatory action research</Res_KW5>
        <Plain_Description>The overall aim is to design, develop, deliver, and evaluate a community-based program for youth with serious mental illness. The tangible outcome of this research will be the development of a trauma-informed, community-based mental health program that has been designed by youth, for youth, to effectively meet their unique psychosocial needs. It is intended that the program improves psychosocial functioning, reduces symptom severity, and enhances the life trajectory of these vulnerable youth.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014148</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Mrs Lorelle Holland</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Aboriginal and Torres Strait Islander Health Research</Sub_Type>
        <Grant_Title>Decolonising approaches for Aboriginal and Torres Strait Islander children with complex health needs exposed to the youth justice system in Australia: Reducing incarceration and recidivism rates</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$115,801.33</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | aboriginal and torres strait islander health | </Field_s__of_Research>
        <Res_KW1>young offenders </Res_KW1>
        <Res_KW2>aboriginal child</Res_KW2>
        <Res_KW3>aboriginal mental health</Res_KW3>
        <Res_KW4>health inequalities</Res_KW4>
        <Res_KW5>neurodevelopmental disorders</Res_KW5>
        <Plain_Description>Urgent research is required to reduce lifelong harm and the over-representation of Aboriginal and Torres Strait Islander youth who are exposed to police custody and youth detention. A co-designed culturally appropriate diversionary model of care is imperative to identify complex health needs and create alternative pathways, away from detention. Scoping literature reviews and yarning circles with Aboriginal and Torres Strait Islander youth and their communities will inform this process.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014162</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Amelia Hyatt</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Determining health system and public policy elements for successful implementation and sustainability of cervical cancer elimination strategies at a country and regional level</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$93,056.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | solid tumours | public health and health services | health promotion | public health and health services | public health and health services not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>cancer prevention </Res_KW1>
        <Res_KW2>population health</Res_KW2>
        <Res_KW3>health policy</Res_KW3>
        <Res_KW4>health systems</Res_KW4>
        <Res_KW5>cervical cancer</Res_KW5>
        <Plain_Description>The global burden of cervical cancer is significant, however elimination is possible. This PhD aims to support global cervical cancer elimination by determining a best practice approach for member states to achieve optimum implementation of WHO strategies and concurrent health system strengthening. Policy analysis, stakeholder consultation and expert consensus will be used to develop a planning tool for governments to optimise implementation of cervical cancer elimination strategies. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014163</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Deonna Ackermann</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Optimising trial processes and generating translational gains: Studies Within A Trial (SWATs) for the MELSELF randomised controlled trial of patient-led melanoma surveillance.</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$62,204.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | cancer diagnosis | public health and health services | epidemiology | public health and health services | public health and health services not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>cutaneous melanoma </Res_KW1>
        <Res_KW2>clinical epidemiology</Res_KW2>
        <Res_KW3>clinical trial</Res_KW3>
        <Res_KW4>diagnostic test</Res_KW4>
        <Res_KW5>screening</Res_KW5>
        <Plain_Description>With increasing concerns about research waste in clinical trials, there is recognition of the need to improve the design and operation of trials. With that in mind the Studies Within a Trial (SWAT) methodology has been developed to generate evidence to inform the conduct of future trials. My research will evaluate strategies to improve participant recruitment, retention, and intervention adherence within a series of SWATs embedded within a melanoma surveillance host trial.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014165</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Mr Alexander Terrill</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Application of advanced manufacturing technologies to offload diabetes-related foot ulceration</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$85,244.83</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | podiatry | biomedical engineering | medical devices | public health and health services | public health and health services not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>chronic leg or foot ulcers </Res_KW1>
        <Res_KW2>diabetic complications</Res_KW2>
        <Res_KW3>biomedical engineering</Res_KW3>
        <Res_KW4>allied health</Res_KW4>
        <Res_KW5>footwear</Res_KW5>
        <Plain_Description>People with diabetes can develop wounds on their feet due to high pressures. These wounds cause significant health and personal impacts for those affected and present a high cost to the health system. Current treatments are not always provided and are often not used by patients. This project explores how 3D scanning, computer aided design, and 3D printing could be used to make a more affordable, accessible and personalised treatment that clinicians are more likely to provide and patients use.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014166</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Stephanie Bond</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Development and evaluation of strategies to improve syphilis screening of pregnant women to prevent congenital syphilis</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | public health and health services not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>syphilis </Res_KW1>
        <Res_KW2>antenatal care</Res_KW2>
        <Res_KW3>antenatal screening</Res_KW3>
        <Res_KW4>congenital disease</Res_KW4>
        <Res_KW5>sexual health</Res_KW5>
        <Plain_Description>This project aims to improve screening for syphilis at a time when increasing numbers of babies are being infected with syphilis. It will have three main aims: to assess the current situation regarding syphilis screening during pregnancy, to implement a new screening policy in pregnancy and to assess the efficacy of the new policy and techniques.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014180</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Erin Madden</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Improving evidence-based practice for comorbid alcohol and other drug and mental health conditions: the role of implementation science and quality improvement toolkits</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$93,056.00</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | mental health | </Field_s__of_Research>
        <Res_KW1>substance use </Res_KW1>
        <Res_KW2>quality improvement</Res_KW2>
        <Res_KW3>evidence-based clinical practice</Res_KW3>
        <Res_KW4>mental health</Res_KW4>
        <Res_KW5>implementation</Res_KW5>
        <Plain_Description>Alcohol and other drug (AOD) and mental disorders frequently co-occur, yet there is a lack of evidence-based treatment in AOD services and a lack of studies focusing on reducing this evidence-to-practice gap. This thesis seeks to improve evidence-based practice in AOD services by developing, implementing and evaluating the effectiveness of a quality improvement toolkit that assists services to implement evidence-based guidelines for managing comorbid mental health conditions in AOD settings.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014206</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Anna Le Fevre</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Investigating epigenetic regulators of disease and novel epigenetic treatment approaches for imprinting disorders </Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>genetics | epigenetics (incl. genome methylation and epigenomics) | </Field_s__of_Research>
        <Res_KW1>epigenetics </Res_KW1>
        <Res_KW2>genomic imprinting</Res_KW2>
        <Res_KW3>gene silencing</Res_KW3>
        <Res_KW4>alternate pharmacotherapies</Res_KW4>
        <Res_KW5>abnormal development</Res_KW5>
        <Plain_Description>Prader-Willi Syndrome (PWS) and Schaaf-Yang syndrome (SYS) are incurable disorders caused by a lack of expression of the paternal copy of particular genes. Patients have normal maternal copies but these are switched off. A potential treatment is to activate the silenced copies by removing the function of proteins that normally repress their expression. Here we will investigate a new potential treatment for PWS/SYS targeting the protein called SMCHD1 that normally switches off these genes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014208</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Bernadette Ricciardo</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Aboriginal and Torres Strait Islander Health Research</Sub_Type>
        <Grant_Title>Koolungar Urban Moorditj Healthy Skin: Determining the burden of skin disease in urban Aboriginal children and adolescents.</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$123,793.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | dermatology | clinical sciences | infectious diseases | public health and health services | aboriginal and torres strait islander health | </Field_s__of_Research>
        <Res_KW1>aboriginal health </Res_KW1>
        <Res_KW2>aboriginal child</Res_KW2>
        <Res_KW3>dermatology</Res_KW3>
        <Res_KW4>skin disease</Res_KW4>
        <Res_KW5>skin infections</Res_KW5>
        <Plain_Description>Skin infections and their complications are very common in remote-living Australian-Aboriginal children, but we do not know if urban Aboriginal children have this same risk. This is despite almost 80% of Australia's Aboriginal and Torres Strait Islander population living in regional and metropolitan areas. Working with Aboriginal Elders, we have designed a project to determine how common skin diseases are in urban Aboriginal youth, in order to improve prevention and treatment of skin infections.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014210</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Victoria Hall</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Defining host immune response and prevention strategies for viral respiratory tract infections in patients with haematological malignancy</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | infectious diseases | </Field_s__of_Research>
        <Res_KW1>respiratory viruses </Res_KW1>
        <Res_KW2>haematological malignancy</Res_KW2>
        <Res_KW3>host response</Res_KW3>
        <Res_KW4>vaccination</Res_KW4>
        <Res_KW5>vaccines</Res_KW5>
        <Plain_Description>Viruses such as COVID-19 and influenza can lead to severe chest infections in patients with blood cancers. This research project aims to study the immune response to infection by these viruses in patients receiving treatment for blood cancers. This information will help us to improve treatment and vaccination against these viruses. A major aim is to prevent further infection. Results from this project may change current vaccination practice in Australia and lead to further research projects. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014215</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Thomas Lew</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Enhancing venetoclax and other pro-apoptotic agents to improve outcomes for patients with haematological malignancies</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | haematological tumours | </Field_s__of_Research>
        <Res_KW1>anticancer drug </Res_KW1>
        <Res_KW2>drug resistance</Res_KW2>
        <Res_KW3>dna barcoding</Res_KW3>
        <Res_KW4>acute myeloid leukaemia (aml)</Res_KW4>
        <Res_KW5>chronic lymphocytic leukaemia (cll)</Res_KW5>
        <Plain_Description>Blood cancers kill &amp;gt;4,500 Australians per year. A new drug, venetoclax, has significantly improved outcomes for these patients, but relapses frequently occur. This PhD will analyse cancer cells at the single cell level to identify and specifically target the resistant populations that cause relapse. We will study how to undermine the energy metabolism of cancer cells, which may synergise with venetoclax. These projects strive to develop new treatments to improve patient care and achieve cures.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014234</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Yin Yuan</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Dissecting the challenge of AML</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | haematological tumours | </Field_s__of_Research>
        <Res_KW1>haematology </Res_KW1>
        <Res_KW2>cancer biology</Res_KW2>
        <Res_KW3>leukaemia</Res_KW3>
        <Res_KW4>molecular basis of disease</Res_KW4>
        <Res_KW5>anticancer drug</Res_KW5>
        <Plain_Description>Acute myeloid leukaemia (AML) is a life-threatening blood cancer that is difficult to treat. Recently, several new “targeted therapy” drugs have been developed, which work by blocking specific changes in cancer cells that help them survive and grow. Unfortunately, resistance to treatment commonly emerges. This project aims to understand how resistance can arise and how they affect responsiveness to different drugs. This information will help us develop better treatments for patients with AML. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014244</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ashwin Bhaskaran</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Ventricular arrhythmia mechanisms and therapies</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>cardiorespiratory medicine and heamatology | cardiology (incl. cardiovascular diseases) | </Field_s__of_Research>
        <Res_KW1>arrhythmia </Res_KW1>
        <Res_KW2>sudden cardiac death</Res_KW2>
        <Res_KW3>cardiomyopathy</Res_KW3>
        <Res_KW4>electrophysiology</Res_KW4>
        <Res_KW5>pharmacotherapy</Res_KW5>
        <Plain_Description>Heart disease is the leading cause of death in Australia, with heart rhythm disorders being a major cause for debilitating symptoms and sudden cardiac death. Our understanding of heart rhythm disorders is incomplete. My aim is to study the mechanisms and therapies of heart rhythm disorders, including medications and procedural technologies, using advanced techniques and diagnostic tools to treat and potentially cure heart rhythm disorders, improve quality of life &amp;amp; prevent sudden cardiac death.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014245</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Sarah Holper</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Untangling Neuroinflammation's Role in Alzheimer's Disease Development (UNRAVEL)</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | geriatrics and gerontology | </Field_s__of_Research>
        <Res_KW1>dementia </Res_KW1>
        <Res_KW2>geriatrics</Res_KW2>
        <Res_KW3>neuroinflammation</Res_KW3>
        <Res_KW4>neurodegeneration</Res_KW4>
        <Res_KW5>aged care</Res_KW5>
        <Plain_Description>My PhD will lead to new understandings around the associations between tau homeostasis, neuroinflammation, and neurodegeneration, as well as identifying clinically useful biomarkers to support the diagnosis, prognosis and monitoring of patients with AD. My work will also shed light on the effects of SAMe on neuroinflammatory pathways, providing further information on the activity of this potential therapeutic, as well as identifying novel potential neuroinflammatory therapeutic targets. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014256</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Yara-Natalie Abo</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title> A randomised controlled human challenge trial to evaluate Strep A vaccine efficacy, safety, and immunogenicity</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | infectious diseases | </Field_s__of_Research>
        <Res_KW1>group a streptococcal disease </Res_KW1>
        <Res_KW2>pharyngitis</Res_KW2>
        <Res_KW3>rheumatic fever</Res_KW3>
        <Res_KW4>immunity</Res_KW4>
        <Res_KW5>vaccine development</Res_KW5>
        <Plain_Description>In human challenge models, healthy volunteers are given a carefully monitored infection to learn how diseases work and how to stop them. In this project, a new Australian strep throat human model will be used to test a vaccine against Strep A, which affects &amp;gt;750 million and kills &amp;gt;500,000 annually.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014258</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Chandana Guha</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Improving care and outcomes for vulnerable patients with chronic kidney disease – the young and the elderly</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$67,346.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | epidemiology | </Field_s__of_Research>
        <Res_KW1>public health </Res_KW1>
        <Res_KW2>kidney disease</Res_KW2>
        <Res_KW3>patient preference</Res_KW3>
        <Res_KW4>paediatric</Res_KW4>
        <Res_KW5>geriatric assessment</Res_KW5>
        <Plain_Description>This study aims to examine patient-centered interventions for vulnerable populations with chronic kidney disease that assist with managing their condition, accessing care to ultimately improve healthcare outcomes. Specifically the study will assess the impact of personalised care plans that integrates patient priorities to improve the quality of life and reduce the burden of disease among children and older frail people with CKD and their families; and engaging patients in translatable research.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014261</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Kasun De Silva</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Novel technologies and strategies to identify arrhythmogenic substrate and triggers for sudden cardiac death</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$90,168.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>cardiorespiratory medicine and heamatology | cardiology (incl. cardiovascular diseases) | </Field_s__of_Research>
        <Res_KW1>cardiac arrhythmia </Res_KW1>
        <Res_KW2>ventricular tachycardia</Res_KW2>
        <Res_KW3>sudden cardiac death</Res_KW3>
        <Res_KW4>non-invasive</Res_KW4>
        <Res_KW5>echocardiography</Res_KW5>
        <Plain_Description>The most common cause of sudden cardiac death is ventricular arrhythmias (VAs) - rapid heart rhythms can cause the heart to stop beating. Catheter ablation (CA), where regions of the heart from which these rhythms arise (scar) are burned can treat VA however requires accurate identification scar with invasive maps. Novel technologies including machine learning, 3D echocardiography and ECG imaging allow for non-invasive characterisation. This project aims to further validate these technologies. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014262</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Alice Powell</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Exceptional cognition in old age and interactions with other aspects of successful ageing</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$123,793.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | geriatrics and gerontology | </Field_s__of_Research>
        <Res_KW1>healthy ageing </Res_KW1>
        <Res_KW2>dementia</Res_KW2>
        <Res_KW3>frailty</Res_KW3>
        <Res_KW4>psychosocial factors</Res_KW4>
        <Res_KW5>cognition</Res_KW5>
        <Plain_Description>Research on adults who function successfully at older ages could provide insights into what determines wellbeing in old age, how dementia could be prevented and what services might be required for older adults. This research will examine not just memory and other cognitive processes but also physical function and social connectedness to see how these aspects of functioning interact in successful ageing.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014266</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Miss Nicola Creagh</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>Evaluating the use of an open access self-collection cervical screening pathway: The solution to declining participation and to long standing inequities?</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$93,056.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | preventive medicine | public health and health services | primary health care | </Field_s__of_Research>
        <Res_KW1>cervical screening </Res_KW1>
        <Res_KW2>women's health</Res_KW2>
        <Res_KW3>health systems</Res_KW3>
        <Res_KW4>evaluation</Res_KW4>
        <Res_KW5>implementation</Res_KW5>
        <Plain_Description>Australia’s renewed National Cervical Screening Program enabled an alternative self-collection pathway for women who were under-screened. Data collected from early adopters indicates it is highly acceptable, however,  significant implementation issues with the strict eligibility criteria and limited promotion have led to a low uptake of the pathway. This research will evaluate the use of open access to self-collection as a solution to addressing longstanding inequities in Australia’s program.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014285</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Huong Nguyen</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Aboriginal and Torres Strait Islander Health Research</Sub_Type>
        <Grant_Title>A Cognitive Ageing Risk Evaluation (CARE) Tool to Support Clinical Diagnosis of Dementia for Aboriginal and Torres Strait Islander Peoples </Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$105,112.67</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | aboriginal and torres strait islander health | clinical sciences | geriatrics and gerontology | </Field_s__of_Research>
        <Res_KW1>aboriginal health </Res_KW1>
        <Res_KW2>cognitive impairment</Res_KW2>
        <Res_KW3>dementia</Res_KW3>
        <Res_KW4>risk factors</Res_KW4>
        <Res_KW5>primary care</Res_KW5>
        <Plain_Description>Dementia among Aboriginal and Torres Strait Islander peoples is much greater than the general Australian population.  There is need to better understand the risk factors that account for this and the role of brain imaging and blood tests in assessment of Aboriginal and Torres Strait Islander peoples vulnerable to cognitive decline.  This research will look at the risk factors and blood markers to improve diagnosis, management and support for patients and families affected.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014292</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Oliver Cronin</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>The Science of Cold Snare Polypectomy</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$101,376.50</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | gastroenterology and hepatology | public health and health services | preventive medicine | </Field_s__of_Research>
        <Res_KW1>colorectal cancer prevention </Res_KW1>
        <Res_KW2>non-familial adenomatous polyposis</Res_KW2>
        <Res_KW3>colonoscopy</Res_KW3>
        <Res_KW4>colorectal cancer risk</Res_KW4>
        <Res_KW5>colorectal cancer</Res_KW5>
        <Plain_Description>Colorectal cancer (CRC) was the third most commonly diagnosed cancer in Australia in 2017 with an estimated incidence rate of 67 per 100,000. Screening by colonoscopy can lead to a reduced cancer incidence as well as mortality through early detection of cancer and pre-cancerous lesions. Endoscopy training is heuristic and imperfect.  Identifying risk factors for incomplete polypectomy and quantifying adequate resection margin will help frame world polypectomy guidelines.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014294</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Thi Tran</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Public Health and Health Services Research</Sub_Type>
        <Grant_Title>How does methamphetamine use, mental health and treatment interventions affect one another?</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$117,839.00</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | mental health | </Field_s__of_Research>
        <Res_KW1>drug dependence </Res_KW1>
        <Res_KW2>mental health</Res_KW2>
        <Res_KW3>amphetamine</Res_KW3>
        <Res_KW4>drug abuse</Res_KW4>
        <Res_KW5>epidemiology</Res_KW5>
        <Plain_Description>Within Australia, an increasing proportion of people are using crystalline methamphetamine, or ice. Using amphetamines has been linked to various harms and an increased risk of comorbid mental health disorders. However, exploring the link between comorbid mental health and treatment outcomes has been limited. The proposed PhD aims to explore this link further through linking multiple cohorts of people dependent on methamphetamine as well as methamphetamine-related hospital presentations. </Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014320</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Robert Little</CIA_Name>
        <Grant_Type>Postgraduate Scholarships</Grant_Type>
        <Sub_Type>Clinical Medicine and Science Research</Sub_Type>
        <Grant_Title>Modulation of the gut microbiome and mucosal immune response in IBD</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$135,002.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>clinical sciences | gastroenterology and hepatology | immunology | cellular immunology | medical microbiology | medical bacteriology | </Field_s__of_Research>
        <Res_KW1>inflammatory bowel disease (ibd) </Res_KW1>
        <Res_KW2>clinical microbiology</Res_KW2>
        <Res_KW3>gut immunity</Res_KW3>
        <Res_KW4>chronic inflammation</Res_KW4>
        <Res_KW5>drug effects</Res_KW5>
        <Plain_Description>Inflammatory bowel disease (IBD) is an incurable condition with significant morbidity and mortality. Australia has one of the highest prevalence rates in the world, costing $3.1 billion dollars annually.  The gut microbiome appears to be a key player in the onset and trajectory of IBD. Over the course of a 4 year PhD, we aim to evaluate how the gut microbiome affects the gut immune system and how this can be utilised to develop and target drug therapy to better control and potentially cure IBD.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2008433</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Pengfei Cai</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>NHMRC e-ASIA 2021 Joint Research Program</Sub_Type>
        <Grant_Title>Innovative point-of-care diagnostics and environmental surveillance tools for the elimination of Asian schistosomiasis</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$749,987.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>medical microbiology | medical parasitology | </Field_s__of_Research>
        <Res_KW1>schistosomiasis </Res_KW1>
        <Res_KW2>molecular diagnostics </Res_KW2>
        <Res_KW3>immunodiagnosis </Res_KW3>
        <Res_KW4>environmental epidemiology </Res_KW4>
        <Res_KW5>quantitative polymerase chain reaction (pcr) </Res_KW5>
        <Plain_Description>Accurate and rapid diagnostics are one of the key cornerstones for control and elimination of schistosomiasis in Asia.  This cooperative research project aims to develop and trial rapid, cost-effective, field-friendly point-of-care (POC) diagnostics  and environmental  DNA (eDNA) detection tests for Asian schistosomiasis. Integrating the POCs and eDNA detection to the current schistosomiasis control programs within Asia and beyond can lead control policy and assess elimination goals.&lt;/field>&lt;field id="e-Asia Project Title">Innovative point-of-care diagnostics and environmental surveillance tools for the elimination of Asian schistosomiasis</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009545</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Jason Ong</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>NHMRC e-ASIA 2021 Joint Research Program</Sub_Type>
        <Grant_Title>Ending HIV transmission by Optimizing Pre-exposure prophylaxis in East Asia (HOPE)</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$667,191.20</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>public health and health services | preventive medicine | </Field_s__of_Research>
        <Res_KW1>human immunodeficiency virus (hiv) </Res_KW1>
        <Res_KW2>infectious diseases </Res_KW2>
        <Res_KW3>public health </Res_KW3>
        <Res_KW4>health economics </Res_KW4>
        <Res_KW5>randomised controlled trial (rct) </Res_KW5>
        <Plain_Description>This cooperative research project aims to bring together regional experts to co-design strategies with affected communities in Australia, Thailand and Philippines to optimize adherence to pre-exposure prophylaxis (PrEP) for HIV. Activities include networking and capacity building through cross-country, multidisciplinary workshops and conferences; and implementing interventions informed by innovative methods (crowdsourcing, discrete choice experiments) to optimize adherence among PrEP users.&lt;/field>&lt;field id="e-Asia Project Title">Ending HIV transmission by Optimizing Pre-exposure prophylaxis in East Asia (HOPE)</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009656</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Prof Freya Fowkes</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>NHMRC e-ASIA 2021 Joint Research Program</Sub_Type>
        <Grant_Title>Vector sero-surveillance tools to accelerate malaria elimination</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$745,125.35</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>medical microbiology | medical parasitology | public health and health services | epidemiology | immunology | immunology not elsewhere classified | </Field_s__of_Research>
        <Res_KW1>malaria transmission </Res_KW1>
        <Res_KW2>mosquito transmission </Res_KW2>
        <Res_KW3>infectious diseases </Res_KW3>
        <Res_KW4>immune surveillance </Res_KW4>
        <Res_KW5>malaria control </Res_KW5>
        <Plain_Description>Measuring antibody responses to mosquito salivary proteins in human sera may be a practical, highly sensitive alternative approach to estimate human biting rates and exposure to vector-borne diseases such as malaria. We will measure these salivary antibodies in a human biting challenge trial where volunteers are repeatedly bitten by mosquitoes to define antibody thresholds which predict biting rates. Furthermore, we will validate this sero-surveillance tool in field trials of vector control.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2009816</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Assoc Prof Tao Liu</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>NHMRC e-ASIA 2021 Joint Research Program</Sub_Type>
        <Grant_Title>Targeting MYCN/NCYM for cancer therapy </Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$699,317.00</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>oncology and carcinogenesis | molecular targets | oncology and carcinogenesis | cancer therapy (excl. chemotherapy and radiation therapy) | </Field_s__of_Research>
        <Res_KW1>p53 </Res_KW1>
        <Res_KW2>neuroblastoma </Res_KW2>
        <Res_KW3>liver cancer </Res_KW3>
        <Res_KW4>gene transcription </Res_KW4>
        <Res_KW5>cancer treatment </Res_KW5>
        <Plain_Description>Primary liver cancer is a common cause of death from cancer in adults. Hepatocellular carcinoma represents approximately 90% of all cases of primary liver cancer. Cancer is the most common cause of death from diseases in children. Neuroblastoma is the most common solid tumour in early childhood. In this project, we will identify a novel therapeutic strategy targeting hepatocellular carcinoma and neuroblastoma for clinical translation.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014513</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Prof Simon Lewis</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2021 NHMRC-European Union Joint Programme on Neurodegenerative Disease Research - JPND</Sub_Type>
        <Grant_Title>COgNiTive propagation in pRodrOmaL Parkinson’s disease: CONTROL-PD</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$462,501.00</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | neurology and neuromuscular diseases | </Field_s__of_Research>
        <Res_KW1>rapid eye movement (rem) sleep </Res_KW1>
        <Res_KW2>parkinson disease </Res_KW2>
        <Res_KW3>dementia with lewy bodies </Res_KW3>
        <Res_KW4>parkinsonism </Res_KW4>
        <Res_KW5>phenotype </Res_KW5>
        <Plain_Description>It has long been felt that not all patients with Parkinson’s disease are affected by the same pattern of cell death, which results in differences in their presentation, progression and response to treatment.  This program will link international research teams who have can perform detailed assessments not only patients with the condition but also in the prodromal phases of disease to help better understand these differences and improve outcomes.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014629</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Prof Sarah Spencer</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2021 NHMRC-European Union Joint Programme on Neurodegenerative Disease Research - JPND</Sub_Type>
        <Grant_Title>Effects of early-Stress On Lipid mediators and Inflammation for early Detection of neurodegeneration (SOLID)</Grant_Title>
        <Admin_Institution>RMIT University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$499,604.90</Total>
        <Broad_Research_Area>Basic Science</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | central nervous system | cognitive science | neurocognitive patterns and neural networks | medical physiology | systems physiology | </Field_s__of_Research>
        <Res_KW1>alzheimer disease </Res_KW1>
        <Res_KW2>microglia </Res_KW2>
        <Res_KW3>omega-3 fatty acids </Res_KW3>
        <Res_KW4>neuroinflammation </Res_KW4>
        <Res_KW5>cognition </Res_KW5>
        <Plain_Description>The next frontier in Alzheimer’s Disease (AD) research is to find easily measurable biomarkers for neurodegeneration and cognitive dysfunction. Our translational project will leverage data and samples from 4 established human cohorts and 10+ rodent models. We will identify i) early biomarkers predictive of neurodegeneration and cognitive dysfunction ii) the causal role of early-life adversity on predisposition to AD and iii) an intervention strategy for alleviating these effects.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014651</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Allan McRae</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2021 NHMRC-European Union Joint Programme on Neurodegenerative Disease Research - JPND</Sub_Type>
        <Grant_Title>Leveraging medical records to identify patients at risk of neurodegenerative disease</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$482,706.14</Total>
        <Broad_Research_Area>Health Services Research</Broad_Research_Area>
        <Field_s__of_Research>neurosciences | neurology and neuromuscular diseases | genetics | neurogenetics | econometrics | economic models and forecasting | </Field_s__of_Research>
        <Res_KW1>neurodegenerative disorders </Res_KW1>
        <Res_KW2>electronic health information </Res_KW2>
        <Res_KW3>complex genetic disease </Res_KW3>
        <Res_KW4>brain imaging </Res_KW4>
        <Res_KW5>health economics </Res_KW5>
        <Plain_Description>Neurodegenerative diseases represent one of the main public health issues in our western societies and one of the greatest challenges in drug development. Therapeutic intervention for these disease works best with early intervention, ideally at pre-symptomatic stages. LeMeReND proposes to use electronic health records (EHR) to identify biomedical risk factors through studying previous diagnoses (pre-clinical comorbidities), drug prescription, clinical care usage, and biological test results.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014745</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Prof Viviana Wuthrich</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2020 NHMRC-NIHR Collaborative Research Grant Scheme Round 3</Sub_Type>
        <Grant_Title>A randomised CONtrolled trial of Tailored Acceptance and Commitment Therapy for older people with treatment resistant Generalised Anxiety Disorder (CONTACT-GAD)</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$358,767.46</Total>
        <Broad_Research_Area>Public Health</Broad_Research_Area>
        <Field_s__of_Research>psychology | health, clinical and counselling psychology | public health and health services | aged health care | </Field_s__of_Research>
        <Res_KW1>general anxiety disorder (GAD)</Res_KW1>
        <Res_KW2>geriatrics</Res_KW2>
        <Res_KW3>clinical trial</Res_KW3>
        <Res_KW4>psychological treatment</Res_KW4>
        <Res_KW5>mental health services</Res_KW5>
        <Plain_Description>Generalised anxiety disorder (GAD) is one of the most common mental disorders in later life. It is characterised by excessive and uncontrollable worry that is often chronic and associated with poorer quality of life, increased disability and greater use of medication and health services. Current treatments for GAD are not always well tolerated in this population. Acceptance and Commitment therapy (ACT) is a promising psychological therapy. This clinical trial will compare ACT to usual care.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2014792</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Calum Roberts</CIA_Name>
        <Grant_Type>International Collaborations</Grant_Type>
        <Sub_Type>2020 NHMRC-NIHR Collaborative Research Grant Scheme Round 3</Sub_Type>
        <Grant_Title>The neoGASTRIC trial: Avoiding routine gastric residual volume measurement in neonatal critical care, a multi-centre, randomised controlled trial</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$739,020.10</Total>
        <Broad_Research_Area>Clinical Medicine and Science</Broad_Research_Area>
        <Field_s__of_Research>paediatrics and reproductive medicine | paediatrics | </Field_s__of_Research>
        <Res_KW1>very preterm birth</Res_KW1>
        <Res_KW2>feeding and nutrition</Res_KW2>
        <Res_KW3>extremely low birth weight</Res_KW3>
        <Res_KW4>abdominal surgery</Res_KW4>
        <Res_KW5>neonatal intensive care (NICU)</Res_KW5>
        <Plain_Description>Before feeding preterm babies, nurses aspirate the contents of the stomach from the feeding tube to assess the ‘residual volume’ of feed, to determine the feeding plan. It is not clear if this is helpful (by detecting gut issues early), or harmful (by unnecessarily delaying feeding). In this trial, half of included infants will have gastric residual volumes routinely measured, and half will not. This will show which approach is best, for establishing feeding and avoiding any harm.</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015634</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Mrs Julie Taranto</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>ANZAC Research Institute</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$6,414.35</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015635</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Marie-Helene Rousseau</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Australian National University</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$87,443.83</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015636</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Cherry Yu</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$52,172.69</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015637</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Haley Jacobi</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Bond University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$26,683.43</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015638</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Nadine Barnes</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$56,285.25</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015639</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr John Williams</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Cancer Council NSW</Admin_Institution>
        <State>NSW</State>
        <Sector>Charities and Philanthropic</Sector>
        <Total>$5,705.78</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015640</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Miss Amy Shelly</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Cancer Council VIC</Admin_Institution>
        <State>VIC</State>
        <Sector>Charities and Philanthropic</Sector>
        <Total>$6,171.32</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015641</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Mr Nicholas Keilar</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Centenary Institute of Cancer Medicine and Cell Biology</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$5,753.55</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015642</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Raja Choudhury</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Centre for Eye Research Australia</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$16,116.04</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015643</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Mr Dhruv Shah</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Curtin University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$41,939.59</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015644</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Kelly Windmill</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Deakin University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$76,782.94</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015645</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Sharon York</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Edith Cowan University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$12,365.71</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015646</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Mr Gareth Rees</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Flinders University</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$96,569.96</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015647</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Andrea Richardson-Wynd</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Florey Institute of Neuroscience and Mental Health</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$75,486.89</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015648</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Lynette Farquhar</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Griffith University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$59,216.91</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015649</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Mr Javier Balanzategui</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>James Cook University</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$30,327.30</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015650</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Georgina Caruana</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>La Trobe University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$64,440.12</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015651</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Erin Semon</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Macquarie University</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$81,317.36</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015652</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Christina Spargo</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Menzies School of Health Research</Admin_Institution>
        <State>NT</State>
        <Sector>Research Institutes</Sector>
        <Total>$90,444.34</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015653</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Mrs Helen Partridge</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Monash University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$799,596.83</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015654</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Marianne Ciavarella</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$184,050.91</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015655</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Lucy Johnston</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Murdoch University</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$10,214.79</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015656</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Katie York</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Queensland University of Technology</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$42,658.52</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015657</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Jane Holt</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>RMIT University</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$29,335.98</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015658</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Leanne Sutherland</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>South Australian Health and Medical Research Institute</Admin_Institution>
        <State>SA</State>
        <Sector>Research Institutes</Sector>
        <Total>$10,963.07</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015659</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Colleen Elso</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>St Vincents Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$47,437.62</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015660</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Sheila Hamilton-Brown</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Swinburne University of Technology</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$15,611.78</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015661</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Janine Clarey</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Bionics Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$8,257.32</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015662</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Marc Campitelli</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$136,321.82</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015663</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Kerry Jenson</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>George Institute for Global Health</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$8,929.21</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015664</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Michael Frommer</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Sax Institute</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$19,445.35</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015665</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Cameron van den Heuvel</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Adelaide</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$145,277.34</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015666</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Judy Alexander</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Newcastle</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$146,290.51</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015667</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Lucy Buzacott</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Queensland</Admin_Institution>
        <State>QLD</State>
        <Sector>University</Sector>
        <Total>$442,841.34</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015668</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Catherine Hayden</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$260,377.21</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015669</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Arvind Reddy</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Canberra</Admin_Institution>
        <State>ACT</State>
        <Sector>University</Sector>
        <Total>$5,198.36</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015670</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Wade Moore</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Melbourne</Admin_Institution>
        <State>VIC</State>
        <Sector>University</Sector>
        <Total>$865,017.58</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015671</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Debbie Docherty</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>University of New South Wales</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$613,830.21</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015672</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Mark Geier</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>University of South Australia</Admin_Institution>
        <State>SA</State>
        <Sector>University</Sector>
        <Total>$87,388.69</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015673</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Nicole Makoviney</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$585,231.86</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015674</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Jodie Lamont</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Tasmania</Admin_Institution>
        <State>TAS</State>
        <Sector>University</Sector>
        <Total>$56,462.17</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015675</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Kerrie Alexander</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Technology Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$43,342.90</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015676</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ieuan Linck</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Western Australia</Admin_Institution>
        <State>WA</State>
        <Sector>University</Sector>
        <Total>$205,719.62</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015677</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Monica Birrento</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Wollongong</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$26,337.26</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>2015678</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Liesel Senn</CIA_Name>
        <Grant_Type>Equipment Grant</Grant_Type>
        <Sub_Type>Equipment Grant</Sub_Type>
        <Grant_Title>2021 Equipment Grant</Grant_Title>
        <Admin_Institution>University of Western Sydney</Admin_Institution>
        <State>NSW</State>
        <Sector>University</Sector>
        <Total>$12,224.39</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>9000699</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Mrs Julie Taranto</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2021</Grant_Title>
        <Admin_Institution>ANZAC Research Institute</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$181,896.26</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>9000700</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Rebecca Erlich</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2021</Grant_Title>
        <Admin_Institution>Baker Heart and Diabetes Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,479,498.74</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>9000714</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Janine Clarey</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2021</Grant_Title>
        <Admin_Institution>Bionics Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$234,158.74</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>9000701</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Nadine Barnes</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2021</Grant_Title>
        <Admin_Institution>Burnet Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,596,121.62</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>9000702</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr John Williams</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2021</Grant_Title>
        <Admin_Institution>Cancer Council NSW</Admin_Institution>
        <State>NSW</State>
        <Sector>Charities and Philanthropic</Sector>
        <Total>$161,803.05</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>9000703</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Amy Shelly</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2021</Grant_Title>
        <Admin_Institution>Cancer Council VIC</Admin_Institution>
        <State>VIC</State>
        <Sector>Charities and Philanthropic</Sector>
        <Total>$175,004.73</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>9000704</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Mr Nicholas Keilar</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2021</Grant_Title>
        <Admin_Institution>Centenary Institute of Cancer Medicine and Cell Biology</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$163,157.50</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>9000705</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Aniruddha Choudhury</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2021</Grant_Title>
        <Admin_Institution>Centre for Eye Research Australia</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$457,014.16</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>9000706</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Ramona Grimm</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2021</Grant_Title>
        <Admin_Institution>Children's Medical Research Institute</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$25,149.17</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>9000707</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Andrea Richardson-Wynd</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2021</Grant_Title>
        <Admin_Institution>Florey Institute of Neuroscience and Mental Health</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$2,140,636.57</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>9000716</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Miss Sonja Bates</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2021</Grant_Title>
        <Admin_Institution>Garvan Institute of Medical Research</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$33,816.14</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>9000717</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Prof Peter Dolnik</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2021</Grant_Title>
        <Admin_Institution>George Institute for Global Health</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$253,212.18</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>9000708</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Rosalba Drummond</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2021</Grant_Title>
        <Admin_Institution>Institute for Breathing and Sleep</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$93,673.50</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>9000709</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Ms Marianne Ciavarella</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2021</Grant_Title>
        <Admin_Institution>Murdoch Childrens Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$5,219,265.21</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>9000710</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Marcia Fearn</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2021</Grant_Title>
        <Admin_Institution>National Ageing Research Institute</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$61,562.69</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>9000715</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Marc Campitelli</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2021</Grant_Title>
        <Admin_Institution>QIMR Berghofer Medical Research Institute</Admin_Institution>
        <State>QLD</State>
        <Sector>Research Institutes</Sector>
        <Total>$3,865,776.91</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>9000711</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Julie Wright</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2021</Grant_Title>
        <Admin_Institution>Royal Brisbane and Women's Hospital Foundation</Admin_Institution>
        <State>QLD</State>
        <Sector>Health</Sector>
        <Total>$48,453.76</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>9000718</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Michael Frommer</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2021</Grant_Title>
        <Admin_Institution>Sax Institute</Admin_Institution>
        <State>NSW</State>
        <Sector>Research Institutes</Sector>
        <Total>$551,425.94</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>9000712</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Leanne Sutherland</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2021</Grant_Title>
        <Admin_Institution>South Australian Health and Medical Research Institute</Admin_Institution>
        <State>SA</State>
        <Sector>Research Institutes</Sector>
        <Total>$310,887.83</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>9000713</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Dr Colleen Elso</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2021</Grant_Title>
        <Admin_Institution>St Vincents Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$1,345,223.00</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID>9000719</APP_ID>
        <Date_Announced>2022-01-11T00:00:00</Date_Announced>
        <CIA_Name>Sejal Kendal</CIA_Name>
        <Grant_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Grant_Type>
        <Sub_Type>Independent Research Institutes Infrastructure Support Scheme (IRIISS)</Sub_Type>
        <Grant_Title>IRIISS - 2021</Grant_Title>
        <Admin_Institution>Walter and Eliza Hall Institute of Medical Research</Admin_Institution>
        <State>VIC</State>
        <Sector>Research Institutes</Sector>
        <Total>$7,383,705.50</Total>
        <Broad_Research_Area>Not Applicable</Broad_Research_Area>
        <Field_s__of_Research>Not Applicable</Field_s__of_Research>
        <Res_KW1>Not Applicable</Res_KW1>
        <Res_KW2>Not Applicable</Res_KW2>
        <Res_KW3>Not Applicable</Res_KW3>
        <Res_KW4>Not Applicable</Res_KW4>
        <Res_KW5>Not Applicable</Res_KW5>
        <Plain_Description>Not Applicable</Plain_Description>
        <Heading18>.</Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
    <row>
        <APP_ID></APP_ID>
        <Date_Announced></Date_Announced>
        <CIA_Name></CIA_Name>
        <Grant_Type></Grant_Type>
        <Sub_Type></Sub_Type>
        <Grant_Title></Grant_Title>
        <Admin_Institution></Admin_Institution>
        <State></State>
        <Sector></Sector>
        <Total></Total>
        <Broad_Research_Area></Broad_Research_Area>
        <Field_s__of_Research></Field_s__of_Research>
        <Res_KW1></Res_KW1>
        <Res_KW2></Res_KW2>
        <Res_KW3></Res_KW3>
        <Res_KW4></Res_KW4>
        <Res_KW5></Res_KW5>
        <Plain_Description></Plain_Description>
        <Heading18></Heading18>
        <Heading19></Heading19>
        <Heading20></Heading20>
        <Heading21></Heading21>
        <Heading22></Heading22>
        <Heading23></Heading23>
        <Heading24></Heading24>
        <Heading25></Heading25>
        <Heading26></Heading26>
        <Heading27></Heading27>
        <Heading28></Heading28>
        <Heading29></Heading29>
    </row>
</root>